<?xml version="1.0" encoding="UTF-8" ?> 
<set>
<DOC>
<DOC_ID>[1]</DOC_ID>
>1.NF00132420
PMID:11856887
TI  - Expression pattern and further characterization of <long_form>human <protein>MAGED2</protein></long_form> and
      identification of rodent orthologues.
AB  - In a search for genes involved in X-linked mental retardation we have
      analyzed the expression pattern and genomic structure of <long_form>human <protein>MAGED2</protein></long_form>.
      This gene is a member of a new defined <protein>MAGE-D</protein> cluster in Xp11.2, a hot
      spot for X-linked mental retardation. Rat and mouse orthologues have been
      isolated. In contrast to the genes of the <protein>MAGE-A</protein>, <protein>MAGE- B</protein> and <protein>MAGE-C</protein>
      clusters, <protein>MAGED2</protein> is expressed ubiquitously. High expression was detected
      in specific brain regions and in the interstitium of testes. Five SNPs in
      the coding region of <long_form>human <protein>MAGED2</protein></long_form> were characterized and their allele
      frequencies determined in a German and Turkish population.
</DOC>
<DOC>
<DOC_ID>[2]</DOC_ID>
>2.NF00118002
PMID:12077706
TI  - Mutations in the <protein>cone photoreceptor G-protein alpha-subunit</protein> gene <protein>GNAT2</protein> in
      patients with achromatopsia.
AB  - Achromatopsia is an autosomal recessively inherited visual disorder that
      is present from birth and that features the absence of color
      discrimination. We here report the identification of five independent
      families with achromatopsia that segregate protein-truncation mutations in
      the <protein>GNAT2</protein> gene, located on chromosome 1p13. <protein>GNAT2</protein> encodes the <protein>cone
      photoreceptor-specific alpha-subunit of transducin</protein>, a <protein>G-protein</protein> of the
      phototransduction cascade, which couples to the <protein>visual pigment</protein>(s). Our
      results demonstrate that <protein>GNAT2</protein> is the third gene implicated in
      achromatopsia.
</DOC>
<DOC>
<DOC_ID>[3]</DOC_ID>
>3.NF00118005
PMID:12149458
TI  - Chimeric <long_form>human <protein>CstF-77</protein></long_form>/<long_form>Drosophila <protein>Suppressor of forked proteins</protein></long_form> rescue
      <protein>suppressor of forked</protein> mutant lethality and mRNA 3' end processing in
      Drosophila.
AB  - The <protein>Suppressor of forked [Su(f)] protein</protein> is the Drosophila homologue of
      <protein>CstF-77</protein>, a <protein>subunit of human cleavage stimulation factor (CstF)</protein> that is
      required for the first step of the mRNA 3' end processing reaction in
      vitro. We have addressed directly the role of <protein>su(f)</protein> in the mRNA 3' end
      processing reaction in vivo. We show that <protein>su(f)</protein> is required for the
      cleavage of pre-mRNA during mRNA 3' end formation. Analysis of the
      functional complementation between <protein>Su(f)</protein> and <protein>CstF-77</protein> shows that most of
      the Drosophila protein (85%) can be exchanged for the human protein to
      produce chimeric <protein>CstF-77</protein>/<protein>Su(f) proteins</protein> that rescue lethality and cleavage
      defect during mRNA 3' end formation in <protein>su(f)</protein> mutants. Interestingly, we
      show that a domain in <long_form>human <protein>CstF-77</protein></long_form> is limiting for the rescue and that
      this domain is not able to reproduce protein interactions with the <protein>CstF
      subunits</protein> of Drosophila. We also show that chimeric <protein>CstF-77</protein>/<protein>Su(f) proteins</protein>
      that rescue lethality of <protein>su(f)</protein> mutants cannot restore utilization of a
      regulated poly(A) site in Drosophila. Taken together, these results
      demonstrate that <protein>CstF-77</protein> and <protein>Su(f)</protein> have the same function in mRNA 3' end
      formation in vivo, but that these two proteins are not interchangeable for
      regulation of poly(A) site utilization.
</DOC>
<DOC>
<DOC_ID>[4]</DOC_ID>
>4.NF00106180
PMID:12196012
TI  - Identification of neurite outgrowth promoting sites on the <protein>laminin alpha 3</protein>
      <protein>chain G</protein> domain.
AB  - <protein>Laminins</protein> are expressed in specific tissues and are involved in various
      biological activities including promoting cell adhesion, growth,
      migration, neurite outgrowth, and differentiation. The <protein>laminin alpha3
      chain</protein> is mainly located in the skin and is also expressed in the floor
      plate of the developing neural tube. Previously, we showed that the <long_form>human
      <protein>laminin alpha3 chain</protein></long_form> LG4 module binds to <long_form><protein>syndecan-2</protein>/4</long_form>, a
      <protein>membrane-associated proteoglycan</protein>, and promotes human fibroblast adhesion.
      Here, we have evaluated the neurite outgrowth activity of the <protein>laminin
      alpha3 chain</protein> LG4 and LG5 modules. Three overlapping recombinant proteins,
      which contained LG4 and/or LG5 modules of the <long_form>human <protein>laminin alpha3 chain</protein></long_form>,
      were prepared using a mammalian cell expression system. Two proteins,
      <protein>rec-alpha3LG4-5</protein> and <protein>rec-alpha3LG4</protein>, promoted cell attachment and neurite
      outgrowth of rat pheochromocytoma PC12 cells, but <protein>rec-alpha3LG5</protein> was
      inactive. Twenty-two peptides covering the entire LG4 module were
      synthesized and tested for cell attachment and neurite outgrowth activity
      to identify active sites of the LG4 module. A3G75 (KNSFMALYLSKG, alpha3
      chain 1411-1422) and A3G83 (GNSTISIRAPVY, alpha3 chain 1476-1487) promoted
      PC12 cell attachment and neurite outgrowth. Additionally, A3G75 and A3G83
      inhibited PC12 cell attachment to <protein>rec-alpha3LG4</protein>. These results suggest
      that the A3G75 and A3G83 sites are important for PC12 cell attachment and
      neurite outgrowth in the <protein>laminin alpha3 chain</protein> LG4 module. We also
      conjugated the A3G75 and A3G83 peptides on chitosan membranes to test
      their potential as bio-materials. These peptide-conjugated chitosan
      membranes were more active for neurite outgrowth than the peptide-coated
      plates. These results suggest that the A3G75- and A3G83-conjugated
      chitosan membranes are applicable as bio-medical materials for neural
      tissue repair and engineering.
</DOC>
<DOC>
<DOC_ID>[5]</DOC_ID>
>5.NF00133153
PMID:12067979
TI  - Aberrant methylation of the <protein>CDH13</protein> (<protein>H-cadherin</protein>) promoter region in
      colorectal cancers and adenomas.
AB  - Expression of the <protein>cadherin</protein> family member <protein>CDH13</protein> (<protein>H-cadherin</protein>) is reduced in
      several human tumors, and it has been hypothesized that this gene
      functions as a <protein>tumor suppressor</protein> gene. Previously, we reported that the 5'
      region of <protein>CDH13</protein> is frequently methylated in breast and lung cancers. Here
      we confirmed the promoter activity of 5' region of <protein>CDH13</protein> by luciferase
      assay and examined its aberrant methylation in colorectal cancers, cell
      lines, and adenomas. Methylation status was investigated by
      methylation-specific PCR (MSP) and by bisulfite DNA sequencing of cloned
      DNA of PCR amplicons. In cell lines, we examined the correlation between
      methylation status and mRNA expression by reverse transcription-PCR.
      Aberrant methylation of <protein>CDH13</protein> was present in 7 of 13 (54%) cell lines, and
      expression was absent in 6 of 13 (46%) cell lines. <protein>CDH13</protein> expression was
      present in six cell lines that showed only the unmethylated form by MSP
      and in one cell line that showed both the methylated and unmethylated
      forms. Treatment with 5-aza-2'-deoxycytidine restored <protein>CDH13</protein> expression in
      methylated cell lines. In surgically resected samples, 17 of 35 (49%)
      cases of primary colorectal cancer, 2 of 33 (6%) cases of corresponding
      nonmalignant colorectal mucosa, and 8 of 19 (42%) adenomas were
      methylated. Sequence data after bisulfite treatment indicated that primary
      cancers and two cell lines with loss of expression were highly methylated
      compared with nonmalignant colorectal epithelial cells, especially at the
      attachment sites of primers for MSP, although there was heterogeneity in
      methylation status. Our results suggest that <protein>CDH13</protein> expression is
      frequently silenced by aberrant methylation in colorectal cancers and
      adenomas and that methylation of <protein>CDH13</protein> commences at an early stage of
      multistep colorectal tumorigenesis.
</DOC>
<DOC>
<DOC_ID>[6]</DOC_ID>
>6.NF00106425
PMID:11836625
TI  - <protein>RFX-B</protein>, a <protein>MHC class II transcription factor</protein>, suppressed in human colorectal
      adenocarcinomas.
AB  - <protein>Regulatory factor X (RFX)</protein> is an essential <protein>MHC class II transcription
      factor</protein> and contains three distinct subunits of which <protein>RFX-B</protein> is one.
      Aberrant expression of <protein>MHC class II</protein> genes is associated with autoimmunity,
      tumour growth and failure to mount an immune response. <protein>RFX-B protein</protein>
      expression in human colorectal adenocarcinomas and in normal adjacent
      tissue was analysed in this study. Western blot analysis showed a
      suppression of <protein>nuclear RFX-B protein</protein> in the tumour tissue.
      Immunohistochemistry revealed that the <protein>RFX-B protein</protein> levels in macrophages
      were generally lower in colorectal cancerous tissue compared to adjacent
      non-cancerous tissue and that focally and not frequently tumour and normal
      epithelial cells were stained weakly for <protein>RFX-B</protein>. As the expression of <protein>MHC
      class II</protein> correlates with the intensity of the immune response system these
      results may support the idea that cancer is associated with
      immunodeficiency and that low levels of <protein>RFX-B</protein> in interstitial macrophages
      could partly explain this thesis.
</DOC>
<DOC>
<DOC_ID>[7]</DOC_ID>
>7.NF00123516
PMID:12037021
TI  - Mutation analysis of the <protein>PIG-A</protein> gene in Korean patients with paroxysmal
      nocturnal haemoglobinuria.
AB  - AIM: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by deficient
      biosynthesis of the glycosylphosphatidylinositol (GPI) anchor in
      haemopoietic stem cells. Mutation of the <protein>phosphatidylinositol glycan class
      A (PIG-A)</protein> gene, an X linked gene that participates in the first step of
      GPI anchor biosynthesis, is responsible for PNH. The characteristics of
      somatic mutation of the <protein>PIG-A</protein> gene in Korean patients with PNH were
      studied. METHODS: Twenty four patients with PNH were selected. Ham tests
      and sucrose haemolysis tests were carried out on all patients. The
      expression of <protein>CD59</protein> in erythrocytes and granulocytes was investigated in 14
      and five patients, respectively, to confirm the diagnosis. Dideoxy
      fingerprinting (ddF) was used to screen mutations, and direct sequencing
      of DNA was performed to characterise the mutations. RESULTS: Gene mutation
      was detected in 12 of the 24 patients. The other 12 patients were negative
      in ddF screening. Ten new mutations and two known mutations were detected.
      The mutations consisted of five deletions, six substitutions, and one
      insertion. These mutations resulted in six premature terminations, three
      abnormal splicings, one missense mutation in exon 2, and two nonsense
      mutations. Two patients with venous thrombosis showed mutations in exon 3
      only. Substitution mutations were seen in six patients and frameshift
      mutations in the other six. CONCLUSIONS: There were 10 new mutations among
      the 12 mutations in the Korean patients with PNH and the characteristics
      of the mutations varied, with no significant hot spots in sites or types.
</DOC>
<DOC>
<DOC_ID>[8]</DOC_ID>
>8.NF00013762
PMID:12223399
TI  - <long_form><protein>COP9 signalosome subunits 4</protein> and 5</long_form> regulate multiple pleiotropic pathways
      in Drosophila melanogaster.
AB  - The <protein>COP9 signalosome (CSN)</protein> is an essential eight-subunit repressor of
      light-regulated development in ARABIDOPSIS: This complex has also been
      identified in animals, though its developmental role remains obscure. <protein>CSN
      subunits</protein> have been implicated in various cellular processes, suggesting a
      possible role for the <protein>CSN</protein> as an integrator of multiple signaling pathways.
      In order to elucidate the function of the <protein>CSN</protein> in animals, a Drosophila
      model system has previously been established. Gel-filtration analysis with
      antibodies against <long_form><protein>CSN subunits 4</protein>, 5 and 7</long_form> revealed that these proteins
      act as a complex in Drosophila that is similar in size to the plant and
      mammalian complexes. Null mutations in either one of two subunits, <protein>CSN4</protein> or
      <protein>CSN5</protein>, are larval lethal. Successful embryogenesis appears to be a
      consequence of maternal contribution of the complex. Biochemical analysis
      indicates that the different subunits are found in both <protein>CSN</protein>-dependent and
      <protein>CSN</protein>-independent forms, and that these forms are differentially affected by
      the mutations. Phenotypic characterization of these two mutants indicates
      that they show both shared and unique phenotypes, which suggest specific
      roles for each subunit. Both mutants have defective oocyte and embryo
      patterning, and defects in response to DNA damage, while <protein>csn5</protein> mutants
      develop melanotic tumors and <protein>csn4</protein> mutants have phenotypes reminiscent of
      defects in ecdysone signaling.
</DOC>
<DOC>
<DOC_ID>[9]</DOC_ID>
>9.NF00124085
PMID:11926999
TI  - Identification of a domain conferring nucleotide binding to the
      <protein>N-acetyl-d-glucosamine 2-epimerase</protein> (<protein>Renin binding protein</protein>).
AB  - <protein>Renin binding protein (RnBP)</protein>, a <protein>cellular renin inhibitor</protein>, has been
      identified as the enzyme <protein>N-acetyl-D-glucosamine (GlcNAc) 2-epimerase</protein>. Our
      recent studies demonstrated that <long_form>rat <protein>GlcNAc 2-epimerase</protein></long_form> has a ten-times
      higher affinity for ATP, dATP, and ddATP than the human enzyme [Takahashi,
      S. et al. (2001) J. Biochem. 130, 815-821]. To identify the domain
      conferring nucleotide binding to <protein>GlcNAc 2-epimerase</protein>, we constructed a
      series of chimeric enzymes successively replacing the three domains of the
      human enzyme (N-terminal, middle, and C-terminal domains) with the
      corresponding domains of the rat enzyme. Chimeras were expressed in
      Escherichia coli JM109 cells under the control of the Taq promoter. The
      purified chimeric enzymes had <protein>GlcNAc 2-epimerase</protein> activity and inhibited
      <protein>renin</protein> activity in a dose-dependent manner. The recombinant human and rat
      enzymes required catalytic amounts of ATP with apparent K(m) values of 73
      and 5.5 microM, respectively. Chimeric enzymes of HHR, RHH, and RHR (H,
      human type domain; R, rat type domain) had nearly the same nucleotide
      specificity as the <long_form>human <protein>GlcNAc 2-epimerase</protein></long_form>. On the other hand, HRR, HRH,
      and RRH chimeras had the same nucleotide specificity as the rat enzyme.
      These results indicate that the middle domain of the <protein>GlcNAc 2-epimerase</protein>
      molecule participates in the specificity for and binding of nucleotides,
      and that nucleotides are essential to form the catalytic domain of the
      enzyme.
</DOC>
<DOC>
<DOC_ID>[10]</DOC_ID>
>10.NF00132428
PMID:12409310
TI  - <protein>alpha 1-Adrenergic receptor subtypes</protein> differentially control the cell cycle
      of transfected CHO cells through a cAMP-dependent mechanism involving
      <protein>p27Kip1</protein>.
AB  - Three distinct <protein>subtypes of alpha(1)-adrenergic receptors</protein> (<long_form>alpha(1)A-,
      alpha(1)B-, and <protein>alpha(1)D-AR</protein></long_form>) play a prominent role in cell growth.
      However, little is known about subtype-specific effects on cell
      proliferation. The activation of <long_form>alpha(1)A- or <protein>alpha(1)B-AR</protein></long_form> inhibits
      serum-promoted cell proliferation, whereas <protein>alpha(1)D-AR</protein> activation does
      not show such an inhibitory effect. Notably, cell-cycle progression was
      blocked at G(1)/S transition after activation of <long_form>alpha(1)A/<protein>alpha(1)B-AR</protein></long_form>
      but not of <protein>alpha(1)D-AR</protein>. In agreement with the differential cell
      proliferation effect, cAMP production was increased after activation of
      <long_form>alpha(1)A/<protein>alpha(1)B-AR</protein></long_form> but not <protein>alpha(1)D-AR</protein>, whereas all <protein>alpha(1)-AR
      subtypes</protein> are associated with inositol 1,4,5-trisphosphate production and
      <protein>mitogen-activated protein kinase</protein> activation in a similar fashion.
      Furthermore, the serum-induced reduction in the levels of the
      <protein>cyclin-dependent kinase inhibitor</protein>, <protein>p27(Kip1)</protein>, was blocked after activation
      of <long_form>alpha(1)A/<protein>alpha(1)B-AR</protein></long_form> but not <protein>alpha(1)D-AR</protein>. These results show that
      <protein>alpha(1)-AR subtypes</protein> differentially activate the cAMP/<protein>p27(Kip1)</protein> pathway
      and thereby have differential inhibitory effects on cell proliferation.
      Subtype-dependent effects should be taken into consideration when
      assessing the physiological response of native cells where <protein>alpha(1)-AR
      subtypes</protein> are generally co-expressed.
</DOC>
<DOC>
<DOC_ID>[11]</DOC_ID>
>11.NF00088410
PMID:12060656
<protein>TI</protein>  - Distinct sets of adjacent <long_form><protein>heterogeneous nuclear ribonucleoprotein (hnRNP)
      A1</protein>/A2</long_form> binding sites control 5' splice site selection in the <protein>hnRNP A1</protein> mRNA
      precursor.
AB  - In the <protein>heterogeneous nuclear ribonucleoprotein (hnRNP) A1</protein> pre-mRNA,
      different regions in the introns flanking alternative exon 7B have been
      implicated in the production of the A1 and A1B mRNA splice isoforms. Among
      these, the CE1a and CE4 elements, located downstream of common exon 7 and
      alternative exon 7B, respectively, are bound by <protein>hnRNP A1</protein> to promote
      skipping of exon 7B in vivo and distal 5' splice site selection in vitro.
      Here, we report that CE1a is flanked by an additional high affinity A1
      binding site (CE1d). In a manner similar to CE1a, CE1d affects 5' splice
      site selection in vitro. Consistent with a role for <protein>hnRNP A1</protein> in the
      activity of CE1d, a mutation that abrogates A1 binding abolishes distal 5'
      splice site activation. Moreover, the ability of CE1d to stimulate distal
      5' splice site usage is lost in an HeLa extract depleted of <protein>hnRNP A/B</protein>
      <protein>proteins</protein>, and the addition of recombinant A1 restores the activity of
      CE1d. Notably, distal 5' splice site selection mediated by A1 binding
      sites is not compromised in an extract prepared from mouse cells that are
      severely deficient in <protein>hnRNP A1 proteins</protein>. In this case, we show that <protein>hnRNP
      A2</protein> compensates for the A1 deficiency. Further studies with the CE4 element
      reveal that it also consists of two distinct portions (CE4m and CE4p),
      each one capable of promoting distal 5' splice site use in an <protein>hnRNP
      A1</protein>-dependent manner. The presence of multiple A1/A2 binding sites
      downstream of common exon 7 and alternative exon 7B probably plays an
      important role in maximizing the activity of <long_form><protein>hnRNP A1</protein>/A2 proteins</long_form>.
</DOC>
<DOC>
<DOC_ID>[12]</DOC_ID>
>12.NF00106186
PMID:11884632
TI  - <protein>Human Rad54B</protein> is a <protein>double-stranded DNA-dependent ATPase</protein> and has biochemical
      properties different from its structural homolog in yeast, <protein>Tid1</protein>/<protein>Rdh54</protein>.
AB  - The <protein>RAD52</protein> epistasis group genes are involved in homologous recombination,
      and they are conserved from yeast to humans. We have cloned a novel human
      gene, <protein>RAD54B</protein>, which is homologous to yeast and <protein>human RAD54</protein>. <protein>Human Rad54B
      (hRad54B)</protein> shares high homology with <protein>human Rad54 (hRad54)</protein> in the central
      region containing the <protein>helicase</protein> motifs characteristic of the <protein>SNF2</protein>/<protein>SWI2</protein>
      family of proteins, but the N-terminal domain is less conserved. In yeast,
      another <protein>RAD54</protein> homolog, <protein>TID1</protein>/<protein>RDH54</protein>, plays a role in recombination.
      <protein>Tid1</protein>/<protein>Rdh54</protein> interacts with yeast <protein>Rad51</protein> and a <protein>meiosis-specific Rad51</protein>
      homolog, <protein>Dmc1</protein>. The N-terminal domain of <protein>hRad54B</protein> shares homology with that
      of <protein>Tid1</protein>/<protein>Rdh54</protein>, suggesting that <protein>Rad54B</protein> may be the human counterpart of
      <protein>Tid1</protein>/<protein>Rdh54</protein>. We purified the <protein>hRad54</protein> and <protein>hRad54B proteins</protein> from
      baculovirus-infected insect cells and examined their biochemical
      properties. <protein>hRad54B</protein>, like <protein>hRad54</protein>, is a <protein>DNA-binding protein</protein> and hydrolyzes
      ATP in the presence of double-stranded DNA, though its rate of ATP
      hydrolysis is lower than that of <protein>hRad54</protein>. <long_form>Human <protein>Rad51</protein></long_form> interacts with <protein>hRad54</protein>
      and enhances its <protein>ATPase</protein> activity. In contrast, neither <long_form>human <protein>Rad51</protein></long_form> nor
      <protein>Dmc1</protein> directly interacts with <protein>hRad54B</protein>. Although <protein>hRad54B</protein> is the putative
      counterpart of <protein>Tid1</protein>/<protein>Rdh54</protein>, our findings suggest that <protein>hRad54B</protein> behaves
      differently from <protein>Tid1</protein>/<protein>Rdh54</protein>.
</DOC>
<DOC>
<DOC_ID>[13]</DOC_ID>
>13.NF00113477
PMID:12044248
TI  - Significance of the <protein>parkin</protein> gene and protein in understanding Parkinson's
      disease.
AB  - Mutations in the <protein>parkin</protein> gene cause autosomal recessive inherited juvenile
      parkinsonism (ARJP) and account for the majority of cases of inherited
      Parkinson's disease (PD) of young onset (&lt;45 years of age). Patients with
      <protein>parkin</protein> mutations commonly have atypical clinical features such as dystonia
      at onset, hyper-reflexia, diurnal fluctuations, and sleep benefit;
      however, <protein>parkin</protein> mutation patients with both typical PD symptoms and older
      age of onset have been identified. <protein>Parkin</protein> is a <protein>ubiquitin protein ligase
      (E3)</protein>, a component in the pathway that attaches <protein>ubiquitin</protein> to specific
      proteins, designating them for degradation by the <protein>proteasome</protein>. Several
      substrates for <protein>parkin</protein> have been identified (<protein>CDCrel-1, o-glycosylated
      alpha-synuclein</protein>, <protein>parkin associated endothelin-like cell receptor</protein>, and
      <protein>synphilin</protein>). The role of these substrates in the pathogenesis of ARJP is
      under active study. Most patients with <protein>parkin</protein> mutations lack Lewy bodies,
      suggesting that functional <protein>parkin</protein> is involved in the formation of these
      highly ubiquitinated inclusions. Furthermore, the recognition that <protein>parkin</protein>
      mutations can lead to a disorder clinically similar to sporadic PD, but
      presumably lacking Lewy bodies, calls into question the necessity of Lewy
      bodies for the diagnosis of PD and nigral cell death. Studies of <protein>parkin</protein>
      are increasing the focus on the role of the <protein>ubiquitin-proteasome system</protein> in
      the pathogenesis of both familial and sporadic PD.
</DOC>
<DOC>
<DOC_ID>[14]</DOC_ID>
>14.NF00101975
PMID:12027902
TI  - Interaction between <protein>p21-activated protein kinase</protein> and <protein>Rac</protein> during
      differentiation of HL-60 human promyelocytic leukemia cell induced by
      all-trans-retinoic acid.
AB  - Undifferentiated human promyelocytic leukemia HL-60 cells show little or
      no superoxide production, but generate a very low O(2)(-) concentration
      upon incubation with all-trans-retinoic acid (ATRA). Its production
      reaches a maximum within 20 h, and thereafter is maintained at an almost
      constant level. The differentiated cells show phorbol 12-myristate
      13-acetate (PMA)-stimulated <protein>NADPH oxidase</protein> activity consistent with the
      amount of <protein>gp91phox</protein> (<protein>phagocytic oxidase</protein>) expressed in the plasma membrane.
      Three <protein>isoforms of p21-activated serine/threonine kinases</protein>, <protein>PAK68</protein>, <protein>PAK65</protein> and
      <protein>PAK62</protein>, were found in both cytosolic and membrane fractions, and their
      contents were significantly increased during induced differentiation. The
      amount of <protein>Rac</protein> identified in the two fractions was also markedly enhanced
      by ATRA- induced differentiation. In contrast, neither <protein>PAK</protein> nor <protein>Rac</protein> was
      seen in the plasma membrane of undifferentiated HL-60 or human neutrophil,
      but they were abundant in the cytoplasmic fraction. Binding of <protein>Rac</protein> with
      <protein>PAK isoforms</protein> was shown in the membrane upon induced differentiation of
      HL-60 cells. Direct binding of purified <protein>Rac1</protein> to <protein>PAK68</protein> was quantified using
      a fluorescent analog of GTP (methylanthraniloyl
      guanosine-5'-[beta,gamma-imido]triphosphate) bound to <protein>Rac</protein> as a reporter
      group. <protein>Rac1</protein> bound to <protein>PAK68</protein> with a 1 : 1 stoichiometry and with a K(d)
      value of 6.7 nm.
</DOC>
<DOC>
<DOC_ID>[15]</DOC_ID>
>15.NF01014359
PMID:12244172
TI  - Evidence for involvement of a hydrophobic patch in framework region 1 of
      <long_form>human <protein>V4-34-encoded Igs</protein></long_form> in recognition of the red blood cell I antigen.
AB  - The <protein>monoclonal IgM cold agglutinins</protein> that bind to the I/i carbohydrate Ags
      on the surface of RBCs all have <protein>Ig H chains</protein> encoded by the <protein>V4-34</protein> gene
      segment. This mandatory use indicates that distinctive amino acid
      sequences may be involved in recognition. Critical amino acids exist in
      framework region 1 (FR1) of <protein>V4-34-encoded Ig</protein>, and these generate a
      specific Id determinant which apparently lies close to the I binding site.
      However, I binding by Id-expressing Ig can be modulated by sequences in
      complementarity-determining region (CDR)(H)3. Examination of the crystal
      structure of an <protein>anti-I cold agglutinin</protein> has revealed a hydrophobic patch in
      FR1 involving residue W7 on beta-strand A and the AVY motif (residues
      23-25) on beta-strand B. In this study we used mutagenesis to show that
      each of the strand components of the hydrophobic patch is required for
      binding the I carbohydrate Ag. In addition, the crystal structure reveals
      that amino acids in the carboxyl-terminal region of CDR(H)3 form a surface
      region adjacent to the hydrophobic patch. We propose that the I
      carbohydrate Ag interacts simultaneously with the entire hydrophobic patch
      in FR1 and with the outside surface of CDR(H)3. This interaction could
      leave most of the conventional binding site available for binding other
      Ags.
</DOC>
<DOC>
<DOC_ID>[16]</DOC_ID>
>16.NF00089060
PMID:11743730
TI  - Solution structures of the <protein>YAP65</protein> WW domain and the variant L30 K in
      complex with the peptides GTPPPPYTVG, N-(n-octyl)-GPPPY and PLPPY and the
      application of peptide libraries reveal a minimal binding epitope.
AB  - The single mutation L30 K in the <protein>Hu-Yap65</protein> WW domain increased the
      stability of the complex with the peptide GTPPPPYTVG (K(d)=40(+/-5)
      microM). Here we report the refined solution structure of this complex by
      NMR spectroscopy and further derived structure-activity relationships by
      using ligand peptide libraries with truncated sequences and a substitution
      analysis that yielded acetyl-PPPPY as the smallest high-affinity binding
      peptide (K(d)=60 microM). The structures of two new complexes with weaker
      binding ligands chosen based on these results (N-(n-octyl)-GPPPYNH(2) and
      Ac-PLPPY) comprising the wild-type WW domain of <protein>Hu-Yap65</protein> were determined.
      Comparison of the structures of the three complexes were useful for
      identifying the molecular basis of high-affinity: hydrophobic and specific
      interactions between the side-chains of Y28 and W39 and P5' and P4',
      respectively, and hydrogen bonds between T37 (donnor) and P5' (acceptor)
      and between W39 (donnor) and T2' (acceptor) stabilize the complex.The
      structure of the complex L30 K <protein>Hu-Yap65</protein> WW domain/GTPPPPYTVG is compared
      to the published crystal structure of the <protein>dystrophin</protein> WW domain bound to a
      segment of the <protein>beta-dystroglycan protein</protein> and to the solution structure of
      the first <protein>Nedd4</protein> WW domain and its prolin-rich ligand, suggesting that WW
      sequences bind proline-rich peptides in an evolutionary conserved fashion.
      The position equivalent to T22 in the <protein>Hu-Yap65</protein> WW domain sequence is seen
      as responsible for differentiation in the binding mode among the WW
      domains of group I.
</DOC>
<DOC>
<DOC_ID>[17]</DOC_ID>
>17.NF00114287
PMID:12606567
TI  - Attenuation of cell adhesion in lymphocytes is regulated by <protein>CYTIP</protein>, a
      protein which mediates signal complex sequestration.
AB  - An important theme in molecular cell biology is the regulation of protein
      recruitment to the plasma membrane. Fundamental biological processes such
      as proliferation, differentiation or leukocyte functions are initiated and
      controlled through the reversible binding of <protein>signaling proteins</protein> to
      phosphorylated membrane components. This is mediated by specialized
      interaction modules, such as SH2 and PH domains. <protein>Cytohesin-1</protein> is an
      <protein>intracellular guanine nucleotide exchange factor</protein>, which regulates
      leukocyte adhesion. The activity of <protein>cytohesin-1</protein> is controlled by phospho
      inositide-dependent membrane recruitment. An <protein>interacting protein</protein> was
      identified, the expression of which is upregulated by <protein>cytokines</protein> in
      hematopoietic cells. This molecule, <protein>CYTIP</protein>, is also recruited to the cell
      cortex by <protein>integrin</protein> signaling via its PDZ domain. However, stimulation of
      Jurkat cells with phorbol ester results in re-localization of <protein>CYTIP</protein> to the
      cytoplasm, and membrane detachment of <protein>cytohesin-1</protein> strictly requires
      co-expression of <protein>CYTIP</protein>. Consequently, stimulated adhesion of Jurkat cells
      to <protein>intracellular adhesion molecule-1</protein> is repressed by <protein>CYTIP</protein>. These findings
      outline a novel mechanism of signal chain abrogation through sequestration
      of a limiting component by specific protein-protein interactions.
</DOC>
<DOC>
<DOC_ID>[18]</DOC_ID>
>18.NF00102867
PMID:12198491
TI  - <protein>Lon protease</protein> preferentially degrades <protein>oxidized mitochondrial aconitase</protein> by
      an ATP-stimulated mechanism.
AB  - <protein>Mitochondrial aconitase</protein> is sensitive to oxidative inactivation and can
      aggregate and accumulate in many age-related disorders. Here we report
      that <protein>Lon protease</protein>, an <protein>ATP-stimulated mitochondrial matrix protein</protein>,
      selectively recognizes and degrades the <protein>oxidized, hydrophobic form of
      aconitase</protein> after mild oxidative modification, but that severe oxidation
      results in <protein>aconitase</protein> aggregation, which makes it a poor substrate for <protein>Lon</protein>.
      Similarly, a morpholino oligodeoxynucleotide directed against the <protein>lon</protein> gene
      markedly decreases the amount of <protein>Lon protein</protein>, <protein>Lon</protein> activity and <protein>aconitase</protein>
      degradation in WI-38 VA-13 human lung fibroblasts and causes accumulation
      of oxidatively modified <protein>aconitase</protein>. The <protein>ATP-stimulated Lon protease</protein> may be
      an essential defence against the stress of life in an oxygen environment.
      By recognizing minor oxidative changes to protein structure and rapidly
      degrading the mildly modified protein, <protein>Lon protease</protein> may prevent extensive
      oxidation, aggregation and accumulation of <protein>aconitase</protein>, which could
      otherwise compromise mitochondrial function and cellular viability.
      <protein>Aconitase</protein> is probably only one of many <protein>mitochondrial matrix proteins</protein> that
      are preferentially degraded by <protein>Lon protease</protein> after oxidative modification.
</DOC>
<DOC>
<DOC_ID>[19]</DOC_ID>
>19.NF00078531
PMID:11745043
TI  - Role of <protein>multidrug resistance 3</protein> deficiency in pediatric and adult liver
      disease: one gene for three diseases.
AB  - <protein>Class III multidrug resistance P-glycoproteins</protein>, <protein>mdr2</protein> in mice and <protein>MDR3</protein> in
      humans, are <protein>canalicular phospholipid translocators</protein> involved in biliary
      phospholipid (phosphatidylcholine) excretion. The role of an <protein>MDR3</protein> gene
      defect in liver disease was initially suspected in a subtype of
      progressive familial intrahepatic cholestasis called PFIC3. Several <protein>MDR3</protein>
      mutations have been identified in children with PFIC3 and are associated
      with a low level of phospholipids in bile, leading to a high biliary
      cholesterol saturation index. Mutations leading to a truncated protein are
      associated with an absence of <protein>canalicular MDR3 protein</protein>. The phenotypic
      spectrum of PFIC3 ranges from neonatal cholestasis to cirrhosis in young
      adults. There is now strong evidence that in addition to PFIC3, an <protein>MDR3</protein>
      defect can be involved in intrahepatic cholestasis of pregnancy and in
      cholesterol gallstone disease. Therefore, at least three human liver
      diseases are due to a single gene deficiency. Patients with PFIC3 due to
      <protein>MDR3</protein> deficiency may benefit from ursodeoxycholic acid therapy and could be
      good candidates for cell therapy in the future.
</DOC>
<DOC>
<DOC_ID>[20]</DOC_ID>
>20.NF00089225
PMID:11558822
TI  - Primary congenital glaucoma: three case reports on novel mutations and
      combinations of mutations in the <protein>GLC3A</protein> (<protein>CYP1B1</protein>) gene.
AB  - PURPOSE: To describe three patients with congenital glaucoma homozygous
      and compound heterozygous for different mutations and benign sequence
      variants in the <protein>cytochrome P 450 1B1 (CYP1B1)</protein> gene. METHODS: All patients
      were examined by slit-lamp biomicroscopy, gonioscopy, measurement of the
      cornea and optic disc, ultrasound biometry, and automated static threshold
      perimetry when possible. Direct sequence analysis was performed on DNA
      extracted from peripheral blood from the patients and their parents.
      RESULTS: For patient 1, a newborn boy with buphthalmos and an opaque
      cornea, a novel homozygous C/T transition in codon 355 (CGA&gt;TGA) led to a
      predicted nonsense codon Arg355X truncating the protein by 188 amino
      acids. For patient 2, a 24-year-old man, a compound heterozygous mutation
      1410-1422del/1546-1555dup was found. For patient 3, a 34-year-old man, two
      novel heterozygous missense mutations resulting in an Ala443Gly and a
      Glu229Lys amino acid exchange and five benign sequence variants were
      found. CONCLUSION: Our results confirm the crucial role of <protein>CYP1B1</protein>
      mutations for congenital glaucoma.
</DOC>
<DOC>
<DOC_ID>[21]</DOC_ID>
>21.NF00982620
PMID:12019563
TI  - <protein>Photoreceptor</protein> renewal: a role for <protein>peripherin/rds</protein>.
AB  - Visual transduction begins with the detection of light within the
      <protein>photoreceptor</protein> cell layer of the retina. Within this layer, specialized
      cells, termed rods and cones, contain the proteins responsible for light
      capture and its transduction to nerve impulses. The phototransductive
      proteins reside within an outer segment region that is connected to an
      inner segment by a thin stalk rich in cytoskeletal elements. A unique
      property of the outer segments is the presence of an elaborate
      intracellular membrane system that holds the phototransduction proteins
      and provides the requisite lipid environment. The maintenance of normal
      physiological function requires that these postmitotic cells retain the
      unique structure of the outer segment regions--stacks of membrane saccules
      in the case of rods and a continuous infolding of membrane in the case of
      cones. Both <protein>photoreceptor</protein> rod and cone cells achieve this through a series
      of coordinated steps. As new membranous material is synthesized,
      transported, and incorporated into newly forming outer segment membranes,
      a compensatory shedding of older membranous material occurs, thereby
      maintaining the segment at a constant length. These processes are
      collectively referred to as ROS (rod outer segment) or COS (cone outer
      segment) renewal. We review the cellular and molecular events responsible
      for these renewal processes and present the recent but compelling
      evidence, drawn from molecular genetic, biochemical, and biophysical
      approaches, pointing to an essential role for a unique <protein>tetraspanning
      membrane protein</protein>, called <protein>peripherin/rds</protein>, in the processes of disk
      morphogenesis.
</DOC>
<DOC>
<DOC_ID>[22]</DOC_ID>
>22.NF00095628
PMID:12060708
TI  - A role for <protein>ASIC3</protein> in the modulation of high-intensity pain stimuli.
AB  - <protein>Acid-sensing ion channel 3 (ASIC3)</protein>, a <protein>proton-gated ion channel</protein> of the
      <protein>degenerins/epithelial sodium channel (DEG/ENaC) receptor</protein> family is
      expressed predominantly in sensory neurons including nociceptive neurons
      responding to protons. To study the role of <protein>ASIC3</protein> in pain signaling, we
      generated <protein>ASIC3</protein> knockout mice. Mutant animals were healthy and responded
      normally to most sensory stimuli. However, in behavioral assays for pain
      responses, <protein>ASIC3</protein> null mutant mice displayed a reduced latency to the onset
      of pain responses, or more pain-related behaviors, when stimuli of
      moderate to high intensity were used. This unexpected effect seemed
      independent of the modality of the stimulus and was observed in the acetic
      acid-induced writhing test (0.6 vs. 0.1-0.5%), in the hot-plate test (52.5
      and 55 vs. 50 degrees C), and in tests for mechanically induced pain
      (tail-pinch vs. von Frey filaments). We postulate that <protein>ASIC3</protein> is involved
      in modulating moderate- to high-intensity pain sensation.
</DOC>
<DOC>
<DOC_ID>[23]</DOC_ID>
>23.NF00866395
PMID:11986327
TI  - Cloning and characterization of <long_form>human <protein>Siglec-11</protein></long_form>. A recently evolved
      signaling that can interact with <protein>SHP-1</protein> and <protein>SHP-2</protein> and is expressed by
      tissue macrophages, including brain microglia.
AB  - <protein>Siglecs</protein> are <protein>sialic acid-recognizing animal lectins</protein> of the <protein>immunoglobulin</protein>
      superfamily. We have cloned and characterized a novel human molecule,
      <protein>Siglec-11</protein>, that belongs to the subgroup of <protein>CD33/Siglec-3-related Siglecs</protein>.
      As with others in this subgroup, the cytosolic domain of <protein>Siglec-11</protein> is
      phosphorylated at tyrosine residue(s) upon pervanadate treatment of cells
      and then recruits the <protein>protein-tyrosine phosphatases SHP-1</protein> and <protein>SHP-2</protein>.
      However, <protein>Siglec-11</protein> has several novel features relative to the other
      <protein>CD33/Siglec-3-related Siglecs</protein>. First, it binds specifically to
      alpha2-8-linked sialic acids. Second, unlike other <protein>CD33/Siglec-3-related
      Siglecs</protein>, <protein>Siglec-11</protein> was not found on peripheral blood leukocytes. Instead,
      we observed its expression on macrophages in various tissues, such as
      liver Kupffer cells. Third, it was also expressed on brain microglia, thus
      becoming the second <protein>Siglec</protein> to be found in the nervous system. Fourth,
      whereas the <protein>Siglec-11</protein> gene is on human chromosome 19, it lies outside the
      previously described <protein>CD33/Siglec-3-related Siglec</protein> cluster on this
      chromosome. Fifth, analyses of genome data bases indicate that <protein>Siglec-11</protein>
      has no mouse ortholog and that it is likely to be the last canonical <long_form>human
      <protein>Siglec</protein></long_form> to be reported. Finally, although <protein>Siglec-11</protein> shows marked sequence
      similarity to <long_form>human <protein>Siglec-10</protein></long_form> in its extracellular domain, the cytosolic
      tail appears only distantly related. Analysis of genomic regions
      surrounding the <protein>Siglec-11</protein> gene suggests that it is actually a chimeric
      molecule that arose from relatively recent gene duplication and
      recombination events, involving the extracellular domain of a closely
      related ancestral <protein>Siglec</protein> gene (which subsequently became a pseudogene) and
      a transmembrane and cytosolic tail derived from another ancestral <protein>Siglec</protein>.
</DOC>
<DOC>
<DOC_ID>[24]</DOC_ID>
>24.NF00866396
PMID:11546873
TI  - Role of the <protein>nonsense-mediated decay factor hUpf3</protein> in the splicing-dependent
      exon-exon junction complex.
AB  - Nonsense-mediated messenger RNA (mRNA) decay, or NMD, is a critical
      process of selective degradation of mRNAs that contain premature stop
      codons. NMD depends on both pre-mRNA splicing and translation, and it
      requires recognition of the position of stop codons relative to exon-exon
      junctions. A key factor in NMD is <protein>hUpf3</protein>, a mostly <protein>nuclear protein</protein> that
      shuttles between the nucleus and cytoplasm and interacts specifically with
      spliced mRNAs. We found that <protein>hUpf3</protein> interacts with Y14, a <protein>component of
      post-splicing mRNA-protein (mRNP) complexes</protein>, and that <protein>hUpf3</protein> is enriched in
      <protein>Y14-containing mRNP complexes</protein>. The <protein>mRNA export factors Aly/REF</protein> and <protein>TAP</protein> are
      also associated with <protein>nuclear hUpf3</protein>, indicating that <protein>hUpf3</protein> is in <protein>mRNP
      complexes</protein> that are poised for nuclear export. Like Y14 and <protein>Aly/REF</protein>, <protein>hUpf3</protein>
      binds to spliced mRNAs specifically ( approximately 20 nucleotides)
      upstream of exon-exon junctions. The splicing-dependent binding of <protein>hUpf3</protein>
      to mRNAs before export, as part of the complex that assembles near
      exon-exon junctions, allows it to serve as a link between splicing and NMD
      in the cytoplasm.
</DOC>
<DOC>
<DOC_ID>[25]</DOC_ID>
>25.NF00779079
PMID:11597141
TI  - Cloning and chromosomal localization of a gene encoding a novel
      <protein>serine/threonine kinase</protein> belonging to the subfamily of <protein>testis-specific
      kinases</protein>.
AB  - Using reverse transcription-polymerase chain reaction (RT-PCR) with
      degenerate oligonucleotides corresponding to two highly conserved motifs
      within the <protein>protein kinase</protein> family of catalytic domains, we isolated a PCR
      fragment encoding a novel member of the <protein>testis-specific serine/threonine
      kinases (STK)</protein> from mouse male mixed germ cell mRNA. This PCR fragment
      recognized a 1020-bp transcript in male germ cells by northern blot
      analysis and was used to clone a full-length cDNA from a mouse mixed germ
      cell cDNA library. This cDNA has an open reading frame of 804 bases
      encoding a protein of 268 amino acids. This novel gene is almost identical
      to <protein>Stk22c</protein>, encoding a recently described <protein>testis-specific protein kinase</protein>,
      except for base-pair deletions that result in a shift in the coding region
      and an alteration of 22 amino acids (residues 109-131). Due to its
      homology with <protein>Stk22c</protein>, we have called this <protein>protein kinase</protein> gene <protein>Stk22d</protein>.
      Northern blot analysis revealed that this <protein>protein kinase</protein> is
      developmentally expressed in testicular germ cells and is not present in
      brain, ovary, kidney, liver, or early embryonic cells. We then cloned the
      human homologue of this <protein>protein kinase</protein> gene (<protein>STK22C</protein>) and found it to be
      expressed exclusively in the testis. Fluorescence in situ hybridization
      with both the human and mouse cDNA clones revealed syntenic localization
      on chromosomes 1p34-p35 and 4E1, respectively.
</DOC>
<DOC>
<DOC_ID>[26]</DOC_ID>
>26.NF00142150
PMID:12037680
TI  - CK2-dependent phosphorylation of the <protein>E2 ubiquitin conjugating enzyme UBC3B</protein>
      induces its interaction with <protein>beta-TrCP</protein> and enhances <protein>beta-catenin</protein>
      degradation.
AB  - <protein>Protein kinase CK2</protein> is a ubiquitous and pleiotropic <protein>Ser/Thr protein kinase</protein>
      involved in cell growth and transformation. Here we report the
      identification by yeast interaction trap of a <protein>CK2 interacting protein</protein>,
      <protein>UBC3B</protein>, which is highly homologous to the <protein>E2 ubiquitin conjugating enzyme</protein>
      <protein>UBC3</protein>/<protein>CDC34</protein>. <protein>UBC3B</protein> complements the <long_form>yeast <protein>cdc34-2</protein></long_form> cell cycle arrest mutant
      in S. cerevisiae and transfers <protein>ubiquitin</protein> to a target substrate in vitro.
      <protein>UBC3B</protein> is specifically phosphorylated by <protein>CK2</protein> in vitro and in vivo. We
      mapped by deletions and site directed mutagenesis the phosphorylation site
      to a serine residue within the C-terminal domain in position 233 of <protein>UBC3B</protein>
      and in the corresponding serine residue of <protein>UBC3</protein>. Following <protein>CK2</protein>-dependent
      phosphorylation both <protein>UBC3B</protein> and <protein>UBC3</protein> bind to the <protein>F-box protein beta-TrCP</protein>,
      the substrate recognition <protein>subunit of an SCF (Skp1, Cul1, F-box) ubiquitin
      <protein>ligase</protein></protein>. Furthermore, we observed that co-transfection of <protein>CK2alpha</protein>'
      together with <protein>UBC3B</protein>, but not with <protein>UBC3DeltaC</protein>, enhances the degradation of
      <protein>beta-catenin</protein>. Taken together these data suggest that <protein>CK2</protein>-dependent
      phosphorylation of <protein>UBC3</protein> and <protein>UBC3B</protein> functions by regulating <protein>beta-TrCP</protein>
      substrate recognition.
</DOC>
<DOC>
<DOC_ID>[27]</DOC_ID>
>27.NF00126031
PMID:12239140
TI  - Transgenic overexpression of <protein>human IL-17E</protein> results in eosinophilia,
      B-lymphocyte hyperplasia, and altered antibody production.
AB  - We have identified and cloned a novel <long_form>human <protein>cytokine</protein></long_form> with homology to
      <protein>cytokines</protein> of the <protein>interleukin-17 (IL-17)</protein> family, which we have termed <protein>human
      IL-17E (hIL-17E)</protein>. With the identification of several <protein>IL-17</protein> family members,
      it is critical to understand the in vivo function of these molecules. We
      have generated transgenic mice overexpressing <protein>hIL-17E</protein> using an
      <protein>apolipoprotein E (ApoE)</protein> hepatic promoter. These mice displayed changes in
      the peripheral blood, particularly, a 3-fold increase in total leukocytes
      consisting of increases in eosinophils, lymphocytes, and neutrophils.
      Splenomegaly and lymphoadenopathy were predominant and included marked
      eosinophil infiltrates and lymphoid hyperplasia. <protein>CCR3</protein>(+) eosinophils
      increased in the blood and lymph nodes of the transgenic mice by 50- and
      300-fold, respectively. Eosinophils also increased 8- to 18-fold in the
      bone marrow and spleen, respectively. In the bone marrow, most of the
      eosinophils had an immature appearance. <protein>CD19</protein>(+) B cells increased 2- to
      5-fold in the peripheral blood, 2-fold in the spleen, and 10-fold in the
      lymph nodes of transgenic mice, whereas <protein>CD4</protein>(+) T lymphocytes increased
      2-fold in both blood and spleen. High serum levels of the <protein>cytokines IL-2</protein>,
      <protein>IL-4</protein>, <protein>IL-5</protein>, <protein>granulocyte colony-stimulating factor</protein>, <protein>eotaxin</protein>, and <protein>interferon
      gamma</protein> were observed. Consistent with B-lymphocyte increases, <protein>serum
      immunoglobulin (Ig) M</protein>, <protein>IgG</protein>, and <protein>IgE</protein> were significantly elevated. Antigenic
      challenge of the transgenic mice with <protein>keyhole limpet hemocyanin (KLH)</protein>
      resulted in a decrease in <protein>anti-KLH IgG</protein> accompanied by increases of
      <long_form><protein>anti-KLH IgA</protein> and <protein>IgE</protein></long_form>. In situ hybridization of transgenic tissues revealed
      that <protein>IL-17Rh1</protein> (<protein>IL-17BR</protein>/<protein>Evi27</protein>), a <protein>receptor</protein> that binds <protein>IL-17E</protein>, is
      up-regulated. Taken together, these data indicate that <protein>IL-17E</protein> regulates
      hematopoietic and immune functions, stimulating the development of
      eosinophils and B lymphocytes. The fact that <protein>hIL-17E</protein> overexpression
      results in high levels of circulating eosinophils, <protein>IL-4</protein>, <protein>IL-5</protein>, <protein>eotaxin</protein>,
      and <protein>IgE</protein> suggests that <protein>IL-17E</protein> may be a <protein>proinflammatory cytokine</protein> favoring
      Th2-type immune responses.
</DOC>
<DOC>
<DOC_ID>[28]</DOC_ID>
>28.NF00108133
PMID:12547166
TI  - Altered splicing pattern of <protein>TACC1</protein> mRNA in gastric cancer.
AB  - <protein>Transforming acidic coiled-coil (TACC) proteins</protein> are <protein>centrosome and
      microtubule-associated proteins</protein> that are essential for mitotic spindle
      function. We identified <protein>TACC1</protein> as an <protein>immunogenic protein</protein> and a potential
      <protein>tumor antigen</protein> by applying serological identification of antigens by
      recombinant expression cloning (SEREX) technique to screen a gastric
      cancer cDNA library. The 5'RLM-RACE and reverse transcriptase polymerase
      chain reaction analyses revealed at least six different transcript
      variants of <protein>TACC1</protein> with variable transcription start sites and alternative
      exon usage (designated <long_form><protein>TACC1-A</protein>-<protein>TACC1-F</protein></long_form>). All transcripts differ in their
      5' ends but share an identical 3' region encoding coiled-coil domain. Four
      transcripts were universally expressed in all normal tissues analyzed but
      <protein>TACC1-D</protein> and <protein>TACC1-F</protein> showed a restricted expression pattern. <protein>TACC1-F</protein>, a
      transcript representing the SEREX-identified cDNA clone, was predominantly
      expressed in brain and gastric tumors to a similar level. <protein>TACC1-D</protein> was only
      weakly detectable in kidney and colon but not in other normal tissues,
      while a relatively strong expression was observed in 50% of gastric cancer
      tissue samples analyzed. These transcript variants are generated possibly
      as a result of alterations in efficiency and pattern of alternative
      splicing; these isoforms may represent genetic markers, for example
      <protein>TACC1-D</protein> for gastric cancer. We also propose that inappropriate expression
      of the isoforms in gastric cancer cells might result in dysfunction of
      <protein>TACC1</protein> thus contributing to the genetic instability.
</DOC>
<DOC>
<DOC_ID>[29]</DOC_ID>
>29.NF00131704
PMID:12058028
TI  - The <protein>stress-activated protein kinases p38 alpha</protein> and <protein>JNK1</protein> stabilize
      <protein>p21</protein>(<protein>Cip1</protein>) by phosphorylation.
AB  - Stress signals activate the <protein>SAPK</protein>/<protein>JNK</protein> and <protein>p38 MAPK</protein> classes of <protein>protein
      kinases</protein>, which mediate cellular responses, including steps in apoptosis
      and the maturation of some cell types. We now show that stress signals
      initiated by <protein>transforming growth factor-beta 1 (TGF-beta 1)</protein> induce G(1)
      arrest through protein stabilization of the <protein>CDK inhibitor p21(Cip1)</protein>.
      <protein>TGF-beta 1</protein> was previously shown to increase <protein>p21 protein</protein> levels, which in
      turn mediated G(1) arrest through inactivation of the <long_form><protein>CDK2</protein>-<protein>cyclin E</protein>
      complex</long_form> in HD3 cells (Yan, Z., Kim, G.-Y., Deng, X., and Friedman, E.
      (2002) J. Biol. Chem. 277, 9870-9879). We now demonstrate that the
      increase in <protein>p21</protein> abundance is caused by a post-transcriptional,
      <protein>SMAD</protein>-independent mechanism. <protein>TGF-beta1</protein> activated <protein>p38 alpha</protein> and <protein>JNK1</protein>, which
      initiated the phosphorylation of <protein>p21</protein>. <protein>TGF-beta1</protein> treatment increased the
      half-life of <protein>p21</protein> by 3-4-fold. The increase in <protein>p21</protein> stability was detected
      following activation of <protein>p38 alpha</protein> and <protein>JNK1</protein>, and treatment of cells with
      the <protein>p38</protein> inhibitor SB203580 prevented this increase in <protein>p21</protein> stability. <protein>p38
      alpha</protein> and <protein>JNK1</protein> phosphorylated <protein>p21</protein> in vivo, and both <protein>p38 alpha</protein> and <protein>JNK1</protein>
      phosphorylated <protein>p21</protein> at Ser(130) in vitro. Peptide mapping demonstrated that
      both <protein>TGF-beta 1</protein> and <protein>p38 alpha</protein> induced phosphorylation of <protein>p21</protein> at Ser(130)
      in vivo, and mutation of Ser(130) to alanine rendered <protein>p21</protein> less stable than
      wild-type <protein>p21</protein>. <protein>TGF-beta 1</protein> increased the stability of wild-type <protein>p21</protein>, but
      not the <protein>p21</protein>-S130A mutant. These findings demonstrate that <protein>SAPKs</protein> can
      mediate cell cycle arrest through post-translational modification of <protein>p21</protein>.
</DOC>
<DOC>
<DOC_ID>[30]</DOC_ID>
>30.NF00142154
PMID:12493765
TI  - <protein>Transcriptional repressor germ cell-less (GCL)</protein> and <protein>barrier to
      autointegration factor (BAF)</protein> compete for binding to <protein>emerin</protein> in vitro.
AB  - <protein>Emerin</protein> belongs to the &quot;LEM domain&quot; family of <protein>nuclear proteins</protein>, which
      contain a characteristic approximately 40-residue LEM motif. The LEM
      domain mediates direct binding to <protein>barrier to autointegration factor (BAF)</protein>,
      a <protein>conserved 10-kDa chromatin protein</protein> essential for embryogenesis in
      Caenorhabditis elegans. In mammalian cells, <protein>BAF</protein> recruits <protein>emerin</protein> to
      chromatin during nuclear assembly. <protein>BAF</protein> also mediates chromatin
      decondensation during nuclear assembly. The LEM domain and central region
      of <protein>emerin</protein> are essential for binding to <protein>BAF</protein> and <protein>lamin A</protein>, respectively.
      However, two other conserved regions of <protein>emerin</protein> lacked ascribed functions,
      suggesting that <protein>emerin</protein> could have additional partners. We discovered that
      these &quot;unascribed&quot; domains of <protein>emerin</protein> mediate direct binding to a
      <protein>transcriptional repressor</protein>, <protein>germ cell-less (GCL)</protein>. <protein>GCL</protein> co-immunoprecipitates
      with <protein>emerin</protein> from HeLa cells. We determined the binding affinities of
      <protein>emerin</protein> for <protein>GCL</protein>, <protein>BAF</protein>, and <protein>lamin A</protein> and analyzed their oligomeric
      interactions. We showed that <protein>emerin</protein> forms stable complexes with either
      <protein>lamin A</protein> plus <protein>GCL</protein> or <protein>lamin A</protein> plus <protein>BAF</protein>. Importantly, <protein>BAF</protein> competed with <protein>GCL</protein>
      for binding to <protein>emerin</protein> in vitro, predicting that <protein>emerin</protein> can form at least
      two distinct types of complexes in vivo. Loss of <protein>emerin</protein> causes
      Emery-Dreifuss muscular dystrophy, a tissue-specific inherited disease
      that affects skeletal muscles, major tendons, and the cardiac conduction
      system. Although <protein>GCL</protein> alone cannot explain the disease mechanism, our
      results strongly support gene expression models for Emery-Dreifuss
      muscular dystrophy by showing that <protein>emerin</protein> binds directly to a
      <protein>transcriptional repressor</protein>, <protein>GCL</protein>, and by suggesting that <long_form><protein>emerin</protein>-repressor
      complexes</long_form> might be regulated by <protein>BAF</protein>. Biochemical roles for <protein>emerin</protein> in gene
      expression are discussed.
</DOC>
<DOC>
<DOC_ID>[31]</DOC_ID>
>31.NF00104652
PMID:11896212
TI  - Infantile dilated X-linked cardiomyopathy, <protein>G4.5</protein> mutations, altered lipids,
      and ultrastructural malformations of mitochondria in heart, liver, and
      skeletal muscle.
AB  - Mutations in the Xq28 gene <protein>G4.5</protein> lead to dilated cardiomyopathy (DCM).
      Differential splicing of <protein>G4.5</protein> results in a family of proteins called
      &quot;<protein>tafazzins</protein>&quot; with homology to <protein>acyltransferases</protein>. These enzymes assemble
      fatty acids into membrane lipids. We sequenced <protein>G4.5</protein> in two kindreds with
      X-linked DCM and in two unrelated men, one with idiopathic DCM and the
      other with DCM of arrhythmogenic right ventricular dysplasia. We examined
      the ultrastructure of heart, liver, and muscle biopsy specimens in these
      three DCM types; we used gas chromatography to compare fatty acid
      composition in heart, liver, and muscle autopsy specimens of two patients
      of kindred 1 with that of controls. In X-linked DCM, <protein>G4.5</protein> had a stop codon
      (E188X), a nonsense mutation, in kindred 1 and an amino acid substitution
      (G240R), a missense mutation, in kindred 2. In the two men with isolated
      DCM, <protein>G4.5</protein> was not mutated. Ultrastructural mitochondrial malformations
      were present in the biopsy tissues of the patients with DCM. Cardiac
      biopsy specimens of both kindreds with X-linked DCM exhibited greatly
      enlarged mitochondria with large bundles of stacked, compacted, disarrayed
      cristae that differed from those of the two types of isolated DCM. Autopsy
      tissue of patients with X-linked DCM had decreased unsaturated and
      increased saturated fatty acid concentrations. Seven of 13 published <protein>G4.5</protein>
      missense mutations, including the one presented here, occur in
      <protein>acyltransferase</protein> motifs. Impaired <protein>acyltransferase</protein> function could result in
      increased fatty acid saturation that would decrease membrane fluidity.
      Mitochondrial membrane proliferation may be an attempt to compensate for
      impaired function of <protein>acyltransferase</protein>. Cardiac ultrastructure separates
      X-linked DCM with <protein>G4.5</protein> mutations from the two types of isolated DCM
      without <protein>G4.5</protein> mutations. Electron microscopy of promptly fixed myocardial
      biopsy specimens has a role in defining the differential diagnosis of DCM.
      Mutational analysis of the <protein>G4.5</protein> gene also serves this purpose.
</DOC>
<DOC>
<DOC_ID>[32]</DOC_ID>
>32.NF00107244
PMID:12054652
TI  - <protein>Phospholipase C-beta 2</protein> interacts with <protein>mitogen-activated protein kinase
      <protein>kinase</protein> 3</protein>.
AB  - <protein>Phospholipase C (PLC)-beta enzymes</protein> (<long_form><protein>isoenzymes beta 1</protein>-beta 4</long_form>) are
      activated by <protein>G protein subunits</protein>, leading to the generation of
      intracellular messengers which mobilize calcium and activate <protein>protein
      kinase C</protein>. It has recently been recognized that these enzymes interact with
      and are regulated by proteins other than <protein>G proteins</protein>. Using the yeast
      two-hybrid technique to screen a leukocyte library we identified
      <protein>mitogen-activated protein kinase kinase 3 (MKK3)</protein> as a partner of <protein>PLC-beta
      2</protein>. The interaction was confirmed by co-immunoprecipitation assays which
      indicated that <protein>MKK3</protein> interacts with <protein>PLC-beta 2</protein>, but not with other
      <protein>PLC-betas</protein>. <protein>PLC-beta 2</protein> interacted weakly with <protein>MKK6</protein>, which is related to
      <protein>MKK3</protein>, but not with the other <protein>MKK3</protein> tested. The region of <protein>PLC-beta 2</protein>
      involved in the interaction with <protein>MKK3</protein> was mapped to the C-terminus of
      <protein>PLC-beta 2</protein>. <protein>p38MAPK</protein> also co-immunoprecipitated with <protein>PLC-beta 2</protein>. The data
      suggest that <protein>PLC-beta 2</protein> serves an unappreciated role assembling components
      of the <protein>p38MAPK</protein> signaling module.
</DOC>
<DOC>
<DOC_ID>[33]</DOC_ID>
>33.NF00108136
PMID:12606047
TI  - <protein>Myeloperoxidase</protein>/nitrite-mediated lipid peroxidation of <protein>low-density
      lipoprotein</protein> as modulated by flavonoids.
AB  - In the presence of a H(2)O(2)-generating system, <protein>myeloperoxidase (MPO)</protein>
      caused conjugated diene formation in <protein>low-density lipoprotein (LDL)</protein>,
      indicating lipid peroxidation which was dependent on nitrite but not on
      chloride. The oxidation of <protein>LDL</protein> was inhibited by micromolar concentrations
      of flavonoids such as (-)-epicatechin, quercetin, rutin, taxifolin and
      luteolin, presumably via scavenging of the <protein>MPO</protein>-derived NO(2) radical. The
      flavonoids served as substrates of <protein>MPO</protein> leading to products with distinct
      absorbance spectra. The <protein>MPO</protein>-catalyzed oxidation of flavonoids was
      accelerated in the presence of nitrite.
</DOC>
<DOC>
<DOC_ID>[34]</DOC_ID>
>34.NF00098301
PMID:11925441
TI  - Determinants of the substrate specificity of <protein>multidrug resistance protein
      1</protein>: role of amino acid residues with hydrogen bonding potential in
      predicted transmembrane helix 17.
AB  - <long_form>Human <protein>multidrug resistance protein 1 (MRP1)</protein></long_form> confers resistance to many
      natural product chemotherapeutic agents and actively transports
      structurally diverse organic anion conjugates. We previously demonstrated
      that two hydrogen-bonding amino acid residues in the predicted
      transmembrane 17 (TM17) of <protein>MRP1</protein>, Thr(1242) and Trp(1246), were important
      for drug resistance and 17beta-estradiol 17-(beta-d-glucuronide)
      (E(2)17betaG) transport. To determine whether other residues with hydrogen
      bonding potential within TM17 influence substrate specificity, we replaced
      Ser(1233), Ser(1235), Ser(1237), Gln(1239), Thr(1241), and Asn(1245) with
      Ala and Tyr(1236) and Tyr(1243) with Phe. Mutations S1233A, S1235A,
      S1237A, and Q1239A had no effect on any substrate tested. In contrast,
      mutations Y1236F and T1241A decreased resistance to vincristine but not to
      VP-16, doxorubicin, and epirubicin. Mutation Y1243F reduced resistance to
      all drugs tested by 2-3-fold. Replacement of Asn(1245) with Ala also
      decreased resistance to VP-16, doxorubicin, and epirubicin but increased
      resistance to vincristine. This mutation also decreased E(2)17betaG
      transport approximately 5-fold. Only mutation Y1243F altered the ability
      of <protein>MRP1</protein> to transport both leukotriene 4 and E(2)17betaG. Together with our
      previous results, these findings suggest that residues with side chain
      hydrogen bonding potential, clustered in the cytoplasmic half of TM17,
      participate in the formation of a substrate binding site.
</DOC>
<DOC>
<DOC_ID>[35]</DOC_ID>
>35.NF00122637
PMID:12393902
TI  - <protein>MdmX</protein> is a <protein>RING finger ubiquitin ligase</protein> capable of synergistically
      enhancing <protein>Mdm2</protein> ubiquitination.
AB  - It has been well documented that <protein>Mdm2</protein> and its homologue <protein>MdmX</protein> not only are
      critical negative regulators of the <protein>tumor suppressor p53</protein> but that both
      <protein>Mdm2</protein> and <protein>MdmX</protein> interact to affect the function of the other. The mechanisms
      through which these effects are manifested, however, remain unclear.
      Although <protein>Mdm2</protein> has been established as a <protein>RING finger ubiquitin ligase</protein>, <protein>MdmX</protein>
      has not been shown to possess this activity despite the extensive sequence
      homology between their respective RING finger domains. Here we demonstrate
      that <protein>MdmX</protein> acts as a <protein>ubiquitin ligase</protein> in vitro, being capable of
      autoubiquitination, as well as mediating the ubiquitination of <protein>p53</protein>. The
      addition of <protein>Mdm2</protein> to in vitro ubiquitination assays containing <protein>MdmX</protein> results
      in a synergistic increase of <protein>ubiquitin</protein> conjugation. Analysis of the
      resulting <protein>ubiquitin</protein> conjugates reveals that this observed synergy reflects
      an increase in <protein>Mdm2</protein> ubiquitination. This study also suggests that
      ubiquitination of <protein>Mdm2</protein> and <protein>MdmX</protein> may not serve as a signal for degradation,
      as we show that each are capable of synthesizing non-lysine 48
      <protein>polyubiquitin chains</protein> and, in fact, utilize multiple lysine linkages. Taken
      together, these findings suggest a more active role for <protein>MdmX</protein> in the
      <protein>Mdm2</protein>-<protein>MdmX</protein>-<protein>p53</protein> regulatory network than has been proposed previously.
</DOC>
<DOC>
<DOC_ID>[36]</DOC_ID>
>36.NF00097330
PMID:12006491
TI  - <long_form>Human <protein>SIR2</protein></long_form> deacetylates <protein>p53</protein> and antagonizes <protein>PML</protein>/<protein>p53</protein>-induced cellular
      senescence.
AB  - The <long_form>yeast <protein>Sir2 protein</protein></long_form> mediates chromatin silencing through an intrinsic
      <protein>NAD-dependent histone deacetylase</protein> activity. <protein>Sir2</protein> is a conserved protein
      and was recently shown to regulate lifespan extension both in budding
      yeast and worms. Here, we show that <protein>SIRT1</protein>, the <long_form>human <protein>Sir2</protein></long_form> homolog, is
      recruited to the <protein>promyelocytic leukemia protein (PML)</protein> nuclear bodies of
      mammalian cells upon overexpression of either <protein>PML</protein> or <protein>oncogenic Ras</protein>
      (<protein>Ha-rasV12</protein>). <protein>SIRT1</protein> binds and deacetylates <protein>p53</protein>, a <long_form><protein>component of PML</protein> nuclear
      bodies</long_form>, and it can repress <protein>p53</protein>-mediated transactivation. Moreover, we show
      that <protein>SIRT1</protein> and <protein>p53</protein> co-localize in nuclear bodies upon <protein>PML</protein> upregulation.
      When overexpressed in primary mouse embryo fibroblasts (MEFs), <protein>SIRT1</protein>
      antagonizes <protein>PML</protein>-induced acetylation of <protein>p53</protein> and rescues <protein>PML</protein>-mediated
      premature cellular senescence. Taken together, our data establish the
      <protein>SIRT1 deacetylase</protein> as a novel negative regulator of <protein>p53</protein> function capable of
      modulating cellular senescence.
</DOC>
<DOC>
<DOC_ID>[37]</DOC_ID>
>37.NF00116239
PMID:11856758
TI  - Role of <protein>integrin-linked kinase</protein> in leukocyte recruitment.
AB  - <protein>Chemokines</protein> modulate <protein>leukocyte integrin</protein> avidity to coordinate adhesion and
      subsequent transendothelial migration, although the sequential signaling
      pathways involved remain poorly characterized. Here we show that
      <protein>integrin-linked kinase (ILK)</protein>, a <protein>59-kDa serine-threonine protein kinase</protein>
      that interacts principally with <protein>beta(1) integrins</protein>, is highly expressed in
      human mononuclear cells and is activated by exposure of leukocytes to the
      <protein>chemokine monocyte chemoattractant protein-1</protein>. Biochemical inhibitor
      studies show that <protein>chemokine</protein>-triggered activation of <protein>ILK</protein> is downstream of
      <protein>phosphoinositide 3-kinase</protein>. In functional assays under physiologically
      relevant flow conditions, overexpression of wild-type <protein>ILK</protein> in human
      monocytic cells diminishes <protein>beta(1) integrin</protein>/<protein>vascular cell adhesion
      molecule-1</protein>-dependent firm adhesion to human endothelial cells. These data
      implicate <protein>ILK</protein> in the dynamic signaling events involved in the regulation
      of <protein>leukocyte integrin</protein> avidity for endothelial substrates.
</DOC>
<DOC>
<DOC_ID>[38]</DOC_ID>
>38.NF00133088
PMID:11809755
TI  - <protein>Insulin-degrading enzyme</protein> rapidly removes the <protein>beta-amyloid precursor
      protein</protein> intracellular domain (AICD).
AB  - The <protein>intramembranous gamma-secretase</protein> cleavage of the <protein>beta-amyloid precursor
      protein (APP)</protein> is dependent on biologically active <protein>presenilins (PS)</protein>. <protein>Notch</protein>
      also undergoes a similar <protein>PS</protein>-dependent <protein>gamma-secretase</protein>-like cleavage,
      resulting in the liberation of the <protein>Notch</protein> intracellular domain (NICD),
      which is critically required for developmental signal transduction.
      <protein>gamma-Secretase</protein> processing of <protein>APP</protein> results in the production of a similar
      fragment called AICD (<protein>APP</protein> intracellular domain), which may function in
      nuclear signaling as well. AICD, like NICD, is rapidly removed. By using a
      battery of <protein>protease</protein> inhibitors we demonstrate that AICD, in contrast to
      NICD, is degraded by a <protein>cytoplasmic metalloprotease</protein>. In vitro degradation
      of AICD can be reconstituted with cytoplasmic fractions obtained from
      neuronal and non-neuronal cells. Taking into account the inhibition
      profile and the cytoplasmic localization, we identified three candidate
      enzymes (<protein>neurolysin</protein>, <protein>thimet oligopeptidase</protein>, and <protein>insulin-degrading enzyme
      (IDE)</protein>, also known as <protein>insulysin</protein>), which all are involved in the degradation
      of bioactive peptides in the brain. When <protein>insulin</protein>, a well characterized
      substrate of <protein>IDE</protein>, was added to the in vitro degradation assay, removal of
      AICD was efficiently blocked. Moreover, overexpression of <protein>IDE</protein> resulted in
      enhanced degradation of AICD, whereas overexpression of the inactive <protein>IDE</protein>
      E111Q mutant did not affect AICD degradation. Finally, immunodepletion of
      <protein>IDE</protein> significantly reduced the AICD degrading activity. Therefore our data
      demonstrate that <protein>IDE</protein>, which is one of the <protein>proteases</protein> implicated in the
      removal of extracellular Abeta, also removes the cytoplasmic product of
      <protein>gamma-secretase</protein> cleaved <protein>APP</protein>.
</DOC>
<DOC>
<DOC_ID>[39]</DOC_ID>
>39.NF00122477
PMID:12508640
TI  - [Mutation analysis of <protein>KLF6</protein> gene in human nasopharyngeal carcinomas]
AB  - BACKGROUND &amp; OBJECTIVE: Nasopharyngeal carcinoma (NPC) is one of the most
      common cancers in South China and Southeast Asia. The etiological factor
      is believed to be the interaction between genetic susceptibility, EBV
      infection and environmental factors, involved in the multi-step process of
      carcinogenesis and development of NPC. However, the molecular pathology of
      NPC is unclear yet. <protein>Kruppel-like factor 6(KLF6)</protein> is a ubiquitously
      expressed <protein>nuclear transcription factor</protein>, which is deleted and/or mutated
      with high frequency in a subset of prostate cancer. This study was
      designed to investigate <protein>KLF6</protein> mutation in NPC tumors and NPC cell lines.
      METHODS: Genomic DNAs from 19 NPC tumor biospies and 3 NPC cell lines were
      used in mutation detection of <protein>KLF6</protein> coding region and splice sites by
      PCR-sequencing. 100 chromosomes from 50 random healthy individuals were
      used as control. RESULTS: In 3 of 19 NPC tissues, 3 different mutations
      (Glu75Val, Ser136Arg, Arg243 Lys) in <protein>KLF6</protein> gene were found by
      PCR-sequencing. None of the 3 mutations were detected in the 50 random
      healthy individuals. CONCLUSION: <protein>KLF6</protein> gene may be involved in
      carcinogenesis of sporadic NPC.
</DOC>
<DOC>
<DOC_ID>[40]</DOC_ID>
>40.NF00085672
PMID:11700562
TI  - Identification of the <protein>cellular receptor</protein> for <long_form>anthrax <protein>toxin</protein></long_form>.
AB  - The <protein>tripartite toxin</protein> secreted by Bacillus anthracis, the causative agent
      of anthrax, helps the bacterium evade the immune system and can kill the
      host during a systemic infection. Two <protein>components of the toxin</protein>
      enzymatically modify substrates within the cytosol of mammalian cells:
      <protein>oedema factor (OF)</protein> is an <protein>adenylate cyclase</protein> that impairs host defences
      through a variety of mechanisms including inhibiting phagocytosis; <protein>lethal
      factor (LF)</protein> is a <protein>zinc-dependent protease</protein> that cleaves <protein>mitogen-activated
      protein kinase kinase</protein> and causes lysis of macrophages. <protein>Protective antigen
      (PA)</protein>, the third component, binds to a <protein>cellular receptor</protein> and mediates
      delivery of the enzymatic components to the cytosol. Here we describe the
      cloning of the <long_form>human <protein>PA receptor</protein></long_form> using a genetic complementation approach.
      The <protein>receptor</protein>, termed <protein>ATR (anthrax toxin receptor)</protein>, is a <protein>type I membrane
      protein</protein> with an extracellular von Willebrand factor A domain that binds
      directly to <protein>PA</protein>. In addition, a soluble version of this domain can protect
      cells from the action of the <protein>toxin</protein>.
</DOC>
<DOC>
<DOC_ID>[41]</DOC_ID>
>41.NF00098308
PMID:11470784
TI  - An isoform-specific inhibitory domain regulates the <protein>LHX3 LIM homeodomain
      factor holoprotein</protein> and the production of a functional alternate
      translation form.
AB  - The <protein>LHX3 LIM homeodomain transcription factor</protein> is required for pituitary
      development and motor neuron specification. The <protein>Lhx3</protein> gene encodes two
      isoforms, <protein>LHX3a</protein> and <protein>LHX3b</protein>, that differ in their amino-terminal sequences.
      Humans and mice with defective <protein>Lhx3</protein> genes are deficient in gonadotrope,
      lactotrope, somatotrope, and thyrotrope pituitary cells. We show that,
      whereas <protein>Lhx3b</protein> is highly expressed in these <protein>Lhx3</protein>-dependent cell types, high
      levels of <protein>Lhx3a</protein> expression are restricted to <protein>alpha glycoprotein
      subunit</protein>-expressing thyrotropes and gonadotropes. Cross-species comparison
      reveals the <protein>LHX3b</protein>-specific domain is more conserved than the
      <protein>LHX3a</protein>-specific domain. We demonstrate that the <protein>LHX3b</protein>-specific domain is a
      transferable inhibitor that reduces gene activation and DNA binding by
      <protein>homeodomain proteins</protein>. In addition, we identify a novel <protein>LHX3 protein</protein>
      (<protein>M2-LHX3</protein>) and determine that this molecule is generated by an internal
      translation initiation codon. The <protein>LHX3a</protein>- and <protein>LHX3b</protein>-specific coding
      sequences regulate differential usage of this internal start codon.
      Further, we identify the major activation domain of <protein>LHX3</protein> in the carboxyl
      terminus of the molecule. <protein>M2-LHX3</protein> is active because it retains this domain
      and binds DNA better than <protein>LHX3a</protein> or <protein>LHX3b</protein>. Other <protein>LIM homeodomain</protein> genes,
      including <protein>Lhx4</protein>, generate similar truncated proteins. These studies
      describe how transcriptional regulatory genes can generate multiple
      functional proteins.
</DOC>
<DOC>
<DOC_ID>[42]</DOC_ID>
>42.NF00094668
PMID:11701952
TI  - Comparative FISH mapping of <protein>Gab1</protein> and <protein>Gab2</protein> genes in human, mouse and rat.
AB  - <protein>Gab1</protein> and <protein>Gab2</protein> are members of the <protein>Gab</protein> family which act as adapters for
      transmitting various signals in response to stimuli through <protein>cytokine</protein> and
      <protein>growth factor receptors</protein>, and <long_form>T- and <protein>B-cell antigen receptors</protein></long_form>. We
      determined chromosome locations of the two genes in human, mouse and rat
      by fluorescence in situ hybridization. The <protein>Gab1</protein> gene was localized to
      chromosome 4q31.1 in human, 8C3 in mouse and 19q11.1--&gt; q11.2 in rat, and
      the <protein>Gab2</protein> gene was located on chromosome 11q13.4--&gt;q13.5 in human, 7E2 in
      mouse and 1q33.2--&gt;q33.3 in rat. All human, mouse and <long_form>rat <protein>Gab1</protein></long_form> and <protein>Gab2</protein>
      genes were localized to chromosome regions where conserved homology has
      been identified among the three species.
</DOC>
<DOC>
<DOC_ID>[43]</DOC_ID>
>43.NF00926992
PMID:11799131
TI  - Molecular mechanics of <protein>cardiac titin</protein>'s PEVK and N2B spring elements.
AB  - <protein>Titin</protein> is a giant <protein>elastic protein</protein> that is responsible for the majority of
      passive force generated by the myocardium. <protein>Titin</protein>'s force is derived from
      its extensible I-band region, which, in the cardiac isoform, comprises
      three main extensible elements: tandem Ig segments, the PEVK domain, and
      the N2B unique sequence (N2B-Us). Using atomic force microscopy, we
      characterized the single molecule force-extension curves of the PEVK and
      N2B-Us spring elements, which together are responsible for physiological
      levels of passive force in moderately to highly stretched myocardium.
      Stretch-release force-extension curves of both the PEVK domain and N2B-Us
      displayed little hysteresis: the stretch and release data nearly
      overlapped. The force-extension curves closely followed worm-like chain
      behavior. Histograms of persistence length (measure of chain bending
      rigidity) indicated that the single molecule persistence lengths are
      approximately 1.4 and approximately 0.65 nm for the PEVK domain and
      N2B-Us, respectively. Using these mechanical characteristics and those
      determined earlier for the tandem Ig segment (assuming folded Ig domains),
      we modeled the <protein>cardiac titin</protein> extensible region in the sarcomere and
      calculated the extension of the various spring elements and the forces
      generated by <protein>titin</protein>, both as a function of sarcomere length. In the
      physiological sarcomere length range, predicted values and those obtained
      experimentally were indistinguishable.
</DOC>
<DOC>
<DOC_ID>[44]</DOC_ID>
>44.NF00866488
PMID:12359327
TI  - Characterisation and expression analysis of the <protein>WDR9</protein> gene, located in the
      Down critical region-2 of the human chromosome 21.
AB  - We report the isolation and characterisation of the gene <protein>WDR9 (WD Repeat
      9)</protein>, located in the Down Syndrome critical region-2 (DCR-2) from the human
      chromosome 21. This gene spans 125 kb of genomic sequence and is organised
      in 41 exons and 40 introns. The <protein>WDR9</protein> cDNA has a size of 13 kb and encodes
      for a putative protein of 2269 amino acids with a potential location in
      the nucleus. Expression analysis in different human adult tissues and in
      cultured cell lines indicates that the gene has several tissue-specific
      transcripts. The more significant protein signatures in the <protein>WDR9 protein</protein>
      sequence are for WD repeats, bromodomain, <protein>beta-ketoacyl synthases</protein>, and
      <protein>ribonucleoprotein (RNP)</protein>. The <protein>WDR9 protein</protein> has a high similarity with the
      Mus musculus <protein>neuronal differentiation protein (NDRP)</protein> and a region of
      similarity with the region of the <protein>Yotiao protein</protein> that has been proposed to
      bind the <protein>NR1 subunit of the NMDA receptor</protein>. The presence of protein-protein
      interaction domains as such the WD repeats, and the similarity of the <protein>WDR9
      protein</protein> to <protein>regulatory proteins</protein> suggest a potential involvement in some of
      the clinical features associated to the DCR-2.
</DOC>
<DOC>
<DOC_ID>[45]</DOC_ID>
>45.NF00103850
PMID:12029094
TI  - <protein>Metallochaperone Atox1</protein> transfers copper to the NH2-terminal domain of the
      <protein>Wilson's disease protein</protein> and regulates its catalytic activity.
AB  - Copper is essential for the growth and development of mammalian cells. The
      key role in the intracellular distribution of copper belongs to the
      recently discovered family of <protein>metallochaperones</protein> and to <protein>copper-transporting
      P-type ATPases</protein>. The mutations in the <protein>ATPase ATP7B</protein>, the <protein>Wilson's disease
      protein (WNDP)</protein>, lead to intracellular accumulation of copper and severe
      hepatic and neurological abnormalities. Several of these mutations were
      shown to disrupt the protein-protein interactions between <protein>WNDP</protein> and the
      <protein>metallochaperone Atox1</protein>, suggesting that these interactions are important
      for normal copper homeostasis. To understand the functional consequences
      of the <protein>Atox1</protein>-<protein>WNDP</protein> interaction at the molecular level, we produced
      recombinant <protein>Atox1</protein> and characterized its effects on <protein>WNDP</protein>. We demonstrate
      that <protein>Atox1</protein> transfers copper to the purified amino-terminal domain of <protein>WNDP</protein>
      (N-<protein>WNDP</protein>) in a dose-dependent and saturable manner. A maximum of six copper
      atoms can be transferred to N-<protein>WNDP</protein> by the <protein>chaperone</protein>. Furthermore, the
      incubation of copper <protein>Atox1</protein> with the full-length <protein>WNDP</protein> leads to the
      stimulation of the <protein>WNDP</protein> catalytic activity, providing strong evidence for
      the direct effect of <protein>Atox1</protein> on the function of this <protein>transporter</protein>. Our data
      also suggest that <protein>Atox1</protein> can regulate the copper occupancy of <protein>WNDP</protein>. The
      incubation with apo-<protein>Atox1</protein> results in the removal of copper from the
      metalated N-<protein>WNDP</protein> and apparent down-regulation of <protein>WNDP</protein> activity.
      Interestingly, at least one copper atom remains tightly bound to N-<protein>WNDP</protein>
      even in the presence of excess apo-<protein>Atox1</protein>. We suggest that this incomplete
      reversibility reflects the functional non-equivalency of the metal-binding
      sites in <protein>WNDP</protein> and speculate about the intracellular consequences of the
      reversible <protein>Atox1</protein>-mediated copper transfer.
</DOC>
<DOC>
<DOC_ID>[46]</DOC_ID>
>46.NF00116407
PMID:11816009
TI  - Development of a rapid and sensitive high-performance liquid
      chromatographic method to determine <protein>CYP2D6</protein> phenotype in human liver
      microsomes.
AB  - Dextromethorphan is a probe substrate to determine <protein>CYP2D6</protein> phenotype. The
      conversion of dextromethorphan to dextrorphan by <protein>CYP2D6</protein> accounts for
      approximately 60% of total metabolism. Most analytical methods utilize
      complicated labor- and time-intensive sample processing methods with
      several liquid-liquid extraction (LLE) steps. Our goal was to develop a
      non-LLE based rapid and sensitive HPLC method, to measure dextromethorphan
      metabolism in human liver microsomes. A solid-phase filtration based
      reverse-phase HPLC method with fluorescence detection was developed and
      validated. Human liver (n = 6) microsomal incubations were carried out
      with dextromethorphan, under optimum conditions. The analytes were
      separated by one-step centrifugal filtration with Nanosep separation
      units. The filtrate was injected ( 50 microL) into a Waters Alliance 2690
      HPLC system. Metabolic incubations were also conducted to determine levels
      using LLE for comparisons. The Nanosep separation step reduced the
      extraction time from 3h to 40 min. The limit of quantitation was 23.8 nM
      (9.7 ng/mL), recovery was approximately 98%, the mean precision values
      were &lt;10% RSD for the controls (80, 320 and 640 nM) and mean percentage
      error was &lt;5%. Michaelis-Menten parameters were determined to distinguish
      <protein>CYP2D6</protein> phenotypes. A rapid and sensitive HPLC method is reported, which
      may be suitable for automation and allows phenotyping of human liver
      microsomes.
</DOC>
<DOC>
<DOC_ID>[47]</DOC_ID>
>47.NF00125317
PMID:12359228
TI  - Identification of a novel <long_form>human <protein>nicotinamide mononucleotide
      adenylyltransferase</protein></long_form>.
AB  - The enzyme <protein>nicotinamide mononucleotide adenylyltransferase</protein> is an
      ubiquitous enzyme catalyzing an essential step in NAD (NADP) biosynthetic
      pathway. In human cells, the <protein>nuclear enzyme</protein>, which we will now call
      <protein>NMNAT-1</protein>, has been the only known enzyme of this type for over 10 years.
      Here we describe the cloning and expression of a human cDNA encoding a
      novel <protein>34.4kDa protein</protein>, that shares significant homology with the <protein>31.9kDa
      NMNAT-1</protein>. We propose to call this enzyme <protein>NMNAT-2</protein>. Purified recombinant
      <protein>NMNAT-2</protein> is endowed with <protein>NMN and nicotinic acid mononucleotide
      adenylyltransferase</protein> activities, but differs from <protein>NMNAT-1</protein> with regard to
      chromosomal and cellular localization, tissue-specificity of expression,
      and molecular properties, supporting the idea that the two enzymes might
      play distinct physiological roles in NAD homeostasis.
</DOC>
<DOC>
<DOC_ID>[48]</DOC_ID>
>48.NF00131475
PMID:12584323
TI  - <protein>Furin</protein> processing and proteolytic activation of Semliki Forest virus.
AB  - The alphavirus Semliki Forest virus (SFV) infects cells via a
      low-pH-dependent membrane fusion reaction mediated by the <protein>E1 envelope
      protein</protein>. Fusion is regulated by the interaction of E1 with the
      <protein>receptor-binding protein E2</protein>. E2 is synthesized as a precursor termed
      &quot;<protein>p62</protein>,&quot; which forms a stable heterodimer with E1 and is processed late in
      the secretory pathway by a <protein>cellular furin-like protease</protein>. Once processing
      to E2 occurs, the E1/E2 heterodimer is destabilized so that it is more
      readily dissociated by exposure to low pH, allowing fusion and infection.
      We have used FD11 cells, a <protein>furin</protein>-deficient CHO cell line, to characterize
      the processing of <protein>p62</protein> and its role in the control of virus fusion and
      infection. <protein>p62</protein> was not cleaved in FD11 cells and cleavage was restored in
      FD11 cell transfectants expressing <long_form>human <protein>furin</protein></long_form>. Studies of unprocessed
      virus produced in FD11 cells (wt/<protein>p62</protein>) demonstrated that the <protein>p62 protein</protein>
      was efficiently cleaved by purified <protein>furin</protein> in vitro, without requiring
      prior exposure to low pH. wt/<protein>p62</protein> virus particles were also processed
      during their endocytic uptake in <protein>furin</protein>-containing cells, resulting in more
      efficient virus infection. wt/<protein>p62</protein> virus was compared with mutant L, in
      which <protein>p62</protein> cleavage was blocked by mutation of the <protein>furin</protein>-recognition motif.
      wt/<protein>p62</protein> and mutant L had similar fusion properties, requiring a much lower
      pH than control virus to trigger fusion and fusogenic E1 conformational
      changes. However, the in vivo infectivity of mutant L was more strongly
      inhibited than that of wt/<protein>p62</protein>, due to additional effects of the mutation
      on virus-cell binding.
</DOC>
<DOC>
<DOC_ID>[49]</DOC_ID>
>49.NF00105475
PMID:12359356
TI  - <protein>Microsomal epoxide hydrolase</protein> and <protein>glutathione S-transferase</protein> polymorphisms
      in relation to laryngeal carcinoma risk.
AB  - Two polymorphic sites of the <protein>microsomal epoxide hydrolase</protein> gene (<protein>EPHX1</protein>,
      113Tyr--&gt;113His, 139His--&gt;139Arg) and four <protein>glutathione S-transferase</protein> genes
      (<protein>GSTM1</protein>, <protein>GSTM3</protein>, <protein>GSTP1</protein>, <protein>GSTT1</protein>) were genotyped in a group of patients with
      larynx cancer (N=204) and in a group of healthy controls (N=203), all
      Spanish caucasians. After adjusting for gender, age, and tobacco smoking,
      none of the polymorphisms alone were found to be associated with larynx
      cancer risk. The analysis of <protein>EPHX1</protein>/<protein>GST</protein> combinations, however, showed a
      significant over-representation of patients with a combination of
      113Tyr/113Tyr <protein>EPHX1</protein> and 105Ile/105Ile <protein>GSTP1</protein> (adjusted odds ratio (OR):
      1.95; 95% confidence interval (CI): 1.02-3.78). The calculation of the
      predicted <protein>epoxide hydrolase (EH)</protein> activity also showed an increased risk
      for the individuals with both predicted high activity <protein>EH</protein> and 105Ile/105Ile
      <protein>GSTP1</protein> (OR: 2.90; 95% CI: 1.10-7.67). These results on larynx cancer tend
      to confirm a former study on lung cancer (Cancer Lett. 173 (2001) 155)
      suggesting the existence of an interaction between variants of <protein>EH</protein> and
      <protein>GSTpi</protein>, both enzymes being involved in the metabolism of aromatic
      hydrocarbons, that may increase susceptibility to tobacco-related cancers.
</DOC>
<DOC>
<DOC_ID>[50]</DOC_ID>
>50.NF00106528
PMID:11778160
TI  - A 117-kb microdeletion removing <long_form><protein>HOXD9</protein>-<protein>HOXD13</protein></long_form> and <protein>EVX2</protein> causes
      synpolydactyly.
AB  - Studies in mouse and chick have shown that the 5' <protein>HoxD</protein> genes play major
      roles in the development of the limbs and genitalia. In humans, mutations
      in <protein>HOXD13</protein> cause the dominantly inherited limb malformation synpolydactyly
      (SPD). Haploinsufficiency for the 5' <protein>HOXD</protein> genes has recently been proposed
      to underlie the monodactyly and penoscrotal hypoplasia in two children
      with chromosomal deletions encompassing the entire <protein>HOXD</protein> cluster. Similar
      deletions, however, have previously been associated with split-hand/foot
      malformation (SHFM), including monodactyly. Here we report a father and
      daughter with SPD who carry a 117-kb microdeletion at the 5' end of the
      <protein>HOXD</protein> cluster. By sequencing directly across the deletion breakpoint, we
      show that this microdeletion removes only <long_form><protein>HOXD9</protein>-<protein>HOXD13</protein></long_form> and <protein>EVX2</protein>. We also
      report a girl with bilateral split foot and a chromosomal deletion that
      includes the entire <protein>HOXD</protein> cluster and extends approximately 5 Mb
      centromeric to it. Our findings indicate that haploinsufficiency for the
      5' <protein>HOXD</protein> genes causes not SHFM but SPD and point to the presence of a novel
      locus for SHFM in the interval between <protein>EVX2</protein> and <protein>D2S294</protein>. They also suggest
      that there is a regulatory region, upstream of the <protein>HOXD</protein> cluster, that is
      responsible for activating the cluster as a whole.
</DOC>
<DOC>
<DOC_ID>[51]</DOC_ID>
>51.NF00131477
PMID:12050117
TI  - <protein>Mastermind</protein> mediates chromatin-specific transcription and turnover of the
      <protein>Notch enhancer complex</protein>.
AB  - Signaling through the <protein>Notch</protein> pathway activates the proteolytic release of
      the <protein>Notch</protein> intracellular domain (ICD), a dedicated <protein>transcriptional
      coactivator of CSL enhancer-binding proteins</protein>. Here we show that
      chromatin-dependent transactivation by the recombinant <long_form><protein>Notch</protein> ICD-<protein>CBF1
      enhancer complex</protein></long_form> in vitro requires an additional coactivator, <protein>Mastermind
      (MAM)</protein>. <protein>MAM</protein> provides two activation domains necessary for <protein>Notch</protein> signaling
      in mammalian cells and in Xenopus embryos. We show that the central <protein>MAM</protein>
      activation domain (TAD1) recruits <protein>CBP</protein>/<protein>p300</protein> to promote nucleosome
      acetylation at <protein>Notch enhancers</protein> and activate transcription in vitro. We
      also find that <protein>MAM</protein> expression induces phosphorylation and relocalization
      of endogenous <protein>CBP</protein>/<protein>p300 proteins</protein> to nuclear foci in vivo. Moreover, we show
      that coexpression with <protein>MAM</protein> and <protein>CBF1</protein> strongly enhances phosphorylation and
      proteolytic turnover of the <protein>Notch</protein> ICD in vivo. Enhanced phosphorylation of
      the ICD and <protein>p300</protein> requires a glutamine-rich region of <protein>MAM</protein> (TAD2) that is
      essential for <protein>Notch</protein> transcription in vivo. Thus <protein>MAM</protein> may function as a
      timer to couple transcription activation with disassembly of the <protein>Notch
      enhancer complex</protein> on chromatin.
</DOC>
<DOC>
<DOC_ID>[52]</DOC_ID>
>52.NF00111959
PMID:12209014
TI  - Dual localization of <long_form>human <protein>DNA topoisomerase IIIalpha</protein></long_form> to mitochondria and
      nucleus.
AB  - The <long_form>human <protein>TOP3alpha</protein></long_form> gene encoding <protein>DNA topoisomerase IIIalpha (hTop3alpha)</protein>
      has two potential start codons for the synthesis of proteins 1,001 and 976
      aa residues in length. The sequence of the N-terminal region of the
      1,001-residue form resembles signal peptide sequences for mitochondrial
      import, and fluorescence microscopy shows that the addition of as few as
      the first 34 aa of the <protein>1,001-residue form of hTop3alpha</protein> to a green
      fluorescent protein can direct the chimeric protein to mitochondria.
      Biochemical analyses of subcellular fractions of HeLa cells further
      demonstrate that a distinctive fraction of <protein>hTop3alpha</protein> is present inside
      mitochondria, as evidenced by its resistance to <protein>proteinase K</protein>. This
      fraction constitutes several percent of the enzyme in the nuclear
      fraction, suggesting that the distribution of the <long_form>mitochondrial and
      <protein>nuclear forms of hTop3alpha</protein></long_form> is roughly in proportion to the DNA contents
      of these cellular compartments. The presence of a <protein>type IA DNA
      topoisomerase</protein> in the mitochondria of other eukaryotes is supported by an
      examination of the amino acid sequences of mouse and <long_form>Drosophila <protein>DNA
      topoisomerase IIIalpha</protein></long_form> and <long_form>Schizosaccharomyces pombe <protein>DNA topoisomerase</protein>
      <protein>III</protein></long_form>. Given the presence of at least one <protein>type IA DNA topoisomerase</protein> in all
      forms of life examined to date, the finding of a type IA enzyme in
      mitochondria further supports the notion of a key role of such enzymes in
      DNA transactions.
</DOC>
<DOC>
<DOC_ID>[53]</DOC_ID>
>53.NF00095807
PMID:12140183
TI  - <protein>Spectrin</protein>-like repeats from <protein>dystrophin</protein> and <protein>alpha-actinin-2</protein> are not
      functionally interchangeable.
AB  - Mutations in the <protein>dystrophin</protein> gene result in Duchenne muscular dystrophy
      (DMD). <protein>Dystrophin</protein> is a multidomain protein that functions to stabilize the
      sarcolemmal membrane during muscle contraction. The central rod domain has
      been proposed to act as a shock absorber, as a force transducer or as a
      spacer separating important N- and C-terminal domains that interact with
      <protein>actin</protein> and the <long_form><protein>dystrophin</protein>-<protein>glycoprotein</protein> complex (DGC)</long_form>. Structure/function
      studies demonstrated that deletion of large portions of the rod domain can
      result in the production of smaller, yet highly functional, <protein>dystrophin</protein>
      <protein>proteins</protein>. In a dramatic example, a 'micro-<protein>dystrophin</protein>' transgene containing
      only four <protein>dystrophin</protein> <protein>spectrin</protein>-like repeats resulted in complete correction
      of most of the symptoms associated with dystrophy in the mdx mouse model
      for DMD. <protein>Dystrophin</protein> shares considerable homology with the multidomain,
      <protein>actin-crosslinking protein alpha-actinin</protein>. To explore the hypothesis that
      the <protein>dystrophin</protein> rod domain acts as a spacer region, a chimeric
      micro-<protein>dystrophin</protein> transgene containing the four-repeat rod domain of
      <protein>alpha-actinin-2</protein> was expressed in mdx mice. This chimeric transgene was
      incapable of correcting the morphological pathology of the mdx mouse, but
      still functioned to assemble the <protein>DGC</protein> at the membrane and provided some
      protection from contraction-induced injury. These data demonstrated that
      different <protein>spectrin</protein>-like repeats are not equivalent, and reinforced the
      suggestion that the <protein>dystrophin</protein> rod domain is not merely a spacer but
      likely contributes an important mechanical role to overall <protein>dystrophin</protein>
      function.
</DOC>
<DOC>
<DOC_ID>[54]</DOC_ID>
>54.NF00087464
PMID:12062429
TI  - The <protein>dystrophin</protein> gene is alternatively spliced throughout its coding
      sequence.
AB  - We have analysed splicing patterns in the <long_form>human <protein>dystrophin</protein></long_form> gene region
      encoding the rod and cysteine-rich domains in normal skeletal muscle,
      brain and heart tissues. Sixteen novel alternative transcripts were
      identified, the majority of them being present in all three tissues.
      Tissue-specific variants were also identified, suggesting a functional
      role of transcriptional diversity. Transcript analysis in
      dystrophinopathic autoptic and bioptic specimens revealed that pre-mRNAs
      secondary structure formation and relative strength of exon/exon
      association play little or no role in directing alternative splicing
      events. This analysis also showed that independent deletion events leading
      to the loss of the same exons may be associated with transcriptional
      variability.
</DOC>
<DOC>
<DOC_ID>[55]</DOC_ID>
>55.NF00095564
PMID:12065429
TI  - <protein>Drf1</protein>, a novel <protein>regulatory subunit for human Cdc7 kinase</protein>.
AB  - Studies in model organisms have contributed to elucidate multiple levels
      at which regulation of eukaryotic DNA replication occurs. <protein>Cdc7</protein>, an
      evolutionarily conserved <protein>serine-threonine kinase</protein>, plays a pivotal role in
      linking cell cycle regulation to genome duplication, being essential for
      the firing of DNA replication origins. Binding of the <protein>cell cycle-regulated
      subunit Dbf4</protein> to <protein>Cdc7</protein> is necessary for in vitro <protein>kinase</protein> activity. This
      binding is also thought to be the key regulatory event that controls <protein>Cdc7</protein>
      activity in cells. Here, we describe a novel human protein, <protein>Drf1</protein>, related
      to both human and <long_form>yeast <protein>Dbf4</protein></long_form>. <protein>Drf1</protein> is a <protein>nuclear cell cycle-regulated
      protein</protein>, it binds to <protein>Cdc7</protein> and activates the <protein>kinase</protein>. Therefore, <long_form>human <protein>Cdc7</protein></long_form>,
      like <protein>cyclin-dependent kinases</protein>, can be activated by alternative <protein>regulatory
      subunits</protein>. Since the <protein>Drf1</protein> gene is either absent or not yet identified in
      the genome of model organisms such as yeast and Drosophila, these findings
      introduce a new level of complexity in the regulation of DNA replication
      of the human genome.
</DOC>
<DOC>
<DOC_ID>[56]</DOC_ID>
>56.NF01154885
PMID:12075506
TI  - Mandibuloacral dysplasia is caused by a mutation in <protein>LMNA</protein>-encoding <protein>lamin
      A/C</protein>.
AB  - Mandibuloacral dysplasia (MAD) is a rare autosomal recessive disorder,
      characterized by postnatal growth retardation, craniofacial anomalies,
      skeletal malformations, and mottled cutaneous pigmentation. The <protein>LMNA</protein> gene
      encoding two <protein>nuclear envelope proteins</protein> (<protein>lamins A and C [lamin A/C]</protein>) maps
      to chromosome 1q21 and has been associated with five distinct pathologies,
      including Dunnigan-type familial partial lipodystrophy, a condition that
      is characterized by subcutaneous fat loss and is invariably associated
      with <protein>insulin</protein> resistance and diabetes. Since patients with MAD frequently
      have partial lipodystrophy and <protein>insulin</protein> resistance, we hypothesized that
      the disease may be caused by mutations in the <protein>LMNA</protein> gene. We analyzed five
      consanguineous Italian families and demonstrated linkage of MAD to
      chromosome 1q21, by use of homozygosity mapping. We then sequenced the
      <protein>LMNA</protein> gene and identified a homozygous missense mutation (R527H) that was
      shared by all affected patients. Patient skin fibroblasts showed nuclei
      that presented abnormal <protein>lamin A/C</protein> distribution and a dysmorphic envelope,
      thus demonstrating the pathogenic effect of the R527H <protein>LMNA</protein> mutation.
</DOC>
<DOC>
<DOC_ID>[57]</DOC_ID>
>57.NF00866570
PMID:11938494
TI  - The <protein>TRIM37</protein> gene encodes a <protein>peroxisomal RING-B-box-coiled-coil protein</protein>:
      classification of mulibrey nanism as a new peroxisomal disorder.
AB  - Mulibrey nanism is a rare growth disorder of prenatal onset caused by
      mutations in the <protein>TRIM37</protein> gene, which encodes a <protein>RING-B-box-coiled-coil
      protein</protein>. The pathogenetic mechanisms of mulibrey nanism are unknown. We
      have used transiently transfected cells and antibodies raised against the
      predicted <protein>TRIM37 protein</protein> to characterize the <protein>TRIM37</protein> gene product and to
      determine its intracellular localization. We show that the <long_form>human <protein>TRIM37</protein></long_form>
      cDNA encodes a <protein>peroxisomal protein</protein> with an apparent molecular weight of
      130 kD. Peroxisomal localization is compromised in mutant protein
      representing the major Finnish <protein>TRIM37</protein> mutation but is retained in the
      protein representing the minor Finnish mutation. Colocalization of
      endogenous <protein>TRIM37</protein> with peroxisomal markers was observed by double
      immunofluorescence staining in HepG2 and human intestinal smooth muscle
      cell lines. In human tissue sections, <protein>TRIM37</protein> shows a granular cytoplasmic
      pattern. Endogenous <protein>TRIM37</protein> is not imported into peroxisomes in <protein>peroxin 1</protein>
      (<protein>PEX1</protein>(-/-)) and <protein>peroxin 5</protein> (<protein>PEX5</protein>(-/-)) mutant fibroblasts but is imported
      normally in <protein>peroxin 7</protein> (<protein>PEX7</protein>(-/-)) deficient fibroblasts, giving further
      evidence for a peroxisomal localization of <protein>TRIM37</protein>. Fibroblasts derived
      from patients with mulibrey nanism lack C-terminal <protein>TRIM37</protein> immunoreactivity
      but stain normally for both peroxisomal matrix and membrane markers,
      suggesting apparently normal peroxisome biogenesis in patient fibroblasts.
      Taken together, this molecular evidence unequivocally indicates that
      <protein>TRIM37</protein> is located in the peroxisomes, and Mulibrey nanism thus can be
      classified as a new peroxisomal disorder.
</DOC>
<DOC>
<DOC_ID>[58]</DOC_ID>
>58.NF01119975
PMID:12210501
TI  - Blocking the <protein>translation elongation factor-1 delta</protein> with its antisense mRNA
      results in a significant reversal of its oncogenic potential.
AB  - In spite of the strong evidence for the carcinogenic activity of cadmium
      and its related compounds, the underlying molecular mechanisms that lead
      to malignant transformation in cells exposed to cadmium remain unknown.
      Recently, Joseph et al. [J. Biol. Chem. 227:6131-6136, 2002] have
      identified, cloned, and characterized the <long_form>mouse <protein>Translation Elongation
      Factor-1 delta sub-unit</protein></long_form> (<protein>TEF-1 delta</protein>, GenBank Accession Number AF304351)
      as a novel cadmium-responsive proto-oncogene. Presently, additional
      studies regarding the oncogenic potential of <protein>TEF-1 delta</protein> have been carried
      out. Transfection of NIH3T3 cells with the pcDNA3.1 expression vector
      containing the <protein>TEF-1 delta</protein> cDNA in the sense (5'--&gt;3') orientation
      resulted in overexpression of the encoded 31 kDa protein.
      Transfection-mediated overexpression of <protein>TEF-1 delta protein</protein> resulted in
      transformation of the cells as evidenced from the appearance of
      transformed foci. Cotransfection of the cells with a mixture of plasmid
      DNA consisting of <protein>TEF-1 delta</protein> cDNA in the sense (5'--&gt;3') and in the
      antisense (3'--&gt;5') orientation resulted in significant inhibition of
      translation of the <protein>TEF-1 delta protein</protein>. Antisense <protein>TEF-1 delta</protein>
      mRNA-mediated inhibition of translation of <protein>TEF-1 delta protein</protein>,
      furthermore, resulted in inhibition of <protein>TEF-1 delta</protein>-mediated transformation
      of NIH3T3 cells as evidenced from the decrease in the number of
      transformed foci. These results further confirm that overexpression of
      <protein>TEF-1 delta</protein> is oncogenic and the antisense <protein>TEF-1 delta</protein> mRNA expression
      reverses its oncogenic potential.
</DOC>
<DOC>
<DOC_ID>[59]</DOC_ID>
>59.NF01235968
PMID:11894099
TI  - An <protein>amino-acid taste receptor</protein>.
AB  - The sense of taste provides animals with valuable information about the
      nature and quality of food. Mammals can recognize and respond to a diverse
      repertoire of chemical entities, including sugars, salts, acids and a wide
      range of toxic substances. Several amino acids taste sweet or delicious
      (umami) to humans, and are attractive to rodents and other animals. This
      is noteworthy because L-amino acids function as the building blocks of
      proteins, as biosynthetic precursors of many biologically relevant small
      molecules, and as metabolic fuel. Thus, having a taste pathway dedicated
      to their detection probably had significant evolutionary implications.
      Here we identify and characterize a <long_form>mammalian <protein>amino-acid taste receptor</protein></long_form>.
      This <protein>receptor</protein>, <protein>T1R1+3</protein>, is a <long_form>heteromer of the taste-specific <protein>T1R1</protein> and <protein>T1R3
      G-protein-coupled receptors</protein></long_form>. We demonstrate that <protein>T1R1</protein> and <protein>T1R3</protein> combine to
      function as a broadly tuned <protein>L-amino-acid sensor</protein> responding to most of the
      20 standard amino acids, but not to their D-enantiomers or other
      compounds. We also show that sequence differences in <protein>T1R receptors</protein> within
      and between species (human and mouse) can significantly influence the
      selectivity and specificity of taste responses.
</DOC>
<DOC>
<DOC_ID>[60]</DOC_ID>
>60.NF00866578
PMID:12081504
TI  - Activation mechanism of <protein>CDK2</protein>: role of <protein>cyclin</protein> binding versus
      phosphorylation.
AB  - Activation of the <protein>cyclin-dependent kinases</protein> is a two-step process involving
      <protein>cyclin</protein> binding followed by phosphorylation at a conserved threonine
      residue within the <protein>kinase</protein> activation loop. In this study, we describe the
      separate roles of <protein>cyclin A</protein> binding versus phosphorylation in the overall
      activation mechanism of <protein>CDK2</protein>. Interaction of <protein>CDK2</protein> with <protein>cyclin A</protein> results in
      a partially active complex that is moderately defective in the binding of
      the protein substrate, but not ATP, and severely defective in both
      phosphoryl group transfer and turnover. Alternatively, phosphorylation of
      the <protein>CDK2 monomer</protein> also results in a partially activated species, but one
      that is severely (&gt; or = 480-fold) defective in substrate binding
      exclusively. Catalytic turnover in the phosphorylated <protein>CDK2 monomer</protein> is
      largely unimpaired (approximately 8-fold lower). Our data support a model
      for the activation of <protein>CDK2</protein> in vivo, in which interaction of
      unphosphorylated <protein>CDK2</protein> with <protein>cyclin A</protein> serves to configure the active site
      for ground-state binding of both ATP and the protein substrate, and
      further aligns ATP in the transition state for phosphoryl transfer.
      Optimizing the alignment of protein substrates in the phosphoryl transfer
      reaction is the principal role of phosphorylation at Thr(160).
</DOC>
<DOC>
<DOC_ID>[61]</DOC_ID>
>61.NF00131800
PMID:11840488
TI  - Association analysis of polymorphisms at the <protein>interleukin-1</protein> locus in
      essential hypertension.
AB  - Infection with microorganisms such as Helicobacter pylori and Chlamydia
      pneumoniae has been associated with coronary heart disease (CAD) and
      hypertension (HT). Infection increases the release of <protein>pro-inflammatory
      cytokines</protein>, thus facilitating interactions that lead to vascular damage and
      other effects. We hypothesized that genetically determined differences in
      activity or responsiveness of <protein>cytokine</protein>(s) might contribute to HT. The
      <protein>interleukin-1</protein> gene (<protein>IL1</protein>) cluster on chromosome 2q14 contains three related
      genes (<protein>IL1A</protein>, <protein>IL1B</protein>, and <protein>IL1RN</protein>) located within a 430-kb region. These encode
      <protein>IL-1alpha</protein> and <protein>IL-1beta</protein>, as well as their endogenous <protein>receptor</protein> antagonist,
      <protein>IL-1ra</protein>. The <protein>IL1RN</protein> gene has a penta-allelic 86-bp tandem repeat in intron
      2. Allele <protein>IL1RN</protein>* 2 is associated with a wide range of chronic inflammatory
      and autoimmune conditions, and its combination with the -31T variant of an
      <protein>IL1B</protein> C(-31)T polymorphism constitutes a pro-inflammatory haplotype that
      leads to vigorous <protein>IL-1beta</protein> production. We therefore tested each of these
      polymorphisms for association with HT. Subjects were white Anglo-Celtic
      residents of Sydney, Australia. Frequencies of <protein>IL1B</protein> C(-31)T genotypes CC,
      CT, and TT were 0.50, 0.40, and 0.10 in normotensive (NT) and 0.46, 0.46,
      and 0.08 in HT, respectively (chi(2) = 1.2, P = 0.55). T allele frequency
      in NT (0.30) was similar to that in HT (0.31). For the <protein>IL1RN</protein> variant,
      frequencies of alleles <protein>IL1RN</protein>* 1 and * 2 and combined minor alleles * 3, *
      4, and * 5 were 0.61, 0.36, and 0.03 in NT and 0.54, 0.36, and 0.10 in HT,
      respectively (chi(2) = 11, P = 0.004). In conclusion, no association of
      the <protein>IL1B</protein> C(- 31)T with HT was found, whereas combined frequency of the
      minor alleles of the <protein>IL1RN</protein> polymorphism was increased in the HT cohort
      studied.
</DOC>
<DOC>
<DOC_ID>[62]</DOC_ID>
>62.NF00989995
PMID:12084581
TI  - Cloning and identification of a new member of <protein>water channel</protein> (<protein>AQP10</protein>) as an
      <protein>aquaglyceroporin</protein>.
AB  - Recently, a new member of <protein>aquaporins</protein> was reported as <protein>AQP10</protein> [Biochem.
      Biophys. Res. Commun. 287 (2001) 814], which is incompletely spliced to
      lose the sixth transmembrane domain and has poor water and no
      glycerol/urea permeabilities. Independently, we identified a similar clone
      in human. Our <protein>AQP10</protein> consists of 301 amino acids with a highly conserved
      sixth transmembrane domain. <protein>AQP10</protein> has higher identity with
      <protein>aquaglyceroporins</protein> (50% with <protein>AQP9</protein>, 48% with <protein>AQP3</protein>, 42% with <protein>AQP7</protein>) and lower
      identity with other <protein>aquaporins</protein> (32% with <protein>AQP1</protein> and <protein>AQP8</protein>). <protein>AQP10</protein> is
      expressed only in the small intestine with (approximately 2 kb). RNase
      protection assay revealed the absence of the unspliced form, supporting
      the authenticity of our clone. When expressed in Xenopus oocytes, <protein>AQP10</protein>
      stimulated osmotic water permeability sixfold in a mercury-sensitive
      manner. Glycerol and urea uptakes were also stimulated, while adenine
      uptake was not. The genome structure of <protein>AQP10</protein> is similar to those of other
      <protein>aquaglyceroporins</protein> (<protein>AQP3</protein>, <protein>AQP7</protein>, <protein>AQP9</protein>) with six exons. We conclude that
      <protein>AQP10</protein> represents a new member of <protein>aquaglyceroporins</protein> functionally as well as
      structurally.
</DOC>
<DOC>
<DOC_ID>[63]</DOC_ID>
>63.NF00124514
PMID:12461076
TI  - A signal peptide derived from <protein>hsp60</protein> binds <protein>HLA-E</protein> and interferes with
      <protein>CD94</protein>/<protein>NKG2A</protein> recognition.
AB  - <protein>Human histocompatibility leukocyte antigen (HLA)-E</protein> is a nonclassical <protein>major
      histocompatibility complex (MHC) class I molecule</protein> which presents a
      restricted set of nonameric peptides, derived mainly from the signal
      sequence of other <protein>MHC class I molecules</protein>. It interacts with <protein>CD94/NKG2
      receptors</protein> expressed on the surface of natural killer (NK) cells and T cell
      subsets. Here we demonstrate that <protein>HLA-E</protein> also presents a peptide derived
      from the leader sequence of <protein>human heat shock protein 60 (hsp60)</protein>. This
      peptide gains access to <protein>HLA-E</protein> intracellularly, resulting in up-regulated
      <protein>HLA-E</protein>/<protein>hsp60</protein> signal peptide cell-surface levels on stressed cells. Notably,
      <protein>HLA-E</protein> molecules in complex with the <protein>hsp60</protein> signal peptide are no longer
      recognized by <protein>CD94/NKG2A inhibitory receptors</protein>. Thus, during cellular
      stress an increased proportion of <protein>HLA-E</protein> molecules may bind the
      nonprotective <protein>hsp60</protein> signal peptide, leading to a reduced capacity to
      inhibit a major NK cell population. Such stress induced peptide
      interference would gradually uncouple <protein>CD94</protein>/<protein>NKG2A</protein> inhibitory recognition
      and provide a mechanism for NK cells to detect stressed cells in a
      peptide-dependent manner.
</DOC>
<DOC>
<DOC_ID>[64]</DOC_ID>
>64.NF00116173
PMID:11741979
TI  - Interaction of the C-terminal domain of <protein>p43</protein> and the <protein>alpha subunit of ATP
      synthase</protein>. Its functional implication in endothelial cell proliferation.
AB  - <long_form>Human <protein>p43</protein></long_form> is associated with <protein>macromolecular tRNA synthase complex</protein> and
      known as a <protein>precursor of endothelial monocyte-activating polypeptide II
      (EMAP II)</protein>. Interestingly, <protein>p43</protein> is also secreted to induce proinflammatory
      genes. Although <protein>p43</protein> itself seems to be a <protein>cytokine</protein> working at physiological
      conditions, most of the functional studies have been obtained with its
      C-terminal equivalent, <protein>EMAP II</protein>. To gain an insight into the working
      mechanism of <protein>p43</protein>/<protein>EMAP II</protein>, we used <protein>EMAP II</protein> and searched for an interacting
      cell surface molecule. The level of <protein>EMAP II-binding molecule(s)</protein> was
      significantly increased in serum-starved tumor cells. Thus, the <protein>EMAP
      II-binding molecule</protein> was isolated from the membrane of the serum-starved
      CEM cell. The isolated protein was determined to be the <protein>alpha subunit of
      ATP synthase</protein>. The interaction of <protein>EMAP II</protein> and <protein>alpha-ATP synthase</protein> was
      confirmed by enzyme-linked immunosorbent assay and in vitro pull down
      assays and blocked with the antibodies raised against <protein>EMAP II</protein> and
      <protein>alpha-ATP synthase</protein>. The binding of <protein>EMAP II</protein> to the surface of serum-starved
      cells was inhibited in the presence of <protein>soluble alpha-ATP synthase</protein>. <protein>EMAP II</protein>
      inhibited the growth of endothelial cells, and this effect was relieved by
      <protein>soluble alpha-ATP synthase</protein>. <protein>Anti-alpha-ATP synthase antibody</protein> also showed
      an inhibitory effect on the proliferation of endothelial cells mimicking
      the activity of <protein>EMAP II</protein>. These results suggest the potential interaction
      of <protein>p43</protein>/<protein>EMAP II</protein> with <protein>alpha-ATP synthase</protein> and its role in the proliferation
      of endothelial cells.
</DOC>
<DOC>
<DOC_ID>[65]</DOC_ID>
>65.NF00131727
PMID:11823532
TI  - Biological activities of <protein>ecalectin</protein>: a novel <protein>eosinophil-activating factor</protein>.
AB  - <protein>Ecalectin</protein>, produced by Ag-stimulated T lymphocytes, is a potent
      <protein>eosinophil-specific chemoattractant</protein> in vitro as well as in vivo and thus
      is implicated in allergic responses. <protein>Ecalectin</protein> differs structurally from
      other known <protein>eosinophil chemoattractants (ECAs)</protein>; <protein>ecalectin</protein> belongs to the
      <protein>galectin</protein> family defined by their affinity for beta-galactosides and by
      their conserved carbohydrate recognition domains. These characteristic
      features suggest that <protein>ecalectin</protein> has unique activities associated with
      allergic inflammation besides <protein>ECA</protein> activity. Conversely, <protein>ecalectin</protein> may
      mediate <protein>ECA</protein> activity by binding to a <protein>receptor</protein> of a known <protein>ECA</protein> via affinity
      for the beta-galactosides present on this <protein>receptor</protein>. In this study, we have
      tested whether <protein>ecalectin</protein> mediates <protein>ECA</protein> activity by binding to a <protein>receptor</protein> of
      a known <protein>ECA</protein>, and we have assessed its effects on eosinophils. <protein>Ecalectin</protein>
      did not mediate <protein>ECA</protein> activity by binding to the <protein>IL-5R</protein> or to <protein>CCR3</protein>. Also, the
      <protein>ECA</protein> activity of <protein>ecalectin</protein> was mainly chemokinetic. In addition, <protein>ecalectin</protein>
      induced concentration-dependent eosinophil aggregation, a marker for
      eosinophil activation. <protein>Ecalectin</protein> induced concentration-dependent
      superoxide production from eosinophils but did not induce degranulation;
      usually these two events are coupled in eosinophil activation. Moreover,
      <protein>ecalectin</protein> directly prolonged eosinophil survival in vitro and did not
      trigger eosinophils to secrete <protein>cytokines</protein> that prolong eosinophil survival.
      These results demonstrate that <protein>ecalectin</protein> has several unique effects on
      eosinophils. Therefore, we conclude that <protein>ecalectin</protein> is a novel
      <protein>eosinophil-activating factor</protein>. Presumably, these effects allow <protein>ecalectin</protein> to
      play a distinctive role in allergic inflammation.
</DOC>
<DOC>
<DOC_ID>[66]</DOC_ID>
>66.NF00105565
PMID:11956185
TI  - Transcriptional control of the <long_form>human <protein>thromboxane synthase</protein></long_form> gene in vivo and
      in vitro.
AB  - <protein>Thromboxane A(2)</protein>, a potent mediator of vasoconstriction and platelet
      aggregation, is synthesized from prostaglandin H(2) by <protein>thromboxane
      synthase (TXAS)</protein>. We report here on promoter analyses of <long_form>human <protein>TXAS</protein></long_form> using
      in vitro transcription and in vivo transfection methods. The 39-bp core
      promoter, containing both TATA and initiator elements, accurately
      initiates transcription in an orientation-dependent manner in a cell-free
      transcription system. Mutation of either TATA or initiator abolished
      transcriptional activity, but the upstream sequence had no effect on <protein>TXAS</protein>
      promoter activities in vitro, suggesting that the core promoter is
      sufficient for transcriptional activity from a naked DNA template. In
      contrast, mutation of both elements drastically decreased the promoter
      activity in vivo. Furthermore, <protein>TXAS</protein> proximal promoter containing the
      nucleotides -90 to -56 relative to the transcriptional start site was
      necessary for promoter transactivation in vivo. Transcriptional activities
      from 5'-deletion mutants indicated that the effects of the nucleotides
      -90/-56 were more pronounced in stably transfected cells (a 150-fold
      difference) than in the transiently transfected cells (an 8-fold
      difference), reflecting the effects of <protein>TXAS</protein> transcriptional activation
      from replicating and nonreplicating DNA templates. Partial <protein>micrococcal
      nuclease</protein> digestion indicated that the sequence -90/-56, where the <protein>NF-E2</protein>
      site is located, is associated with alterations of nucleosomal structure
      at the regions of promoter and reporter gene but not the region further
      downstream. Mutagenesis and forced expression studies demonstrated a
      critical role of <protein>p45 NF-E2</protein> in controlling <protein>TXAS</protein> expression under native
      chromatin conditions. Band shifting and chromatin immunoprecipitation
      assays indicated that <protein>p45 NF-E2</protein> was bound to the <protein>TXAS</protein> promoter in vitro
      and in vivo. Indirect end labeling and ligation-mediated PCR analyses
      further demonstrated that the occupation of <protein>TXAS</protein> promoter <protein>NF-E2</protein> site was
      associated with disruption of nucleosomal structure. Collectively, these
      results indicate that binding of <protein>NF-E2</protein> is critical both for alteration of
      the nucleosomal structure and for activation of the <protein>TXAS</protein> promoter, whereas
      the TATA and initiator elements are essential for transcription.
</DOC>
<DOC>
<DOC_ID>[67]</DOC_ID>
>67.NF00123385
PMID:11895916
TI  - High prevalence of decreased expression of <protein>KAI1 metastasis suppressor</protein> in
      human oral carcinogenesis.
AB  - PURPOSE: <protein>KAI1</protein> was originally identified in prostate cancer as a <protein>metastasis
      suppressor</protein> gene. Recent studies have shown a frequent down-regulation of
      <protein>KAI1</protein> expression in many tumor types, whereas mutation or hypermethylation
      of the gene is infrequent. The aim of the present study was to examine
      whether loss of <protein>KAI1</protein> expression that might be caused by genetic or
      epigenetic alterations could contribute to oral carcinogenesis.
      EXPERIMENTAL DESIGN : We analyzed mutational and methylation status of the
      <protein>KAI1</protein> gene and both the mRNA and protein level in a series of oral tumors
      [28 precancerous lesions, 101 primary oral squamous cell carcinomas
      (OSCCs), and 30 metastatic OSCCs] and OSCC-derived cell lines. We also
      examined <protein>p53 protein</protein> expression, which has been reported to be a candidate
      activator for the <protein>KAI1</protein> gene. RESULTS: With the exception of three
      microsatellite instabilities in the <protein>KAI1</protein> gene, we found no mutations in
      the coding sequence of the <protein>KAI1</protein> gene, no loss of heterozygosity, and no
      hypermethylation of the <protein>KAI1</protein> promoter region in all samples investigated.
      By immunohistochemistry, however, high frequencies of <protein>KAI1</protein> down-regulation
      were evident not only in the metastatic OSCCs [29 of 30 (97%)] but also in
      the primary OSCCs [83 of 101 (82%)] and in the precancerous lesions [13 of
      28 (46%)]. There was a significant relationship between down-regulation of
      <protein>KAI1 protein</protein> expression and primary tumors associated with lymph node
      metastases (P = 0.0115), whereas there was no statistical correlation
      between <protein>p53</protein> status and <protein>KAI1</protein> expression. Taken together, reverse
      transcription-PCR data were consistent with the protein expression status
      in 16 patients from whom mRNA was available. CONCLUSIONS: Our data suggest
      that whereas loss of <protein>KAI1 protein</protein> expression is associated with primary
      tumors with lymph node metastases, the down-regulation of <protein>KAI1</protein> is an early
      event in the progression of human oral cancer. The down-regulation of <protein>KAI1</protein>
      is not associated with either mutation, allelic loss, methylation of the
      promoter, or <protein>p53</protein> regulation.
</DOC>
<DOC>
<DOC_ID>[68]</DOC_ID>
>68.NF01031557
PMID:12649177
TI  - A novel gene, <protein>MSI2</protein>, encoding a putative <protein>RNA-binding protein</protein> is recurrently
      rearranged at disease progression of chronic myeloid leukemia and forms a
      fusion gene with <protein>HOXA9</protein> as a result of the cryptic t(7;17)(p15;q23).
AB  - The pathogenetic role of the <protein>P210 BCR</protein>/<protein>ABL1</protein> fusion gene in the chronic
      phase of chronic myeloid leukemia (CML) has been well established.In
      contrast, the genetic mechanisms underlying the disease progression into
      the accelerated phase (AP) and the final blast crisis (BC) remain poorly
      understood. We have previously identified (A. Barbouti et al., Genes
      Chromosomes Cancer, 35: 127-137, 2002) two cryptic balanced
      translocations, t(7;17)(p15;q23) and t(7;17)(q32-34;q23), in CML AP/BC
      using multicolor fluorescence in situ hybridization. In this study, we
      show that a novel gene in 17q23, <protein>Musashi-2 (MSI2)</protein>, encoding a putative
      <protein>RNA-binding protein</protein>, is rearranged in both cases and that a <protein>MSI2</protein>/<protein>HOXA9</protein>
      fusion gene is formed in the case with the 7p15 breakpoint. The identified
      in-frame <protein>MSI2</protein>/<protein>HOXA9</protein> fusion transcript retains both of the RNA recognition
      motif domains of <protein>MSI2</protein>, which is fused to the homeobox domain of <protein>HOXA9</protein>, and
      is likely to play an important role in the disease progression of CML.
</DOC>
<DOC>
<DOC_ID>[69]</DOC_ID>
>69.NF00106457
PMID:11992112
TI  - <protein>ROCK</protein> and <protein>Dia</protein> have opposing effects on adherens junctions downstream of
      <protein>Rho</protein>.
AB  - Adherens junctions (AJs) are crucial for maintaining the integrity of
      epithelial tissues and are often disrupted during tumour progression. <protein>Rho</protein>
      family proteins have been shown to regulate adherens junctions. We find
      that activation of the <protein>effector kinase ROCK</protein> and <protein>acto-myosin</protein> contraction
      disrupts AJs downstream of <protein>Rho</protein>. In contrast, signalling through the <protein>Rho
      effector Dia1</protein> is required to ensure a dynamically stable interface between
      cells and the maintenance of adherens junction complexes. The ability of
      <protein>Dia1</protein> to regulate the <protein>actin</protein> network is crucial for the localization of
      adherens junction components to the cell periphery.
</DOC>
<DOC>
<DOC_ID>[70]</DOC_ID>
>70.NF00130676
PMID:12372421
TI  - The <long_form>human <protein>perforin</protein></long_form> gene is a direct target of <protein>STAT4</protein> activated by <protein>IL-12</protein> in
      NK cells.
AB  - <protein>IL-12</protein> activates <protein>STAT4</protein> by inducing tyrosine phosphorylation,
      homo-dimerization, and nuclear translocation in NK cells and thereby
      stimulates proliferation and activation of these cells. The <protein>pore-forming
      protein perforin</protein> is a key effector protein for NK cell- and cytotoxic T
      lymphocyte-mediated cytolysis. Here we demonstrate that <protein>IL-12</protein> induces the
      expression of the <protein>perforin</protein> gene in human NK cell line, NKL.
      Electrophoretic mobility shift assays using a probe containing two
      putative <protein>STAT</protein>-binding sequences located at -1085 and -1059 in the <long_form>human
      <protein>perforin</protein></long_form> gene showed that <protein>STAT4</protein> or <protein>STAT5</protein> activated by <protein>IL-12</protein> or <protein>IL-2</protein>,
      respectively, in NKL cells binds this region. Further analyses using
      various probes with or without mutated <protein>STAT</protein>-binding sequences showed that,
      although either of the two tandem <protein>STAT</protein>-binding sequences binds <protein>STAT4</protein>
      weakly, the presence of both is required for significant binding of
      activated <protein>STAT4</protein> and for formation of the <protein>STAT4</protein>-DNA-binding complex with
      lower electrophoretic mobility. Furthermore, mutation of either of the
      tandem <protein>STAT</protein>-binding sequences abolished the <protein>IL-12</protein>-induced activation of
      the <protein>perforin</protein> gene promoter in reporter gene assays. These results indicate
      that the <protein>IL-12</protein>-induced expression of the <protein>perforin</protein> gene in NK cells is
      directly regulated by <protein>STAT4</protein>, which binds, most likely as a homo-tetramer,
      to the tandem <protein>STAT</protein>-binding sequences in the <protein>perforin</protein> gene promoter.
</DOC>
<DOC>
<DOC_ID>[71]</DOC_ID>
>71.NF00094921
PMID:11868823
TI  - Human bronchial epithelium expresses <protein>interleukin-9 receptors</protein> and releases
      <protein>neutrophil chemotactic factor</protein>.
AB  - Growing evidence obtained from human genomic analysis and
      antigen-challenged transgenic mice suggests that <protein>interleukin-9 (IL-9)</protein> is a
      candidate factor in <protein>immunoglobulin E (IgE)</protein> production and thus is thought
      to be associated with bronchial inflammation and bronchial
      hyperresponsiveness (BHR). To evaluate the expression of the <protein>IL-9 receptor</protein>
      and its effect on the <protein>IL-9</protein> human bronchial cell line BEAS-2B cells,
      reverse transcriptase-polymerase chain reaction (RT-PCR),
      immunohistochemical investigation, and chemotaxis assay were performed.
      The <protein>components of the IL-9 receptor</protein>, consisting of <protein>IL-9 receptor alpha</protein>
      (<protein>CD129</protein>) and <protein>IL-2 receptory</protein> ((1)132), were expressed on BEAS-2B cells as
      determined by RT-PCR and flow cytometry. BEAS-2B cells exposed to <protein>IL-9</protein>
      released neutrophil chemotactic activity (NCA) in a time- and
      dose-dependent manner, and the presence of <protein>granulocyte colony-stimulating
      factor (G-CSF)</protein> was also detected. This factor is primarily involved in NCA
      for the measurement of <protein>cytokines</protein> and in the inhibition assay of neutrophil
      chemotaxis. These findings suggest that bronchial epithelial cells may
      express <protein>IL-9 receptors</protein>, and that <protein>IL-9</protein> may induce airway inflammation
      through the release of <protein>G-CSF</protein> from bronchial epithelial cells.
</DOC>
<DOC>
<DOC_ID>[72]</DOC_ID>
>72.NF01196118
PMID:11938437
TI  - <protein>Merosin</protein>-deficient congenital muscular dystrophy, autosomal recessive
      (<protein>MDC1A</protein>, MIM#156225, <protein>LAMA2</protein> gene coding for <protein>alpha2 chain of laminin</protein>).
AB  - Congenital muscular dystrophies (CMDs) are a highly heterogeneous group of
      neuromuscular disorders. A subgroup displays a specific deficiency in a
      protein of the extracellular matrix, the <protein>alpha2 chain of laminin-2</protein>
      (<protein>merosin</protein>). A number of mutations in the gene encoding this protein have
      been identified in patients who present with a severe phenotype and white
      matter changes.
</DOC>
<DOC>
<DOC_ID>[73]</DOC_ID>
>73.NF00089173
PMID:11840499
TI  - <long_form>Human <protein>metabotropic glutamate receptor 2</protein></long_form> gene (<protein>GRM2</protein>): chromosomal
      sublocalization (3p21.1-p21.2) and genomic organization.
AB  - Imbalances in glutamatergic function have been implicated in the
      pathogenesis of neuropsychiatric disorders. Consequently, <protein>glutamate
      receptors</protein> genes are promising candidates in search of susceptibility genes
      for these disorders. In the present study, we report the chromosomal
      sublocalization and genomic organization of the <long_form>human <protein>metabotropic
      glutamate receptor 2</protein></long_form> gene (<protein>GRM2</protein>). Using monochromosomal hybrid cell lines
      of NIGMS Mapping Panel 2 (Coriell Cell Repository), the <protein>GRM2</protein> gene was
      localized to human chromosome 3, confirming previously reported
      localization. In addition, using the radiation hybrid panel RH3 (Research
      Genetics), we sublocalized the <protein>GRM2</protein> gene to chromosomal region
      3p21.1-p21.2. The genomic organization of the <protein>GRM2</protein> gene was established
      using a premade library of adaptor-ligated, human-specific genomic DNA
      fragments. The gene consists of 5 exons, with sizes ranging from 74 to
      1,076 bp.
</DOC>
<DOC>
<DOC_ID>[74]</DOC_ID>
>74.NF00088609
PMID:11818523
TI  - Expression and modulation of <protein>Rho kinase</protein> in human pregnant myometrium.
AB  - There is little information outlining the role of <protein>Rho kinase</protein>, <protein>RhoA</protein>, and
      calcium sensitization in regulation of human uterine contractility during
      pregnancy. The aims of this study were to investigate the expression of
      <protein>RhoA</protein>, and the <protein>Rho kinases ROCK I</protein> and <protein>ROCK II</protein> in human pregnant myometrium,
      to evaluate the effects of <protein>Rho kinase</protein> inhibition on pregnant human
      myometrial contractility in vitro, and to compare these effects with those
      of the <protein>calcium channel</protein> blocker nifedipine. RT-PCR using primers for <protein>RhoA</protein>,
      <protein>ROCK I</protein> and <protein>ROCK II</protein> was performed on mRNA isolated from human pregnant
      myometrium. Isometric recording was performed in isolated myometrial
      strips obtained at Caesarean section. The effects of the <protein>Rho kinase</protein>
      inhibitor Y-27632 (1 nmol/l to 10 mmol/l), and nifedipine (1 nmol/l to 10
      mmol/l), on <protein>oxytocin</protein> (0.5 nmol/l) induced contractions were measured and
      compared. Expression of <protein>RhoA</protein>, <protein>ROCK I</protein> and <protein>ROCK II</protein> mRNA was identified in
      human pregnant myometrium (n = 3). Y-27632 exerted a potent relaxant
      effect on myometrial contractility with a pD(2) value (+/- SEM) of 7.63
      +/- 0.38 (n = 6). The maximum net relaxant effect (+/- SEM) was 72.3 +/-
      6.1% (n = 6). Corresponding values for nifedipine were 7.24 +/- 0.48 (n =
      6; P = 0.469) and 93.40 +/- 3.1% (n = 6; P = 0.028). <protein>Rho A</protein>/<protein>Rho
      kinase</protein>-mediated calcium sensitization may play role in the physiology of
      human parturition, and pharmacological inhibition of this pathway may
      therefore provide a novel approach to tocolysis for pre-term labour.
</DOC>
<DOC>
<DOC_ID>[75]</DOC_ID>
>75.NF00085856
PMID:11932251
TI  - <protein>Ran-binding protein 3</protein> links <protein>Crm1</protein> to the <protein>Ran guanine nucleotide exchange
      factor</protein>.
AB  - <protein>Ran-binding protein 3 (RanBP3)</protein> is an approximately 55-kDa protein that
      functions as a cofactor for <protein>Crm1</protein>-mediated nuclear export. <protein>RanBP3</protein>
      stimulates export by enhancing the affinity of <protein>Crm1</protein> for <protein>Ran</protein>.GTP and cargo.
      However, important additional functions for this cofactor may exist. We
      now report that <protein>RanBP3</protein> associates with the <protein>Ran-specific guanine nucleotide
      exchange factor</protein>, <protein>regulator of chromosome condensation 1 (RCC1)</protein>. This
      interaction was stimulated by the addition of <protein>Ran</protein>; moreover, <protein>Ran</protein>.GDP,
      <protein>Ran</protein>.GTP, and <protein>Ran</protein> without nucleotide could all stimulate complex formation
      between <protein>RanBP3</protein> and <protein>RCC1</protein> even though binding of <protein>Ran</protein>.GDP to <protein>RanBP3</protein> alone was
      undetectable. <protein>RanBP3</protein> could also promote binding of <protein>Crm1</protein> to <protein>RCC1</protein> in the
      presence of <protein>Ran</protein>. Binding of <protein>RanBP3</protein> to <protein>RCC1</protein> increased the catalytic
      activity of <protein>RCC1</protein> toward <protein>Ran</protein>, and importantly, the ability of <protein>RanBP3</protein> to
      stimulate <protein>RCC1</protein> was not affected by the presence of <protein>Crm1</protein>. These data
      indicate that <protein>RanBP3</protein> acts as a <protein>scaffold protein</protein> to promote the efficient
      assembly of export complexes. By tethering <protein>Crm1</protein> to catalytically enhanced
      <protein>RCC1</protein>, <protein>RanBP3</protein> may lower the entropic barrier for the loading of <protein>Ran</protein>.GTP
      onto <protein>Crm1</protein>. We propose that this provides an additional mechanism by which
      <protein>RanBP3</protein> facilitates export.
</DOC>
<DOC>
<DOC_ID>[76]</DOC_ID>
>76.NF00076948
PMID:11859273
TI  - mRNA expression of <protein>EGF receptor ligands</protein> in atrophic gastritis before and
      after Helicobacter pylori eradication.
AB  - BACKGROUND: <protein>Epidermal growth factor (EGF) receptor ligands (EGFRL)</protein>
      including <protein>transforming growth factor alpha (TGF-alpha)</protein>, <protein>amphiregulin</protein>, and
      <protein>heparin binding-EGF (HB-EGF)</protein> are involved in gastric mucosal repair in
      chronic gastritis. Their mRNA expression has been shown to be upregulated
      after Helicobacter pylori (H.p.)-eradication but little is known about
      this gene expression in atrophic gastritis. The purpose of our study was
      to investigate <protein>EGFRL</protein> mRNA expression in gastric mucosa of patients with
      atrophic gastritis before and after H.p.-eradication. MATERIAL/METHODS:
      Antral mucosal biopsies were obtained during endoscopy in 10 H.p. positive
      patients with atrophic gastritis and in 10 H.p. negative controls with
      intact mucosa. Total RNA of antral biopsies was extracted and RT-PCR was
      performed, the PCR-products being measured densitometrically. Values were
      compared with mRNA expressions in H.p. negative antral mucosa (n=10).
      RESULTS: Gastric biopsies revealed mRNA expression for <protein>TGF-alpha</protein>,
      <protein>amphiregulin</protein> and <protein>HB-EGF</protein>, both in H.p. positive atrophic antritis and in
      H.p. negative healthy mucosa. The mRNA expression of <protein>TGF-alpha</protein> in atrophic
      gastritis was significantly upregulated after H.p.-eradication, whereas
      that of <protein>amphiregulin</protein> did not change after this eradication. Expression of
      <protein>HB-EGF</protein> mRNA was higher in H.p.-infection than after H.p.-eradication or in
      H.p. negative healthy subjects. CONCLUSIONS: H.p. positive atrophic
      gastritis is associated with differential mRNA expression of <protein>EGF receptor
      ligands</protein>. H.p.-eradication in this entity leads to unequal changes of these
      <protein>growth factor</protein> expressions compared to chronic active gastritis without
      atrophy.
</DOC>
<DOC>
<DOC_ID>[77]</DOC_ID>
>77.NF00100002
PMID:12122017
TI  - <protein>Head involution defective (Hid)</protein>-triggered apoptosis requires <protein>caspase-8</protein> but
      not <protein>FADD (Fas-associated death domain)</protein> and is regulated by <protein>Erk</protein> in
      mammalian cells.
AB  - The molecular machinery of apoptosis is evolutionarily conserved with some
      exceptions. One such example is the Drosophila proapoptotic gene <protein>Head
      involution defective (Hid)</protein>, whose mammalian homologue is not known. <protein>Hid</protein> is
      apoptotic to mammalian cells, and we have examined the mechanism by which
      <protein>Hid</protein> induces death. We demonstrate for the first time a role for the
      <protein>extracellular signal-related kinase-1/2 (Erk-1/2)</protein> in the regulation of <protein>Hid</protein>
      function in mammalian cells. <protein>Bcl-2</protein> and an <protein>inhibitor of caspase-9</protein> blocked
      apoptosis, indicative of a role for the mitochondrion in this pathway, and
      we provide evidence for a role for <protein>caspase-8</protein> in <protein>Hid</protein>-induced apoptosis.
      Thus, apoptosis was blocked by an <protein>inhibitor of caspase-8</protein>, deletion of
      <protein>caspase-8</protein> rendered cells resistant to <protein>Hid</protein>-induced apoptosis, and <protein>Hid</protein>
      associated with <protein>caspase-8</protein> in cell lysates. The <protein>Fas-associated death domain
      (FADD)</protein> was dispensable for the apoptotic function of <protein>Hid</protein>, indicating that
      <protein>Hid</protein> does not require <protein>extracellular death receptor</protein> signaling for the
      activation of <protein>caspase-8</protein>. In activated T cells, the <protein>cytokine interleukin-2</protein>
      blocked <protein>caspase-8</protein> processing and apoptosis, suggesting that survival cues
      from trophic factors may target a <protein>Hid</protein>-like intermediate present in
      mammalian cells. Thus, this study shows that <protein>Hid</protein> engages with conserved
      components of cellular death machinery and suggests that apoptotic
      paradigms characterized by <protein>FADD</protein>-independent activation of <protein>caspase-8</protein> may
      involve a <protein>Hid</protein>-like molecule in mammalian cells.
</DOC>
<DOC>
<DOC_ID>[78]</DOC_ID>
>78.NF00866584
PMID:11992252
TI  - Mutations in <protein>COL6A3</protein> cause severe and mild phenotypes of Ullrich congenital
      muscular dystrophy.
AB  - Ullrich congenital muscular dystrophy (UCMD) is an autosomal recessive
      disorder characterized by generalized muscular weakness, contractures of
      multiple joints, and distal hyperextensibility. Homozygous and compound
      heterozygous mutations of <protein>COL6A2</protein> on chromosome 21q22 have recently been
      shown to cause UCMD. We performed a genomewide screening with
      microsatellite markers in a consanguineous family with three sibs affected
      with UCMD. Linkage of the disease to chromosome 2q37 was found in this
      family and in two others. We analyzed <protein>COL6A3</protein>, which encodes the <protein>alpha3
      chain of collagen VI</protein>, and identified one homozygous mutation per family.
      In family I, the three sibs carried an A--&gt;G transition in the
      splice-donor site of intron 29 (6930+5A--&gt;G), leading to the skipping of
      exon 29, a partial reduction of <protein>collagen VI</protein> in muscle biopsy, and an
      intermediate phenotype. In family II, the patient had an unusual mild
      phenotype, despite a nonsense mutation, R465X, in exon 5. Analysis of the
      patient's <protein>COL6A3</protein> transcripts showed the presence of various mRNA
      species-one of which lacked several exons, including the exon containing
      the nonsense mutation. The deleted splice variant encodes <protein>collagen</protein>
      molecules that have a shorter N-terminal domain but that may assemble with
      other chains and retain a functional role. This could explain the mild
      phenotype of the patient who was still ambulant at age 18 years and who
      showed an unusual combination of hyperlaxity and finger contractures. In
      family III, the patient had a nonsense mutation, R2342X, causing absence
      of <protein>collagen VI</protein> in muscle and fibroblasts, and a severe phenotype, as has
      been described in patients with UCMD. Mutations in <protein>COL6A3</protein> are described in
      UCMD for the first time and illustrate the wide spectrum of phenotypes
      which can be caused by <protein>collagen VI</protein> deficiency.
</DOC>
<DOC>
<DOC_ID>[79]</DOC_ID>
>79.NF00135134
PMID:12080057
TI  - <protein>p52</protein> Mediates <protein>XPB</protein> function within the <protein>transcription/repair factor TFIIH</protein>.
AB  - To further our understanding of the <protein>transcription/DNA repair factor TFIIH</protein>,
      we investigated the role of its <protein>p52 subunit</protein> in TFIIH function. Using a
      completely reconstituted in vitro transcription or nucleotide excision
      repair (NER) system, we show that deletion of the C-terminal region of <protein>p52</protein>
      results in a dramatic reduction of <protein>TFIIH</protein> NER and transcription activities.
      This mutation prevents promoter opening and has no effect on the other
      enzymatic activities of <protein>TFIIH</protein>. Moreover, we demonstrate that intact <protein>p52</protein> is
      needed to anchor the <protein>XPB helicase</protein> within <protein>TFIIH</protein>, providing an explanation
      for the transcription and NER defects observed with the mutant <protein>p52</protein>. We
      show that these two subunits physically interact and map domains involved
      in the interface. Taken together, our results show that the <protein>p52/Tfb2
      <protein>subunit</protein> of TFIIH</protein> regulates the function of <protein>XPB</protein> through pair-wise
      interactions as described previously for <protein>p44</protein> and <protein>XPD</protein>.
</DOC>
<DOC>
<DOC_ID>[80]</DOC_ID>
>80.NF00141372
PMID:12397057
TI  - Identification of a specific molecular repressor of the <protein>peroxisome
      proliferator-activated receptor gamma Coactivator-1 alpha (PGC-1alpha)</protein>.
AB  - The <protein>nuclear co-activator PGC-1alpha</protein> is a pivotal regulator of numerous
      pathways controlling both metabolism and overall energy homeostasis.
      Inappropriate increases in <protein>PGC-1alpha</protein> activity have been linked to a
      number of pathological conditions including heart failure and diabetes
      mellitus. Previous studies (Puigserver, P., Adelmant, G., Wu, Z., Fan, M.,
      Xu, J., O'Malley, B., and Spiegelman, B. M. (1999) Science 286, 1368-1371)
      have demonstrated an inhibitory domain within <protein>PGC-1alpha</protein> that limits
      transcriptional activity. Using this inhibitory domain in a yeast
      two-hybrid screen, we demonstrate that <protein>PGC-1alpha</protein> directly associates with
      the <protein>orphan nuclear receptor estrogen-related receptor-alpha (ERR-alpha)</protein>.
      The binding of <protein>ERR-alpha</protein> to <protein>PGC-1alpha</protein> requires the C-terminal AF2 domain
      of <protein>ERR-alpha</protein>. <protein>PGC-1alpha</protein> and <protein>ERR-alpha</protein> have a similar pattern of
      expression in human tissues, with both being present predominantly in
      organs with high metabolic needs such as skeletal muscle and kidney.
      Similarly, we show that in mice physiological stimuli such as fasting
      coordinately induces <protein>PGC-1alpha</protein> and <protein>ERR-alpha</protein> transcription. We also
      demonstrate that under normal conditions <protein>PGC-1alpha</protein> is located within
      discrete nuclear speckles, whereas the expression of <protein>ERR-alpha</protein> results in
      <protein>PGC-1alpha</protein> redistributing uniformly throughout the nucleoplasm. Finally,
      we show that the expression of <protein>ERR-alpha</protein> can dramatically and specifically
      repress <protein>PGC-1alpha</protein> transcriptional activity. These results suggest a novel
      mechanism of transcriptional control wherein <protein>ERR-alpha</protein> can function as a
      specific molecular repressor of <protein>PGC-1alpha</protein> activity. In addition, our
      results suggest that other co-activators might also have specific
      repressors, thereby identifying another layer of combinatorial complexity
      in transcriptional regulation.
</DOC>
<DOC>
<DOC_ID>[81]</DOC_ID>
>81.NF00133354
PMID:12409289
TI  - Alternative core promoters regulate tissue-specific transcription from the
      <protein>autoimmune diabetes-related ICA1</protein> (<protein>ICA69</protein>) gene locus.
AB  - <protein>Islet cell autoantigen 69-kDa (ICA69)</protein>, protein product of the <long_form>human <protein>ICA1</protein></long_form>
      gene, is one target of the immune processes defining the pathogenesis of
      Type 1 diabetes. We have characterized the genomic structure and
      functional promoters within the 5'-regulatory region of <protein>ICA1</protein>. 5'-RNA
      ligase-mediated rapid amplification of cDNA ends evaluation of <protein>ICA1</protein>
      transcripts expressed in human islets, testis, heart, and cultured
      neuroblastoma cells reveals that three 5'-untranslated region exons are
      variably expressed from the <protein>ICA1</protein> gene in a tissue-specific manner.
      Surrounding the transcription initiation sites are motifs characteristic
      of non-TATA, non-CAAT, GC-rich promoters, including consensus <protein>Sp1</protein>/GC
      boxes, an initiator element, <protein>cAMP-responsive element-binding protein
      (CREB)</protein> sites, and clusters of other <protein>putative transcription factor</protein> sites
      within a genomic CpG island. Luciferase reporter constructs demonstrate
      that the first two <protein>ICA1</protein> exon promoters reciprocally stimulate luciferase
      expression within islet- (RIN 1046-38 cells) and brain-derived (NMB7)
      cells in culture; the exon A promoter exhibits greater activity in islet
      cells, whereas the exon B promoter more efficiently activates
      transcription in neuronal cells. Mutation of a <protein>CREB</protein> site within the <protein>ICA1</protein>
      exon B promoter significantly enhances transcriptional activity in both
      cell lines. Our basic understanding of expression from the functional core
      promoter elements of <protein>ICA1</protein> is an important advance that will not only add
      to our knowledge of the <protein>ICA69 autoantigen</protein> but will also facilitate a
      rational approach to discover the function of <protein>ICA69</protein> and to identify
      relevant <protein>ICA1</protein> promoter polymorphisms and their potential associations with
      disease.
</DOC>
<DOC>
<DOC_ID>[82]</DOC_ID>
>82.NF00124284
PMID:12031497
TI  - <long_form>Human <protein>uroplakin lb</protein></long_form> gene structure and promoter analysis.
AB  - The <protein>uroplakin Ib (UPIb)</protein> gene is predominantly expressed in urothelium and
      is overexpressed in 50% of transitional cell carcinoma (TCC). Molecular
      cloning of the genomic 5' region and comparison to a chromosome 3q genomic
      contig determined that the gene spans 31 kb and has eight exons including
      a noncoding exon 1. Multiple transcription start sites were identified in
      exon 1 by 5'RACE and ribonuclease protection assay (RPA). In vitro
      reporter gene analysis was performed with 2.3 kb of genomic DNA sequence
      flanking the 5' end of <protein>UPIb</protein>. A 235-bp 5' fragment that included <protein>UPIb</protein> exon
      1 generated strong transcriptional activity in normal and malignant human
      urothelial cell lines. Established malignant cell lines had greater
      transcriptional activity from the <protein>UPIb</protein> promoter than normal human cells.
      The identification of a functional <long_form>human <protein>UPIb</protein></long_form> gene promoter may find
      application in targeting gene therapy strategies for bladder cancer.
</DOC>
<DOC>
<DOC_ID>[83]</DOC_ID>
>83.NF00141618
PMID:12015329
TI  - An essential role for <protein>DNA methyltransferase DNMT3B</protein> in cancer cell
      survival.
AB  - Abnormal methylation and associated silencing of <protein>tumor suppressor</protein> genes is
      a common feature of many types of cancers. The observation of persistent
      methylation in human cancer cells lacking the maintenance
      <protein>methyltransferase DNMT1</protein> suggests the involvement of other <protein>DNA
      methyltransferases</protein> in gene silencing in cancer. To test this hypothesis,
      we have evaluated methylation and gene expression in cancer cells
      specifically depleted of <protein>DNMT3A</protein> or <protein>DNMT3B</protein>, de novo <protein>methyltransferases</protein> that
      are expressed in adult tissues. Here we have shown that depletion of
      <protein>DNMT3B</protein>, but not <protein>DNMT3A</protein>, induced apoptosis of human cancer cells but not
      normal cells. <protein>DNMT3B</protein> depletion reactivated methylation-silenced gene
      expression but did not induce global or juxtacentromeric satellite
      demethylation as did specific depletion of <protein>DNMT1</protein>. Furthermore, the effect
      of <protein>DNMT3B</protein> depletion was rescued by exogenous expression of either of the
      splice variants <protein>DNMT3B2</protein> or <protein>DNMT3B3</protein> but not <protein>DNMT1</protein>. These results indicate
      that <protein>DNMT3B</protein> has significant site selectivity that is distinct from <protein>DNMT1</protein>,
      regulates aberrant gene silencing, and is essential for cancer cell
      survival.
</DOC>
<DOC>
<DOC_ID>[84]</DOC_ID>
>84.NF00113836
PMID:12359251
TI  - Palmitoylation-defective <protein>asialoglycoprotein receptors</protein> are normal in their
      cellular distribution and ability to bind ligand, but are defective in
      ligand uptake and degradation.
AB  - The <protein>hepatic asialoglycoprotein receptor (ASGP-R)</protein> is an endocytic recycling
      <protein>receptor</protein> that mediates the endocytosis of <protein>desialylated glycoproteins</protein>. The
      <long_form>human <protein>ASGP-R</protein></long_form> is composed of two homologous subunits, H1 and H2, and the
      cytoplasmic Cys residues in both subunits are palmitoylated. To study the
      effects of palmitoylation on <protein>ASGP-R</protein> activity and function, we generated
      four types of stably transfected cell lines in SK-Hep-1 hepatoma cells,
      expressing wild-type, or partially or completely palmitoylation-defective
      <protein>ASGP-Rs</protein> containing Cys-to-Ser mutations in either one or both subunits.
      Scatchard analysis showed that all four stable cell lines expressed a
      similar number of binding sites for asialo-orosomucoid, with comparable
      dissociation constants of approximately 1-3nM. Immunofluorescence confocal
      microscopy indicated a normal distribution of the palmitoylation-defective
      H1 and H2 subunits compared to the wild-type. However, cell lines
      expressing palmitoylation-defective <protein>ASGP-Rs</protein> had markedly reduced rates of
      ligand uptake and degradation compared to cells expressing wild-type
      <protein>ASGP-Rs</protein>. We conclude that failure to palmitoylate Cys residues in either
      or both <protein>subunits of human ASGP-Rs</protein> results in very inefficient uptake and
      degradation of ligands.
</DOC>
<DOC>
<DOC_ID>[85]</DOC_ID>
>85.NF00103794
PMID:12200141
TI  - <protein>RNA polymerase II large subunit</protein> is cleaved by <protein>caspases</protein> during DNA
      damage-induced apoptosis.
AB  - UV radiation induces DNA lesions that are repaired by the nucleotide
      excision repair (NER) pathway. Cells that are NER deficient such as those
      derived from xeroderma pigmentosum (XP) patients are susceptible to
      apoptosis after 10J/m(2) UV radiation, a dose largely survivable by repair
      proficient cells. Herein, we report that <protein>RNA polymerase II large subunit
      (RNAP II-LS)</protein> undergoes <protein>caspase</protein>-mediated cleavage, yielding a 140kDa
      C-terminal fragment in XP lymphoblasts but not NER proficient lymphoblasts
      after 10J/m(2) UV irradiation. Cleavage could also be induced by cisplatin
      or oxaliplatin, but not transplatin, an isomer of cisplatin that does not
      induce DNA adducts. The cleavage of <protein>RNAP II-LS</protein> was blocked by a panel of
      <protein>caspase</protein> inhibitors but not by proteasomal inhibitors or inhibitors of
      other <protein>proteases</protein>. In vitro cleavage with <protein>caspase 8</protein> yielded the same 140kDa
      <protein>RNAP II-LS</protein> fragment observed in vivo. Using site-directed mutagenesis, the
      <protein>RNAP II-LS</protein> cleavage site was localized to an LETD sequence ending at
      residue 1339, which is near its C-terminal domain.
</DOC>
<DOC>
<DOC_ID>[86]</DOC_ID>
>86.NF00098331
PMID:11750878
TI  - Alternate signalling pathways from the <protein>interleukin-2 receptor</protein>.
AB  - <protein>Interleukin-2 (IL-2)</protein> plays a major role in the proliferation of cell
      populations during an immune reaction. The <long_form>beta(c) and <protein>gamma(c) subunits
      of the IL-2 receptor (IL-2R)</protein></long_form> are sufficient and necessary for signal
      transduction. Despite lacking known catalytic domains, <protein>receptor</protein> engagement
      leads to the activation of a diverse array <protein>protein tyrosine kinases
      (PTKs)</protein>. In resting or anergised T cells, <protein>Jak3</protein> is not activated. Signals
      arising from the PROX domain of the gamma(c) subunit activate <protein>p56(lck)</protein>
      (<protein>lck</protein>) leading to the induction of anti-apoptotic mechanisms. When <protein>Jak3</protein> is
      activated, in primed T cells, other <protein>PTKs</protein> predominantly mediate the
      induction of anti-apoptotic mechanisms and drive cellular proliferation.
      This review intends to suggest a role for these differences within the
      context of the immune system.
</DOC>
<DOC>
<DOC_ID>[87]</DOC_ID>
>87.NF00087720
PMID:12082086
TI  - <protein>cGMP-dependent protein kinase I beta</protein> physically and functionally interacts
      with the <protein>transcriptional regulator TFII-I</protein>.
AB  - Transcriptional regulation of the <protein>fos</protein> promoter by nitric oxide and cGMP
      can occur by nuclear translocation of <protein>cGMP-dependent protein kinase I
      (G-kinase I)</protein> (Gudi, T., Lohmann, S. M., and Pilz, R. B. (1997) Mol. Cell.
      Biol. 17, 5244-5254). To identify nuclear targets of <protein>G-kinase I</protein>, we
      performed a yeast two-hybrid screen with <protein>G-kinase I beta</protein> as bait. We found
      that <protein>G-kinase I beta</protein> interacted specifically with <protein>TFII-I</protein>, an unusual
      <protein>transcriptional regulator</protein> that associates with multiple proteins to
      modulate both basal and signal-induced transcription. By using purified
      recombinant proteins, the interaction was mapped to the N-terminal 93
      amino acids of <protein>G-kinase I beta</protein> and one of six 95-amino acid repeats found
      in <protein>TFII-I</protein>. In baby hamster kidney cells, cGMP analogs enhanced
      co-immunoprecipitation of <protein>G-kinase I beta</protein> and <protein>TFII-I</protein> by inducing
      co-localization of both proteins in the nucleus, but in other cell types
      containing <protein>cytoplasmic TFII-I</protein> the <protein>G-kinase</protein>-<protein>TFII-I</protein> interaction was largely
      cGMP-independent. <protein>G-kinase</protein> phosphorylated <protein>TFII-I</protein> in vitro and in vivo on
      Ser(371) and Ser(743) outside of the interaction domain. <protein>G-kinase</protein> strongly
      enhanced <protein>TFII-I</protein> transactivation of a serum-response element-containing
      promoter in COS7 cells, and this effect was lost when Ser(371) and
      Ser(743) of <protein>TFII-I</protein> were mutated. <protein>TFII-I</protein> by itself had little effect on a
      full-length <protein>fos</protein> promoter in baby hamster kidney cells, but it
      synergistically enhanced transcriptional activation by <protein>G-kinase I beta</protein>.
      Binding of <protein>G-kinase</protein> to <protein>TFII-I</protein> may position the <protein>kinase</protein> to phosphorylate and
      regulate <protein>TFII-I</protein> and/or factors that interact with <protein>TFII-I</protein> at the
      serum-response element.
</DOC>
<DOC>
<DOC_ID>[88]</DOC_ID>
>88.NF00142189
PMID:11788600
TI  - Consequences of mevalonate depletion. Differential transcriptional,
      translational, and post-translational up-regulation of <protein>Ras</protein>, <protein>Rap1a</protein>, <protein>RhoA</protein>,
      AND <protein>RhoB</protein>.
AB  - <protein>Ras-related proteins</protein> are <protein>small GTPases</protein> that are post-translationally
      modified with mevalonate-derived isoprenoids. Although the effects of
      inhibition of isoprenylation on protein function have been examined, the
      consequences of depletion of isoprenoid pools on regulation of expression
      of <protein>isoprenylated proteins</protein> have yet to be investigated. In these studies we
      have shown that depletion of mevalonate results in increased total levels
      of <protein>Ras</protein>, <protein>Rap1a</protein>, <protein>RhoA</protein>, and <protein>RhoB</protein> in K562 cells. Cycloheximide and
      [(35)S]methionine pulse/pulse-chase experiments reveal that mevalonate
      depletion increases the de novo synthesis of <protein>Ras</protein> and <protein>RhoA</protein> and decreases
      the degradation of existing <protein>Ras</protein> and <protein>RhoA protein</protein>. Pretreatment with
      actinomycin D completely prevents the induced up-regulation of <protein>RhoB</protein> and
      only partially prevents the up-regulation of <protein>Ras</protein>, <protein>Rap1a</protein>, and <protein>RhoA</protein>.
      Although depletion of mevalonate does not alter steady state levels of <protein>Ras</protein>
      mRNA, there is an increase in <protein>RhoB</protein> mRNA. Our results are the first to
      demonstrate that mevalonate depletion induces up-regulation of <protein>Ras</protein> and
      <protein>Ras-related proteins</protein> by discrete mechanisms that include modulation of
      transcriptional, translational, and post-translational processes.
</DOC>
<DOC>
<DOC_ID>[89]</DOC_ID>
>89.NF00132388
PMID:12077440
TI  - Crystallization and preliminary X-ray crystallographic studies on
      recombinant <long_form>human <protein>carnitine acetyltransferase</protein></long_form>.
AB  - In this paper, the purification, crystallization and preliminary X-ray
      crystallographic studies of <long_form>human <protein>carnitine acetyltransferase</protein></long_form> are
      reported. Recombinant <long_form>human <protein>carnitine acetyltransferase</protein></long_form> crystals were
      grown by the hanging-drop vapor-diffusion method and belong to the
      orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a =
      137.65, b = 84.76, c = 57.65 A and one molecule per asymmetric unit. The
      intensity data were collected from a cryocooled crystal to 1.6 A
      resolution using a conventional X-ray source.
</DOC>
<DOC>
<DOC_ID>[90]</DOC_ID>
>90.NF00121778
PMID:12082095
TI  - Interaction of <protein>p58(PITSLRE)</protein>, a <protein>G2/M-specific protein kinase</protein>, with <protein>cyclin
      D3</protein>.
AB  - The <protein>p58(PITSLRE)</protein> is a <protein>p34(cdc2)-related protein kinase</protein> that plays an
      important role in normal cell cycle progression. Elevated expression of
      <protein>p58(PITSLRE)</protein> in eukaryotic cells prevents them from undergoing normal
      cytokinesis and appears to delay them in late telophase. To investigate
      the molecular mechanism of <protein>p58(PITSLRE)</protein> action, we used the yeast
      two-hybrid system, screened a human fetal liver cDNA library, and
      identified <protein>cyclin D3</protein> as an interacting partner of <protein>p58(PITSLRE)</protein>. In vitro
      binding assay, in vivo coimmunoprecipitation, and immunofluorescence cell
      staining further confirmed the association of <protein>p58(PITSLRE)</protein> with <protein>cyclin D3</protein>.
      This binding was observed only in the G(2)/M phase but not in the G(1)/S
      phase of the cell cycle; meanwhile, no interaction between <protein>p110(PITSLRE)</protein>
      and <protein>cyclin D3</protein> was observed in all the cell cycle. The overexpression of
      <protein>cyclin D3</protein> in 7721 cells leads to an exclusively accumulation of
      <protein>p58(PITSLRE)</protein> in the nuclear region, affecting its cellular distribution.
      <protein>Histone H1 kinase</protein> activity of <protein>p58(PITSLRE)</protein> was greatly enhanced upon
      interaction with <protein>cyclin D3</protein>. Furthermore, <protein>kinase</protein> activity of <protein>p58(PITSLRE)</protein>
      was found to increase greatly in the presence of <protein>cyclin D3</protein> using a
      specific substrate, <protein>beta-1,4-galactosyltransferase 1</protein>. These data provide a
      new clue to our understanding of the cellular function of <protein>p58(PITSLRE)</protein> and
      <protein>cyclin D3</protein>.
</DOC>
<DOC>
<DOC_ID>[91]</DOC_ID>
>91.NF00076952
PMID:12391192
TI  - Regulatory effect of <protein>IFN-kappa</protein>, a novel <protein>type I IFN</protein>, on <protein>cytokine</protein> production
      by cells of the innate immune system.
AB  - <protein>IFN-kappa</protein> is a recently identified <protein>type I IFN</protein> that exhibits both
      structural and functional homology with the other <protein>type I IFN</protein> subclasses.
      In this study, we have investigated the effect of <protein>IFN-kappa</protein> on cells of
      the innate immune system by comparing <protein>cytokine</protein> release following treatment
      of human cells with either <protein>IFN-kappa</protein> or two recombinant <protein>IFN subtypes</protein>,
      <protein>IFN-beta</protein> and <protein>IFN-alpha2a</protein>. Although <protein>IFN-alpha2a</protein> failed to stimulate
      <protein>monocyte cytokine</protein> secretion, <protein>IFN-kappa</protein>, like <protein>IFN-beta</protein>, induced the release
      of several <protein>cytokines</protein> from both monocytes and dendritic cells, without the
      requirement of a costimulatory signal. <protein>IFN-kappa</protein> was particularly
      effective in inhibiting <protein>inducible IL-12</protein> release from monocytes. Unlike
      <protein>IFN-beta</protein>, <protein>IFN-kappa</protein> did not induce release of <protein>IFN-gamma</protein> by PBL. Expression
      of the <protein>IFN-kappa</protein> mRNA was observed in resting dendritic cells and
      monocytes, and it was up-regulated by <protein>IFN-gamma</protein> stimulation in monocytes,
      while <protein>IFN-beta</protein> mRNA was minimally detectable under the same conditions.
      Monocyte and dendritic cell expression of <protein>IFN-kappa</protein> was also confirmed in
      vivo in chronic lesions of psoriasis vulgaris and atopic dermatitis.
      Finally, biosensor-based binding kinetic analysis revealed that <protein>IFN-kappa</protein>,
      like <protein>IFN-beta</protein>, binds strongly to heparin (K(d): 2.1 nM), suggesting that
      the <protein>cytokine</protein> can be retained close to the local site of production. The
      pattern of <protein>cytokines</protein> induced by <protein>IFN-kappa</protein> in monocytes, coupled with the
      unique induction of <protein>IFN-kappa</protein> mRNA by <protein>IFN-gamma</protein>, indicates a potential
      role for <protein>IFN-kappa</protein> in the regulation of immune cell functions.
</DOC>
<DOC>
<DOC_ID>[92]</DOC_ID>
>92.NF00078494
PMID:11967569
TI  - Structural insights into the pro-apoptotic function of <protein>mitochondrial
      serine protease HtrA2</protein>/<protein>Omi</protein>.
AB  - <protein>HtrA2</protein>/<protein>Omi</protein>, a <protein>mitochondrial serine protease</protein> in mammals, is important in
      programmed cell death. However, the underlining mechanism of
      <protein>HtrA2</protein>/<protein>Omi</protein>-mediated apoptosis remains unclear. Analogous to the bacterial
      homolog <protein>HtrA</protein> (<protein>DegP</protein>), the mature <protein>HtrA2 protein</protein> contains a central <protein>serine
      protease</protein> domain and a C-terminal PDZ domain. The 2.0 A crystal structure
      of <protein>HtrA2</protein>/<protein>Omi</protein> reveals the formation of a pyramid-shaped homotrimer mediated
      exclusively by the <protein>serine protease</protein> domains. The peptide-binding pocket of
      the PDZ domain is buried in the intimate interface between the PDZ and the
      <protein>protease</protein> domains. Mutational analysis reveals that the <protein>monomeric HtrA2</protein>/<protein>Omi</protein>
      mutants are unable to induce cell death and are deficient in <protein>protease</protein>
      activity. The PDZ domain modulates <protein>HtrA2</protein>/<protein>Omi</protein>-mediated cell death activity
      by regulating its <protein>serine protease</protein> activity. These structural and
      biochemical observations provide an important framework for deciphering
      the mechanisms of <protein>HtrA2</protein>/<protein>Omi</protein>-mediated apoptosis.
</DOC>
<DOC>
<DOC_ID>[93]</DOC_ID>
>93.NF00100014
PMID:12386154
TI  - Absence of <protein>calsequestrin 2</protein> causes severe forms of catecholaminergic
      polymorphic ventricular tachycardia.
AB  - Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare
      arrhythmogenic disorder characterized by syncopal events and sudden
      cardiac death at a young age during physical stress or emotion, in the
      absence of structural heart disease. We report the first nonsense
      mutations in the <protein>cardiac calsequestrin</protein> gene, <protein>CASQ2</protein>, in three CPVT
      families. The three mutations, a nonsense R33X, a splicing 532+1 G&gt;A, and
      a 1-bp deletion, 62delA, are thought to induce premature stop codons. Two
      patients who experienced syncopes before the age of 7 years were
      homozygous carriers, suggesting a complete absence of <protein>calsequestrin 2</protein>. One
      patient was heterozygous for the stop codon and experienced syncopes from
      the age of 11 years. Despite the different mutations, there is little
      phenotypic variation of CPVT for the <protein>CASQ2</protein> mutations. Of the 16
      heterozygous carriers of these various mutations, 14 were devoid of
      clinical symptoms or ECG anomalies, whereas 2 of them had ventricular
      arrhythmias at ECG on exercise tests. In line with this, the diagnosis of
      the probands was difficult because of the absence of a positive family
      history. In conclusion, these additional three <protein>CASQ2</protein> CPVT families suggest
      that <protein>CASQ2</protein> mutations are more common than previously thought and produce a
      severe form of CPVT. The full text of this article is available at
      http://www.circresaha.org.
</DOC>
<DOC>
<DOC_ID>[94]</DOC_ID>
>94.NF00080301
PMID:12483523
TI  - Modulation of <protein>cystatin C</protein> expression impairs the invasive and tumorigenic
      potential of human glioblastoma cells.
AB  - Increases in the abundance of <protein>cathepsin B</protein> transcript and protein with
      increased tumor grade and changes in subcellular localization and activity
      of this enzyme. We observed progressive reductions in levels of the
      <protein>protease inhibitor cystatin C</protein>, an inhibitor of <protein>cathepsin B</protein> with
      corresponding increases in the malignancy of glioma cell lines, implying
      an inverse correlation between <protein>cystatin C</protein> and tumor grade. To investigate
      the role of <protein>cystatin C</protein> in the invasion of brain tumor cells, we stably
      transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct
      of <protein>human cystatin C</protein> in the sense orientation or an empty vector. Clones
      expressing sense-cystatin C cDNA had higher <protein>cystatin C</protein> mRNA and protein
      levels than did control cells. Sense-transfected cells were also markedly
      less invasive than control cells in a Matrigel invasion assay and in a
      coculture assay of SNB19 spheroids and fetal rat brain aggregates.
      Finally, the sense-transfected cells did not form tumors in nude mice upon
      intracerebral injection. These results strongly implicate <protein>cystatin C</protein> in
      the invasiveness of human glioblastoma cells and suggest that sense
      transcripts of <protein>cystatin C</protein> may prove useful in cancer therapy.
</DOC>
<DOC>
<DOC_ID>[95]</DOC_ID>
>95.NF00090104
PMID:12138086
TI  - <protein>Epidermal growth factor</protein> and <protein>transforming growth factor alpha</protein> mimic the
      effects of <protein>insulin</protein> in human fat cells and augment downstream signaling in
      <protein>insulin</protein> resistance.
AB  - The ability of the growth factors <protein>epidermal growth factor (EGF)</protein>,
      <protein>transforming growth factor alpha</protein>, and <protein>platelet-derived growth factor</protein> to
      exert <protein>insulin</protein>-like effects on glucose transport and lipolysis were
      examined in human and rat fat cells. No effects were found in rat fat
      cells, whereas <protein>EGF</protein> (EC(50) for glucose transport approximately 0.02 nm)
      and <protein>transforming growth factor alpha</protein> (EC(50) approximately 0.2 nm), but
      not <protein>platelet-derived growth factor</protein>, mimicked the effects of <protein>insulin</protein>
      (EC(50) approximately 0.2 nm) on both pathways. <protein>EGF receptors</protein>, but not
      <protein>EGF</protein>, were abundantly expressed in human fat cells as well as in human
      skeletal muscle. <protein>EGF</protein> increased the tyrosine phosphorylation of several
      proteins (the <protein>EGF receptor</protein>, <protein>insulin receptor substrate (IRS)-1</protein>, <protein>IRS-2</protein>, and
      <protein>Grb2-associated binder 1</protein>), whereas <protein>Shc</protein> and <protein>Gab2</protein> were only weakly and
      inconsistently phosphorylated. <protein>p85</protein>, the <protein>regulatory subunit of
      phosphatidylinositol 3-kinase (PI 3-kinase)</protein>, was also found to associate
      with all of these docking molecules, showing that <protein>EGF</protein> activated <protein>PI
      3-kinase</protein> pools that were additional to those of <protein>insulin</protein>. <protein>EGF</protein> and/or
      <protein>insulin</protein> increased <protein>protein kinase B</protein>/<protein>Akt</protein> serine phosphorylation to a similar
      extent, whereas <protein>mitogen-activated protein kinase</protein> phosphorylation was more
      pronounced for <protein>EGF</protein> than for <protein>insulin</protein>. The impaired <protein>insulin</protein>-stimulated
      downstream signaling, measured as <protein>protein kinase B</protein>/<protein>Akt</protein> serine
      phosphorylation, in <protein>insulin</protein>-resistant cells (Type 2 diabetes) was improved
      by the addition of <protein>EGF</protein>. Thus, <protein>EGF receptors</protein>, but not <protein>EGF</protein>, are abundantly
      expressed in human fat cells and skeletal muscle. <protein>EGF</protein> mimics the effects
      of <protein>insulin</protein> on both the metabolic and mitogenic pathways but utilize in
      part different signaling pathways. Both <protein>insulin</protein> and <protein>EGF</protein> increase the
      tyrosine phosphorylation and activation of <protein>IRS-1</protein> and <protein>IRS-2</protein>, whereas <protein>EGF</protein> is
      also capable of activating additional <protein>PI 3-kinase</protein> pools and, thus, can
      augment the downstream signaling of <protein>insulin</protein> in <protein>insulin</protein>-resistant states
      like Type 2 diabetes.
</DOC>
<DOC>
<DOC_ID>[96]</DOC_ID>
>96.NF00136114
PMID:12445830
TI  - Identification and recombinant production of <long_form>human <protein>laminin alpha4 subunit</protein></long_form>
      splice variants.
AB  - <protein>Laminins</protein>, the major <protein>basement membrane glycoproteins</protein>, are composed of three
      subunits. We identified a splice variant of the <long_form>human <protein>laminin alpha4
      subunit</protein></long_form> transcript containing 21 extra nucleotides. A heptapeptide
      sequence, MDCPTIS, was inserted close to the two cysteine residues
      possibly involved in the intersubunit disulfide bonds. Both the authentic
      alpha4 subunit (alpha4A) and the variant with the heptapeptide insertion
      (alpha4B) were readily secreted as <protein>laminin-8 trimers</protein> (alpha4Abeta1gamma1
      or alpha4Bbeta1gamma1) upon cotransfection with expression vectors for the
      beta1 and gamma1 subunits. The purified recombinant <protein>laminin-8</protein> containing
      the alpha4B subunit was more potent in promoting cell spreading than that
      containing alpha4A, raising the possibility that the alternative splicing
      of the alpha4 subunit transcript regulates the cell-adhesive activity of
      <protein>laminin-8</protein>. Since both alpha4A and alpha4B transcripts were detected by
      RT-PCR in several human cell lines, these two <protein>isoforms of laminin-8</protein> with
      differing cell-adhesive activities are present in the basement membranes
      of human tissues.
</DOC>
<DOC>
<DOC_ID>[97]</DOC_ID>
>97.NF00125261
PMID:12008951
TI  - Differential effects of <protein>fibroblast growth factors</protein> on expression of genes
      of the <protein>plasminogen activator</protein> and <protein>insulin-like growth factor</protein> systems by
      human breast fibroblasts.
AB  - In <protein>breast stroma urokinase plasminogen activator (uPA)</protein> is predominantly
      expressed by fibroblasts located in the near vicinity of tumor cells, and
      fibroblast-derived <protein>insulin-like growth factor-1 (IGF-1)</protein> may be involved in
      inhibiting the expression of <protein>uPA</protein> in these fibroblasts. To investigate a
      possible role for <protein>fibroblast growth factors (FGFs)</protein>, we evaluated the
      expression of <long_form><protein>components of the PA system</protein> and the <protein>IGF system</protein></long_form> in normal and
      tumor-tissue-derived human breast fibroblasts exposed to various <protein>FGFs</protein> in
      vitro. mRNA analysis revealed that <protein>FGF-1</protein>, <protein>FGF-2</protein> and <protein>FGF-4</protein> induced the mRNA
      expression levels of <protein>uPA</protein>, <protein>tPA</protein>, <protein>uPAR</protein>, <protein>PAI-1</protein> and <protein>PAI-2</protein>, and reduced those of
      <protein>IGF-1</protein>, <protein>IGF-1R</protein>, <protein>IGF-2R</protein> and <protein>IGFBP-4</protein>, without significantly affecting the
      levels of <protein>IGFBP-3</protein>, <protein>IGFBP-5</protein> and <protein>IGFBP-6</protein> mRNA. Concerning the expression of
      <protein>IGF-2</protein> mRNA, the effects mediated by <protein>FGF-1</protein>, <protein>FGF-2</protein> and <protein>FGF-4</protein> were divergent.
      In general, the effects elicited by <protein>FGF-1</protein> on the various mRNA levels
      studied were rapid and short-term. Those mediated by <protein>FGF-2</protein> overall lagged
      behind but were longer-lasting. For <protein>FGF-4</protein> an in between pattern was
      observed. Blocking transcription and translation demonstrated that a) both
      the <protein>FGF-1</protein> and <protein>FGF-2</protein> induced effects were the result of altered gene
      transcription or mRNA stability, b) the short-term effects mediated by
      <protein>FGF-1</protein> and <protein>FGF-2</protein> required de novo protein synthesis, and c) the long-term
      effects elicited by <protein>FGF-2</protein> did not depend on de novo protein synthesis
      during the first 24 h, but were triggered by proteins produced or made
      available thereafter. The data presented propose that of the <protein>FGFs</protein> studied
      (<long_form><protein>FGF-1</protein>, -2, -4, -5, and -7</long_form>), <protein>FGF-2</protein> is the most attractive target for
      therapeutical strategies aimed at diminishing the contribution of stromal
      fibroblasts in the <protein>PA</protein>-directed breast tumor proteolysis.
</DOC>
<DOC>
<DOC_ID>[98]</DOC_ID>
>98.NF00080307
PMID:12183469
TI  - Two highly related <protein>p66 proteins</protein> comprise a new family of potent
      <protein>transcriptional repressors</protein> interacting with <protein>MBD2</protein> and <protein>MBD3</protein>.
AB  - <protein>Methyl-CpG-binding domain proteins (MBD)</protein> mediate functional responses of
      methylated DNA. <protein>MBD2</protein> and <protein>MBD3</protein> are <protein>components of the MeCP1 protein complex</protein>,
      which contains the <long_form><protein>Mi-2</protein>/<protein>NuRD</protein> complex</long_form> and includes 66- and 68-kDa
      polypeptides. Here we identified two highly related <protein>66-kDa proteins</protein> in a
      yeast two-hybrid screen with <protein>MBD2b</protein>. Based on the high degree of sequence
      conservation to the previously identified Xenopus <long_form><protein>p66 subunit</protein> of the
      <protein>Mi-2</protein>/<protein>NuRD</protein> complex</long_form>, we termed these proteins <protein>hp66alpha</protein> and <protein>hp66beta</protein>.
      <protein>hp66alpha</protein> is the human orthologue of Xenopus <protein>p66</protein>, whereas <protein>hp66beta</protein>,
      previously identified as a <protein>component of the human MeCP1 complex</protein>, is a
      second member of a <protein>p66</protein> gene family. Coprecipitation of <protein>hp66alpha</protein> and <protein>MBD2</protein>
      demonstrates their in vivo association. Furthermore, confocal microscopy
      shows a nuclear colocalization of <protein>hp66alpha</protein> with <protein>hp66beta</protein> and <protein>MBD2</protein> in a
      speckled pattern. <protein>hp66alpha</protein> is a potent <protein>transcriptional repressor</protein> reducing
      gene activity about 100-fold and is ubiquitously coexpressed with <protein>hp66beta</protein>
      in cell lines and in fetal and adult tissues. We demonstrate direct
      binding of both <protein>p66</protein> family members to <protein>MBD2</protein> as well as <protein>MBD3</protein>. Interestingly,
      <protein>hp66alpha</protein>, which binds with a higher affinity than <protein>hp66beta</protein>, interacts via
      two interaction domains in contrast to a single interaction domain present
      in <protein>hp66beta</protein>. These results demonstrate that two highly related <long_form>mammalian
      <protein>p66 proteins</protein></long_form> display overlapping functions and are involved in methylation
      dependent transcriptional repression.
</DOC>
<DOC>
<DOC_ID>[99]</DOC_ID>
>99.NF00131661
PMID:11713982
TI  - Regulation of <protein>neuronal cholecystokinin</protein> gene transcription.
AB  - <protein>Cholecystokinin (CCK)</protein> is a <protein>neuroendocrine peptide</protein> expressed in I-cells of
      the small intestine and in central and peripheral neurons. Whereas
      <protein>intestinal CCK</protein> is involved in the release of <protein>pancreatic enzymes</protein> and the
      contraction of the gallbladder, <protein>cerebral CCK</protein> is implicated in a variety of
      functions, such as feeding behaviour, anxiety and memory. The expression
      of <protein>CCK</protein> is developmentally regulated. <protein>Brain CCK</protein> mRNA levels are low before
      birth, but increase markedly shortly after birth and reach adult like
      patterns of expression three weeks after birth during the final maturation
      of the central nervous system. In the adult, several substances induce
      <protein>neuronal CCK</protein> mRNA expression via activation of <protein>transcription factors</protein>
      binding to regulatory elements in the <protein>CCK</protein> promoter. Recent studies have
      examined the signaling pathways, <protein>transcription factors</protein> and regulatory
      elements involved in cAMP, <protein>fibroblast growth factor-2</protein>, and <protein>calcium</protein>-induced
      <protein>CCK</protein> gene transcription in neuronal cells. The review describes the
      signaling pathways and <protein>transcription factors</protein> involved in <protein>neuronal CCK</protein> gene
      transcription.
</DOC>
<DOC>
<DOC_ID>[100]</DOC_ID>
>100.NF00107282
PMID:10559186
TI  - The gamma subunit modulates Na(+) and K(+) affinity of the <protein>renal
      Na,K-ATPase</protein>.
AB  - The <protein>Na(+),K(+)-ATPase</protein> catalyzes the active transport of ions. It has two
      necessary subunits, alpha and beta, but in kidney it is also associated
      with a <protein>7.4-kDa protein</protein>, the gamma subunit. Stable transfection was used to
      determine the effect of gamma on <protein>Na, K-ATPase</protein> properties. When isolated
      from either kidney or transfected cells, alphabetagamma had lower
      affinities for both Na(+) and K(+) than alphabeta. A post-translational
      modification of gamma selectively eliminated the effect on Na(+) affinity,
      suggesting three configurations (alphabeta, alphabetagamma, and
      alphabetagamma*) conferring different stable properties to <protein>Na, K-ATPase</protein>.
      In the nephron, segment-specific differences in Na(+) affinity have been
      reported that cannot be explained by the known <long_form>alpha and <protein>beta subunit
      isoforms of Na,K-ATPase</protein></long_form>. Immunofluorescence was used to detect gamma in
      rat renal cortex. Cortical ascending limb and some cortical collecting
      tubules lacked gamma, correlating with higher Na(+) affinities in those
      segments reported in the literature. Selective expression in different
      segments of the nephron is consistent with a modulatory role for the gamma
      subunit in renal physiology.
</DOC>
<DOC>
<DOC_ID>[101]</DOC_ID>
>101.NF00103962
PMID:12351790
TI  - Role of <protein>Hec1</protein> in spindle checkpoint signaling and <protein>kinetochore</protein> recruitment
      of <protein>Mad1</protein>/<protein>Mad2</protein>.
AB  - The spindle checkpoint delays sister chromatid separation until all
      chromosomes have undergone bipolar spindle attachment. Checkpoint failure
      may result in chromosome mis-segregation and may contribute to
      tumorigenesis. We showed that the <long_form>human protein <protein>Hec1</protein></long_form> was required for the
      recruitment of <protein>Mps1 kinase</protein> and <long_form><protein>Mad1</protein>/<protein>Mad2</protein> complexes</long_form> to kinetochores.
      Depletion of <protein>Hec1</protein> impaired chromosome congression and caused persistent
      activation of the spindle checkpoint, indicating that high steady-state
      levels of <long_form><protein>Mad1</protein>/<protein>Mad2</protein> complexes</long_form> at kinetochores were not essential for
      checkpoint signaling. Simultaneous depletion of <protein>Hec1</protein> and <protein>Mad2</protein> caused
      catastrophic mitotic exit, making <protein>Hec1</protein> an attractive target for the
      selective elimination of spindle checkpoint-deficient cells.
</DOC>
<DOC>
<DOC_ID>[102]</DOC_ID>
>102.NF00131908
PMID:11590544
TI  - Hermansky-Pudlak syndrome type 3 in Ashkenazi Jews and other non-Puerto
      Rican patients with hypopigmentation and platelet storage-pool deficiency.
AB  - Hermansky-Pudlak syndrome (HPS), consisting of oculocutaneous albinism and
      a bleeding diathesis due to the absence of platelet dense granules,
      displays extensive locus heterogeneity. <protein>HPS1</protein> mutations cause HPS-1
      disease, and <protein>ADTB3A</protein> mutations cause HPS-2 disease, which is known to
      involve abnormal intracellular vesicle formation. A third HPS-causing
      gene, <protein>HPS3</protein>, was recently identified on the basis of homozygosity mapping
      of a genetic isolate of HPS in central Puerto Rico. We now describe the
      clinical and molecular characteristics of eight patients with HPS-3 who
      are of non-Puerto Rican heritage. Five are Ashkenazi Jews; three of these
      are homozygous for a 1303+1G--&gt;A splice-site mutation that causes skipping
      of exon 5, deleting an RsaI restriction site and decreasing the amounts of
      mRNA found on northern blotting. The other two are heterozygous for the
      1303+1G--&gt;A mutation and for either an 1831+2T--&gt;G or a 2621-2A--&gt;G
      splicing mutation. Of 235 anonymous Ashkenazi Jewish DNA samples, one was
      heterozygous for the 1303+1G--&gt;A mutation. One seven-year-old boy of
      German/Swiss extraction was compound heterozygous for a 2729+1G--&gt;C
      mutation, causing skipping of exon 14, and resulting in a C1329T missense
      (R396W), with decreased mRNA production. A 15-year-old Irish/English boy
      was heterozygous for an 89-bp insertion between exons 16 and 17 resulting
      from abnormal splicing; his <protein>fibroblast HPS3</protein> mRNA is normal in amount but
      is increased in size. A 12-year-old girl of Puerto Rican and Italian
      background has the 3,904-bp founder deletion from central Puerto Rico on
      one allele. All eight patients have mild symptoms of HPS; two Jewish
      patients had received the diagnosis of ocular, rather than oculocutaneous,
      albinism. These findings expand the molecular diagnosis of HPS, provide a
      screening method for a mutation common among Jews, and suggest that other
      patients with mild hypopigmentation and decreased vision should be
      examined for HPS.
</DOC>
<DOC>
<DOC_ID>[103]</DOC_ID>
>103.NF00116518
PMID:12401728
TI  - Association of <protein>IL4R</protein> haplotypes with type 1 diabetes.
AB  - We have investigated, in 282 multiplex Caucasian families (the Human
      Biological Data Interchange Repository), the association of type 1
      diabetes with polymorphisms in the <protein>IL4R</protein> gene. <protein>IL4R</protein> encodes a <protein>subunit of
      the interleukin-4 receptor</protein>, a molecule critical to T-helper cell
      development. By genotyping eight different <protein>IL4R</protein> single-nucleotide
      polymorphisms (SNPs) and identifying haplotypes (complex alleles) in the
      multiplex type 1 diabetic families who were stratified for <protein>HLA</protein> genotype,
      we have observed significant evidence of linkage and association of the
      <protein>IL4R</protein> gene to type 1 diabetes. In particular, we have identified a specific
      haplotype that appears to be protective and observed that this protective
      effect is strongest among individuals not carrying the <protein>HLA</protein> <protein>DR3</protein>/<protein>DR4</protein>
      genotype (which confers the strongest genetic risk for type 1 diabetes).
      These findings suggest an important role for the <protein>IL4R</protein> gene in
      immune-related disease susceptibility and illustrate the value of using
      multi-SNP haplotype information in association studies.
</DOC>
<DOC>
<DOC_ID>[104]</DOC_ID>
>104.NF00140656
PMID:12161434
TI  - <protein>Cytoplasmic serine hydroxymethyltransferase</protein> mediates competition between
      folate-dependent deoxyribonucleotide and S-adenosylmethionine
      biosyntheses.
AB  - Folate-dependent one-carbon metabolism is required for the synthesis of
      purines and thymidylate and for the remethylation of homocysteine to
      methionine. Methionine is subsequently adenylated to S-adenosylmethionine
      (SAM), a cofactor that methylates DNA, RNA, proteins, and many
      metabolites. Previous experimental and theoretical modeling studies have
      indicated that folate cofactors are limiting for cytoplasmic
      folate-dependent reactions and that the synthesis of DNA precursors
      competes with SAM synthesis. Each of these studies concluded that SAM
      synthesis has a higher metabolic priority than dTMP synthesis. The
      influence of <protein>cytoplasmic serine hydroxymethyltransferase (cSHMT)</protein> on this
      competition was examined in MCF-7 cells. Increases in <protein>cSHMT</protein> expression
      inhibit SAM concentrations by two proposed mechanisms: (1) <protein>cSHMT</protein>-catalyzed
      serine synthesis competes with the enzyme <protein>methylenetetrahydrofolate
      reductase</protein> for methylenetetrahydrofolate in a glycine-dependent manner, and
      (2) <protein>cSHMT</protein>, a <protein>high affinity 5-methyltetrahydrofolate-binding protein</protein>,
      sequesters this cofactor and inhibits methionine synthesis in a
      glycine-independent manner. Stable isotope tracer studies indicate that
      <protein>cSHMT</protein> plays an important role in mediating the flux of one-carbon units
      between dTMP and SAM syntheses. We conclude that <protein>cSHMT</protein> has three important
      functions in the cytoplasm: (1) it preferentially supplies one-carbon
      units for thymidylate biosynthesis, (2) it depletes
      methylenetetrahydrofolate pools for SAM synthesis by synthesizing serine,
      and (3) it sequesters 5-methyltetrahydrofolate and inhibits SAM synthesis.
      These results indicate that <protein>cSHMT</protein> is a metabolic switch that, when
      activated, gives dTMP synthesis higher metabolic priority than SAM
      synthesis.
</DOC>
<DOC>
<DOC_ID>[105]</DOC_ID>
>105.NF00943007
PMID:12297480
TI  - Expression of <protein>trophinin</protein> in the cycling endometrium and its association
      with infertility.
AB  - OBJECTIVE: To observe the expression of <protein>trophinin</protein> in the cycling
      endometrium and investigate its relationship with infertility. METHODS:
      <protein>Trophinin</protein> expression in the endometrium was observed in 39 normal cycling
      women during different menstrual phases and 24 women with infertility
      during mid-luteal phase by immunohistochemical technique. RESULTS:
      <protein>Trophinin</protein> expression was detected in the luteal-phase endometrium of both
      normal and infertile women, which peaked in the mid-luteal phase. In
      comparison with normal women, infertile women with endometriosis or
      unexplained infertility had significantly weakened <protein>trophinin</protein> expression in
      the endometrium in the mid-luteal (P&lt;0.001). CONCLUSIONS: <protein>Trophinin</protein> may
      play an important role in the process of implantation, and abnormal
      <protein>endometrial trophinin</protein> expression might be one of the major causes of
      infertility.
</DOC>
<DOC>
<DOC_ID>[106]</DOC_ID>
>106.NF00120976
PMID:12242338
TI  - External control of <protein>Her2</protein> expression and cancer cell growth by targeting a
      <protein>Ras-linked coactivator</protein>.
AB  - Overproduction of the <protein>Her2 oncoprotein</protein> has been found in approximately 30%
      of breast tumors, and patients who have <protein>Her2</protein> excesses typically have more
      aggressive disease. Here we show that the expression of the <protein>Her2</protein> gene can
      be decreased by inhibiting the interaction of the two cancer-linked
      proteins, <protein>DRIP130</protein>/<protein>CRSP130</protein>/<protein>Sur-2</protein> (a <protein>Ras-linked subunit of human mediator
      complexes</protein>) and <protein>ESX</protein> (an <protein>epithelial-restricted transcription factor</protein>).
      Disruption of the interaction by a short cell-permeable peptide reduced
      the expression of the <protein>Her2</protein> gene and specifically impaired the growth and
      viability of <protein>Her2</protein>-overexpressing breast cancer cells. The association of
      <protein>ESX</protein> with <protein>DRIP130</protein> is mediated by a small hydrophobic face of an 8-aa helix
      in <protein>ESX</protein>, suggesting a therapeutic approach to incapacitating the <protein>Her2</protein> gene
      by small organic molecules.
</DOC>
<DOC>
<DOC_ID>[107]</DOC_ID>
>107.NF00132559
PMID:11815617
TI  - Two proteins essential for <protein>apolipoprotein B</protein> mRNA editing are expressed
      from a single gene through alternative splicing.
AB  - <protein>Apolipoprotein B (apoB)</protein> mRNA editing involves site-specific deamination of
      cytidine to form uridine, resulting in the production of an in-frame stop
      codon. Protein translated from edited mRNA is associated with a reduced
      risk of atherosclerosis, and hence the protein factors that regulate
      <protein>hepatic apoB</protein> mRNA editing are of interest. A human protein essential for
      <protein>apoB</protein> mRNA editing and an eight-amino acid-longer variant of no known
      function have been recently cloned. We report that both proteins,
      henceforth referred to as <protein>ACF64</protein> and <protein>ACF65</protein>, supported <protein>APOBEC-1</protein> (the
      <protein>catalytic subunit of the editosome</protein>) equivalently in editing of <protein>apoB</protein> mRNA.
      They are encoded by a single 82-kb gene on chromosome 10. The transcripts
      are encoded by 15 exons that are expressed from a tissue-specific promoter
      minimally contained within the -0.33-kb DNA sequence. <protein>ACF64</protein> and <protein>ACF65</protein>
      mRNAs are expressed in both liver and intestinal cells in an approximate
      1:4 ratio. Exon 11 is alternatively spliced to include or exclude 24
      nucleotides of exon 12, thereby encoding <protein>ACF65</protein> and <protein>ACF64</protein>, respectively.
      Recognition motifs for the <protein>serine/arginine-rich (SR) proteins SC35</protein>, <protein>SRp40</protein>,
      <protein>SRp55</protein>, and <protein>SF2</protein>/<protein>ASF</protein> involved in alternative RNA splicing were predicted in
      exon 12. Overexpression of these <protein>SR proteins</protein> in liver cells demonstrated
      that alternative splicing of a minigene-derived transcript to express
      <protein>ACF65</protein> was enhanced 6-fold by <protein>SRp40</protein>. The data account for the expression of
      two editing factors and provide a possible explanation for their different
      levels of expression.
</DOC>
<DOC>
<DOC_ID>[108]</DOC_ID>
>108.NF00015676
PMID:11847339
TI  - <protein>Rap1 GTPase</protein> regulation of adherens junction positioning and cell adhesion.
AB  - Cell-cell junctions are distributed evenly around the lateral
      circumference of cells within an epithelium. We find that the even
      distribution of adherens junctions is an active process that requires the
      <protein>small guanosine triphosphatase Rap1</protein>. Cells mutant for <protein>Rap1</protein> condensed their
      adherens junctions to one side of the cell. This disrupted normal
      epithelial cell behavior, and mutant cell clones dispersed into the
      surrounding wild-type tissue. <protein>Rap1</protein> is enriched at adherens junctions,
      particularly between newly divided sister cells where it may reseal the
      adherens junction ring. The regulation of adherens junction positioning
      could play a role in cell mobility and cell division.
</DOC>
<DOC>
<DOC_ID>[109]</DOC_ID>
>109.NF00104938
PMID:12023287
TI  - Molecular basis of the globoside-deficient P(k) blood group phenotype.
      Identification of four inactivating mutations in the
      <protein>UDP-N-acetylgalactosamine: globotriaosylceramide
      3-beta-N-acetylgalactosaminyltransferase</protein> gene.
AB  - The biochemistry and molecular genetics underlying the related
      carbohydrate blood group antigens P, P(k), and LKE in the GLOB collection
      and P1 in the P blood group system are complex and not fully understood.
      Individuals with the rare but clinically important erythrocyte phenotypes
      P(1)(k) and P(2)(k) lack the capability to synthesize P antigen identified
      as globoside, the <protein>cellular receptor</protein> for Parvo-B19 virus and some
      P-fimbriated Escherichia coli. As in the ABO system, naturally occurring
      antibodies, anti-P of the <protein>IgM</protein> and <protein>IgG</protein> class with hemolytic and cytotoxic
      capacity, are formed. To define the molecular basis of the P(k) phenotype
      we analyzed the full coding region of a candidate gene reported in 1998 as
      a member of the <protein>3-beta-galactosyltransferase</protein> family but later shown to
      possess <protein>UDP-N-acetylgalactosamine:globotriaosylceramide
      3-beta-N-acetylgalactosaminyltransferase</protein> or <protein>globoside synthase</protein> activity.
      Homozygosity for different nonsense mutations (C(202) --&gt; T and 538insA)
      resulting in premature stop codons was found in blood samples from two
      individuals of the P(2)(k) phenotype. Two individuals with P(1)(k) and
      P(2)(k) phenotypes were homozygous for missense mutations causing amino
      acid substitutions (E266A or G271R) in a highly conserved region of the
      enzymatically active carboxyl-terminal domain in the <protein>transferase</protein>. We
      conclude that crucial mutations in the <protein>globoside synthase</protein> gene cause the
      P(k) phenotype.
</DOC>
<DOC>
<DOC_ID>[110]</DOC_ID>
>110.NF00099314
PMID:12111645
TI  - A novel polymorphism in exon 11 of the <protein>WKL1</protein> gene, shows no association
      with schizophrenia.
AB  - A missense mutation in exon 11 of the <protein>WKL1</protein> gene on chromosome 22 was found
      to be associated with cases of catatonic schizophrenia in a single large
      pedigree. We have screened exon 11 of the <protein>WKL1</protein> gene in 174 cases of
      schizophrenia, including cases of 22 cases of catatonic schizophrenia, but
      could not detect the previously reported mis-sense mutation. However in
      exon 11, we observed an insertion/deletion polymorphism, one-missense
      substitution and two synonymous substitutions. In addition, we also
      identified a nucleotide substitution in intron 11. All these polymorphisms
      appeared to be in complete linkage disequilibrium with one another. The
      polymorphisms were also identified in a UK pedigree with schizophrenia,
      however the polymorphisms did not segregate with the disease. To test for
      potential association between these polymorphisms and schizophrenia we
      sequenced an equal number of UK control individuals who were free of all
      psychiatric symptoms and had negative family histories for mental illness;
      the frequency of the insertion/deletion polymorphism was not significantly
      different in schizophrenia cases (42 out of 348 chromosomes, allele
      frequency 12%) compared to normal controls (40 out of 356 chromosomes,
      allele frequency 11%). The insertion/deletion was found to be in Hardy
      Weinberg equilibrium in both the schizophrenic and control groups. The
      insertion/deletion is composed of repeated sequence from exon 11 and
      intron 11 and is predicted to affect <protein>WKL1 protein</protein> structure.
</DOC>
<DOC>
<DOC_ID>[111]</DOC_ID>
>111.NF00088546
PMID:11531333
TI  - Structure of the C-terminal RNA-binding domain of <protein>hnRNP D0</protein> (AUF1), its
      interactions with RNA and DNA, and change in backbone dynamics upon
      complex formation with DNA.
AB  - <protein>Heterogeneous nuclear ribonucleoprotein (hnRNP) D0</protein> has two
      <protein>ribonucleoprotein (RNP)</protein> -type RNA-binding domains (RBDs), each of which
      can specifically bind to the UUAG-sequence. <protein>hnRNP D0</protein> also binds
      specifically to single-stranded d(TTAGGG)(n), the human telomeric DNA
      repeat. We have already reported the structure and interactions with RNA
      of the N-terminal RBD (RBD1). Here, the structure of the C-terminal RBD
      (RBD2) determined by NMR is presented. It folds into a compact alpha beta
      structure comprising an antiparallel beta-sheet packed against two
      alpha-helices, which is characteristic of <protein>RNP</protein>-type RBDs. In addition to
      the four beta-strands commonly found in <protein>RNP</protein>-type RBDs, an extra
      beta-strand, termed beta 4(-), was found just before the fourth
      beta-strand, yielding a five-stranded beta-sheet. Candidate residues of
      RBD2 involved in the interactions with RNA were identified by chemical
      shift perturbation analysis. Perturbation was detected on the beta-sheet
      side, not on the opposite alpha-helix side, as observed for RBD1. It is
      notable that the beta 4(-) to beta 4 region of RBD2 is involved in the
      interactions in contrast to the case of RBD1. The chemical shift
      perturbation analysis also showed that RBD2 interacts with DNA in
      essentially the same way as with RNA. Changes in the backbone dynamics
      upon complex formation with DNA were examined by means of model free
      analysis of relaxation data. In free RBD2, the beta 4(-) to beta 4 region
      exhibits slow conformational exchange on the milli- to microsecond time
      scale. The exchange is quenched upon complex formation. The flexibility of
      free RBD2 may be utilized in the recognition process by allowing different
      conformational states to be accessed and facilitating induced fit.
      Additionally, faster flexibility on the nano- to picosecond time scale was
      observed for loop 3 located between beta 2 and beta 3 in free RBD2, which
      is retained by the complex as well.
</DOC>
<DOC>
<DOC_ID>[112]</DOC_ID>
>112.NF01235993
PMID:11827176
TI  - Consequences of <protein>CK2</protein> signaling to the nuclear matrix.
AB  - <protein>Protein kinase CK2</protein> is recognized as one of the key cellular signals for
      cell growth and proliferation. Its nuclear targeting appears to be
      critical to its role in these functions. In the nucleus, nuclear matrix
      (NM) which plays a major role in growth-related activities is a primary
      locus for <protein>CK2</protein> signaling. A variety of growth stimuli evoke a rapid
      translocation of the <protein>CK2</protein> to the NM whereas removal of these factors has
      the opposite effect. These studies, employing various experimental models
      of cell growth (involving different <protein>growth-stimulatory factors</protein>), have
      suggested that rapid shuttling of <protein>CK2</protein> to the NM is a key feature of early
      growth control. By contrast, removal of <protein>growth-stimulatory factors</protein> leading
      to the loss of cell viability is associated with early loss of <protein>CK2</protein> from
      the NM (and chromatin). This indicates that absence of <protein>CK2</protein> from the
      nuclear compartment is contributory to induction of cell death via
      apoptosis, implying a protective role for <protein>CK2</protein> against cell death. Here, we
      review the evidence that suggests that <protein>CK2</protein> signaling in the NM is not only
      involved in cell growth but also in cell survival.
</DOC>
<DOC>
<DOC_ID>[113]</DOC_ID>
>113.NF00990692
PMID:12122014
TI  - <protein>Csk homologous kinase (CHK)</protein> and <protein>ErbB-2</protein> interactions are directly coupled
      with <protein>CHK</protein> negative growth regulatory function in breast cancer.
AB  - Our previous studies demonstrated that <protein>Csk homologous kinase (CHK)</protein> acts as
      a <protein>negative growth regulator</protein> of human breast cancer through inhibition of
      <long_form><protein>ErbB-2</protein>/neu-mediated <protein>Src family kinase</protein></long_form> activity (Bougeret, C., Jiang, S.,
      Keydar, I., and Avraham, H. (2001) J. Biol. Chem. 276, 33711-33720. The
      interaction between the <protein>CHK</protein> SH2 domain and Tyr(P)(1248) of the <protein>ErbB-2
      receptor</protein> has been shown to be specific and critical for <protein>CHK</protein> function. In
      this report, we investigated whether the interaction of the <protein>CHK</protein> SH2 domain
      and <protein>ErbB-2</protein> is directly related to the inhibition of <protein>heregulin-stimulated
      Src kinase</protein> activity. We constructed three <protein>CHK</protein> SH2 domain binding mutants:
      G129R (enhanced binding), R147K (inhibited binding), and R147A (disrupted
      binding). NMR spectra for the domains of each construct were used to
      evaluate their interaction with a Tyr(P)(1248)-containing <protein>ErbB-2</protein> peptide.
      G129R showed enhanced binding to <protein>ErbB-2</protein>, whereas binding was completely
      disrupted by R147A. The enhanced binding mutant showed chemical shift
      changes at the same residues as wild-type <protein>CHK</protein>, indicating that this mutant
      has the same binding characteristics as the wild-type protein.
      Furthermore, inhibition of <protein>heregulin-stimulated Src kinase</protein> activity was
      markedly diminished by R147A, whereas G129R-mediated inhibition was
      stronger as compared with wild-type <protein>CHK</protein>. These results indicate that the
      specific interaction of <protein>CHK</protein> and <protein>ErbB-2</protein> via the SH2 domain of <protein>CHK</protein> is
      directly related to the growth inhibitory effects of <protein>CHK</protein>. These new <protein>CHK</protein>
      high affinity binding constructs may serve as good candidates for
      inhibition of the <protein>ErbB-2</protein>/<protein>Src</protein> transduction pathway in gene therapy studies
      in breast cancer.
</DOC>
<DOC>
<DOC_ID>[114]</DOC_ID>
>114.NF00076969
PMID:12015308
TI  - Extracellular and cytoplasmic domains of <protein>endoglin</protein> interact with the
      <long_form><protein>transforming growth factor-beta receptors I</protein> and II</long_form>.
AB  - <protein>Endoglin</protein> is an auxiliary <protein>component of the transforming growth factor-beta
      (TGF-beta) receptor system</protein>, able to associate with the <long_form><protein>signaling receptor
      types I (TbetaRI)</protein> and II (TbetaRII)</long_form> in the presence of ligand and to
      modulate the cellular responses to <protein>TGF-beta1</protein>. <protein>Endoglin</protein> cannot bind ligand
      on its own but requires the presence of the <protein>signaling receptors</protein>,
      supporting a critical role for the interaction between <protein>endoglin</protein> and
      <protein>TbetaRI</protein> or <protein>TbetaRII</protein>. This study shows that full-length <protein>endoglin</protein> interacts
      with both <protein>TbetaRI</protein> and <protein>TbetaRII</protein>, independently of their <protein>kinase</protein> activation
      state or the presence of exogenous <protein>TGF-beta1</protein>. Truncated constructs
      encoding either the extracellular or the cytoplasmic domains of <protein>endoglin</protein>
      demonstrated that the association with the <protein>signaling receptors</protein> occurs
      through both extracellular and cytoplasmic domains. However, a more
      specific mapping revealed that the <protein>endoglin</protein>/<protein>TbetaRI</protein> interaction was
      different from that of <protein>endoglin</protein>/<protein>TbetaRII</protein>. <protein>TbetaRII</protein> interacts with the
      amino acid region 437-558 of the extracellular domain of <protein>endoglin</protein>, whereas
      <protein>TbetaRI</protein> interacts not only with the region 437-558 but also with the
      protein region located between amino acid 437 and the N terminus. Both
      <protein>TbetaRI</protein> and <protein>TbetaRII</protein> interact with the cytoplasmic domain of <protein>endoglin</protein>, but
      <protein>TbetaRI</protein> only interacts when the <protein>kinase</protein> domain is inactive, whereas
      <protein>TbetaRII</protein> remains associated in its active and inactive forms. Upon
      association, <protein>TbetaRI</protein> and <protein>TbetaRII</protein> phosphorylate the <protein>endoglin</protein> cytoplasmic
      domain, and then <protein>TbetaRI</protein>, but not <protein>TbetaRII</protein>, <protein>kinase</protein> dissociates from the
      complex. Conversely, <protein>endoglin</protein> expression results in an altered
      phosphorylation state of <protein>TbetaRII</protein>, <protein>TbetaRI</protein>, and downstream <protein>Smad proteins</protein>
      as well as a modulation of <protein>TGF-beta</protein> signaling, as measured by the reporter
      gene expression. These results suggest that by interacting through its
      extracellular and cytoplasmic domains with the <protein>signaling receptors</protein>,
      <protein>endoglin</protein> might affect <protein>TGF-beta</protein> responses.
</DOC>
<DOC>
<DOC_ID>[115]</DOC_ID>
>115.NF00776855
PMID:11894222
TI  - <protein>FOXP2</protein> is not a major susceptibility gene for autism or specific language
      impairment.
AB  - The <protein>FOXP2</protein> gene, located on human 7q31 (at the SPCH1 locus), encodes a
      <protein>transcription factor</protein> containing a polyglutamine tract and a forkhead
      domain. <protein>FOXP2</protein> is mutated in a severe monogenic form of speech and language
      impairment, segregating within a single large pedigree, and is also
      disrupted by a translocation in an isolated case. Several studies of
      autistic disorder have demonstrated linkage to a similar region of 7q (the
      <protein>AUTS1</protein> locus), leading to the proposal that a single genetic factor on 7q31
      contributes to both autism and language disorders. In the present study,
      we directly evaluate the impact of the <protein>FOXP2</protein> gene with regard to both
      complex language impairments and autism, through use of association and
      mutation screening analyses. We conclude that coding-region variants in
      <protein>FOXP2</protein> do not underlie the <protein>AUTS1</protein> linkage and that the gene is unlikely to
      play a role in autism or more common forms of language impairment.
</DOC>
<DOC>
<DOC_ID>[116]</DOC_ID>
>116.NF00136200
PMID:12021920
TI  - Expression of <long_form><protein>somatostatin receptor types 1</protein>-5</long_form> in 81 cases of
      gastrointestinal and pancreatic endocrine tumors. A correlative
      immunohistochemical and reverse-transcriptase polymerase chain reaction
      analysis.
AB  - <protein>Somatostatin receptors (SSTRs)</protein> have been extensively mapped in human
      tumors by means of autoradiography, reverse-transcriptase polymerase chain
      reaction (RT-PCR), in situ hybridization (ISH) and immunohistochemistry
      (IHC). We analyzed the <long_form><protein>SSTR type 1</protein>-5</long_form> expression by means of RT-PCR and/or
      IHC in a series of 81 functioning and non-functioning
      gastroenteropancreatic (GEP) endocrine tumors and related normal tissues.
      Moreover, we compared the results with clinical, pathological and hormonal
      features. Forty-six cases (13 intestinal and 33 pancreatic) were studied
      for <long_form><protein>SSTR 1</protein>-5</long_form> expression using RT-PCR, IHC with antibodies to <protein>SSTR types 2</protein>,
      3, 5 and ISH for <protein>SSTR2</protein> mRNA. The vast majority of tumors expressed <long_form><protein>SSTR
      types 1</protein>, 2, 3 and 5</long_form>, while <protein>SSTR4</protein> was detected in a small minority. Due to
      the good correlation between RT-PCR and IHC data on <long_form><protein>SSTR types 2</protein>, 3, and
      5</long_form>, thirty-five additional GEP endocrine tumors were studied with IHC
      alone. Pancreatic insulinomas had an heterogeneous <protein>SSTR</protein> expression, while
      100% of somatostatinomas expressed <protein>SSTR5</protein> and 100% gastrinomas and
      glucagonomas expressed <protein>SSTR2</protein>. Pre-operative biopsy material showed an
      overlapping immunoreactivity with that of surgical specimens, suggesting
      that the <protein>SSTR</protein> status can be detected in the diagnostic work-up. It is
      concluded that <long_form><protein>SSTRs 1</protein>-5</long_form> are heterogeneously expressed in GEP endocrine
      tumors and that IHC is a reliable tool to detect <long_form><protein>SSTR types 2</protein>, 3 and 5</long_form> in
      surgical and biopsy specimens.
</DOC>
<DOC>
<DOC_ID>[117]</DOC_ID>
>117.NF00109313
PMID:12135940
TI  - Regulation of <protein>Kv4.3</protein> current by <protein>KChIP2</protein> splice variants: a <protein>component of
      native cardiac I(to)</protein>?
AB  - BACKGROUND: The <protein>transient outward potassium current (I(to))</protein> encoded by the
      <protein>Kv4</protein> family of <protein>potassium channels</protein> is important in the repolarization of
      cardiac myocytes. <protein>KChIPs</protein> are a recently identified group of <protein>Ca2+-binding
      accessory subunits</protein> that modulate <protein>Kv4</protein>-encoded currents. <protein>KChIP2</protein> is the only
      family member expressed in the heart. METHODS AND RESULTS: We previously
      cloned 2 novel splice variants of <protein>KChIP2</protein> from human heart, named <protein>KChIP2S</protein>
      and <protein>KChIP2T</protein>. The transmural distribution of <protein>KChIP2</protein> mRNA and protein in
      human and canine left ventricle was examined using kinetic RT-PCR and
      Western blots in the same tissues. A steep gradient of mRNA with greater
      <protein>KChIP2</protein> expression in the epicardium was observed. However, no gradient of
      <protein>immunoreactive protein</protein> was observed. Immunocytochemistry reveals <protein>KChIP2</protein>
      expression in the t-tubules and the nucleus. The predominant effects of
      all 3 <protein>KChIP2</protein> splice variants on <protein>hKv4.3-encoded current</protein> are to increase the
      density, slow the current decay in a Ca2+-dependent manner, and hasten
      recovery from inactivation in a splice variant-specific fashion.
      CONCLUSIONS: A family of <protein>KChIP2 proteins</protein> is expressed in human hearts that
      exhibits differential modulation of <protein>hKv4.3</protein> current in a Ca2+-dependent
      fashion. The effect of <protein>KChIP2</protein> on the biophysical properties of expressed
      <protein>Kv4.3</protein> current and the absence of a gradient of protein across the
      ventricular wall suggest that <protein>KChIP2</protein> is either not a requisite <protein>component
      of human or canine ventricular I(to)</protein> or that its functional effect is
      being affected or additionally modified by other factors present in
      myocardial cells.
</DOC>
<DOC>
<DOC_ID>[118]</DOC_ID>
>118.NF00140660
PMID:12393884
TI  - <protein>Apocytochrome c</protein> blocks <protein>caspase-9</protein> activation and <protein>Bax</protein>-induced apoptosis.
AB  - Complex networks of signaling pathways control the apoptotic response and,
      therefore, cell survival. However, these networks converge on a common
      machinery, of which the <protein>caspase cysteine proteases</protein> are key components.
      Diverse apoptotic stimuli release <protein>holocytochrome c</protein> from mitochondria,
      allowing <protein>holocytochrome c</protein> to bind <protein>apoptotic protease activating factor-1
      (Apaf-1)</protein>, which in turn binds <protein>caspase-9</protein> both activating this <protein>caspase</protein> and
      forming an <long_form><protein>Apaf-1</protein>/<protein>caspase-9</protein> holoenzyme</long_form>. <protein>Cytochrome c</protein> lacking heme (the apo
      form) cannot support <protein>caspase</protein> activation, although the reason for this has
      not been studied. Here we show that <protein>apocytochrome c</protein> still binds <protein>Apaf-1</protein> and
      that it can block holo-dependent <protein>caspase</protein> activation in a cell-free system.
      In addition we show that overexpression of <protein>apocytochrome c</protein> blocks
      <protein>Bax</protein>-induced apoptosis in cells. Thus it is possible to modulate cell
      survival by interfering with the <protein>Apaf-1</protein>/<protein>cytochrome c</protein> interaction. Given
      the key role played by <protein>Apaf-1</protein>/<protein>cytochrome c</protein> in the apoptotic process, and
      the role of apoptosis in degenerative disease, this interaction may serve
      as a novel therapeutic target.
</DOC>
<DOC>
<DOC_ID>[119]</DOC_ID>
>119.NF00141471
PMID:12226101
TI  - Expression of <protein>calcineurin B homologous protein 2</protein> protects serum
      deprivation-induced cell death by serum-independent activation of <protein>Na+/H+
      exchanger</protein>.
AB  - The <protein>calcineurin B homologous protein</protein> (designated <protein>CHP1</protein>) has been shown to
      be a common essential cofactor for the <protein>plasma membrane Na(+)/H(+)
      exchangers (NHEs)</protein> (Pang, T., Su, X., Wakabayashi, S., and Shigekawa, M.
      (2001) J. Biol. Chem. 276, 17367-17372). In this study, we characterized
      the function of another <protein>isoform of CHP</protein> (designated <protein>CHP2</protein>) that has a 61%
      amino acid identity with <protein>CHP1</protein>. <protein>CHP2</protein>, like <protein>CHP1</protein>, conferred the ability to
      <long_form><protein>NHEs 1</protein>-3</long_form> to express a high exchange activity by binding to the
      juxtamembrane region of the cytoplasmic domain of the <protein>exchanger</protein>, but it
      interacts more strongly (approximately 5-fold) with <protein>NHE1</protein> than does <protein>CHP1</protein>.
      Although <protein>CHP1</protein> is expressed ubiquitously at relatively high levels, <protein>CHP2</protein>
      expression was extremely low in most human tissues but was higher in tumor
      cells. We produced stable cell clones overexpressing either <protein>CHP1</protein> or <protein>CHP2</protein>
      in which one of them is predominantly bound to <protein>NHE1</protein>. Serum (10%) induced a
      significant cytoplasmic alkalinization (0.1-0.2 pH unit) in cells
      co-expressing <protein>CHP1</protein> and <protein>NHE1</protein> but not in cells co-expressing <protein>CHP2</protein> and <protein>NHE1</protein>.
      In the latter, pH(i) was high (7.4-7.5) even in the absence of serum,
      suggesting that <protein>NHE1</protein> was already activated. Surprisingly, most (&gt;80%) of
      <protein>CHP2</protein>/<protein>NHE1</protein> cells unlike <protein>CHP1</protein>/<protein>NHE1</protein> cells were viable even after long serum
      starvation (&gt;7 days). Thus, the expression of <protein>CHP2</protein> appears to protect
      cells from serum deprivation-induced death by increasing pH(i). These
      properties of <protein>CHP2</protein>/<protein>NHE1</protein> cells are similar to those of malignantly
      transformed cells. We propose that serum-independent activation of <protein>NHE1</protein> by
      bound <protein>CHP2</protein> is one of the key mechanisms for the maintenance of high pH(i)
      and the resistance to serum deprivation-induced cell death in malignantly
      transformed cells.
</DOC>
<DOC>
<DOC_ID>[120]</DOC_ID>
>120.NF00122681
PMID:12068077
TI  - Further characterization of the molecular interaction between <protein>PSD-95</protein> and
      <protein>NMDA receptors</protein>: the effect of the <protein>NR1</protein> splice variant and evidence for
      modulation of channel gating.
AB  - Coexpression of <protein>PSD-95</protein>(<protein>c-Myc</protein>) with <long_form><protein>NR1-1a</protein>/<protein>NR2A NMDA receptors</protein></long_form> in human
      embryonic kidney (HEK) 293 cells resulted in a decrease in efficacy for
      the glycine stimulation of [3 H]MK801 binding similar to that previously
      described for l-glutamate. The inhibition constants (K (I) s) for the
      binding of l-glutamate and glycine to <protein>NR1-1a</protein>/<protein>NR2A</protein> determined by [3 H]CGP
      39653 and [3 H]MDL 105 519 displacement assays, respectively, were not
      significantly different between <long_form><protein>NR1-1a</protein>/<protein>NR2A receptors</protein></long_form> coexpressed +/-
      <protein>PSD-95</protein>(<protein>c-Myc</protein>). The increased EC(50) for l-glutamate enhancement of [3
      H]MK801 binding was also found for <long_form><protein>NR1-2a</protein>/<protein>NR2A</protein> and <protein>NR1-4b</protein>/<protein>NRA receptors</protein></long_form>
      thus the altered EC(50) is not dependent on the N1, C1 or C2 exon of the
      <protein>NR1 subunit</protein>. The <protein>NR1-4b</protein> but not the <protein>NR1-1a subunit</protein> was expressed
      efficiently at the cell surface in the absence of <protein>NR2 subunits</protein>. Total
      <protein>NR1-4b</protein> and <protein>NR1-4b</protein>/<protein>NR2A</protein> expression was enhanced by <protein>PSD-95</protein>(<protein>c-Myc</protein>) but whole
      cell enzyme-linked immunoadsorbent assays (ELISAs) showed that this
      increase was not due to increased expression at the cell surface. It is
      suggested that <protein>PSD-95</protein>(<protein>c-Myc</protein>) has a dual effect on <protein>NMDA receptors</protein> expressed
      in mammalian cells, a reduction in channel gating and an enhanced
      expression of <protein>NMDA receptor subunits</protein> containing C-terminal E(T/S)XV <protein>PSD-95</protein>
      binding motifs.
</DOC>
<DOC>
<DOC_ID>[121]</DOC_ID>
>121.NF00116445
PMID:12082094
TI  - Functions of <protein>transforming growth factor-beta family type I receptors</protein> and
      <protein>Smad proteins</protein> in the hypertrophic maturation and osteoblastic
      differentiation of chondrocytes.
AB  - We investigated the effects of <protein>bone morphogenetic protein (BMP)-2</protein>, a
      member of the <protein>transforming growth factor-beta</protein> superfamily, on the
      regulation of the chondrocyte phenotype, and we identified signaling
      molecules involved in this regulation. <protein>BMP-2</protein> triggers three concomitant
      responses in mouse primary chondrocytes and chondrocytic MC615 cells.
      First, <protein>BMP-2</protein> stimulates expression or synthesis of <protein>type II collagen</protein>.
      Second, <protein>BMP-2</protein> induces expression of molecular markers characteristic of
      pre- and hypertrophic chondrocytes, such as <protein>Indian hedgehog</protein>, <protein>parathyroid
      hormone/parathyroid hormone-related peptide receptor</protein>, <protein>type X collagen</protein>, and
      <protein>alkaline phosphatase</protein>. Third, <protein>BMP-2</protein> induces <protein>osteocalcin</protein> expression, a
      specific trait of osteoblasts. Constitutively active forms of <protein>transforming
      growth factor-beta family type I receptors</protein> and <protein>Smad proteins</protein> were
      overexpressed to address their role in this process. <protein>Activin receptor-like
      kinase (ALK)-1</protein>, <protein>ALK-2</protein>, <protein>ALK-3</protein>, and <protein>ALK-6</protein> were able to reproduce the
      hypertrophic maturation of chondrocytes induced by <protein>BMP-2</protein>. In addition,
      <protein>ALK-2</protein> mimicked further the osteoblastic differentiation of chondrocytes
      induced by <protein>BMP-2</protein>. In the presence of <protein>BMP-2</protein>, <protein>Smad1</protein>, <protein>Smad5</protein>, and <protein>Smad8</protein>
      potentiated the hypertrophic maturation of chondrocytes, but failed to
      induce <protein>osteocalcin</protein> expression. <protein>Smad6</protein> and <protein>Smad7</protein> impaired chondrocytic
      expression and osteoblastic differentiation induced by <protein>BMP-2</protein>. Thus, our
      results indicate that <protein>Smad</protein>-mediated pathways are essential for the
      regulation of the different steps of chondrocyte and osteoblast
      differentiation and suggest that additional <protein>Smad</protein>-independent pathways
      might be activated by <protein>ALK-2</protein>.
</DOC>
<DOC>
<DOC_ID>[122]</DOC_ID>
>122.NF00126408
PMID:12540637
TI  - Large-scale association studies of variants in genes encoding the
      <protein>pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11)</protein> and <protein>SUR1</protein>
      (<protein>ABCC8</protein>) confirm that the <protein>KCNJ11</protein> E23K variant is associated with type 2
      diabetes.
AB  - The genes <protein>ABCC8</protein> and <protein>KCNJ11</protein>, which encode the subunits <protein>sulfonylurea
      receptor 1 (SUR1)</protein> and <protein>inwardly rectifying potassium channel (Kir6.2) </protein>of
      the <protein>beta-cell ATP-sensitive potassium (K(ATP)) channel</protein>, control <protein>insulin</protein>
      secretion. Common polymorphisms in these genes (<protein>ABCC8</protein> exon 16-3t/c, exon
      18 T/C, KCNJ11 E23K) have been variably associated with type 2 diabetes,
      but no large ( approximately 2,000 subjects) case-control studies have
      been performed. We evaluated the role of these three variants by studying
      2,486 U.K. subjects: 854 with type 2 diabetes, 1,182 population control
      subjects, and 150 parent-offspring type 2 diabetic trios. The E23K allele
      was associated with diabetes in the case-control study (odds ratio [OR]
      1.18 [95% CI 1.04-1.34], P = 0.01) but did not show familial association
      with diabetes. Neither the exon 16 nor the exon 18 <protein>ABCC8</protein> variants were
      associated with diabetes (1.04 [0.91-1.18], P = 0.57; 0.93 [0.71-1.23], P
      = 0.63, respectively). Meta-analysis of all case-control data showed that
      the E23K allele was associated with type 2 diabetes (K allele OR 1.23
      [1.12-1.36], P = 0.000015; KK genotype 1.65 [1.34-2.02], P = 0.000002);
      but the <protein>ABCC8</protein> variants were not associated. Our results confirm that E23K
      increases risk of type 2 diabetes and show that large-scale association
      studies are important for the identification of diabetes susceptibility
      alleles.
</DOC>
<DOC>
<DOC_ID>[123]</DOC_ID>
>123.NF00105835
PMID:12367750
TI  - Regulation of HIV-1 transcription by <protein>NF-IL6</protein> in activated Jurkat T cells.
AB  - To examine the mechanism of HIV-1 regulation by <protein>NF-IL6</protein> in activated human
      cells, we selected a Jurkat cell line that did not contain endogenous
      <protein>NF-IL6</protein>. In this cellular environment, we evaluated the effect of exogenous
      <protein>NF-IL6</protein> on transcription mediated by native and deleted LTR sequences. In
      Jurkat cells stimulated with LPS and PMA, LTR-mediated transcription was
      enhanced by <protein>NF-IL6</protein>. The results of deletion studies revealed a central
      role for the basal LTR region and the TATA element in the LTR, in
      upregulation of reporter gene expression by <protein>NF-IL6</protein> in activated cells. In
      the selected cellular environment, regulation of transcription by <protein>NF-IL6</protein>
      was not evident in studies of promoter regions of other genes. The results
      implied that the basal region of HIV-1 LTR includes molecular properties
      that support activation of HIV-1 by <protein>NF-IL6</protein> in stimulated cells.
</DOC>
<DOC>
<DOC_ID>[124]</DOC_ID>
>124.NF00028075
PMID:12110845
TI  - <long_form><protein>Synaptotagmins I</protein> and IV</long_form> promote transmitter release independently of
      Ca(2+) binding in the C(2)A domain.
AB  - At nerve terminals, a focal and transient increase in intracellular Ca(2+)
      triggers the fusion of neurotransmitter-filled vesicles with the plasma
      membrane. The most extensively studied candidate for the Ca(2+)-sensing
      <protein>trigger</protein> is <protein>synaptotagmin I</protein>, whose Ca(2+)-dependent interactions with
      acidic phospholipids and <protein>syntaxin</protein> have largely been ascribed to its C(2)A
      domain, although the C(2)B domain also binds Ca(2+) (refs 7, 8). Genetic
      tests of <protein>synaptotagmin I</protein> have been equivocal as to whether it is the
      Ca(2+)-sensing trigger of fusion. <protein>Synaptotagmin IV</protein>, a related isoform that
      does not bind Ca(2+) in the C(2)A domain, might be an inhibitor of
      release. We mutated an essential aspartate of the Ca(2+)-binding site of
      the <protein>synaptotagmin I</protein> C(2)A domain and expressed it in Drosophila lacking
      <protein>synaptotagmin I</protein>. Here we show that, despite the disruption of the binding
      site, the Ca(2+)-dependent properties of transmission were not altered.
      Similarly, we found that <protein>synaptotagmin IV</protein> could substitute for
      <protein>synaptotagmin I</protein>. We conclude that the C(2)A domain of <protein>synaptotagmin</protein> is not
      required for Ca(2+)-dependent synaptic transmission, and that
      <protein>synaptotagmin IV</protein> promotes rather than inhibits transmission.
</DOC>
<DOC>
<DOC_ID>[125]</DOC_ID>
>125.NF00943016
PMID:12445816
TI  - <protein>ABCC13</protein>, an unusual truncated <protein>ABC transporter</protein>, is highly expressed in fetal
      human liver.
AB  - In the present study, we have cloned the cDNA of <protein>ABCC13</protein>, a novel <protein>ABC</protein>
      <protein>transporter</protein>, from the cDNA library of adult human placenta. The <protein>ABCC13</protein>
      gene spans approximately 70kb on human chromosome 21q11.2 and consists of
      14 exons. The open reading frame of the <protein>ABCC13</protein> cDNA encodes a peptide
      consisting of 325 amino acid residues. The amino acid sequence
      corresponding to putative membrane-spanning domains was remarkably similar
      to <protein>ABCC1</protein>, <protein>ABCC2</protein>, <protein>ABCC3</protein>, and <protein>ABCC6</protein>. The <protein>ABCC13</protein> gene was expressed in the
      fetal liver at the highest level among the organs studied. While <protein>ABCC13</protein>
      was expressed in the bone marrow, its expression in peripheral blood
      leukocytes of adult humans was much lower and no detectable levels were
      observed in differentiated hematopoietic cells. The expression of <protein>ABCC13</protein>
      in K562 cells decreased during cell differentiation induced by TPA. These
      results suggest that the expression of <long_form>human <protein>ABCC13</protein></long_form> is related with
      hematopoiesis.
</DOC>
<DOC>
<DOC_ID>[126]</DOC_ID>
>126.NF00115637
PMID:11933207
TI  - Five novel mutations in the <protein>C1 inhibitor</protein> gene (<protein>C1NH</protein>) leading to a
      premature stop codon in patients with type I hereditary angioedema.
AB  - Hereditary angioedema (HAE) is a disorder characterised by recurrent
      attacks of localized subcutaneous or submucosal edema. It is inherited in
      an autosomal dominant fashion and caused by a deficiency of <protein>C1 inhibitor
      (C1 inh, or C1NH)</protein>. Most patients with HAE have an absolute deficiency of
      <protein>C1 inh</protein> (type I HAE) while the rest (15% of kindreds) synthetize a
      dysfunctional <protein>C1 inh protein</protein> (type II HAE). In this report a novel use of
      denaturing gradient gel electrophoresis (DGGE) followed by direct
      sequencing of the <protein>C1 inhibitor</protein> gene is presented. Five novel mutations,
      one nonsense (p.S48X) and four small deletions resulting in frameshifts
      (g.2264-2265delAG, g.2304delC, g.8493-8494delCC and g.16676-16677delTG)
      have been identified in the <protein>C1 inhibitor</protein> gene in five families with type I
      HAE. All of these mutations lead to premature termination of translation
      and thus can be considered causative of the <protein>C1 inh</protein> deficiency. Moreover,
      two previously described mutations in the reactive center of <protein>C1 inh</protein>,
      p.R444C and p.R444H, have been detected in four unrelated patients with
      type II HAE.
</DOC>
<DOC>
<DOC_ID>[127]</DOC_ID>
>127.NF00097702
PMID:11991731
TI  - Cardiac expression and subcellular localization of the <protein>p38
      mitogen-activated protein kinase</protein> member, <protein>stress-activated protein kinase-3
      (SAPK3)</protein>.
AB  - Despite the interest in the roles that <protein>mitogen-activated protein kinases
      (MAPKs)</protein> play in the heart, the role of the different <protein>MAPK isoforms</protein> has
      been relatively poorly defined. A third <protein>isoform of p38 MAPK</protein>, known
      variously as <protein>stress-activated protein kinase-3 (SAPK3)</protein>, <protein>p38- gamma</protein> or
      <protein>ERK6</protein>, has been previously shown to differ from <long_form><protein>p38- alpha</protein>/ beta</long_form> both in
      its molecular weight and its lack of inhibition by the compound SB203580.
      We have generated monoclonal antibodies with specificity for <protein>SAPK3</protein>
      demonstrated by immunoblot analysis, immunofluorescence studies, and
      cloning of <protein>SAPK3</protein> from a rat heart cDNA expression library. By
      immunoblotting, we confirmed high expression of <protein>SAPK3</protein> in fast, slow and
      mixed fibre types of murine skeletal muscle and observed significant
      expression restricted to heart, lung, thymus and testes. In addition to
      expression in normal heart (human, mouse, rat, dog and pig), we observed
      constant expression in diseased human heart, as well as control and
      hypertrophic cultured neonatal rat cardiac myocytes. Immunolocalization in
      cultured cardiac myocytes followed by confocal microscopy showed punctate,
      non-nuclear <protein>SAPK3</protein> staining. In contrast, <long_form><protein>p38- alpha</protein>/ beta</long_form> staining was
      non-punctate and distributed throughout the cytosol and nucleus. Whereas
      treatment with Leptomycin B to prevent nuclear export processes promoted
      higher levels of <long_form><protein>p38- alpha</protein>/ beta</long_form> staining in cardiac myocyte nuclei,
      there was no apparent change in <protein>SAPK3</protein> localization under these conditions.
      These differences between <long_form><protein>p38- alpha</protein>/ beta</long_form> and <protein>SAPK3</protein> probably reflect the
      specialized functions of <protein>SAPK3</protein> and emphasize the need to evaluate <protein>SAPK3</protein>
      upstream activators and downstream targets in the heart.
</DOC>
<DOC>
<DOC_ID>[128]</DOC_ID>
>128.NF00115397
PMID:11994747
TI  - Closing in on the biological functions of <protein>Fps</protein>/<protein>Fes</protein> and <protein>Fer</protein>.
AB  - <protein>Fps</protein>/<protein>Fes</protein> and <protein>Fer</protein> are the only known members of a distinct subfamily of the
      <protein>non-receptor protein-tyrosine kinase</protein> family. Recent studies indicate that
      these <protein>kinases</protein> have roles in regulating cytoskeletal rearrangements and
      inside out signalling that accompany <protein>receptor</protein> ligand, cell matrix and cell
      cell interactions. Genetic analysis using transgenic mouse models also
      implicates these <protein>kinases</protein> in the regulation of inflammation and innate
      immunity.
</DOC>
<DOC>
<DOC_ID>[129]</DOC_ID>
>129.NF00088551
PMID:12054582
TI  - Chromosomal organization and localization of the <long_form>human <protein>histone deacetylase
      9</protein></long_form> gene (<protein>HDAC9</protein>).
AB  - Epigenetically mediated modulation of gene promoter function through
      <protein>histone acetylation modifying enzymes</protein>, which regulate the acetylation
      state of <protein>histone proteins</protein> and other promoter-bound <protein>transcription factors</protein>,
      is increasingly appreciated as a key component in the regulation of
      reversible gene expression. While <protein>histone acetyltransferases (HATs)</protein>, which
      are frequently part of <protein>multisubunit coactivator complexes</protein>, lead to the
      relaxation of chromatin structure and transcriptional activation, <protein>histone
      deacetylases (HDACs)</protein> tend to associate with <protein>multisubunit corepressor
      complexes</protein>, which result in chromatin condensation and transcriptional
      repression of specific target genes. We have isolated and characterized
      the <long_form>human <protein>HDAC9</protein></long_form> genomic sequence, which spans a region of 458 kb and which
      has one single chromosomal locus. Determination of the exon-intron
      splice-junctions established that <protein>HDAC9</protein> is encoded by 23 exons ranging in
      size from 22 bp (exon 1) to 264 bp (exon 11). Characterization of the 5'
      flanking genomic region revealed that the <long_form>human <protein>HDAC9</protein></long_form> promoter lacks both
      the canonical TATA and CCAAT boxes; CpG elements are missing. The <long_form>human
      <protein>HDAC9</protein></long_form> open reading frame is 3036 bp long and encodes a 1011 aa protein
      with a predictive molecular weight of 111.3 kDa and an isoelectric point
      of 6.41. Fluorescence in situ hybridization analysis localized the <long_form>human
      <protein>HDAC9</protein></long_form> gene to chromosome 7p21, a region which has been associated
      particularly with the pathogenesis of gynecological tumors.
</DOC>
<DOC>
<DOC_ID>[130]</DOC_ID>
>130.NF01099109
PMID:11840501
TI  - Lack of association between <protein>HoxA1</protein> and <protein>HoxB1</protein> gene variants and autism in
      110 multiplex families.
AB  - A recent report suggested that the <protein>HoxA1</protein> and/or <protein>HoxB1</protein> genes play a role in
      susceptibility to autism. To determine whether these findings could be
      confirmed, we screened these genes for DNA polymorphisms by sequencing all
      exons in 24 individuals with autism. We identified the same sequence
      variants in the genes that appeared in this report, which include one
      single-base substitution variant in <protein>HoxA1</protein> and a common haplotype in <protein>HoxB1</protein>.
      We performed an association study by applying the transmission
      disequilibrium test to detect possible association of these variants to
      autism in 110 multiplex families. Our results demonstrated no deviation
      from the null hypothesis of no association. We have also separately
      examined transmissions within individual mating types, for paternal versus
      maternal alleles, to affected versus unaffected children, and for
      transmission to affected boys versus girls. None of these subsets revealed
      significant deviation from the null expectation. Our interpretation of
      these findings is that it is unlikely that <protein>HoxA1</protein> and <protein>HoxB1</protein> play a
      significant role in the genetic predisposition to autism.
</DOC>
<DOC>
<DOC_ID>[131]</DOC_ID>
>131.NF00089606
PMID:11831556
TI  - CSF total <protein>tau</protein>, <protein>Abeta42</protein> and phosphorylated <protein>tau protein</protein> as biomarkers for
      Alzheimer's disease.
AB  - With the arrival of effective symptomatic treatments and the promise of
      drugs that may delay progression, we now need to identify Alzheimer's
      disease (AD) at an early stage of the disease. To diagnose AD earlier and
      more accurately, attention has been directed toward peripheral biochemical
      markers. This article reviews promising potential cerebrospinal fluid
      (CSF) biomarkers for AD focussing on their role in clinical diagnosis. In
      particular, two biochemical markers, CSF total <protein>tau</protein> (t-tau) protein and the
      <protein>42 amino acid form of beta-amyloid (Abeta42)</protein>, perform satisfactorily
      enough to achieve a role in the clinical diagnostic settings of patients
      with dementia together with the cumulative information from basic clinical
      work-up, genetic screening, and brain imaging. These CSF markers are
      particularly useful to discriminate early or incipient AD from
      age-associated memory impairment, depression, and some secondary
      dementias. In order to discriminate AD from other primary dementia
      disorders, however, more accurate and specific markers are needed.
      Preliminary evidence strongly suggests that quantification of <protein>tau</protein>
      phosphorylated at specific sites in CSF improves early detection,
      differential diagnosis, and tracking of disease progression in AD.
</DOC>
<DOC>
<DOC_ID>[132]</DOC_ID>
>132.NF00095768
PMID:12112824
TI  - Cytological grading, apoptosis, and <protein>Bcl-2 protein</protein> expression in breast
      cancer.
AB  - A prospective study was conducted on 27 cases of infiltrating duct
      carcinoma of breast diagnosed by fine-needle aspirate cytology (FNAC),
      subjected to mastectomy following the FNA diagnosis. Cytological grading,
      <protein>Bcl-2</protein> score, and quantification of apoptotic cell count were done on FNA
      material. Next, the carcinomas were graded on the corresponding
      histopathological sections. The overall concordance between cytological
      and histological gradings was 77.7%, with maximum concordance in Grade I
      tumors and minimum in Grade II. The mean apoptotic rates were 0.59 +/-
      0.722, 2.11 +/- 0.707, and 2.95 +/- 0.854 in Grades I, II, and III,
      respectively. Similarly <protein>Bcl-2</protein> scores were 1.36 +/- 0.82, 0.22 +/- 0.13,
      and 0.14 +/- 0.116, in Grades I, II, and III lesions, respectively. When
      the cytological grade was correlated with histological grade alone, and
      subsequently along with <protein>Bcl-2</protein> scores and apoptotic rates, there was a
      significant improvement from 0.662-0.713 (P value, 0.001).
</DOC>
<DOC>
<DOC_ID>[133]</DOC_ID>
>133.NF01222501
PMID:12386808
TI  - <protein>Cdk9</protein>, a member of the <protein>cdc2</protein>-like family of <protein>kinases</protein>, binds to <protein>gp130</protein>, the
      <protein>receptor</protein> of the <protein>IL-6</protein> family of <protein>cytokines</protein>.
AB  - <protein>Cdk9</protein> is a member of the <protein>Cdc2</protein>-like family of <protein>kinases</protein>. It binds to members
      of the family of <long_form><protein>cyclin T</protein> (T1, T2a and T2b)</long_form> and to <protein>cyclin K</protein>. The
      <long_form><protein>Cdk9</protein>/<protein>cyclin T</protein> complex</long_form> appears to be involved in regulating several
      physiological processes. In fact <protein>Cdk9</protein> is the <protein>kinase of the P-TEFb complex</protein>,
      involved in basal transcription. <protein>Cdk9</protein> has also been described as the
      <protein>kinase of the TAK complex</protein>, homologous to <protein>P-TEFb</protein> and involved in HIV
      replication. Here we show that <protein>Cdk9</protein> interacts with <protein>gp130</protein>, the <protein>receptor</protein> of
      the <protein>Interleukin-6 (IL-6)</protein> family of <protein>cytokines</protein>, which includes <protein>Leukemia
      Inhibitory Factor (LIF)</protein>, <protein>Oncostatin M (OSM)</protein>, <protein>Ciliary Neurotrophic Factor
      (CNTF)</protein>, <protein>Interleukin-11 (IL-11)</protein> and <protein>Cardiotrophin (CT-1)</protein>. <protein>IL-6</protein> is a key
      regulator of hematopoiesis, immunological responses and inflammation. In
      addition, <protein>IL-6</protein> plays a major role in the endocrine and nervous systems.
      Signal transduction by <protein>gp130</protein> is mediated by physical interaction of the
      cytoplasmic region of <protein>gp130</protein> with <protein>cellular kinases</protein> and results in the
      transcriptional activation of cellular and viral genes. We found that <protein>Cdk9</protein>
      interacts in vitro with the cytoplasmic region of <protein>gp130</protein> and we succeded in
      reproducing this interaction in vivo. <protein>Cdk9</protein> expression was found both in
      the nucleus and in the cytoplasm. The binding occurring between <protein>Cdk9</protein> and
      <protein>gp130</protein> increased upon <protein>IL-6</protein> stimulation. We also observed that <protein>Cdk9</protein>
      synergized with <protein>IL-6</protein> in inducing the activation of an <protein>IL-6</protein>-responsive
      reporter plasmid. In summary, these results point to a previously
      undisclosed role for <protein>Cdk9</protein> in signal transduction.
</DOC>
<DOC>
<DOC_ID>[134]</DOC_ID>
>134.NF01070140
PMID:12531696
TI  - <protein>Notch2 protein</protein> distribution in human teeth under normal and pathological
      conditions.
AB  - <protein>Notch</protein> signaling is essential for the appropriate differentiation of many
      cell types during development and, furthermore, is implicated in a variety
      of human diseases. Previous studies have shown that although the <long_form><protein>Notch1</protein>,
      -2, and -3 <protein>receptors</protein></long_form> are expressed in developing and injured rodent teeth,
      <protein>Notch2</protein> expression was predominant after a lesion. To pursue the role of
      the <protein>Notch</protein> pathway in tooth development and disease, we have analyzed the
      expression of the <protein>Notch2 protein</protein> in embryonic and adult wounded human
      teeth. During the earlier stages of tooth development, the <protein>Notch2 protein</protein>
      was expressed in the epithelium, but was absent from proliferating cells
      of the inner enamel epithelium. At more advanced stages, <protein>Notch2</protein> was
      expressed in the enamel-producing ameloblasts, while it was absent in
      mesenchyme-derived odontoblasts that synthesize the dentin matrix.
      Although <protein>Notch2</protein> was not expressed in the pulp of adult intact teeth, it
      was reexpressed during dentin repair processes in odontoblasts and
      subodontoblastic cells. <protein>Transforming growth factor beta-1</protein>, which
      stimulates odontoblast differentiation and hard tissue formation after
      dental injury, downregulated <protein>Notch2</protein> expression in cultured human dental
      slices, in vitro. These observations are consistent with the notion that
      <protein>Notch</protein> signaling is an important element in dental physiological and
      pathogenic conditions.
</DOC>
<DOC>
<DOC_ID>[135]</DOC_ID>
>135.NF01070224
PMID:12124628
TI  - <long_form>Adenovirus <protein>oncoproteins</protein></long_form> inactivate the <long_form><protein>Mre11</protein>-<protein>Rad50</protein>-<protein>NBS1</protein> DNA repair
      complex</long_form>.
AB  - In mammalian cells, a conserved <long_form>multiprotein complex of <protein>Mre11</protein>, <protein>Rad50</protein> and
      <protein>NBS1</protein></long_form> (also known as <protein>nibrin</protein> and <protein>p95</protein>) is important for double-strand break
      repair, meiotic recombination and telomere maintenance. This complex forms
      nuclear foci and may be a sensor of double-strand breaks. In the absence
      of the early region E4, the double-stranded DNA genome of adenovirus is
      joined into concatemers too large to be packaged. We have investigated the
      <protein>cellular proteins</protein> involved in this concatemer formation and how they are
      inactivated by E4 products during a wild-type infection. Here we show that
      concatemerization requires functional <protein>Mre11</protein> and <protein>NBS1</protein>, and that these
      proteins are found at foci adjacent to viral replication centres.
      Infection with wild-type virus results in both reorganization and
      degradation of members of the <long_form><protein>Mre11</protein>-<protein>Rad50</protein>-<protein>NBS1</protein> complex</long_form>. These activities
      are mediated by three <long_form>viral <protein>oncoproteins</protein></long_form> that prevent concatemerization.
      This targeting of <protein>cellular proteins</protein> involved in genomic stability suggests
      a mechanism for 'hit-and-run' transformation observed for these <long_form>viral
      <protein>oncoproteins</protein></long_form>.
</DOC>
<DOC>
<DOC_ID>[136]</DOC_ID>
>136.NF00137104
PMID:12107724
TI  - Impaired glucose tolerance is associated with increased serum
      concentrations of <protein>interleukin 6</protein> and co-regulated <protein>acute-phase proteins</protein> but
      not <protein>TNF-alpha</protein> or its <protein>receptors</protein>.
AB  - AIMS/HYPOTHESIS: A population-based sample was studied to define immune
      abnormalities in individuals at risk of Type II (non-insulin-dependent)
      diabetes mellitus because of impaired glucose tolerance. METHODS: A total
      of 1653 individuals aged 55 to 74 years participated in a population based
      survey in Southern Germany (KORA Survey 2000). Those without a history of
      diabetes were subjected to an OGTT. Randomly selected subjects with IGT (
      n=80) were compared with non-diabetic control subjects ( n=77) and
      patients with Type II diabetes ( n=152) of the same population-based
      sample after matching for age and sex. Immune parameters were analysed in
      serum with rigidly evaluated ELISA. RESULTS: Serum <protein>pro-inflammatory
      cytokine interleukin 6 (IL-6) </protein>concentrations were higher in subjects with
      IGT and Type II diabetes than in the control subjects (median 1.8 and 2.5
      vs 0.8 pg/ml, p&lt;0.0001). <protein>Soluble IL-6 receptors</protein> potentiate <protein>IL-6</protein>
      bioactivity and their concentrations were mildly increased in Type II
      diabetes ( p&lt;0.05). These immune changes seem relevant because <protein>IL-6</protein>
      dependent <protein>acute-phase proteins C-reactive protein</protein>, <protein>serum amyloid A protein</protein>
      and <protein>fibrinogen</protein> were also increased in IGT and Type II diabetes.
      Circulating concentrations of <protein>TNF-alpha</protein> and its two <protein>receptors</protein> <protein>sTNF-R60</protein> and
      <protein>sTNF-R80</protein> were not increased in IGT subjects compared with the control
      subjects. CONCLUSION/INTERPRETATION: Our study shows systemic
      up-regulation of selected inflammatory mediators in patients with Type II
      diabetes and IGT. The pattern observed is non-random and fits with an <protein>IL-6</protein>
      associated rather than <protein>TNF-alpha</protein> associated response.
</DOC>
<DOC>
<DOC_ID>[137]</DOC_ID>
>137.NF00140831
PMID:11911837
TI  - Association of <protein>dopamine D(3) receptors</protein> with <protein>actin-binding protein 280
      (ABP-280)</protein>.
AB  - Proteins that bind to <protein>G protein-coupled receptors</protein> have been identified as
      regulators of <protein>receptor</protein> localization and signaling. In our previous
      studies, a <protein>cytoskeletal protein</protein>, <protein>actin-binding protein 280 (ABP-280)</protein>, was
      found to associate with the third cytoplasmic loop of <protein>dopamine D(2)
      receptors</protein>. In this study, we demonstrate that <protein>ABP-280</protein> also interacts with
      <protein>dopamine D(3) receptors</protein>, but not with <protein>D(4) receptors</protein>. Similar to the
      <protein>dopamine D(2) receptor</protein>, the D(3)/<protein>ABP-280</protein> association is of signaling
      importance. In human melanoma M2 cells lacking <protein>ABP-280</protein>, <protein>D(3) receptors</protein>
      were unable to inhibit forskolin-stimulated cyclic AMP (cAMP) production
      significantly. <protein>D(4) receptors</protein>, however, exhibited a similar degree of
      inhibition of forskolin-stimulated cAMP production in <protein>ABP-280</protein>-deficient M2
      cells and <protein>ABP-280</protein>-replent M2 subclones (A7 cells). Further experiments
      revealed that the D(3)/<protein>ABP-280</protein> interaction was critically dependent upon a
      36 amino acid carboxyl domain of the <protein>D(3) receptor</protein> third loop, which is
      conserved in the <protein>D(2) receptor</protein> but not in the <protein>D(4) receptor</protein>. Our results
      demonstrate a subtype-specific regulation of <protein>dopamine D(2)-family receptor</protein>
      signaling by the <protein>cytoskeletal protein ABP-280</protein>.
</DOC>
<DOC>
<DOC_ID>[138]</DOC_ID>
>138.NF00090206
PMID:12141441
TI  - <protein>PAX</protein> genes in development and disease: the role of <protein>PAX2</protein> in urogenital tract
      development.
AB  - <protein>PAX</protein> genes play an important role in fetal development. Moreover,
      heterozygous mutations in several <protein>PAX</protein> genes cause human disease. Here we
      review the role of <protein>PAX2</protein> in kidney development, focusing on the
      morphological effects of <protein>PAX2</protein> mutations. We discuss the role of <protein>PAX2</protein> in
      the context of an inhibitory field model of kidney branching morphogenesis
      and summarize recent progress in this area.
</DOC>
<DOC>
<DOC_ID>[139]</DOC_ID>
>139.NF00081216
PMID:12547701
TI  - <protein>CC chemokine receptor 8</protein> in the central nervous system is associated with
      phagocytic macrophages.
AB  - <protein>CC chemokine receptor 8 (CCR8)</protein> has been detected in vitro on type 2 helper
      and regulatory lymphocytes, which might exert beneficial functions in
      multiple sclerosis (MS) and on macrophages and microglia, possibly
      promoting tissue injury in MS lesions. To discriminate the relevant
      expression pattern in vivo, we defined the cell types that expressed <protein>CCR8</protein>
      in MS lesions and determined the relationship of <protein>CCR8</protein> expression and
      demyelinating activity. <protein>CCR8</protein> was not expressed on T cells but was
      associated with phagocytic macrophages and activated microglia in MS
      lesions and directly correlated with demyelinating activity. To identify
      factors associated with <protein>CCR8</protein> expression, the study was extended to other
      central nervous system (CNS) pathologies. <protein>CCR8</protein> was consistently expressed
      on phagocytic macrophages and activated microglia in stroke and
      progressive multifocal leukoencephalopathy, but not expressed on microglia
      in pathologies that lacked phagocytic macrophages such as senile change of
      the Alzheimer's type. <protein>CCR8</protein> was up-regulated by macrophage differentiation
      and activating stimuli in vitro. In summary <protein>CNS CCR8</protein> expression was
      associated with phagocytic macrophages and activated microglial cells in
      human CNS diseases, suggesting that <protein>CCR8</protein> may be a feasible target for
      therapeutic intervention in MS. <protein>CCR8</protein> expression may also indicate a
      selective program of mononuclear phagocyte gene expression.
</DOC>
<DOC>
<DOC_ID>[140]</DOC_ID>
>140.NF00126254
PMID:12297502
TI  - Inhibition of silencing and accelerated aging by nicotinamide, a putative
      negative regulator of yeast <protein>sir2</protein> and <long_form>human <protein>SIRT1</protein></long_form>.
AB  - The Saccharomyces cerevisiae <protein>Sir2 protein</protein> is an <protein>NAD(+)-dependent histone
      deacetylase</protein> that plays a critical role in transcriptional silencing,
      genome stability, and longevity. A human homologue of <protein>Sir2</protein>, <protein>SIRT1</protein>,
      regulates the activity of the <protein>p53 tumor suppressor</protein> and inhibits apoptosis.
      The <protein>Sir2</protein> deacetylation reaction generates two products:
      O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a
      form of niacin/vitamin B(3). We show here that nicotinamide strongly
      inhibits yeast silencing, increases rDNA recombination, and shortens
      replicative life span to that of a <protein>sir2</protein> mutant. Nicotinamide abolishes
      silencing and leads to an eventual delocalization of <protein>Sir2</protein> even in
      G(1)-arrested cells, demonstrating that silent heterochromatin requires
      continual <protein>Sir2</protein> activity. We show that physiological concentrations of
      nicotinamide noncompetitively inhibit both <protein>Sir2</protein> and <protein>SIRT1</protein> in vitro. The
      degree of inhibition by nicotinamide (IC(50) &lt; 50 microm) is equal to or
      better than the most effective known synthetic inhibitors of this class of
      proteins. We propose a model whereby nicotinamide inhibits deacetylation
      by binding to a conserved pocket adjacent to NAD(+), thereby blocking
      NAD(+) hydrolysis. We discuss the possibility that nicotinamide is a
      physiologically relevant regulator of <protein>Sir2 enzymes</protein>.
</DOC>
<DOC>
<DOC_ID>[141]</DOC_ID>
>141.NF01222508
PMID:11927593
TI  - The newly identified <long_form>human <protein>nuclear protein NXP-2</protein></long_form> possesses three distinct
      domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains.
AB  - Using a <protein>monoclonal antibody</protein> that recognizes a <protein>nuclear matrix protein</protein>, we
      selected a cDNA clone from a lambdagt11 human placenta cDNA library. This
      cDNA encoded a 939-amino acid protein designated <protein>nuclear matrix protein
      NXP-2</protein>. Northern blot analysis indicated that <protein>NXP-2</protein> was expressed in
      various tissues at different levels. Forcibly expressed green fluorescent
      protein-tagged <protein>NXP-2</protein> as well as endogenous <protein>NXP-2</protein> was localized in the
      nucleus and distributed to the nuclear matrix. <protein>NXP-2</protein> was released from the
      nuclear matrix when <protein>RNase A</protein> was included in the buffer for nuclear matrix
      preparation. Mapping of functional domains was carried out using green
      fluorescent protein-tagged truncated mutants of <protein>NXP-2</protein>. The region of amino
      acids 326-353 was responsible for nuclear matrix binding and contained a
      cluster of hydrophobic amino acids that was similar to the nuclear matrix
      targeting signal of <protein>acute myeloleukemia protein</protein>. The central region (amino
      acids 500-591) was demonstrated to be required for RNA binding by
      Northwestern analysis, although <protein>NXP-2</protein> lacked a known RNA binding motif.
      The region of amino acid residues 682-876 was predicted to have a
      coiled-coil structure. The RNA-binding, nuclear matrix-binding, and
      coiled-coil domains are structurally separated, suggesting that <protein>NXP-2</protein>
      plays important roles in diverse nuclear functions, including RNA
      metabolism and maintenance of nuclear architecture.
</DOC>
<DOC>
<DOC_ID>[142]</DOC_ID>
>142.NF01070309
PMID:12481029
TI  - The <protein>DNA methyltransferase-like protein DNMT3L</protein> stimulates de novo
      methylation by <protein>Dnmt3a</protein>.
AB  - <protein>Dnmt3L</protein> is required for the establishment of maternal methylation imprints
      at imprinting centers (ICs). <protein>Dnmt3L</protein>, however, lacks the conserved
      catalytic domain common to <protein>DNA methyltransferases</protein>. In an attempt to define
      its function, we coexpressed <protein>DNMT3L</protein> with each of the two known de novo
      <protein>methyltransferases</protein>, <protein>Dnmt3a</protein> and <protein>DNMT3B</protein>, in human cells and monitored de
      novo methylation by using replicating minichromosomes carrying various ICs
      as targets. Coexpression of <protein>DNMT3L</protein> with <protein>DNMT3B</protein> led to little or no change
      in target methylation. However, coexpression of <protein>DNMT3L</protein> with <protein>Dnmt3a</protein>
      resulted in a striking stimulation of de novo methylation by <protein>Dnmt3a</protein>.
      Stimulation was observed at maternally methylated ICs such as <protein>small
      nuclear ribonucleoprotein polypeptide N (SNRPN)</protein>, <protein>Snrpn</protein>, and <protein>Igf2rAir</protein>, as
      well as at various nonimprinted sequences present on the episomes.
      Stimulation of <protein>Dnmt3a</protein> by <protein>DNMT3L</protein> was also observed at endogenous sequences
      in the genome. Therefore, <protein>DNMT3L</protein> acts as a general stimulatory factor for
      de novo methylation by <protein>Dnmt3a</protein>. The implications of these findings for the
      function of <protein>DNMT3L</protein> and <protein>Dnmt3a</protein> in DNA methylation and genomic imprinting
      are discussed.
</DOC>
<DOC>
<DOC_ID>[143]</DOC_ID>
>143.NF00108436
PMID:11980634
TI  - <protein>Platelet-derived growth factor D</protein>: tumorigenicity in mice and dysregulated
      expression in human cancer.
AB  - <protein>Platelet-derived growth factor (PDGF)</protein> has been directly implicated in
      developmental and physiological processes, as well as in human cancer and
      other proliferative disorders. We have recently isolated and characterized
      a novel <protein>protease</protein>-activated member of the <protein>PDGF</protein> family, <protein>PDGF D</protein>. <protein>PDGF D</protein> has
      been shown to be proliferative for cells of mesenchymal origin, signaling
      through <protein>PDGF receptors</protein>. Comprehensive and systematic <protein>PDGF D</protein> transcript
      analysis revealed expression in many cell lines derived from ovarian,
      renal, and lung cancers, as well as from astrocytomas and
      medulloblastomas. beta <protein>PDGF receptor</protein> profiling further suggested autocrine
      signaling in several brain tumor cell lines. <protein>PDGF D</protein> transforming ability
      and tumor formation in SCID mice was further demonstrated. Exploiting a
      sensitive <protein>PDGF D</protein> sandwich ELISA using fully human monoclonal antibodies,
      <protein>PDGF D</protein> was detected at elevated levels in the sera of ovarian, renal,
      lung, and brain cancer patients. Immunohistochemical analysis confirmed
      <protein>PDGF D</protein> localization to ovarian and lung tumor tissues. Together, these
      data demonstrate that <protein>PDGF D</protein> plays a role in certain human cancers.
</DOC>
<DOC>
<DOC_ID>[144]</DOC_ID>
>144.NF00911921
PMID:11810296
TI  - A major marker for normal tension glaucoma: association with polymorphisms
      in the <protein>OPA1</protein> gene.
AB  - Normal tension glaucoma (NTG) is a major form of glaucoma, associated with
      intraocular pressures that are within the statistically normal range of
      the population. <protein>OPA1</protein>, the gene responsible for autosomal dominant optic
      atrophy represents an excellent candidate gene for NTG, as the clinical
      phenotypes are similar and <protein>OPA1</protein> is expressed in the retina and optic
      nerve. Eighty-three well-characterized NTG patients were screened for
      mutations in <protein>OPA1</protein> by heteroduplex analysis and bi-directional sequencing.
      Sequences found to be altered in NTG subjects were examined for variations
      in 100 population controls. A second cohort of 80 NTG patients and 86
      population controls was subsequently screened to determine whether the
      initial findings could be replicated. A single nucleotide polymorphism
      (SNP) on intervening sequence (IVS) 8 (IVS8 + 4 C/T) was found to be
      strongly associated with the occurrence of NTG in both cohorts
      (chi(2)=7.97, P=0.005 in the first cohort, chi(2)=9.93, P=0.002 in the
      second cohort; odds ratio 3.1 (95% CI: 1.8-5.6). A second SNP (IVS8 + 32
      T/C) appeared to be associated with disease in the first cohort
      (chi(2)=4.71, P=0.030), but this finding could not be replicated in the
      second cohort. In the combined cohort, the compound at-risk genotype IVS8
      + 4 C/T, + 32 T/C was strongly associated with the occurrence of NTG
      (chi(2)=22.04, P=0.00001 after correcting for testing four genotypes).
      These results indicate that polymorphisms in the <protein>OPA1</protein> gene are associated
      with NTG and may be a marker for the disease.
</DOC>
<DOC>
<DOC_ID>[145]</DOC_ID>
>145.NF00114756
PMID:12095614
TI  - Direct addition of <protein>BimL</protein> to mitochondria does not lead to <protein>cytochrome c</protein>
      release.
AB  - Pro-apoptotic members of the <protein>Bcl-2</protein> family can be subdivided in two classes
      according to their structure: a group including <protein>Bax</protein>, <protein>Bak</protein>, and <protein>Bok</protein> that
      display <protein>Bcl-2</protein> homology (BH) 1, BH2 and BH3 domains and a second group
      including <protein>Bid (BH3 interacting domain death agonist)</protein>, <protein>Bad</protein>, <protein>Bim (Bcl-2
      interacting mediator of cell death)</protein> and several others that contain only a
      BH3 domain, the <protein>BH3-only proteins</protein>. The <protein>BH3-only proteins</protein> have been
      proposed to activate pro-apoptotic members of the <protein>Bax</protein> subfamily to trigger
      a mitochondrial pathway that leads to the release of <protein>cytochrome c</protein> and
      other apoptogenic factors. Here we report that the mechanism of action of
      <protein>Bim</protein> is different from that of <protein>Bid</protein>. Although overexpression of <protein>Bid</protein> or <protein>Bim</protein>
      in cells leads to <protein>cytochrome c</protein> release, only <protein>Bid</protein> is able to trigger the
      release of <protein>cytochrome c</protein> through <protein>Bax</protein> activation when added directly to
      isolated mitochondria. <protein>Bim</protein>(L), although unable to activate <protein>Bax</protein>, can
      directly inhibit <protein>Bcl-2</protein> or <protein>Bcl-x</protein>(L). Our data suggest two functional
      classes of <protein>BH3-only proteins</protein>: those such as <protein>Bid</protein> which directly activate
      <protein>Bax-like proteins</protein> leading to mitochondrial membrane permeability and
      apoptosis and those such as <protein>Bim</protein> which inhibit <protein>anti-apoptotic proteins</protein> and
      render the cells more susceptible to apoptogenic stimuli.
</DOC>
<DOC>
<DOC_ID>[146]</DOC_ID>
>146.NF00097631
PMID:11991808
TI  - <long_form>Human <protein>CCS</protein></long_form> gene: genomic organization and exclusion as a candidate for
      amyotrophic lateral sclerosis (ALS).
AB  - BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive lethal
      disorder of large motor neurons of the spinal cord and brain. In
      approximately 20% of the familial and 2% of sporadic cases the disease is
      due to a defect in the gene encoding the <protein>cytosolic antioxidant enzyme Cu,
      Zn-superoxide dismutase (SOD1)</protein>. The underlying molecular defect is known
      only in a very small portion of the remaining cases and therefore
      involvement of other genes is likely. As <protein>SOD1</protein> receives copper, essential
      for its normal function, by the <protein>copper chaperone</protein>, <protein>CCS (Copper Chaperone
      for SOD)</protein>, we considered <protein>CCS</protein> as a potential candidate gene for ALS.
      RESULTS: We have characterized the genomic organization of <protein>CCS</protein> and
      determined exon-intron boundaries. The 823 bp coding region of the <protein>CCS</protein> is
      organized in 8 exons. We have evaluated involvement of the <protein>CCS</protein> in ALS by
      sequencing the entire coding region for mutations in 20 sporadic ALS
      patients. CONCLUSIONS: No causative mutations for the ALS have been
      detected in the <protein>CCS</protein> gene in 20 sporadic ALS patients analyzed, but an
      intragenic single nucleotide polymorphism has been identified.
</DOC>
<DOC>
<DOC_ID>[147]</DOC_ID>
>147.NF00097555
PMID:12147251
TI  - Both <protein>tissue inhibitors of metalloproteinases-1 (TIMP-1)</protein> and <protein>TIMP-2</protein>
      activate <protein>Ras</protein> but through different pathways.
AB  - <protein>Tissue inhibitors of metalloproteinases-1 (TIMP-1)</protein> and <protein>TIMP-2</protein> have
      growth-stimulating activity for a wide range of cell types. <protein>Ras</protein>, which
      comprises a family of three members, i.e, <protein>Ha-Ras</protein>, <protein>Ki-Ras</protein>, and <protein>H-Ras</protein>, is
      known to participate in growth control in all its facets, including cell
      proliferation, transformation, differentiation, and apoptosis. In this
      study, we tested the hypothesis that <protein>Ras</protein> might be involved in the cell
      growth-promoting activity of <protein>TIMPs</protein>. Using MG-63 human osteosarcoma cells,
      we demonstrated that both <protein>TIMP-1</protein> and <protein>TIMP-2</protein> caused an increase in the
      <protein>Ras</protein>-GTP level in a dose-dependent manner. Our previous results indicated
      that <protein>TIMP-1</protein> activity is mediated through the <protein>tyrosine kinase
      (TYK)</protein>/<protein>mitogen-activated protein kinase (MAPK)</protein> pathway. Here, we
      demonstrated that <protein>Ras</protein> activation by <protein>TIMP-1</protein> was inhibited by a specific <protein>TYK</protein>
      inhibitor, herbimycin A, suggesting that the <protein>TYK</protein>/<protein>MAPK</protein> signaling pathway
      was involved in <protein>Ras</protein> activation by <protein>TIMP-1</protein>. However, the activation of <protein>Ras</protein>
      by <protein>TIMP-2</protein> was inhibited by an inhibitor specific for <protein>cyclic AMP-dependent
      protein kinase (PKA)</protein>, H89, suggesting the involvement of the <protein>PKA</protein>-mediated
      pathway. Furthermore, <protein>TIMP-2</protein> promoted the formation of a complex between
      <protein>Ras</protein>-GTP and <protein>phosphoinositide 3-kinase</protein>.
</DOC>
<DOC>
<DOC_ID>[148]</DOC_ID>
>148.NF00079574
PMID:12213900
TI  - Human fallopian tubes express <protein>prostacyclin (PGI) synthase</protein> and
      <protein>cyclooxygenases</protein> and synthesize abundant PGI.
AB  - Animal studies unequivocally support the indispensable role of
      prostaglandin (PG) and <protein>cyclooxygenase (COX)</protein> in ovulation and implantation.
      Available data also suggest that PG and <protein>COX</protein> may be important in the
      transport of embryos. The effects of PGE(2) and PGF(2alpha) on the
      contractility of human tubal muscle have been studied extensively; the
      expression of <protein>COX</protein> in human fallopian tubes was also reported. Despite all
      these, two fundamentally important questions remained to be answered: 1)
      which PGs are produced by human fallopian tubes; and 2) which <protein>COX
      isoform</protein>(s) is expressed by the fallopian tubes. We used reverse-phase HPLC
      to study the metabolism of [1-(14)C] arachidonic acid by the fallopian
      tubes. We found that 6 keto-PGF(1alpha), a stable metabolite of
      prostacyclin (PGI), and PGE(2) constituted 56% +/- 10% and 35% +/- 10%
      (mean +/- SEM, four samples), respectively, of total eicosanoids
      synthesized. Western blot analysis revealed the expression of both <protein>COX
      isoforms</protein>. Immunohistochemistry study showed that both <long_form><protein>COX-1</protein> and -2</long_form> were
      localized to nonciliated epithelia and tubal smooth muscle. In addition,
      <protein>COX-2</protein> was also expressed in ciliated epithelial cells. Western blot
      analysis revealed the expression of <protein>PGI synthase (PGIS)</protein> and <protein>PGI receptor</protein>
      by fallopian tubes. Immunohistochemistry confirmed the expression of <protein>PGIS</protein>
      by luminal epithelia, tubal smooth muscle, vascular endothelial cells, and
      vascular smooth muscle cells. Iloprost, a PGI analog, inhibited the
      activities of circular and longitudinal muscles of the fallopian tube.
      Thus, the fallopian tube expresses both <protein>COX isoforms</protein> and <protein>PGIS</protein>.
      Furthermore, it is a source and a target of PGI. PGI and <protein>COX</protein> may be
      important to gamete function, embryo transport, and embryo development.
</DOC>
<DOC>
<DOC_ID>[149]</DOC_ID>
>149.NF00079494
PMID:11847269
TI  - Alternative type I and I' turn conformations in the beta8/beta9
      beta-hairpin of <long_form>human <protein>acidic fibroblast growth factor</protein></long_form>.
AB  - <long_form>Human <protein>acidic fibroblast growth factor (FGF-1)</protein></long_form> has a beta-trefoil
      structure, one of the fundamental protein superfolds. The X-ray crystal
      structures of wild-type and various mutant forms of <protein>FGF-1</protein> have been solved
      in five different space groups: C2, C222(1), P2(1) (four molecules/asu),
      P2(1) (three molecules/asu), and P2(1)2(1)2(1). These structures reveal
      two characteristically different conformations for the beta8/beta9
      beta-hairpin comprising residue positions 90-94. This region in the
      wild-type <protein>FGF-1</protein> structure (P2(1), four molecules/asu), a his-tagged
      His93--&gt;Gly mutant (P2(1), three molecules/asu) and a his-tagged
      Asn106--&gt;Gly mutant (P2(1)2(1)2(1)) adopts a 3:5 beta-hairpin known as a
      type I (1-4) G1 beta-bulge (containing a type I turn). However, a
      his-tagged form of wild-type <protein>FGF-1</protein> (C222(1)) and a his-tagged Leu44--&gt;Phe
      mutant (C2) adopt a 3:3 beta-hairpin (containing a type I' turn) for this
      same region. A feature that distinguishes these two types of beta-hairpin
      structures is the number and location of side chain positions with
      eclipsed C(beta) and main-chain carbonyl oxygen groups (Psi is equivalent
      to +60 degrees). The effects of glycine mutations upon stability, at
      positions within the hairpin, have been used to identify the most likely
      structure in solution. Type I' turns in the structural data bank are quite
      rare, and a survey of these turns reveals that a large percentage exhibit
      crystal contacts within 3.0 A. This suggests that many of the type I'
      turns in X-ray structures may be adopted due to crystal packing effects.
</DOC>
<DOC>
<DOC_ID>[150]</DOC_ID>
>150.NF00329866
PMID:12114499
TI  - <protein>HIV-1 Tat</protein> interaction with <protein>RNA polymerase II</protein> C-terminal domain (CTD) and a
      dynamic association with <protein>CDK2</protein> induce CTD phosphorylation and transcription
      from HIV-1 promoter.
AB  - Human immunodeficiency virus, type 1 (HIV-1), <protein>Tat protein</protein> activates viral
      gene expression through promoting transcriptional elongation by <protein>RNA
      polymerase II (RNAPII)</protein>. In this process <protein>Tat</protein> enhances phosphorylation of
      the C-terminal domain (CTD) of <protein>RNAPII</protein> by activating <protein>cell cycle-dependent
      kinases (CDKs)</protein> associated with <protein>general transcription factors</protein> of the
      promoter complex, specifically <protein>CDK7</protein> and <protein>CDK9</protein>. We reported a <protein>Tat-associated
      T-cell-derived kinase</protein>, which contained <protein>CDK2</protein>. Here, we provide further
      evidence that <protein>CDK2</protein> is involved in <protein>Tat</protein>-mediated CTD phosphorylation and in
      HIV-1 transcription in vitro. <protein>Tat</protein>-mediated CTD phosphorylation by <protein>CDK2</protein>
      required cysteine 22 in the activation domain of <protein>Tat</protein> and amino acids 42-72
      of <protein>Tat</protein>. <protein>CDK2</protein> phosphorylated <protein>Tat</protein> itself, apparently by forming dynamic
      contacts with amino acids 15-24 and 36-49 of <protein>Tat</protein>. Also, amino acids 24-36
      and 45-72 of <protein>Tat</protein> interacted with CTD. <protein>CDK2</protein> associated with <protein>RNAPII</protein> and was
      found in elongation complexes assembled on HIV-1 long-terminal repeat
      template. Recombinant <protein>CDK2</protein>/<protein>cyclin E</protein> stimulated <protein>Tat</protein>-dependent HIV-1
      transcription in reconstituted transcription assay. Immunodepletion of
      <protein>CDK2</protein>/<protein>cyclin E</protein> in HeLa nuclear extract blocked <protein>Tat</protein>-dependent transcription.
      We suggest that <protein>CDK2</protein> is part of a <protein>transcription complex</protein> that is required
      for <protein>Tat</protein>-dependent transcription and that interaction of <protein>Tat</protein> with CTD and a
      dynamic association of <protein>Tat</protein> with <protein>CDK2</protein>/<protein>cyclin E</protein> stimulated CTD
      phosphorylation by <protein>CDK2</protein>.
</DOC>
<DOC>
<DOC_ID>[151]</DOC_ID>
>151.NF00777929
PMID:12101186
TI  - The <protein>transcriptional regulating protein of 132 kDa (TReP-132)</protein> enhances
      <protein>P450scc</protein> gene transcription through interaction with <protein>steroidogenic factor-1</protein>
      in human adrenal cells.
AB  - The <long_form>human <protein>P450scc</protein></long_form> gene is regulated by the <protein>tissue-specific orphan nuclear
      receptor</protein>, <protein>steroidogenic factor-1 (SF-1)</protein>, which plays a key role in several
      physiologic processes including steroid synthesis, adrenal and gonadal
      development, and sexual differentiation. Several studies have demonstrated
      the interaction of <protein>SF-1</protein> with different proteins. However, it is clear that
      additional factors not yet identified are involved with <protein>SF-1</protein> to regulate
      different target genes. Recently, it was demonstrated that a novel
      <protein>transcriptional regulating protein of 132 kDa (TReP-132)</protein> regulates
      expression of the <long_form>human <protein>P450scc</protein></long_form> gene. The overexpression of <protein>TReP-132</protein> in
      adrenal cells increases the production of pregnenolone, which is
      associated with the activation of <protein>P450scc</protein> gene expression. Considering the
      colocalization of <protein>TReP-132</protein> and <protein>SF-1</protein> in steroidogenic tissues such as the
      adrenal and testis, and the presence of two putative LXXLL motifs in
      <protein>TReP-132</protein> that can potentially interact with <protein>SF-1</protein>, the relationship between
      these two factors on the <protein>P450scc</protein> gene promoter was determined. The
      coexpression of <protein>SF-1</protein> and <protein>TReP-132</protein> in adrenal NCI-H295 cells cooperates to
      increase promoter activity. Pull-down experiments demonstrated the
      interaction between <protein>TReP-132</protein> and <protein>SF-1</protein>, and this was further confirmed in
      intact cells by coimmunoprecipitation/Western blot and two-hybrid
      analyses. Deletions and mutations of the <protein>TReP-132</protein> cDNA sequence
      demonstrate that <protein>SF-1</protein> interaction requires the LXXLL motif found at the
      amino-terminal region of the protein. Also, the &quot;proximal activation
      domain&quot; and the &quot;AF-2 hexamer&quot; motif of <protein>SF-1</protein> are involved in interaction
      with <protein>TReP-132</protein>. Consistent with previous studies showing interaction
      between <protein>CBP</protein>/<protein>p300</protein> and <protein>SF-1</protein> or <protein>TReP-132</protein>, the coexpression of these three
      proteins results in a synergistic effect on <protein>P450scc</protein> gene promoter
      activity. Taken together the results in this study identify a novel
      function of <protein>TReP-132</protein> as a partner in a complex with <protein>SF-1</protein> and <protein>CBP</protein>/<protein>p300</protein> to
      regulate gene transcription involved in steroidogenesis.
</DOC>
<DOC>
<DOC_ID>[152]</DOC_ID>
>152.NF00091024
PMID:11931760
TI  - The dissociation of <protein>cohesin</protein> from chromosomes in prophase is regulated by
      <protein>Polo-like kinase</protein>.
AB  - The separation of sister chromatids in anaphase depends on the
      dissociation of <protein>cohesin</protein> from chromosomes. In vertebrates, some <protein>cohesin</protein> is
      removed from chromosomes at the onset of anaphase by proteolytic cleavage.
      In contrast, the bulk of <protein>cohesin</protein> is removed from chromosomes already in
      prophase and prometaphase by an unknown mechanism that does not involve
      <protein>cohesin</protein> cleavage. We show that <protein>Polo-like kinase</protein> is required for the
      cleavage-independent dissociation of <protein>cohesin</protein> from chromosomes in Xenopus.
      <protein>Cohesin</protein> phosphorylation depends on <protein>Polo-like kinase</protein> and reduces the
      ability of <protein>cohesin</protein> to bind to chromatin. These results suggest that
      <protein>Polo-like kinase</protein> regulates the dissociation of <protein>cohesin</protein> from chromosomes
      early in mitosis.
</DOC>
<DOC>
<DOC_ID>[153]</DOC_ID>
>153.NF00135250
PMID:11716065
TI  - <protein>Hyaluronate receptors</protein> mediating glioma cell migration and proliferation.
AB  - The extracellular matrix (ECM) of the central nervous system (CNS) is
      enriched in hyaluronate (HA). Ubiquitous <protein>receptors</protein> for HA are <protein>CD44</protein> and the
      <protein>Receptor</protein> for HA-Mediated Motility known as <protein>RHAMM</protein>. In the present study, we
      have investigated the potential role of <protein>CD44</protein> and <protein>RHAMM</protein> in the migration
      and proliferation of human astrocytoma cells. <protein>HA-receptor</protein> expression in
      brain tumor cell lines and surgical specimens was determined by
      immunocytochemistry and western blot analyses. The ability of <protein>RHAMM</protein> to
      bind ligand was determined through cetylpyridinium chloride (CPC)
      precipitations of brain tumor lysates in HA-binding assays. The effects of
      HA, <protein>CD44</protein> blocking antibodies, and <protein>RHAMM</protein> soluble peptide on astrocytoma
      cell growth and migration was determined using MTT and migration assays.
      Our results show that the expression of the <protein>HA-receptors</protein>, <protein>CD44</protein>, and <protein>RHAMM</protein>,
      is virtually ubiquitous amongst glioma cell lines, and glioma tumor
      specimens. There was a gradient of expression amongst gliomas with high
      grade gliomas expressing more <protein>RHAMM</protein> and <protein>CD44</protein> than did lower grade lesions
      or did normal human astrocytes or non-neoplastic specimens of human brain.
      Specific <protein>RHAMM</protein> variants of 85- and 58-kDa size were shown to bind avidly
      to HA following CPC precipitations. <protein>RHAMM</protein> soluble peptide inhibited glioma
      cell line proliferation in a dose-dependent fashion. Finally, while
      <protein>anti-CD44 antibodies</protein> did not inhibit the migration of human glioma cells,
      soluble peptides directed at the HA-binding domain of <protein>RHAMM</protein> inhibited
      glioma migration both on and off an HA-based ECM. These data support the
      notion that <protein>HA-receptors</protein> contribute to brain tumor adhesion,
      proliferation, and migration, biological features which must be better
      understood before more effective treatment strategies for these tumors can
      be found.
</DOC>
<DOC>
<DOC_ID>[154]</DOC_ID>
>154.NF01222518
PMID:11690642
TI  - Expression pattern of <long_form>human <protein>P2Y receptor subtypes</protein></long_form>: a quantitative reverse
      transcription-polymerase chain reaction study.
AB  - The diverse biological actions of extracellular nucleotides in tissues and
      cells are mediated by two distinct classes of <protein>P2 receptor</protein>, <protein>P2X</protein> and <protein>P2Y</protein>.
      The <protein>G protein-coupled P2Y receptors</protein> comprise at least six mammalian
      subtypes (<long_form><protein>P2Y</protein>(1,2,4,6,11,12)</long_form>), all of which have been cloned from human
      tissues, as well as other species. The <protein>P2Y receptor subtypes</protein> differ in
      their pharmacological selectivity for various adenosine and uridine
      nucleotides, which overlap in some cases. Data concerning the mRNA
      expression patterns of five <protein>P2Y receptors</protein> (<long_form><protein>P2Y</protein>(1,2,4,6,11)</long_form>) in different
      human tissues and cells are currently quite limited, while <protein>P2Y</protein> mRNA
      distribution in the human brain has not previously been studied. In this
      study, we have addressed this deficiency in <protein>receptor</protein> expression data by
      using a quantitative reverse transcription-polymerase chain reaction
      approach to measure the precise mRNA expression pattern of each <protein>P2Y
      receptor subtype</protein> in a number of human peripheral tissues and brain
      regions, from multiple individuals, as well as numerous human cell lines
      and primary cells. All five <protein>P2Y receptors</protein> exhibited widespread yet
      subtype-selective mRNA expression profiles throughout the human tissues,
      brain regions and cells used. Our extensive expression data indicate the
      many potentially important roles of <protein>P2Y receptors</protein> throughout the human
      body, and will help in elucidating the physiological function of each
      <protein>receptor subtype</protein> in a wide variety of human systems.
</DOC>
<DOC>
<DOC_ID>[155]</DOC_ID>
>155.NF00109417
PMID:12151397
TI  - Induction of homologue of <protein>Slimb ubiquitin ligase receptor</protein> by mitogen
      signaling.
AB  - <protein>Homologue of Slimb (HOS)</protein> is the substrate-recognizing <protein>component of the
      SCF(HOS)-Roc1 E3 ubiquitin protein ligase</protein>. This <protein>ligase</protein> mediates
      ubiquitination of the <protein>inhibitor of NF-kappaB transcription factor
      (IkappaB)</protein>. We have found that <protein>HOS</protein> is highly expressed in a number of human
      cancer cell lines. The rates of the <protein>HOS</protein> gene transcription as well as <protein>HOS</protein>
      mRNA and protein levels were up-regulated in cells treated with mitogens
      or transfected with the inducers of <protein>mitogen-activated protein kinase</protein>
      pathway. Conversely, mitogen withdrawal strikingly reduced <protein>HOS</protein> levels
      during differentiation of mouse myoblasts. Activators of <protein>mitogen-activated
      protein kinase</protein> accelerated <protein>IkappaBalpha</protein> degradation and increased
      <protein>NF-kappaB</protein> transcriptional activity. Inhibition of <protein>HOS</protein> function via
      expression of dominant negative <protein>HOS</protein> (<protein>HOS</protein>(DeltaF)) initiated mouse myoblast
      differentiation and prevented <protein>Ras</protein>-mediated acceleration of <protein>IkappaBalpha</protein>
      degradation as well as <protein>NF-kappaB</protein> trans-activation and transformation of
      NIH3T3 cells. These data link the induction of <protein>HOS</protein> in proliferating cells
      with mitogen-signaling-dependent inhibition of cell differentiation and
      promotion of cell transformation.
</DOC>
<DOC>
<DOC_ID>[156]</DOC_ID>
>156.NF00114683
PMID:12478664
TI  - Hodgkin's lymphoma cell lines are characterized by frequent aberrations on
      chromosomes 2p and 9p including <protein>REL</protein> and <protein>JAK2</protein>.
AB  - Four Hodgkin's lymphoma cell lines (KM-H2, HDLM-2, L428, L1236) were
      analyzed for cytogenetic aberrations, applying multiplex fluorescence in
      situ hybridization, chromosome banding and comparative genomic
      hybridization. Each line was characterized by a highly heterogeneous
      pattern of karyotypic changes with a large spectrum of different
      translocated chromosomes (range 22-57). A recurrent finding in all cell
      lines was the presence of chromosomal rearrangements of the short arm of
      chromosome 2 involving the <protein>REL oncogene</protein> locus. Furthermore, multiple
      translocated copies of telomeric chromosomal segments were frequently
      detected. This resulted in a copy number increase of putative oncogenes,
      e.g., <protein>JAK2</protein> (9p24) in 3 cell lines, <protein>FGFR3</protein> (4p16) and <protein>CCND2</protein> (12p13) in 2
      cell lines as well as <protein>MYC</protein> (8q24) in 1 cell line. Our data confirm previous
      cytogenetic results from primary Hodgkin's tumors suggesting an important
      pathogenic role of <protein>REL</protein> and <protein>JAK2</protein> in this disease. In addition, they provide
      evidence for a novel cytogenetic pathomechanism leading to increased copy
      numbers of putative oncogenes from terminal chromosomal regions, most
      probably in the course of chromosomal stabilization by telomeric capture.
</DOC>
<DOC>
<DOC_ID>[157]</DOC_ID>
>157.NF01223249
PMID:12359436
TI  - <protein>Vpr</protein>- and <protein>Nef</protein>-dependent induction of <protein>RANTES</protein>/<protein>CCL5</protein> in microglial cells.
AB  - Microglia are pivotal in the pathogenesis of AIDS dementia, as they serve
      as the major target of HIV infection in the CNS. In addition, activation
      of microglia correlates best with clinical dementia. Although the
      <protein>beta-chemokine RANTES</protein>/<protein>CCL5</protein> is important in modulating HIV infection as
      well as cellular activation, no information is available regarding how its
      expression is regulated in microglia by HIV-1. Here we report that
      <protein>RANTES</protein>/<protein>CCL5</protein> expression is induced in microglia by HIV-1, but that this
      requires infection by HIV-1. This conclusion was supported by (1) the
      delayed kinetics coinciding with viral replication; (2) the lack of effect
      of X4 viruses; (3) inhibition by the <protein>reverse transcriptase</protein> inhibitor AZT,
      and (4) the lack of effect of <protein>cytokine</protein> antagonists or antibodies.
      Interestingly, <protein>RANTES</protein>/<protein>CCL5</protein> production was dependent on the <long_form>viral <protein>accessory
      protein Vpr</protein></long_form>, in addition to <protein>Nef</protein>, demonstrating a novel role for <protein>Vpr</protein> in
      <protein>chemokine</protein> induction in primary macrophage-type cells. Furthermore, the
      specific <protein>p38 MAP kinase</protein> inhibitor SB203580 augmented <protein>chemokine</protein> expression
      in microglia, indicating a negative role played by <protein>p38</protein>. These data suggest
      unique features of <protein>RANTES</protein>/<protein>CCL5</protein> regulation by HIV-1 in human microglial
      cells.
</DOC>
<DOC>
<DOC_ID>[158]</DOC_ID>
>158.NF01196322
PMID:12207029
TI  - Dissection of the functional differences between <long_form><protein>sarco(endo)plasmic
      reticulum Ca2+-ATPase (SERCA) 1</protein> and 3 isoforms</long_form> by steady-state and
      transient kinetic analyses.
AB  - Steady-state and transient-kinetic studies were conducted to characterize
      the overall and partial reactions of the Ca(2+)-transport cycle mediated
      by the <long_form>human <protein>sarco(endo)plasmic reticulum Ca(2+)-ATPase 3 (SERCA3)
      isoforms</protein></long_form>: <protein>SERCA3a</protein>, <protein>SERCA3b</protein>, and <protein>SERCA3c</protein>. Relative to <protein>SERCA1a</protein>, all three
      <long_form>human <protein>SERCA3 enzymes</protein></long_form> displayed a reduced apparent affinity for cytosolic
      Ca(2+) in activation of the overall reaction due to a decreased E(2) to
      E(1)Ca(2) transition rate and an increased rate of Ca(2+) dissociation
      from E(1)Ca(2). At neutral pH, the <protein>ATPase</protein> activity of the <protein>SERCA3 enzymes</protein>
      was not significantly enhanced upon permeabilization of the microsomal
      vesicles with calcium ionophore, indicating a difference from <protein>SERCA1a</protein> with
      respect to regulation of the lumenal Ca(2+) level (either an enhanced
      efflux of lumenal Ca(2+) through the pump in E(2) form or insensitivity to
      inhibition by lumenal Ca(2+)). Other differences from <protein>SERCA1a</protein> with respect
      to the overall <protein>ATPase</protein> reaction were an alkaline shift of the pH optimum,
      increased catalytic turnover rate at pH optimum (highest for <protein>SERCA3b</protein>, the
      isoform with the longest C terminus), and an increased sensitivity to
      inhibition by vanadate that disappeared under equilibrium conditions in
      the absence of Ca(2+) and ATP. The transient-kinetic analysis traced
      several of the differences from <protein>SERCA1a</protein> to an enhancement of the rate of
      dephosphorylation of the E(2)P phosphoenzyme intermediate, which was most
      pronounced at alkaline pH and increased with the length of the
      alternatively spliced C terminus.
</DOC>
<DOC>
<DOC_ID>[159]</DOC_ID>
>159.NF00080178
PMID:12200142
TI  - Interaction of <protein>oncogenic papillomavirus E6 proteins</protein> with <protein>fibulin-1</protein>.
AB  - Human papillomavirus (HPV) infection is the primary risk factor for the
      development of cervical cancer. The <protein>papillomavirus E6</protein> gene is essential
      for virus-induced cellular transformation and the viral life cycle.
      Important insight into the mechanism of E6 function came from the
      discovery that cancer-related <protein>HPV E6 proteins</protein> promote the degradation of
      the <protein>tumor suppressor p53</protein>. However, mounting evidence indicates that
      interaction with <protein>p53</protein> does not mediate all E6 activities. To explore the
      <protein>p53</protein>-independent functions of E6, we performed a yeast two-hybrid screen
      and identified <protein>fibulin-1</protein> as an <protein>E6 binding protein</protein>. <protein>Fibulin-1</protein> is a
      calcium-binding plasma and <protein>extracellular matrix protein</protein> that has been
      implicated in cellular transformation and tumor invasion. The interaction
      between E6 and <protein>fibulin-1</protein> was demonstrated by both in vitro and in vivo
      assays. <protein>Fibulin-1</protein> is associated specifically with <protein>cancer-related HPV E6s</protein>
      and the <protein>transforming bovine papillomavirus type 1 E6</protein>. Significantly,
      overexpression of <protein>fibulin-1</protein> specifically inhibited E6-mediated
      transformation. These results suggest that <protein>fibulin-1</protein> plays an important
      role in the biological activities of E6.
</DOC>
<DOC>
<DOC_ID>[160]</DOC_ID>
>160.NF00116385
PMID:12134158
TI  - Unconventional <protein>Rac</protein>-GEF activity is mediated through the <long_form><protein>Dock180</protein>-<protein>ELMO</protein>
      complex</long_form>.
AB  - <long_form>Mammalian <protein>Dock180</protein></long_form> and <protein>ELMO proteins</protein>, and their homologues in
      Caenorhabditis elegans and Drosophila melanogaster, function as critical
      upstream regulators of <protein>Rac</protein> during development and cell migration. The
      mechanism by which <protein>Dock180</protein> or <protein>ELMO</protein> mediates <protein>Rac</protein> activation is not
      understood. Here, we identify a domain within <protein>Dock180</protein> (denoted Docker)
      that specifically recognizes nucleotide-free <protein>Rac</protein> and can mediate GTP
      loading of <protein>Rac</protein> in vitro. The Docker domain is conserved among known
      <protein>Dock180</protein> family members in metazoans and in a yeast protein. In cells,
      binding of <protein>Dock180</protein> to <protein>Rac</protein> alone is insufficient for GTP loading, and a
      <protein>Dock180</protein> <protein>ELMO1</protein> interaction is required. We can also detect a <long_form>trimeric <protein>ELMO1</protein>
      <protein>Dock180</protein> <protein>Rac1</protein> complex</long_form> and <protein>ELMO</protein> augments the interaction between <protein>Dock180</protein> and
      <protein>Rac</protein>. We propose that the <long_form><protein>Dock180</protein> <protein>ELMO</protein> complex</long_form> functions as an
      unconventional two-part exchange factor for <protein>Rac</protein>.
</DOC>
<DOC>
<DOC_ID>[161]</DOC_ID>
>161.NF00943036
PMID:12096920
TI  - <protein>Interleukin-1F7B</protein> (<protein>IL-1H4</protein>/<protein>IL-1F7</protein>) is processed by <protein>caspase-1</protein> and mature
      <protein>IL-1F7B</protein> binds to the <protein>IL-18 receptor</protein> but does not induce <protein>IFN-gamma</protein>
      production.
AB  - We have recently reported the identification of four novel members of the
      <protein>interleukin-1 (IL-1)</protein> family which we designated as <long_form><protein>IL-1 homologue 1</protein>-4
      (<protein>IL-1H1</protein>-4)</long_form>. These proteins exhibit significant sequence homology to other
      members of the <protein>IL-1</protein> family. Of these homologues, only <protein>IL-1H4</protein> (renamed
      <protein>IL-1F7b</protein>) was predicted to contain a propeptide domain and a <protein>caspase</protein>
      cleavage site. We now report that <protein>caspase-1</protein> cleaves <protein>IL-1F7b</protein> at the
      predicted site to generate mature <protein>IL-1F7b</protein>. <protein>Caspase-4</protein> was also able to
      process <protein>IL-1F7b</protein>, albeit inefficiently. Other <protein>caspases</protein> and <protein>Granzyme-B</protein> did
      not cleave <protein>IL-1F7b</protein>. Furthermore, adenovirus-mediated expression of <protein>IL-1F7b</protein>
      in HEK 293 cells led to in situ processing and secretion of mature
      <protein>IL-1F7b</protein>. In a screen to identify a potential <protein>receptor</protein>, both pro and mature
      <protein>IL-1F7b</protein> bound to the <protein>soluble IL-18 receptor alpha</protein>-Fc (<protein>IL-18Ralpha</protein>-Fc) but
      not to the <protein>soluble IL-1R</protein>-Fc or <protein>ST2R</protein>-Fc fusion proteins. Mature <protein>IL-1F7b</protein>
      bound to the <protein>IL-18Ralpha</protein>-Fc protein with higher affinity than the pro
      form, although the affinities for both proteins were significantly lower
      than that observed for <protein>IL-18</protein>. Consistent with this observation, only <protein>IL-18</protein>
      and not <protein>IL-1F7b</protein> induced <protein>IFN-gamma</protein> production by KG1a cells. We also report
      that pro and mature <protein>IL-1F7b</protein> form homodimers with association constants of
      4 microM and 5 nM, respectively, suggesting biological relevance to
      <protein>IL-1F7b</protein> processing. Finally, we have localized the expression of <protein>IL-1F7b
      protein</protein> in discrete cell populations including plasma cells and tumor
      cells. These data suggest that <protein>IL-1F7b</protein> may be involved in immune response,
      inflammatory diseases and/or cancer.
</DOC>
<DOC>
<DOC_ID>[162]</DOC_ID>
>162.NF00113796
PMID:12070015
TI  - Novel <protein>transcription factors</protein> in <long_form>human <protein>CD34 antigen</protein></long_form>-positive hematopoietic
      cells.
AB  - <protein>Transcription factors (TFs)</protein> and the <protein>regulatory proteins</protein> that control them
      play key roles in hematopoiesis, controlling basic processes of cell
      growth and differentiation; disruption of these processes may lead to
      leukemogenesis. Here we attempt to identify functionally novel and
      partially characterized <protein>TFs</protein>/<protein>regulatory proteins</protein> that are expressed in
      undifferentiated hematopoietic tissue. We surveyed our database of 15 970
      genes/expressed sequence tags (ESTs) representing the normal <long_form>human <protein>CD34</protein></long_form>(+)
      cells transcriptosome (http://westsun.hema.uic.edu/cd34.html), using the
      UniGene annotation text descriptor, to identify genes with motifs
      consistent with <protein>transcriptional regulators</protein>; 285 genes were identified. We
      also extracted the human homologues of the <protein>TFs</protein> reported in the murine stem
      cell database (SCdb; http://stemcell.princeton.edu/), selecting an
      additional 45 genes/ESTs. An exhaustive literature search of each of these
      330 unique genes was performed to determine if any had been previously
      reported and to obtain additional characterizing information. Of the
      resulting gene list, 106 were considered to be potential <protein>TFs</protein>. Overall, the
      <protein>transcriptional regulator</protein> dataset consists of 165 novel or poorly
      characterized genes, including 25 that appeared to be <protein>TFs</protein>. Among these
      novel and poorly characterized genes are a <protein>cell growth regulatory with
      ring finger domain protein</protein> (<protein>CGR19</protein>, Hs.59106), an <protein>RB-associated CRAB
      <protein>repressor</protein></protein> (<protein>RBAK</protein>, Hs.7222), a <protein>death-associated transcription factor 1</protein>
      (<protein>DATF1</protein>, Hs.155313), and a <protein>p38-interacting protein</protein> (<protein>P38IP</protein>, Hs. 171185). The
      identification of these novel and partially characterized potential
      <protein>transcriptional regulators</protein> adds a wealth of information to understanding
      the molecular aspects of hematopoiesis and hematopoietic disorders.
</DOC>
<DOC>
<DOC_ID>[163]</DOC_ID>
>163.NF00122868
PMID:11712085
TI  - Expression and function of <protein>adrenomedullin</protein> and its <protein>receptors</protein> in Conn's
      adenoma cells.
AB  - <protein>Adrenomedullin (ADM)</protein> is a <protein>hypotensive peptide</protein>, that derives from the
      proteolytic cleavage of <protein>pro(p)ADM</protein> and acts through two subtypes of
      <protein>receptors</protein>, called <protein>L1-receptor (L1-R)</protein> and <protein>calcitonin receptor-like receptor
      (CRLR)</protein>. <protein>CRLR</protein> may function as a <protein>calcitonin gene-related peptide</protein> or a
      <protein>selective ADM receptor</protein> depending on the expression of the subtype 1 or the
      subtypes 2 and 3 of a family of proteins, named <protein>receptor-activity
      modifying proteins (RAMPs)</protein>. Reverse transcription (RT)-polymerase chain
      reaction (PCR) allowed the detection of <protein>pADM</protein> mRNA in dispersed cells of
      eight Conn's adenomas (aldosteronomas). These cells also expressed
      <protein>peptidyl-glycine alpha-amidating monooxigenase</protein>, the enzyme converting
      <protein>immature ADM</protein> to the mature form, and contained sizeable amounts of
      <protein>ADM</protein>-immunoreactivity as measured by radioimmunoassay. RT-PCR also
      demonstrated the presence in aldosteronoma cells of the specific mRNAs of
      <protein>L1-R</protein>, <protein>CRLR</protein> and <long_form><protein>RAMPs 1</protein>-3</long_form>. <protein>ADM</protein> (10(-8) M) inhibited <protein>angiotensin-II</protein> (10(-9)
      M)-simulated aldosterone secretion from cultured aldosteronoma cells,
      without affecting basal production. <protein>ADM</protein> (10(-8) M) also enhanced basal
      proliferation rate of cultured cells, as estimated by the
      5-bromo-2'-deoxyuridine immunocytochemical technique. Both effects of <protein>ADM</protein>
      were annulled by the <protein>ADM-receptor</protein> selective antagonist ADM22-52 (10(-7)
      M). In conclusion, our study provides evidence that aldosteronoma cells
      express both <protein>ADM</protein> and ADM22-52-sensitive <protein>receptors</protein>. These findings, coupled
      with the demonstration that <protein>ADM</protein> exerts an aldosterone antisecretagogue
      action and a proliferogenic effect on cultured aldosteronoma cells, make
      it likely that endogenous <protein>ADM</protein> system plays a potentially important role in
      the paracrine or autocrine functional control of Conn's adenomas.
</DOC>
<DOC>
<DOC_ID>[164]</DOC_ID>
>164.NF01030797
PMID:11739281
TI  - Modulation of endothelial cell growth arrest and apoptosis by <protein>vascular
      endothelial growth inhibitor</protein>.
AB  - <protein>Vascular endothelial growth inhibitor (VEGI)</protein>, a new member of the <protein>tumor
      necrosis factor</protein> family, is an endothelial cell-specific gene and a potent
      inhibitor of endothelial cell proliferation, angiogenesis, and tumor
      growth. We report here that <protein>VEGI</protein> mediates the following two activities in
      endothelial cells: early G(1) arrest in G(0)/G(1) cells responding to
      growth stimuli, and programmed death in proliferating cells.
      G(0)/G(1)-synchronized bovine aortic endothelial cells were treated with
      <protein>VEGI</protein> before and after the onset of the growth cycle. When the cells were
      stimulated with growth conditions but treated simultaneously with <protein>VEGI</protein>, a
      reversible, early-G(1) growth arrest occurred, evidenced by the lack of
      late G(1) markers such as hyperphosphorylation of the <protein>retinoblastoma gene
      product</protein> and upregulation of the <protein>c-myc</protein> gene. Additionally, <protein>VEGI</protein> treatment
      led to inhibition of the activities of <protein>cyclin-dependent kinases CDK2</protein>,
      <protein>CDK4</protein>, and <protein>CDK6</protein>. In contrast, <protein>VEGI</protein> treatment of cells that had entered the
      growth cycle resulted in apoptotic cell death, as evidenced by <protein>terminal
      deoxytransferase</protein> labeling of fragmented DNA, <protein>caspase 3</protein> activation, and
      <protein>annexin V</protein> staining, all of which were lacking in nonproliferating cells
      treated with <protein>VEGI</protein>. Additionally, <protein>stress-signaling proteins p38</protein> and <protein>JNK</protein>
      were not as fully activated by <protein>VEGI</protein> in quiescent as compared with
      proliferating populations. These findings suggest a dual role for <protein>VEGI</protein>,
      the maintenance of growth arrest and induction of apoptosis, in the
      modulation of the endothelial cell cycle.
</DOC>
<DOC>
<DOC_ID>[165]</DOC_ID>
>165.NF00015868
PMID:11867536
TI  - The <protein>roX</protein> genes encode redundant male-specific lethal transcripts required
      for targeting of the <protein>MSL complex</protein>.
AB  - The <protein>roX1</protein> and <protein>roX2</protein> genes of Drosophila produce male-specific non-coding
      RNAs that co-localize with the <protein>Male-Specific Lethal (MSL) protein complex</protein>.
      This complex mediates up-regulation of the male X chromosome by increasing
      <protein>histone H4</protein> acetylation, thus contributing to the equalization of X-linked
      gene expression between the sexes. Both <protein>roX</protein> genes overlap two of
      approximately 35 chromatin entry sites, DNA sequences proposed to act in
      cis to direct the <protein>MSL complex</protein> to the X chromosome. Although dosage
      compensation is essential in males, an intact <protein>roX1</protein> gene is not required by
      either sex. We have generated flies lacking <protein>roX2</protein> and find that this gene
      is also non-essential. However, simultaneous removal of both <protein>roX</protein> RNAs
      causes a striking male-specific reduction in viability accompanied by
      relocation of the <protein>MSL proteins</protein> and acetylated <protein>histone H4</protein> from the X
      chromosome to autosomal sites and heterochromatin. Males can be rescued by
      <protein>roX</protein> cDNAs from autosomal transgenes, demonstrating the genetic separation
      of the chromatin entry and RNA-encoding functions. Therefore, the <protein>roX1</protein> and
      <protein>roX2</protein> genes produce redundant, male-specific lethal transcripts required
      for targeting the <protein>MSL complex</protein>.
</DOC>
<DOC>
<DOC_ID>[166]</DOC_ID>
>166.NF00079829
PMID:11901358
TI  - Fine mapping of the chromosome 2p12-16 dyslexia susceptibility locus:
      quantitative association analysis and positional candidate genes <protein>SEMA4F</protein>
      and <protein>OTX1</protein>.
AB  - A locus on chromosome 2p12-16 has been implicated in dyslexia
      susceptibility by two independent linkage studies, including our own study
      of 119 nuclear twin-based families, each with at least one
      reading-disabled child. Nonetheless, no variant of any gene has been
      reported to show association with dyslexia, and no consistent clinical
      evidence exists to identify candidate genes with any strong a priori
      logic. We used 21 microsatellite markers spanning 2p12-16 to refine our
      1-LOD unit linkage support interval to 12cM between D2S337 and D2S286.
      Then, in quantitative association analysis, two microsatellites yielded P
      values&lt;0.05 across a range of reading-related measures (D2S2378 and
      D2S2114). The exon/intron borders of two positional candidate genes within
      the region were characterized, and the exons were screened for
      polymorphisms. The genes were <protein>Semaphorin4F (SEMA4F)</protein>, which encodes a
      protein involved in axonal growth cone guidance, and <protein>OTX1</protein>, encoding a
      <protein>homeodomain transcription factor</protein> involved in forebrain development. Two
      non-synonymous single nucleotide polymorphisms were found in <protein>SEMA4F</protein>, each
      with a heterozygosity of 0.03. One intronic single nucleotide polymorphism
      between exons 12 and 13 of <protein>SEMA4F</protein> was tested for quantitative association,
      but no significant association was found. Only one single nucleotide
      polymorphism was found in <protein>OTX1</protein>, which was exonic but silent. Our data
      therefore suggest that linkage with reading disability at 2p12-16 is not
      caused by coding variants of <protein>SEMA4F</protein> or <protein>OTX1</protein>. Our study outlines the
      approach necessary for the identification of genetic variants causing
      dyslexia susceptibility in an epidemiological population of dyslexics.
</DOC>
<DOC>
<DOC_ID>[167]</DOC_ID>
>167.NF00088497
PMID:12393185
TI  - Genomic organization of an intron-containing <protein>sperm protein 17</protein> gene
      (<protein>Sp17-1</protein>) and an intronless pseudogene (<protein>Sp17-2</protein>) in humans: a new model.
AB  - <protein>Sp17</protein> was initially thought to be a <protein>sperm specific protein</protein> involved in the
      interaction of the spermatozoon with the oocyte's surrounding
      <protein>extracellular glycoprotein</protein> matrix. Recent reports, however, indicate that
      <protein>Sp17</protein> expression is neither testis-specific nor is it exclusively used for
      binding to the zona pellucida of the oocyte. In this study, we provide
      comprehensive characterization of the genomic structure of <protein>Sp17</protein>. We
      identified an intron-containing gene (<protein>Sp17-1</protein>) containing five exonic and
      four intronic sequences. Analysis of <protein>Sp17</protein> transcripts using rapid
      amplification of DNA complementary to RNA (cDNA) ends (RACE) and
      polymerase chain reaction (PCR) techniques showed the presence of
      alternative polyadenylation resulting in the production of varying lengths
      of mRNAs as well as the usage of different transcriptional start sites.
      Moreover, an earlier description of the <long_form>human <protein>Sp17</protein></long_form> mRNA describing a
      splice variant could not be confirmed. Comparison to <long_form>mouse <protein>Sp17</protein></long_form> gene
      organization demonstrated a high degree of conservation, suggesting
      selective evolutionary pressure for this protein to retain a conserved
      gene architecture. Additionally, we identified a second gene (<protein>Sp17-2</protein>),
      whose most striking characteristic was the complete absence of introns.
      This <protein>Sp17-2</protein> gene has likely arisen by reverse transcription (RT) of a
      spliced <protein>Sp17-1</protein> mRNA with subsequent integration into the human genome. Its
      open reading frame (ORF) is interrupted by stop codons, giving rise to a
      pseudogene. Furthermore, Southern blot analysis of human genomic DNA
      indicated the possibility of additional <protein>Sp17</protein> species within the human
      genome.
</DOC>
<DOC>
<DOC_ID>[168]</DOC_ID>
>168.NF00100215
PMID:12208868
TI  - Overexpression of <protein>ABCG5</protein> and <protein>ABCG8</protein> promotes biliary cholesterol secretion
      and reduces fractional absorption of dietary cholesterol.
AB  - Two <protein>ATP-binding cassette (ABC) transporters</protein>, <protein>ABCG5</protein> and <protein>ABCG8</protein>, have been
      proposed to limit sterol absorption and to promote biliary sterol
      excretion in humans. To test this hypothesis, a P1 clone containing the
      <long_form>human <protein>ABCG5</protein></long_form> and <protein>ABCG8</protein> genes was used to generate transgenic mice. The
      transgenes were expressed primarily in the liver and small intestine,
      mirroring the expression pattern of the endogenous genes. Transgene
      expression only modestly affected plasma and liver cholesterol levels but
      profoundly altered cholesterol transport. The fractional absorption of
      dietary cholesterol was reduced by about 50%, and biliary cholesterol
      levels were increased more than fivefold. Fecal neutral sterol excretion
      was increased three- to sixfold and hepatic cholesterol synthesis
      increased two- to fourfold in the transgenic mice. No significant changes
      in the pool size, composition, and fecal excretion of bile acids were
      observed in the transgenic mice. Transgene expression attenuated the
      increase in hepatic cholesterol content induced by consumption of a high
      cholesterol diet. These results demonstrate that increased expression of
      <protein>ABCG5</protein> and <protein>ABCG8</protein> selectively drives biliary neutral sterol secretion and
      reduces intestinal cholesterol absorption, leading to a selective increase
      in neutral sterol excretion and a compensatory increase in cholesterol
      synthesis.
</DOC>
<DOC>
<DOC_ID>[169]</DOC_ID>
>169.NF00074103
PMID:12054167
TI  - Localization of the gene causing autosomal dominant osteopetrosis type I
      to chromosome 11q12-13.
AB  - The osteopetroses are a heterogeneous group of genetic conditions
      characterized by increased bone density due to impaired bone resorption by
      osteoclasts. Within the autosomal dominant form of osteopetrosis, the
      radiological type I (ADOI) is characterized by a generalized
      osteosclerosis, most pronounced at the cranial vault. The patients are
      often asymptomatic but some suffer from pain and hearing loss. ADOI is the
      only type of osteopetrosis not associated with an increased fracture rate.
      Linkage analysis in two families with ADOI from Danish origin enabled us
      to assign the disease-causing gene to chromosome 11q12-13. A summated
      maximum lod score of +6.54 was obtained with marker D11S1889 and key
      recombinants allowed delineation of a candidate region of 6.6 cM between
      markers D11S1765 and D11S4113. Previously, genes causing other conditions
      with abnormal bone density have been identified from this chromosomal
      region. The <protein>TCIRG1</protein> gene was shown to underly autosomal recessive
      osteopetrosis (ARO), and, recently, mutations in the <protein>LRP5</protein> gene were found
      both in the osteoporosis-pseudoglioma syndrome and the high bone mass
      trait. Because both genes map within the candidate region for ADOI, it can
      not be excluded that ADOI is caused by mutations in either the <protein>TCIRG1</protein> or
      the <protein>LRP5</protein> gene.
</DOC>
<DOC>
<DOC_ID>[170]</DOC_ID>
>170.NF00137122
PMID:11846562
TI  - Crystal structure of a ternary <protein>SAP-1</protein>/<protein>SRF</protein>/<protein>c-fos</protein> SRE DNA <protein>complex</protein>.
AB  - Combinatorial DNA binding by proteins for promoter-specific gene
      activation is a common mode of DNA regulation in eukaryotic organisms, and
      occurs at the promoter of the <protein>c-fos</protein> proto-oncogene. The <protein>c-fos</protein> promoter
      contains a serum response element (SRE) that mediates ternary complex
      formation with the <protein>Ets proteins SAP-1</protein> or <protein>Elk-1</protein> and the <protein>MADS-box protein</protein>,
      <protein>serum response factor (SRF)</protein>. Here, we report the crystal structure of a
      ternary <protein>SAP-1</protein>/<protein>SRF</protein>/<protein>c-fos</protein> SRE DNA complex containing the minimal DNA-binding
      domains of each protein. The structure of the complex reveals that the
      <protein>SAP-1 monomer</protein> and <protein>SRF dimer</protein> are bound on opposite faces of the DNA, and
      that the DNA recognition helix of <protein>SAP-1</protein> makes direct contact with the DNA
      recognition helix of one of the two <protein>SRF subunits</protein>. These interactions
      facilitate an 82 degrees DNA bend around <protein>SRF</protein> and a modulation of
      protein-DNA contacts by each protein when compared to each of the binary
      DNA complexes. A comparison with a recently determined complex containing
      <protein>SRF</protein>, an idealized DNA site, and a <protein>SAP-1</protein> fragment containing a
      <protein>SRF</protein>-interacting B-box region, shows a similar overall architecture but
      also shows important differences. Specifically, the comparison suggests
      that the B-box region of the <protein>Ets protein</protein> does not significantly influence
      DNA recognition by either of the proteins, and that the sequence of the
      DNA target effects the way in which the two proteins cooperate for DNA
      recognition. These studies have implications for how DNA-bound <protein>SRF</protein> may
      modulate the DNA-binding properties of other <protein>Ets proteins</protein> such as <protein>Elk-1</protein>,
      and for how other <protein>Ets proteins</protein> may modulate the DNA-binding properties of
      other DNA-bound accessory factors to facilitate promoter-specific
      transcriptional responses.
</DOC>
<DOC>
<DOC_ID>[171]</DOC_ID>
>171.NF00107800
PMID:10512872
TI  - <protein>GERp95</protein>, a <protein>membrane-associated protein</protein> that belongs to a family of proteins
      involved in stem cell differentiation.
AB  - A panel of mAbs was elicited against intracellular membrane fractions from
      rat pancreas. One of the antibodies reacted with a <protein>95-kDa protein</protein> that
      localizes primarily to the Golgi complex or the endoplasmic reticulum
      (ER), depending on cell type. The corresponding cDNA was cloned and
      sequenced and found to encode a <protein>protein of 97.6 kDa</protein> that we call <protein>GERp95
      (Golgi ER protein 95 kDa)</protein>. The protein copurifies with intracellular
      membranes but does not contain hydrophobic regions that could function as
      signal peptides or transmembrane domains. Biochemical analysis suggests
      that <protein>GERp95</protein> is a cytoplasmically exposed <protein>peripheral membrane protein</protein> that
      exists in a protease-resistant complex. <protein>GERp95</protein> belongs to a family of
      highly conserved proteins in metazoans and Schizosaccharomyces pombe. It
      has recently been determined that plant and Drosophila homologues of
      <protein>GERp95</protein> are important for controlling the differentiation of stem cells
      (Bohmert et al., 1998; Cox et al., 1998; Moussian et al., 1998). In
      Caenorhabditis elegans, there are at least 20 members of this protein
      family. To this end, we have used RNA interference to show that the <protein>GERp95</protein>
      orthologue in C. elegans is important for maturation of germ-line stem
      cells in the gonad. <protein>GERp95</protein> and related proteins are an emerging new family
      of proteins that have important roles in metazoan development. The present
      study suggests that these proteins may exert their effects on cell
      differentiation from the level of intracellular membranes.
</DOC>
<DOC>
<DOC_ID>[172]</DOC_ID>
>172.NF00119061
PMID:12482858
TI  - Evidence for a role of <protein>p38 kinase</protein> in <protein>hypoxia-inducible factor
      1</protein>-independent induction of <protein>vascular endothelial growth factor</protein> expression
      by sodium arsenite.
AB  - Recently we have demonstrated that sodium arsenite induces the expression
      of <protein>hypoxia-inducible factor 1alpha (HIF-1alpha) protein</protein> and <protein>vascular
      endothelial growth factor (VEGF)</protein> in OVCAR-3 human ovarian cancer cells. We
      now show that arsenic trioxide, an experimental anticancer drug, exerts
      the same effects. The involvement of <protein>phosphatidylinositol 3-kinase</protein> and
      <protein>mitogen-activated protein kinase (MAPK)</protein> pathways in the effects of sodium
      arsenite was investigated. By using <protein>kinase</protein> inhibitors in OVCAR-3 cells,
      both effects of sodium arsenite were found to be independent of
      <protein>phosphatidylinositol 3-kinase</protein> and <long_form><protein>p44</protein>/<protein>p42 MAPKS</protein></long_form> but were attenuated by
      inhibition of <protein>p38 MAPK</protein>. A role for <protein>p38</protein> in the regulation of <protein>HIF-1alpha</protein> and
      <protein>VEGF</protein> expression was supported further by analysis of activation kinetics.
      Experiments in mouse fibroblast cell lines, lacking expression of <long_form><protein>c-Jun
      N-terminal kinases 1</protein> and 2</long_form>, suggested that these <protein>kinases</protein> are not required
      for induction of <protein>HIF-1alpha protein</protein> and <protein>VEGF</protein> mRNA. Unexpectedly, sodium
      arsenite did not activate a <protein>HIF-1</protein>-dependent reporter gene in OVCAR-3
      cells, indicating that functional <protein>HIF-1</protein> was not induced. In agreement with
      this hypothesis, up-regulation of <protein>VEGF</protein> mRNA was not reduced in
      <protein>HIF-1alpha</protein>(-/-) mouse fibroblast cell lines. Altogether, these data
      suggest that not <protein>HIF-1</protein>, but rather <protein>p38</protein>, mediates induction of <protein>VEGF</protein> mRNA
      expression by sodium arsenite.
</DOC>
<DOC>
<DOC_ID>[173]</DOC_ID>
>173.NF00118414
PMID:12444553
TI  - Expression of <protein>hpttg</protein> proto-oncogene in lymphoid neoplasias.
AB  - Pituitary tumor-transforming gene (pttg) is a distinct proto-oncogene
      which is expressed in certain normal tissues with high proliferation rate
      and in a variety of tumors. <protein>PTTG</protein> is the vertebrate analog of <long_form>yeast
      <protein>securins Pds1</protein></long_form> and <protein>Cut2</protein> with a key role in the regulation of sister
      chromatid separation during mitosis. Impairment of <protein>PTTG</protein> regulated
      functions is expected to lead to chromosomal instability and aneuploidy.
      <protein>Human pttg (hpttg)</protein> is abundantly expressed in Jurkat T lymphoblastic
      lymphoma cells but not in normal peripheral blood leukocytes. To obtain
      additional data on the potential role of <protein>hpttg</protein> in lymphomagenesis we
      selected 150 cases of lymphoid tumors for the assessment of <protein>hpttg</protein>
      expression in tumor tissues. Immunohistochemical studies on
      formalin-fixed, paraffin-embedded tissues revealed <protein>hPTTG</protein> in 38.8% of
      B-cell lymphomas, 70.2% of T-cell lymphomas, and 73.1% of Hodgkin's
      lymphomas. Among B-cell lymphomas, the most frequently immunostained
      tumors were plasma cell tumors, diffuse large cell lymphomas, and follicle
      center cell lymphomas. In Hodgkin's disease, immunoreactivity was mainly
      noted in Reed-Sternberg cells. In conclusion, the frequent overexpression
      of <protein>hpttg</protein> in many histological subtypes of lymphoma suggests the
      involvement of this proto-oncogene in lymphomagenesis.
</DOC>
<DOC>
<DOC_ID>[174]</DOC_ID>
>174.NF00117443
PMID:12411432
TI  - Identification and characterization of a novel <long_form>human
      <protein>sphingosine-1-phosphate phosphohydrolase</protein></long_form>, <protein>hSPP2</protein>.
AB  - Sphingosine 1-phosphate (S1P) is a bioactive lipid molecule that acts as
      both an extracellular signaling mediator and an intracellular second
      messenger. S1P is synthesized from sphingosine by <protein>sphingosine kinase</protein> and
      is degraded either by <protein>S1P lyase</protein> or by <protein>S1P phosphohydrolase</protein>. Recently,
      <long_form>mammalian <protein>S1P phosphohydrolase (SPP1)</protein></long_form> was identified and shown to
      constitute a novel <protein>lipid phosphohydrolase</protein> family, the <protein>SPP</protein> family. In this
      study we have identified a second <long_form>human <protein>S1P phosphohydrolase</protein></long_form>, <protein>SPP2</protein>, based
      on sequence homology to <long_form>human <protein>SPP1</protein></long_form>. <protein>SPP2</protein> exhibited high <protein>phosphohydrolase</protein>
      activity against S1P and dihydrosphingosine 1-phosphate. The
      <protein>dihydrosphingosine-1-phosphate phosphohydrolase</protein> activity was efficiently
      inhibited by excess S1P but not by lysophosphatidic acid, phosphatidic
      acid, or glycerol 3-phosphate, indicating that <protein>SPP2</protein> is highly specific to
      sphingoid base 1-phosphates. Immunofluorescence microscopic analysis
      demonstrated that <protein>SPP2</protein> is localized to the endoplasmic reticulum. Although
      the enzymatic properties and localization of <protein>SPP2</protein> were similar to those of
      <protein>SPP1</protein>, the tissue-specific expression pattern of <protein>SPP2</protein> was different from
      that of <protein>SPP1</protein>. Thus, <protein>SPP2</protein> is another member of the <protein>SPP</protein> family that may play
      a role in attenuating intracellular S1P signaling.
</DOC>
<DOC>
<DOC_ID>[175]</DOC_ID>
>175.NF00114852
PMID:12496348
TI  - Up-regulation of <protein>neuronal calcium sensor-1 (NCS-1)</protein> in the prefrontal
      cortex of schizophrenic and bipolar patients.
AB  - The delineation of dopamine dysfunction in the mentally ill has been a
      long-standing quest of biological psychiatry. The present study focuses on
      a recently recognized group of <protein>dopamine receptor-interacting proteins</protein> as
      possible novel sites of dysfunction in schizophrenic and bipolar patients.
      We demonstrate that the dorsolateral prefrontal cortex in schizophrenia
      and bipolar cases from the Stanley Foundation Neuropathology Consortium
      display significantly elevated levels of the <protein>D2 dopamine receptor
      desensitization regulatory protein</protein>, <protein>neuronal calcium sensor-1</protein>. These
      levels of <protein>neuronal calcium sensor-1</protein> were not influenced by age, gender,
      hemisphere, cause of death, postmortem period, alcohol consumption, or
      antipsychotic and mood stabilizing medications. The present study supports
      the hypothesis that schizophrenia and bipolar disorder may be associated
      with abnormalities in <protein>dopamine receptor-interacting proteins</protein>.
</DOC>
<DOC>
<DOC_ID>[176]</DOC_ID>
>176.NF01222528
PMID:11574907
TI  - Mutations in the human orthologue of the mouse underwhite gene (uw)
      underlie a new form of oculocutaneous albinism, OCA4.
AB  - Oculocutaneous albinism (OCA) affects approximately 1/20,000 people
      worldwide. All forms of OCA exhibit generalized hypopigmentation. Reduced
      pigmentation during eye development results in misrouting of the optic
      nerves, nystagmus, alternating strabismus, and reduced visual acuity. Loss
      of pigmentation in the skin leads to an increased risk for skin cancer.
      Two common forms and one infrequent form of OCA have been described. OCA1
      (MIM 203100) is associated with mutations of the <protein>TYR</protein> gene encoding
      <protein>tyrosinase</protein> (the rate-limiting enzyme in the production of melanin pigment)
      and accounts for approximately 40% of OCA worldwide. OCA2 (MIM 203200),
      the most common form of OCA, is associated with mutations of the P gene
      and accounts for approximately 50% of OCA worldwide. OCA3 (MIM 203290), a
      rare form of OCA and also known as &quot;rufous/red albinism,&quot; is associated
      with mutations in <protein>TYRP1</protein> (encoding <protein>tyrosinase-related protein 1</protein>). Analysis
      of the <protein>TYR</protein> and P genes in patients with OCA suggests that other genes may
      be associated with OCA. We have identified the mouse underwhite gene (uw)
      and its human orthologue, which underlies a new form of human OCA, termed
      &quot;OCA4.&quot; The encoded protein, <protein>MATP</protein> (for &quot;<protein>membrane-associated transporter
      protein</protein>&quot;) is predicted to span the membrane 12 times and likely functions
      as a <protein>transporter</protein>.
</DOC>
<DOC>
<DOC_ID>[177]</DOC_ID>
>177.NF00019355
PMID:12446795
TI  - The <long_form>Drosophila <protein>atypical protein kinase C</protein>-<protein>ref(2)p</protein> complex</long_form> constitutes a
      conserved module for signaling in the <protein>toll</protein> pathway.
AB  - Recent results showed the critical role of the <long_form>mammalian <protein>p62</protein>-<protein>atypical
      protein kinase C (aPKC)</protein> complex</long_form> in the activation of <protein>NF-kappaB</protein> in response
      to different stimuli. Here we demonstrate using the RNA interference
      technique on Schneider cells that the <protein>Drosophila aPKC (DaPKC)</protein> is required
      for the stimulation of the <protein>Toll</protein>-signaling pathway, which activates the
      <protein>NF-kappaB</protein> homologues <protein>Dif</protein> and <protein>Dorsal</protein>. However, <protein>DaPKC</protein> does not appear to be
      important for the other <long_form>Drosophila <protein>NF-kappaB</protein></long_form> signaling cascade, which
      activates the <protein>NF-kappaB</protein> homologue <protein>Relish</protein> in response to
      lipopolysaccharides. Interestingly, <protein>DaPKC</protein> functions downstream of the
      nuclear translocation of <protein>Dorsal</protein> or <protein>Dif</protein>, controlling the transcriptional
      activity of the <protein>Drosomycin</protein> promoter. We also show that the <long_form>Drosophila
      <protein>Ref(2)P protein</protein></long_form> is the homologue of <long_form>mammalian <protein>p62</protein></long_form> as it binds to <protein>DaPKC</protein>,
      its overexpression is sufficient to activate the <protein>Drosomycin</protein> but not the
      <protein>Attacin</protein> promoter, and its depletion severely impairs <protein>Toll</protein> signaling.
      Collectively, these results demonstrate the conservation of the <long_form><protein>p62</protein>-<protein>aPKC</protein>
      complex</long_form> for the control of innate immunity signal transduction in
      Drosophila melanogaster.
</DOC>
<DOC>
<DOC_ID>[178]</DOC_ID>
>178.NF00127248
PMID:11857550
TI  - Hydrocephalus and intestinal aganglionosis: is <protein>L1CAM</protein> a modifier gene in
      Hirschsprung disease?
AB  - Congenital hydrocephalus associated with aqueductal stenosis and/or
      agenesis of the corpus callosum has been described in newborn males with
      mutations in <protein>L1CAM</protein>, a gene that encodes a <protein>neural cell adhesion molecule</protein>.
      These males usually have severe mental retardation and may have spastic
      paraplegia and adducted thumbs. In contrast, Hirschsprung disease, or
      absence of ganglion cells in the distal gut, has rarely been described in
      such individuals. We report a male infant who had severe hydrocephalus
      identified in the prenatal period with evidence of aqueductal stenosis and
      adducted thumbs at birth. He developed chronic constipation, and rectal
      biopsy confirmed the diagnosis of Hirschsprung disease. Molecular testing
      of the <protein>L1CAM</protein> gene revealed a G2254A mutation, resulting in a V752M amino
      acid substitution. A common polymorphism in <protein>RET</protein>, but no mutation, was
      identified. Our patient represents the third example of coincident
      hydrocephalus and Hirschsprung disease in an individual with an identified
      <protein>L1CAM</protein> mutation. We hypothesize that <protein>L1CAM</protein>-mediated cell adhesion may be
      important for the ability of ganglion cell precursors to populate the gut,
      and that <protein>L1CAM</protein> may modify the effects of a Hirschsprung disease-associated
      gene to cause intestinal aganglionosis.
</DOC>
<DOC>
<DOC_ID>[179]</DOC_ID>
>179.NF00123684
PMID:11741957
TI  - A lipid-regulated docking site on <protein>vinculin</protein> for <protein>protein kinase C</protein>.
AB  - During cell spreading, binding of <protein>actin-organizing proteins</protein> to acidic
      phospholipids and phosphorylation are important for localization and
      activity of these proteins at nascent cell-matrix adhesion sites. Here, we
      report on a transient interaction between the <protein>lipid-dependent protein
      kinase Calpha</protein> and <protein>vinculin</protein>, an early component of these sites, during
      spreading of HeLa cells on <protein>collagen</protein>. In vitro binding of <protein>protein kinase
      Calpha</protein> to <protein>vinculin</protein> tail was found dependent on free calcium and acidic
      phospholipids but independent of a functional <protein>kinase</protein> domain. The
      interaction was enhanced by conditions that favor the oligomerization of
      <protein>vinculin</protein>. Phosphorylation by <protein>protein kinase Calpha</protein> reached 1.5 mol of
      phosphate/mol of <protein>vinculin</protein> tail and required the C-terminal hydrophobic
      hairpin, a putative phosphatidylinositol 4,5-bisphosphate-binding site.
      Mass spectroscopy of peptides derived from in vitro phosphorylated
      <protein>vinculin</protein> tail identified phosphorylation of serines 1033 and 1045.
      Inhibition of C-terminal phospholipid binding at the <protein>vinculin</protein> tail by
      mutagenesis or deletion reduced the rate of phosphorylation to &lt; or =50%.
      We suggest a possible mechanism whereby phospholipid-regulated
      conformational changes in <protein>vinculin</protein> may lead to exposure of a docking site
      for <protein>protein kinase Calpha</protein> and subsequent phosphorylation of <protein>vinculin</protein>
      and/or <protein>vinculin</protein> interaction partners, thereby affecting the formation of
      cell adhesion complexes.
</DOC>
<DOC>
<DOC_ID>[180]</DOC_ID>
>180.NF00132596
PMID:12016134
TI  - Analysis of <long_form>human <protein>cellular retinol-binding protein II</protein></long_form> promoter during
      enterocyte differentiation.
AB  - <protein>Cellular retinol binding protein II (CRBP II)</protein> is a <protein>vitamin A-binding
      protein</protein> that is expressed specifically in small intestinal villus
      absorptive cells. Previous studies have shown that retinoic acid
      upregulates endogenous <long_form>human <protein>CRBP II</protein></long_form> gene expression in differentiated
      Caco-2 cells. To better characterize the regulation of <long_form>human <protein>CRBP II</protein></long_form>
      expression, we analyzed the ability of <protein>receptor</protein>-selective agonists to
      enhance transcription from the 5'-upstream flanking region of the <long_form>human
      <protein>CRBP II</protein></long_form> gene. Stable transfection experiments showed that the proximal
      2.8-kb region of the <long_form>human <protein>CRBP II</protein></long_form> gene is sufficient for retinoic acid
      inducibility in differentiated Caco-2 cells. However, direct sequence
      analysis and transient transfection experiments indicate that, unlike the
      <long_form>rat <protein>CRBP II</protein></long_form> promoter, the <long_form>human <protein>CRBP II</protein></long_form> promoter is not a direct <protein>retinoid
      X receptor</protein> target. The results indicate that the retinoic acid
      responsiveness of the <long_form>human <protein>CRBP II</protein></long_form> promoter is mediated by an indirect
      mechanism and that this mechanism is associated with enterocyte
      differentiation.
</DOC>
<DOC>
<DOC_ID>[181]</DOC_ID>
>181.NF00106676
PMID:12084720
TI  - Identification of <protein>human male germ cell-associated kinase</protein>, a <protein>kinase</protein>
      transcriptionally activated by androgen in prostate cancer cells.
AB  - Androgen is involved in both normal development and malignant
      transformation of prostate cells. The signal transduction pathways
      associated with these processes are not well understood. Using a novel
      <protein>kinase</protein> display approach, we have identified a <protein>protein kinase</protein>, <protein>human male
      germ cell-associated kinase (hMAK)</protein>, which is transcriptionally induced by
      the androgenic hormone 5alpha-dihydrotestosterone (DHT). The kinetics of
      induction is rapid and dose-dependent, and the induction is not blocked by
      cycloheximide treatment. Real time reverse transcription-PCR studies
      demonstrated a 9-fold induction of <protein>hMAK</protein> by 10 nm DHT at 24 h
      post-stimulation. The expression levels of <protein>hMAK</protein> in prostate cancer cell
      lines are in general higher than those of normal prostate epithelial
      cells. A reverse transcription-PCR product encompassing the entire <protein>hMAK</protein>
      open reading frame was isolated. The results from sequencing analysis
      showed that the <protein>hMAK protein</protein> is 623 amino acids in length and contains a
      <protein>kinase</protein> catalytic domain at its N terminus, followed by a
      proline/glutamine-rich domain. The catalytic domain of this <protein>kinase</protein>
      contains sequence motifs related to both the <protein>cyclin-dependent kinase</protein> and
      the <protein>mitogen-activated protein kinase</protein> families. When expressed in COS1
      cells, <protein>hMAK</protein> is <protein>kinase</protein>-active as demonstrated by autophosphorylation and
      phosphorylation of exogenous substrate and is localized in the nucleus. A
      3.7-kilobase pair promoter of the <protein>hMAK</protein> locus was isolated from a human
      genomic DNA bacterial artificial chromosome clone and was shown to be
      activated by DHT. This activation can be blocked by an anti-androgen drug
      bicalutamide (Casodex), implicating the involvement of <protein>androgen receptor</protein>
      in this process. Taken together, these data suggest that <protein>hMAK</protein> is a <protein>protein
      kinase</protein> targeted by androgen that may participate in androgen-mediated
      signaling in prostate cancer cells.
</DOC>
<DOC>
<DOC_ID>[182]</DOC_ID>
>182.NF00124497
PMID:12368450
TI  - Mycobacterium tuberculosis-infected human macrophages exhibit enhanced
      cellular adhesion with increased expression of <protein>LFA-1</protein> and <protein>ICAM-1</protein> and
      reduced expression and/or function of <protein>complement receptors</protein>, <protein>FcgammaRII</protein> and
      the <protein>mannose receptor</protein>.
AB  - The entry of Mycobacterium tuberculosis (Mtb) into the host macrophage and
      its survival in this environment are key components of tuberculosis
      pathogenesis. Following intracellular replication of the bacterium within
      alveolar macrophages, there is spread of bacilli to regional lymph nodes
      in the lungs and subsequent presentation of antigens to the host immune
      system. How this process occurs remains poorly understood, but one
      mechanism may involve the migration of macrophages containing Mtb across
      the alveoli to lymph nodes, where there is development of a protective
      host response with formation of granulomas composed in part of aggregated
      and fused, apoptotic, infected macrophages. <protein>Leukocyte integrins</protein>, including
      <protein>lymphocyte function-associated antigen-1 (LFA-1)</protein> and <protein>complement receptors
      CR3</protein> and <protein>CR4</protein>, and their counter <protein>receptors</protein> play a major role in macrophage
      adhesion processes and phagocytosis. In this study, the appearance of
      Mtb-infected macrophages over time was examined, using inverted-phase
      microscopy and an in vitro culture model of human monocyte-derived
      macrophages (MDMs). Prior to and immediately following infection of the
      MDMs with Mtb, the macrophages appeared as individual cells in monolayer
      culture; however, within 24 h of infection with Mtb, the MDMs began to
      migrate and adhere to each other. The kinetics of this response were
      dependent on both the m.o.i. and the length of infection. Quantitative
      transmission electron microscopy studies revealed that macrophage adhesion
      was accompanied by increases in levels of <protein>LFA-1</protein> and its counter <protein>receptor</protein>
      (<protein>ICAM-1</protein>), decreases in surface levels of the <protein>phagocytic receptors</protein> <protein>CR3</protein>, <protein>CR4</protein>
      and <protein>FcgammaRII</protein>, and an increase in <protein>major histocompatibility complex Class
      II (MHC-II) molecules</protein> at 72 h post-infection. Decreases in surface levels
      of <protein>CR3</protein> and <protein>CR4</protein> had a functional correlate, with macrophages containing
      live bacilli showing a diminished phagocytic capacity for
      <protein>complement</protein>-opsonized sheep erythrocytes; macrophages containing
      heat-killed bacilli did not show this diminished capacity. The modulation
      of <protein>macrophage adhesion and phagocytic proteins</protein> may influence the
      trafficking of Mtb-infected macrophages within the host, with increases in
      levels of <protein>LFA-1</protein> and <protein>ICAM-1</protein> enhancing the adhesive properties of the
      macrophage and decreases in <protein>phagocytic receptors</protein> diminishing the
      phagocytic capacity of an already-infected cell, potentially allowing for
      maintenance of the intracellular niche of Mtb.
</DOC>
<DOC>
<DOC_ID>[183]</DOC_ID>
>183.NF00118098
PMID:12010812
TI  - Inactivating mutations of <protein>CASP10</protein> gene in non-Hodgkin lymphomas.
AB  - <protein>Caspase 10</protein> (<protein>Mch4</protein>/<protein>FLICE2</protein>) is a <protein>caspase</protein> homologous to <protein>caspase 8</protein>. A recent
      report described that inherited <protein>CASP10</protein> gene mutations underlie defective
      lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative
      syndrome (ALPS). In this study, to explore the possibility that mutation
      of this gene might be involved in the development of non-Hodgkin lymphoma
      (NHL), we have analyzed the entire coding region and all splice sites of
      the <protein>CASP10</protein> gene for the detection of somatic mutations in 117 human NHLs.
      Overall, 17 NHLs (14.5%) were found to have <protein>CASP10</protein> mutations, which were
      identified in the coding regions of the prodomain (n = 3), the <protein>p17 large
      protease subunit</protein> (n = 11), and the <protein>p12 small protease subunit</protein> (n = 3). We
      expressed the <protein>tumor-derived caspase 10</protein> mutants in 293 cells and found that
      apoptosis was suppressed. These data suggest that the inactivating
      mutations of the <protein>CASP10</protein> gene might lead to the loss of its apoptotic
      function and contribute to the pathogenesis of some human NHLs.
</DOC>
<DOC>
<DOC_ID>[184]</DOC_ID>
>184.NF00125389
PMID:11793467
TI  - New insights into ocular albinism type 1 (<protein>OA1</protein>): Mutations and
      polymorphisms of the OA1 gene.
AB  - Albinism ocular type 1 (<protein>OA1</protein>) is an X-linked type of albinism that mainly
      effects pigment production in the eye, resulting in hypopigmentation of
      the retina, nystagmus, strabismus, foveal hypoplasia, abnormal crossing of
      the optic fibers, and reduced visual acuity. The <protein>OA1</protein> gene is located on
      chromosome Xp22.32 and the coding sequence is divided into nine exons. The
      protein is an <protein>integral transmembrane protein</protein> that has weak similarities to
      <protein>G protein-coupled receptors</protein>. A total of 25 missense, two nonsense, nine
      frameshift, and five splicing mutations have been reported in the <protein>OA1</protein> gene
      associated with <protein>OA1</protein>. There are also several deletions of some or all exons
      of the <protein>OA1</protein> gene with deletions of exon 2 resulting from unequal
      crossing-over, due to flanking Alu repeats. Mutation and polymorphism data
      on this gene is available from the International Albinism Center -
      Albinism Database web site (http://www.cbc.umn.edu/tad).
</DOC>
<DOC>
<DOC_ID>[185]</DOC_ID>
>185.NF00079670
PMID:12376704
TI  - <protein>Subthalamic GAD</protein> gene therapy in a Parkinson's disease rat model.
AB  - The motor abnormalities of Parkinson's disease (PD) are caused by
      alterations in basal ganglia network activity, including disinhibition of
      the subthalamic nucleus (STN), and excessive activity of the major output
      nuclei. Using adeno-associated viral vector-mediated somatic cell gene
      transfer, we expressed <protein>glutamic acid decarboxylase (GAD)</protein>, the enzyme that
      catalyzes synthesis of the neurotransmitter GABA, in excitatory
      glutamatergic neurons of the STN in rats. The transduced neurons, when
      driven by electrical stimulation, produced mixed inhibitory responses
      associated with GABA release. This phenotypic shift resulted in strong
      neuroprotection of nigral dopamine neurons and rescue of the parkinsonian
      behavioral phenotype. This strategy suggests that there is plasticity
      between excitatory and inhibitory neurotransmission in the mammalian brain
      that could be exploited for therapeutic benefit.
</DOC>
<DOC>
<DOC_ID>[186]</DOC_ID>
>186.NF00888340
PMID:11929878
TI  - <protein>Sec34</protein> is implicated in traffic from the endoplasmic reticulum to the Golgi
      and exists in a complex with <protein>GTC-90</protein> and <protein>ldlBp</protein>.
AB  - <protein>Sec34p</protein>/<protein>Grd20p</protein> has been implicated in endoplasmic reticulum (ER)-to-Golgi
      transport and/or post-Golgi trafficking events and exists in a protein
      complex consisting of at least eight subunits in yeast. Although the
      mammalian counterpart (<protein>Sec34</protein>) of <protein>Sec34p</protein> has been molecularly identified,
      its role and interacting partners remain undefined. In this study, we have
      prepared antibodies specifically against the recombinant N-terminal
      fragment of <protein>Sec34</protein> that recognize a polypeptide of about 93 kDa and label
      the Golgi apparatus. In a well-characterized semi-intact cell assay that
      reconstitutes transport of the <protein>envelope glycoprotein</protein> (<protein>VSVG</protein>) of vesicular
      stomatitis virus from the ER to the Golgi apparatus, <protein>anti-Sec34 antibodies</protein>
      inhibited the transport in a dose-dependent manner. The inhibition by
      <protein>anti-Sec34 antibodies</protein> could be neutralized by a noninhibitory amount of
      the antigen. Large-scale immunoprecipitation of rat liver cytosol with
      immobilized <protein>anti-Sec34 antibodies</protein> has co-immunoprecipitated <protein>GTC-90</protein> and
      <protein>ldlBp</protein>, two <protein>peripheral Golgi proteins</protein> previously shown to exist in separate
      protein complexes. Two mammalian homologues (<protein>Dor1</protein> and <protein>Cod1</protein>) of the <long_form>yeast
      <protein>Sec34 complex</protein></long_form> were similarly recovered in the <protein>Sec34</protein> immunoprecipitates.
      When expressed in transfected cells, epitope-tagged <protein>ldlCp</protein> and <protein>Cod2</protein> were
      co-immunoprecipitated with <protein>anti-Sec34 antibodies</protein> with efficiencies
      comparable to that observed for tagged <protein>ldlBp</protein>, <protein>Dor1</protein>, and <protein>Cod1</protein>. Direct
      interactions of <protein>Sec34</protein> with <protein>ldlBp</protein> and <protein>ldlCp</protein> were further demonstrated in
      vitro. These results suggest that <protein>Sec34</protein>, <protein>GTC-90</protein>, and <protein>ldlBp</protein>/<protein>ldlCp</protein> are part
      of the same protein complex(es) that regulates diverse aspects of Golgi
      function, including transport from the ER to the Golgi apparatus.
</DOC>
<DOC>
<DOC_ID>[187]</DOC_ID>
>187.NF00099193
PMID:11801662
TI  - <protein>Fc alpha RI</protein>/<protein>CD89</protein> circulates in human serum covalently linked to <protein>IgA</protein> in a
      polymeric state.
AB  - The <protein>FcR</protein> for <protein>IgA</protein> <protein>CD89</protein>/<protein>FcalphaRI</protein>, is a <protein>type I receptor glycoprotein</protein>,
      expressed on myeloid cells, with important immune effector functions. In
      vitro <protein>CD89</protein> can be released from <protein>CD89</protein>-expressing cells upon activation.
      Little information is available on the existence of this soluble molecule
      in vivo. Using specific and sensitive ELISA techniques (detection limit 50
      pg/ml), we were not able to detect circulating <protein>CD89</protein> in human sera.
      However, using Western blotting, a <protein>30-kDa soluble CD89 molecule</protein> was
      demonstrated in both serum and plasma. Moreover, using a specific
      semiquantitative dot-blot system, we found <protein>CD89</protein> in all human sera tested
      (mean concentration 1900 ng/ml). Size fractionation of human serum using
      gel filtration chromatography showed that the <protein>CD89 molecule</protein> was
      predominantly present in larger molecular mass fractions. Direct complexes
      between <protein>IgA</protein> and <protein>CD89</protein> were demonstrated by anti-<protein>IgA</protein> affinity purification,
      and when analyzed under nonreducing conditions appeared to be covalently
      linked. Size fractionation of affinity-purified <protein>IgA</protein> showed the presence of
      <protein>soluble</protein> CD89 only in the high molecular mass fractions of <protein>IgA</protein>, but not in
      <protein>monomeric IgA</protein>. High molecular mass <long_form>complexes of <protein>CD89</protein>-<protein>IgA</protein></long_form> could be
      distinguished from J chain containing <protein>dimeric IgA</protein>. These data show that
      <protein>CD89</protein> circulates in complex with <protein>IgA</protein>, and suggest that <protein>CD89</protein> might
      contribute to the formation of polymeric serum <protein>IgA</protein>.
</DOC>
<DOC>
<DOC_ID>[188]</DOC_ID>
>188.NF01099219
PMID:12596048
TI  - Influence of <protein>interleukin-12 receptor beta1</protein> polymorphisms on tuberculosis.
AB  - Host genetic factors may be important determinants of susceptibility to
      tuberculosis, and several candidate gene polymorphisms have been shown to
      date. A series of recent reports concerning rare human deficiencies in the
      <protein>type-1 cytokine</protein> pathway suggest that more subtle variants of relevant
      genes may also contribute to susceptibility to tuberculosis at the general
      population level. To investigate whether polymorphisms in the
      <protein>interleukin-12 receptor (IL-12R)</protein> gene predispose individuals to
      tuberculosis, we studied these genes by single-strand conformational
      polymorphism analysis and direct sequencing. Although no common
      polymorphisms could be identified in the <protein>IL-12R beta 2</protein> gene ( <protein>IL-12RB2</protein>),
      we confirmed four single nucleotide polymorphisms (SNPs; 641A--&gt;G,
      684C--&gt;T, 1094T--&gt;C, and 1132G--&gt;C) causing three missense variants
      (Q214R, M365T, G378R) and one synonymous substitution in the extracellular
      domain of the <protein>IL-12R beta 1</protein> gene ( <protein>IL12RB1</protein>). All SNPs were in almost
      perfect linkage disequilibrium (D'=0.98), and two common haplotypes of
      <protein>IL12RB1</protein>(allele 1: Q214-M365-G378; allele 2: R214-T365-R378) were revealed.
      Polymerase chain reaction/restriction fragment length polymorphism and
      sequence analyses were used to type <protein>IL12RB1</protein>polymorphisms in 98 patients
      with tuberculosis and 197 healthy controls in Japanese populations. In our
      case-control association study of tuberculosis, the R214-T365-R378 allele
      (allele 2) was over-represented in patients with tuberculosis, and
      homozygosity for R214-T365-R378 (the 2/2 genotype) was significantly
      associated with tuberculosis (odds ratio: 2.45; 95% CI: 1.20-4.99;
      P=0.013). In healthy subjects, homozygotes for R214-T365-R378 had lower
      levels of <protein>IL-12</protein>-induced signaling, according to differences in cellular
      responses to <protein>IL-12</protein> between two haplotypes. These data suggest that the
      R214-T365-R378 allele, i.e., variation in <protein>IL12RB1</protein>, contribute to
      tuberculosis susceptibility in the Japanese population. This genetic
      variation may predispose individuals to tuberculosis infection by
      diminishing <protein>receptor</protein> responsiveness to <protein>IL-12</protein> and to <protein>IL-23</protein>, leading to
      partial dysfunction of <protein>interferon-gamma</protein>-mediated immunity.
</DOC>
<DOC>
<DOC_ID>[189]</DOC_ID>
>189.NF00095955
PMID:12439719
TI  - Quantitative analysis of <long_form>human <protein>kallikrein</protein></long_form> gene 14 expression in breast
      tumours indicates association with poor prognosis.
AB  - <protein>KLK14</protein> (formerly known as <protein>KLK-L6</protein>) is a recently identified member of the
      <long_form>human <protein>kallikrein</protein></long_form> gene family. This family harbours several genes
      aberrantly expressed in various cancers as well as established (<protein>PSA</protein>/<protein>hK3</protein>,
      <protein>hK2</protein>) and potential (<protein>hK6</protein>, <protein>hK10</protein>) cancer markers. Similar to other <protein>kallikrein</protein>
      genes, <protein>KLK14</protein> was found to be regulated by steroid hormones, particularly
      androgens and progestins, in breast and ovarian cancer cell lines.
      Preliminary studies indicated that <protein>KLK14</protein> is differentially expressed in
      breast, ovarian, prostatic and testicular tumours. Given the above, we
      determined the prognostic significance of <protein>KLK14</protein> expression in breast
      cancer. We studied <protein>KLK14</protein> expression in 178 histologically confirmed
      epithelial breast carcinomas by quantitative reverse
      transcription-polymerase chain reaction and correlated with
      clinicopathological variables (tumour stage, grade, histotype etc.) and
      with outcome (disease-free survival and overall survival), monitored over
      a median of 76 months. <protein>KLK14</protein> mRNA levels ranged from 0 to 1,219 arbitrary
      units in breast cancer tissues, with a mean+/-s.e. of 136+/-22. An optimal
      cutoff value of 40.5 arbitrary units was selected, to categorise tumours
      as <protein>KLK14</protein>-positive or negative. Higher concentrations of <protein>KLK14</protein> mRNA were
      more frequently found in patients with advanced stage (III) disease
      (P=0.032). No statistically significant association was found between
      <protein>KLK14</protein> and the other clinicopathological variables. <protein>KLK14</protein> overexpression
      was found to be a significant predictor of decreased disease-free survival
      (hazard ratio of 2.31, P=0.001) and overall survival (hazard ratio of
      2.21, P=0.005). Cox multivariate analysis indicated that <protein>KLK14</protein> was an
      independent prognostic indicator of disease-free survival and overall
      survival. <protein>KLK14</protein> also has independent prognostic value in subgroups of
      patients with a tumour size &lt;/=2 cm and positive nodal, <protein>oestrogen receptor</protein>
      and <protein>progestin receptor</protein> status. We conclude that <protein>KLK14</protein> expression, as
      assessed by quantitative reverse transcription-polymerase chain reaction,
      is an independent marker of unfavourable prognosis for breast cancer.
</DOC>
<DOC>
<DOC_ID>[190]</DOC_ID>
>190.NF00097656
PMID:11815625
TI  - <protein>Cytokine</protein> signaling: <protein>STATS</protein> in plasma membrane rafts.
AB  - <protein>STAT transcription factors</protein> signal from the plasma membrane to the nucleus
      in response to <protein>growth factors</protein> and <protein>cytokines</protein>. We have investigated whether
      plasma membrane &quot;rafts&quot; are involved in <protein>cytokine</protein>-activated <protein>STAT</protein> signaling.
      <protein>Cytokine</protein>-free human hepatoma Hep3B cells or cells treated with
      <protein>interleukin-6 (IL-6)</protein> or orthovanadate (a general activator of <protein>STATs</protein>) were
      fractionated, and plasma membrane raft fractions were obtained by
      equilibrium sedimentation or flotation through discontinuous sucrose
      gradients using either non-detergent or detergent-based (saponin or Triton
      X-100) methods. By Western blotting the plasma membrane raft fractions
      obtained using either non-detergent or detergent-based methods contained
      significant amounts of <protein>STAT1</protein> and <protein>STAT3</protein> (up to approximately 10% of the
      total cytoplasmic amount) as well as the <protein>integral raft proteins caveolin-1</protein>
      and <protein>flotillin-1</protein>, the <protein>IL-6-receptor</protein> signal transducing chain <protein>gp130</protein>, the
      <protein>interferon-gamma receptor alpha chain (IFN-gammaRalpha)</protein>, and the <protein>chaperone
      glucose-regulated protein 58</protein> (<protein>GRP58</protein>/<protein>ER-60</protein>/<protein>ERp57</protein>). Upon activation of
      signaling by <protein>IL-6</protein> or orthovanadate the respective Tyr-phosphorylated <protein>STAT</protein>
      species were now also observed in the membrane raft fraction but in a form
      deficient in DNA binding. The data show pre-association of <protein>STATs</protein> with
      plasma membrane rafts in flotation fractions, which also contained
      <protein>caveolin-1</protein> and <protein>flotillin-1</protein>, and suggest that Tyr phosphorylation may not
      in itself be sufficient to cause the departure of PY-<protein>STATs</protein> from plasma
      membrane rafts. Methyl-beta-cyclodextrin, which sequesters cholesterol and
      disrupts plasma membrane rafts, markedly inhibited <protein>IL-6</protein>- and
      <protein>IFN-gamma</protein>-induced <protein>STAT</protein> signaling. Signaling through specialized raft
      microdomains may be a general mechanism operating at the level of the
      plasma membrane through which <protein>cytokines</protein> and <protein>growth factors</protein> activate <protein>STAT</protein>
      species (the &quot;raft-<protein>STAT</protein> signaling hypothesis&quot;).
</DOC>
<DOC>
<DOC_ID>[191]</DOC_ID>
>191.NF00083100
PMID:11950878
TI  - <long_form>Human <protein>CAP1</protein></long_form> is a key factor in the recycling of <protein>cofilin</protein> and <protein>actin</protein> for rapid
      <protein>actin</protein> turnover.
AB  - <protein>Cofilin</protein>-<protein>ADF (actin-depolymerizing factor)</protein> is an essential driver of
      <protein>actin</protein>-based motility. We discovered two proteins, <protein>p65</protein> and <protein>p55</protein>, that are
      <long_form>components of the <protein>actin</protein>-<protein>cofilin</protein> complex</long_form> in a human HEK293 cell extract and
      identified <protein>p55</protein> as <protein>CAP1</protein>/<protein>ASP56</protein>, a human homologue of <long_form>yeast <protein>CAP</protein></long_form>/<protein>SRV2</protein>
      (<protein>cyclase-associated protein</protein>). <protein>CAP</protein> is a <protein>bifunctional protein</protein> with an
      N-terminal domain that binds to <protein>Ras-responsive adenylyl cyclase</protein> and a
      C-terminal domain that inhibits <protein>actin</protein> polymerization. Surprisingly, we
      found that the N-terminal domain of <protein>CAP1</protein>, but not the C-terminal domain,
      is responsible for the interaction with the <long_form><protein>actin</protein>-<protein>cofilin</protein> complex</long_form>. The
      N-terminal domain of <protein>CAP1</protein> was also found to accelerate the
      depolymerization of <protein>F-actin</protein> at the pointed end, which was further enhanced
      in the presence of <protein>cofilin</protein> and/or the C-terminal domain of <protein>CAP1</protein>. Moreover,
      <protein>CAP1</protein> and its C-terminal domain were observed to facilitate filament
      elongation at the barbed end and to stimulate ADP-ATP exchange on <protein>G-actin</protein>,
      a process that regenerates easily polymerizable <protein>G-actin</protein>. Although <protein>cofilin</protein>
      inhibited the nucleotide exchange on <protein>G-actin</protein> even in the presence of the
      C-terminal domain of <protein>CAP1</protein>, its N-terminal domain relieved this inhibition.
      Thus, <protein>CAP1</protein> plays a key role in speeding up the turnover of <protein>actin</protein> filaments
      by effectively recycling <protein>cofilin</protein> and <protein>actin</protein> and through its effect on both
      ends of <protein>actin</protein> filament.
</DOC>
<DOC>
<DOC_ID>[192]</DOC_ID>
>192.NF00137212
PMID:11854171
TI  - <protein>KRIT1</protein> association with the <protein>integrin-binding protein ICAP-1</protein>: a new
      direction in the elucidation of cerebral cavernous malformations (CCM1)
      pathogenesis.
AB  - Mutations in <protein>KRIT1</protein>, a protein initially identified based on a yeast
      two-hybrid interaction with the <protein>RAS-family GTPase RAP1A</protein>, are responsible
      for the development of the inherited vascular disorder cerebral cavernous
      malformations (CCM1). As the function of the <protein>KRIT1 protein</protein> and its role in
      CCM pathogenesis remain unknown, we performed yeast two-hybrid screens to
      identify additional protein binding partners. A fragment containing the
      N-terminal 272 amino acid residues of <protein>KRIT1</protein>, a region lacking similarity
      to any known protein upon database searches, was used as bait. From
      parallel screens of human fetal brain and HeLa cDNA libraries, we obtained
      multiple independent isolates of <long_form>human <protein>integrin cytoplasmic
      domain-associated protein-1 (ICAP-1)</protein></long_form> as interacting clones. The
      interaction of <protein>KRIT1</protein> and <protein>ICAP-1</protein> was confirmed by GST-<protein>KRIT1</protein> trapping of
      endogenous <protein>ICAP-1</protein> from 293T cells. The <protein>alpha isoform of ICAP-1</protein> is a 200
      amino acid <protein>serine/threonine-rich phosphoprotein</protein> which binds the
      cytoplasmic tail of <protein>beta1 integrins</protein>. We show that mutagenesis of the
      N-terminal <protein>KRIT1</protein> NPXY amino acid sequence, a motif critical for <protein>ICAP-1</protein>
      binding to <protein>beta1 integrin</protein> molecules, completely abrogates the <protein>KRIT1</protein>/<protein>ICAP-1</protein>
      interaction. The interaction between <protein>ICAP-1</protein> and <protein>KRIT1</protein>, and the presence of
      a FERM domain in the latter, suggest that <protein>KRIT1</protein> might be involved in the
      bidirectional signaling between <protein>integrin</protein> molecules and the cytoskeleton.
      Furthermore, these data suggest that <protein>KRIT1</protein> might affect cell adhesion
      processes via <protein>integrin</protein> signaling in CCM1 pathogenesis.
</DOC>
<DOC>
<DOC_ID>[193]</DOC_ID>
>193.NF00115830
PMID:12417738
TI  - In vivo interference with <protein>Skp1</protein> function leads to genetic instability and
      neoplastic transformation.
AB  - <protein>Skp1</protein> is involved in a variety of crucial cellular functions, among which
      the best understood is the formation together with <protein>Cul1</protein> of
      <protein>Skp1-cullin-F-box protein ubiquitin ligases</protein>. To investigate the role of
      <protein>Skp1</protein>, we generated transgenic (Tg) mice expressing a <protein>Cul1</protein> deletion mutant
      (<protein>Cul1</protein>-N252) able to sequestrate and inactivate <protein>Skp1</protein>. In vivo interference
      with <protein>Skp1</protein> function through expression of the <protein>Cul1</protein>-N252 mutant into the
      T-cell lineage results in lymphoid organ hypoplasia and reduced
      proliferation. Nonetheless, after a period of latency, <protein>Cul1</protein>-N252 Tg mice
      succumb to T-cell lymphomas with high penetrance (&gt;80%). Both T-cell
      depletion and the neoplastic phenotype of <protein>Cul1</protein>-N252 Tg mice are largely
      rescued in <protein>Cul1</protein>-N252, <protein>Skp1</protein> double-Tg mice, indicating that the effects of
      <protein>Cul1</protein>-N252 are due to a sequestration of the endogenous <protein>Skp1</protein>. Analysis of
      <protein>Cul1</protein>-N252 lymphomas demonstrates striking karyotype heterogeneity
      associated with <protein>c-myc</protein> amplification and <protein>c-Myc</protein> overexpression. We show that
      the in vitro expression of the <protein>Cul1</protein>-N252 mutant causes a pleiotrophic
      phenotype, which includes the formation of multinucleated cells,
      centrosome and mitotic spindle abnormalities, and impaired chromosome
      segregation. Our findings support a crucial role for <protein>Skp1</protein> in proper
      chromosomal segregation, which is required for the maintenance of euploidy
      and suppression of transformation.
</DOC>
<DOC>
<DOC_ID>[194]</DOC_ID>
>194.NF00082217
PMID:12086470
TI  - Infertility of <protein>CD9</protein>-deficient mouse eggs is reversed by <long_form>mouse <protein>CD9</protein></long_form>, <long_form>human
      <protein>CD9</protein></long_form>, or <long_form>mouse <protein>CD81</protein></long_form>; polyadenylated mRNA injection developed for molecular
      analysis of sperm-egg fusion.
AB  - <protein>CD9</protein> is a <protein>membrane protein</protein> belonging to the <protein>tetraspanin</protein> family. Despite
      <protein>CD9</protein>'s broad tissue distribution, the only abnormality observed in
      <protein>CD9</protein>-deficient mice was infertility of females, which was responsible for a
      defect in the sperm-egg fusion process. However, the function of <protein>CD9</protein> in
      sperm-egg fusion is not clear at all because the technique to analyze the
      activity of molecules in sperm-egg fusion has not been established. We
      demonstrated that the exogenous <long_form>mouse <protein>CD9</protein></long_form>, expressed by polyadenylated
      mRNA injection at the germinal-vesicle stage oocytes, was precisely
      localized to the egg plasma membrane, and the expression reversed the
      infertility of <protein>CD9</protein>(-/-) eggs. Then, two other <protein>tetraspanins</protein>, <long_form>human <protein>CD9</protein></long_form> and
      <long_form>mouse <protein>CD81</protein></long_form>, overexpressed with this technique on <protein>CD9</protein>(-/-) eggs restored
      the fertilization rate up to approximately 90 and approximately 50%
      against that of wild type eggs, respectively. Moreover, in the presence of
      an <protein>anti-mouse CD9 mAb</protein>, which blocks sperm-egg fusion, expression of <long_form>human
      <protein>CD9</protein></long_form> or <long_form>mouse <protein>CD81</protein></long_form> on eggs also rescued the fusibility. These results
      suggested that <long_form>human <protein>CD9</protein></long_form> plays a crucial role in human fertilization, and
      <long_form>mouse <protein>CD81</protein></long_form> has the potential to compensate for <protein>CD9</protein> function in sperm-egg
      fusion. In addition, the polyadenylated mRNA injection is effective for
      molecular analysis of sperm-egg fusion.
</DOC>
<DOC>
<DOC_ID>[195]</DOC_ID>
>195.NF00126362
PMID:11904153
TI  - Conformational change and destabilization of cataract <protein>gammaC-crystallin</protein>
      T5P mutant.
AB  - <long_form>Human <protein>lens gammaC-crystallin</protein></long_form> and T5P mutant were cloned, and their
      biophysical properties and thermodynamic stability were studied. <protein>CRYGC</protein>
      (T5P) is one of the many <protein>gamma-crystallin</protein> mutant genes for autosomal
      dominant congenital cataracts. This mutation is associated with
      Coppock-like cataract, and has the phenotype of a dust-like opacity of the
      fetal lens nucleus. During cloning and overexpression, the majority of T5P
      mutant was found in the inclusion body. This property is unique among the
      many cataract <protein>gamma-crystallin</protein> mutant genes. It is thus worthwhile to
      study what factors contribute to this unique property of
      <protein>gammaC-crystallin</protein>. One possibility is changes in conformation and
      stability, which can be studied using spectroscopic measurements. In this
      study, conformational change was studied by circular dichroism and
      fluorescence measurements, and conformational stability was determined by
      thermal unfolding probed by Trp fluorescence and time-dependent light
      scattering. The T5P mutation obviously changes conformation and decreases
      conformational stability.
</DOC>
<DOC>
<DOC_ID>[196]</DOC_ID>
>196.NF00119154
PMID:12121992
TI  - <protein>SNAP-23</protein> is a target for <protein>calpain</protein> cleavage in activated platelets.
AB  - The role of <protein>calpain</protein> in platelet function is generally associated with
      aggregation and clot retraction. In this report, data are presented to
      show that one component of the platelet secretory machinery, <protein>SNAP-23</protein>, is
      specifically cleaved by <protein>calpain</protein> in activated cells. Other proteins of the
      membrane fusion machinery, e.g. <long_form><protein>syntaxins 2</protein> and 4</long_form> and <protein>alpha-SNAP</protein>, are not
      affected. In vitro studies, using permeabilized platelets, demonstrate
      that cleavage is time- and calcium-dependent. Analysis of <protein>SNAP-23</protein> cleavage
      products suggests that the <protein>calpain</protein> cleavage site(s) is in the C-terminal
      third of the molecule potentially between the cysteine-rich acyl
      attachment sites and the C-terminal coiled-coil domain. The time course of
      cleavage is most consistent with late <protein>calpain</protein>-mediated events such as
      <protein>pp60</protein>(<protein>c-src</protein>) cleavage, but not early events such as <protein>protein-tyrosine
      phosphatase-1B</protein> activation. <protein>SNAP-23</protein> cleavage is inhibited by <protein>calpeptin</protein>,
      <protein>calpastatin</protein>, <protein>calpain</protein> inhibitor IV, and E-64d, but not by <protein>caspase 3</protein>
      inhibitor III or <protein>cathepsin</protein> inhibitor I. When tested for their effect on
      secretion, none of the <protein>calpain</protein>-specific inhibitors significantly affected
      release of soluble components from any of the three platelet granule
      storage pools. These results indicate that <protein>SNAP-23</protein> cleavage occurs after
      granule release and therefore may play a role in affecting granule
      membrane exteriorization. This is consistent with the ultrastructural
      morphology of <protein>calpeptin</protein>-treated platelets after activation.
</DOC>
<DOC>
<DOC_ID>[197]</DOC_ID>
>197.NF00126282
PMID:12105219
TI  - Mass spectrometric analysis of <protein>GAP-43</protein>/<protein>neuromodulin</protein> reveals the presence of
      a variety of fatty acylated species.
AB  - <protein>GAP-43</protein> (<protein>neuromodulin</protein>) is a <protein>protein kinase C substrate</protein> that is abundant in
      developing and regenerating neurons. Thioester-linked palmitoylation at
      two cysteines near the <protein>GAP-43</protein> N terminus has been implicated in directing
      membrane binding. Here, we use mass spectrometry to examine the
      stoichiometry of palmitoylation and the molecular identity of the fatty
      acid(s) attached to <protein>GAP-43</protein> in vivo. <protein>GAP-43</protein> expressed in either PC12 or
      COS-1 cells was acetylated at the N-terminal methionine. Approximately 35%
      of the N-terminal <protein>GAP-43</protein> peptides were also modified by palmitate and/or
      stearate on Cys residues. Interestingly, a variety of acylated species was
      detected, in which one of the Cys residues was acylated by either
      palmitate or stearate, or both Cys residues were acylated by palmitates or
      stearates or a combination of palmitate and stearate. Depalmitoylation of
      <protein>membrane-bound GAP-43</protein> did not release the protein from the membrane,
      implying that additional forces function to maintain membrane binding.
      Indeed, mutation of four basic residues within the N-terminal domain of
      <protein>GAP-43</protein> dramatically reduced membrane localization of <protein>GAP-43</protein> without
      affecting palmitoylation. These data reveal the heterogeneous nature of
      S-acylation in vivo and illustrate the power of mass spectrometry for
      identification of key <protein>regulatory protein</protein> modifications.
</DOC>
<DOC>
<DOC_ID>[198]</DOC_ID>
>198.NF00080518
PMID:12089359
TI  - The mRNA structure has potent regulatory effects on <protein>type 2 iodothyronine
      deiodinase</protein> expression.
AB  - <protein>Type 2 deiodinase</protein> (D2) is a <protein>selenoenzyme</protein> catalyzing the activation of T(4)
      to T(3). D2 activity/mRNA ratios are often low, suggesting that there is
      significant posttranscriptional regulation. The D2 mRNA in higher
      vertebrates is more than 6 kb, containing long 5' and 3' untranslated
      regions (UTRs). The D2 5'UTRs are greater than 600 nucleotides and contain
      3-5 short open reading frames. These full-length 5'UTRs reduce the D2
      translation efficiency approximately 5-fold. The inhibition by human D2
      5'UTR is localized to a region containing the first short open reading
      frame encoding a tripeptide-MKG. This inhibition was abolished by mutating
      the AUG start codon and weakened by modification of the essential purine
      of the Kozak consensus. Deletion of the 3.7-kb 3'UTR of the chicken D2
      mRNA increased D2 activity approximately 3.8-fold due to an increase in D2
      mRNA half-life. In addition, alternatively spliced D2 mRNA transcripts
      similar in size to the major 6- to 7-kb D2 mRNAs but not encoding an
      active enzyme are present in both human and chicken tissues. Our results
      indicate that a number of factors reduce the D2 protein levels. These
      mechanisms, together with the short half-life of the protein, ensure
      limited expression of this key regulator of T(4) activation.
</DOC>
<DOC>
<DOC_ID>[199]</DOC_ID>
>199.NF00113973
PMID:11577372
TI  - <protein>Alpha-B crystallin</protein> gene (<protein>CRYAB</protein>) mutation causes dominant congenital
      posterior polar cataract in humans.
AB  - Congenital cataracts are an important cause of bilateral visual impairment
      in infants. In a four-generation family of English descent, we mapped
      dominant congenital posterior polar cataract to chromosome 11q22-q22.3.
      The maximum LOD score, 3.92 at recombination fraction 0, was obtained for
      marker D11S898, near the gene that encodes <protein>crystallin alpha-B protein
      (CRYAB)</protein>. By sequencing the coding regions of <protein>CRYAB</protein>, we found in exon 3 a
      deletion mutation, 450delA, that is associated with cataract in this
      family. The mutation resulted in a frameshift in codon 150 and produced an
      aberrant protein consisting of 184 residues. This is the first report of a
      mutation, in this gene, resulting in isolated congenital cataract.
</DOC>
<DOC>
<DOC_ID>[200]</DOC_ID>
>200.NF00122964
PMID:10898795
TI  - <protein>BCoR</protein>, a novel corepressor involved in <protein>BCL-6</protein> repression.
AB  - <protein>BCL-6</protein> encodes a <protein>POZ/zinc finger transcriptional repressor</protein> that is required
      for germinal center formation and may influence apoptosis. Aberrant
      expression of <protein>BCL-6</protein> due to chromosomal translocations is implicated in
      certain subtypes of non-Hodgkin's lymphoma. The POZ domains of <protein>BCL-6</protein> and
      several other <protein>POZ proteins</protein> interact with <protein>corepressors N-CoR</protein> and <protein>SMRT</protein>. Here
      we identify and characterize a novel <protein>corepressor BCoR (BCL-6 interacting
      corepressor)</protein>, which is expressed ubiquitously in human tissues. <protein>BCoR</protein> can
      function as a corepressor when tethered to DNA and, when overexpressed,
      can potentiate <protein>BCL-6</protein> repression. Specific <long_form>class I and II <protein>histone
      deacetylases (HDACs)</protein></long_form> interact in vivo with <protein>BCoR</protein>, suggesting that <protein>BCoR</protein> may
      functionally link these two classes of <protein>HDACs</protein>. Strikingly, <protein>BCoR</protein> interacts
      selectively with the POZ domain of <protein>BCL-6</protein> but not with eight other <protein>POZ
      proteins</protein> tested, including <protein>PLZF</protein>. Additionally, interactions between the
      <protein>BCL-6</protein> POZ domain and <protein>SMRT</protein>, <protein>N-CoR</protein>, and <protein>BCoR</protein> are mutually exclusive. The
      specificity of the <protein>BCL-6</protein>/<protein>BCoR</protein> interaction suggests that <protein>BCoR</protein> may have a
      role in <protein>BCL-6</protein>-associated lymphomas.
</DOC>
<DOC>
<DOC_ID>[201]</DOC_ID>
>201.NF00564623
PMID:11856366
TI  - <protein>Ornithine decarboxylase-antizyme</protein> is rapidly degraded through a mechanism
      that requires functional <protein>ubiquitin</protein>-dependent proteolytic activity.
AB  - <protein>Antizyme</protein> is a polyamine-induced <protein>cellular protein</protein> that binds to <protein>ornithine
      decarboxylase (ODC)</protein>, and targets it to rapid <protein>ubiquitin</protein>-independent
      degradation by the <protein>26S proteasome</protein>. However, the metabolic fate of <protein>antizyme</protein>
      is not clear. We have tested the stability of <protein>antizyme</protein> in mammalian cells.
      In contrast with previous studies demonstrating stability in vitro in a
      reticulocyte lysate-based degradation system, in cells <protein>antizyme</protein> is rapidly
      degraded and this degradation is inhibited by specific <protein>proteasome</protein>
      inhibitors. While the degradation of <protein>ODC</protein> is stimulated by the presence of
      cotransfected <protein>antizyme</protein>, degradation of <protein>antizyme</protein> seems to be independent of
      <protein>ODC</protein>, suggesting that <protein>antizyme</protein> degradation does not occur while presenting
      <protein>ODC</protein> to the <protein>26S proteasome</protein>. Interestingly, both species of <protein>antizyme</protein>, which
      represent initiation at two in-frame initiation codons, are rapidly
      degraded. The degradation of both <protein>antizyme proteins</protein> is inhibited in ts20
      cells containing a <protein>thermosensitive ubiquitin-activating enzyme</protein>, E1.
      Therefore we conclude that in contrast with <protein>ubiquitin</protein>-independent
      degradation of <protein>ODC</protein>, degradation of <protein>antizyme</protein> requires a functional
      <protein>ubiquitin</protein> system.
</DOC>
<DOC>
<DOC_ID>[202]</DOC_ID>
>202.NF00927018
PMID:12133833
TI  - Association of the <protein>adaptor TANK</protein> with the <protein>I kappa B kinase (IKK) regulator
      NEMO</protein> connects <protein>IKK complexes</protein> with <protein>IKK epsilon</protein> and <protein>TBK1 kinases</protein>.
AB  - Canonical activation of <protein>NF-kappa B</protein> is mediated via phosphorylation of the
      <protein>inhibitory I kappa B proteins</protein> by the <protein>I kappa B kinase complex (IKK)</protein>. <protein>IKK</protein>
      is composed of a <long_form>heterodimer of the catalytic <protein>IKK alpha</protein> and <protein>IKK beta
      subunits</protein></long_form> and a presumed <protein>regulatory protein</protein> termed <protein>NEMO (NF-kappa B
      essential <protein>modulator</protein>)</protein> or <protein>IKK gamma</protein>. <protein>NEMO</protein>/<protein>IKK gamma</protein> is indispensable for
      activation of the <protein>IKKs</protein> in response to many signals, but its mechanism of
      action remains unclear. Here we identify <protein>TANK (TRAF family
      member-associated NF-kappa B activator)</protein> as a <protein>NEMO/IKK gamma-interacting
      protein</protein> via yeast two-hybrid analyses. This interaction is confirmed in
      mammalian cells, and the domains required are mapped. <protein>TANK</protein> was previously
      shown to assist <protein>NF-kappa B</protein> activation in a complex with <protein>TANK-binding
      kinase 1 (TBK1)</protein> or <protein>IKK epsilon</protein>, two <protein>kinases</protein> distantly related to <long_form><protein>IKK
      alpha</protein>/beta</long_form>, but the underlying mechanisms remained unknown. Here we show
      that <protein>TBK1</protein> and <protein>IKK epsilon</protein> synergize with <protein>TANK</protein> to promote interaction with
      the <protein>IKKs</protein>. The <protein>TANK</protein> binding domain within <protein>NEMO</protein>/<protein>IKK gamma</protein> is required for
      proper functioning of this <protein>IKK subunit</protein>. These results indicate that <protein>TANK</protein>
      can synergize with <protein>IKK epsilon</protein> or <protein>TBK1</protein> to link them to <protein>IKK complexes</protein>,
      where the two <protein>kinases</protein> may modulate aspects of <protein>NF-kappa B</protein> activation.
</DOC>
<DOC>
<DOC_ID>[203]</DOC_ID>
>203.NF01196429
PMID:12504121
TI  - Genomic structure, expression, and transcriptional regulation of <protein>human Gal
      beta 1,3 GalNAc alpha 2,3-sialyltransferase</protein> gene.
AB  - In this report, we describe transcriptional regulation of the <protein>human Gal
      beta 1,3 GalNAc alpha 2,3-sialyltransferase II (hST3Gal II)</protein> gene. The
      results of 5'-RACE showed that the forms of two mRNAs differed only in the
      5'-untranslated region (Types 1 and 2). According to analysis of the
      genomic structure, the transcriptional regulation of Type 1 and Type 2
      mRNA isoforms depended on the p1 and p2 promoters, respectively. Both the
      mRNA isoforms were detected in various human tissues except colon,
      skeletal muscle, and peripheral blood leukocytes by RT-PCR analysis. In
      colon tissue, the Type 2 mRNA was detected, however, Type 1 mRNA was not
      detected. To elucidate the molecular basis of <protein>hST3Gal II</protein> gene expression,
      we isolated and characterized the function of the genomic region of
      <protein>hST3Gal II</protein> containing the p1 and p2 promoters. The activity of p2 promoter
      is much higher than that of the p1 promoter in the colon adenocarcinoma
      cell line, COLO205. These results suggest that the <protein>hST3Gal II</protein> gene is
      expressed specifically by alternative promoter utilization and is
      regulated in a tissue-restricted fashion at the level of transcription.
</DOC>
<DOC>
<DOC_ID>[204]</DOC_ID>
>204.NF00099608
PMID:12011764
TI  - Is the <protein>CD14 receptor</protein> gene a marker for smoking dependence?
AB  - BACKGROUND: The <protein>CD14 receptor</protein> is a <protein>myeloid cell-specific receptor</protein>, which
      plays a role in host defense and cell stimulation. <protein>CD14</protein> positive cells
      have been detected in lung, and also in brain, and the <protein>CD14 receptor</protein> is
      thought to play a role in asthma and allergy reactions. C-159--&gt;T
      polymorphism in the promoter of the <protein>CD14</protein> gene has been associated with
      myocardial infarction, but not in all studies. Our goal was to establish
      whether this polymorphism is associated with some of the risk factors of
      MI. MATERIAL/METHODS: With PCR and subsequent restriction analysis we
      evaluated C-159--&gt;T polymorphism in the <protein>CD14</protein> gene in 135 representative
      selected male Caucasians. RESULTS: We detected a significantly higher
      frequency of T/T homozygotes (p&lt;0.025) in subjects who had never smoked
      (15 of 60, 25.0%) as compared to smokers and past smokers (6 of 75, 8.0%).
      CONCLUSIONS: The C-159--&gt;T polymorphism in the <protein>CD14</protein> gene could be a
      genetic marker associated with smoking dependence, but confirmation in a
      large population study is necessary.
</DOC>
<DOC>
<DOC_ID>[205]</DOC_ID>
>205.NF00078954
PMID:11729309
TI  - Delineation of mRNA export pathways by the use of cell-permeable peptides.
AB  - The transport of messenger RNAs (mRNAs) from the nucleus to the cytoplasm
      involves <protein>adapter proteins</protein> that bind the mRNA as well as <protein>receptor proteins</protein>
      that interact with the <protein>nuclear pore complex</protein>. We demonstrate the utility of
      cell-permeable peptides designed to interfere with interactions between
      potential adapter and <protein>receptor proteins</protein> to define the pathways accessed by
      particular mRNAs. We show that <protein>HuR</protein>, a protein implicated in the
      stabilization of short-lived mRNAs containing AU-rich elements (AREs),
      serves as an adapter for <protein>c-fos</protein> mRNA export through two pathways. One
      involves the <protein>HuR</protein> shuttling domain, HNS, which exhibits a heat
      shock-sensitive interaction with <protein>transportin 2 (Trn2)</protein>; the other involves
      two protein ligands of <protein>HuR</protein>-<protein>pp32</protein> and <protein>APRIL</protein>-which contain leucine-rich
      nuclear export signals (NES) recognized by the <protein>export receptor CRM1</protein>.
      Heterokaryon and in situ hybridization experiments reveal that the
      peptides selectively block the nucleocytoplasmic shuttling of their
      respective <protein>adapter proteins</protein> without perturbing the overall cellular
      distribution of polyadenylated mRNAs.
</DOC>
<DOC>
<DOC_ID>[206]</DOC_ID>
>206.NF00086973
PMID:12225856
TI  - Unique assignment of inter-subunit association in <protein>GABA(A) alpha 1 beta 3
      gamma 2 receptors</protein> determined by molecular modeling.
AB  - Recent publications defined requirements for inter-subunit contacts in a
      <protein>benzodiazepine-sensitive GABA(A) receptor</protein> (<protein>GABA(A)R alpha 1 beta 3 gamma
      2</protein>). There is strong evidence that the <protein>heteropentameric receptor</protein> contains
      two alpha 1, two beta 3, and one gamma 2 subunit. However, the available
      data do not distinguish two possibilities: When viewed clockwise from an
      extracellular viewpoint the subunits could be arranged in either gamma 2
      beta 3 alpha 1 beta 3 alpha 1 or gamma 2 alpha 1 beta 3 alpha 1 beta 3
      configurations. Here we use molecular modeling to thread the relevant
      <protein>GABA(A)R subunit</protein> sequences onto a template of homopentameric subunits in
      the crystal structure of the <protein>acetylcholine binding protein (AChBP)</protein>. The
      <protein>GABA(A) sequences</protein> are known to have 15-18% identity with the <protein>acetylcholine
      binding protein</protein> and nearly all residues that are conserved within the
      <protein>nAChR</protein> family are present in <protein>AChBP</protein>. The correctly aligned <protein>GABA(A) sequences</protein>
      were threaded onto the <protein>AChBP</protein> template in the gamma 2 beta 3 alpha 1 beta 3
      alpha 1 or gamma 2 alpha 1 beta 3 alpha 1 beta 3 arrangements. Only the
      gamma 2 alpha 1 beta 3 alpha 1 beta 3 arrangement satisfied three known
      criteria: (1) alpha 1 His(102) binds at the gamma 2 subunit interface in
      proximity to gamma 2 residues Thr(142), Phe(77), and Met(130); (2) alpha 1
      residues 80-100 bind near gamma 2 residues 91-104; and (3) alpha 1
      residues 58-67 bind near the beta 3 subunit interface. In addition to
      predicting the most likely inter-subunit arrangement, the model predicts
      which residues form the GABA and benzodiazepine binding sites.
</DOC>
<DOC>
<DOC_ID>[207]</DOC_ID>
>207.NF00089567
PMID:12107172
TI  - Nuclear localization of <protein>CDC25B1</protein> and serine 146 integrity are required for
      induction of mitosis.
AB  - <protein>CDC25B phosphatases</protein> are essential regulators that control <protein>cyclin-dependent
      kinases</protein> activities at the entry into mitosis. In this study, we
      demonstrate that serine 146 is required for two crucial features of
      <protein>CDC25B1</protein>. It is essential for <protein>CDC25B1</protein> to function as a mitotic inducer and
      to prevent <protein>CDC25B1</protein> export from the nucleus. We also show that serine 146
      is phosphorylated in vitro by <protein>CDK1</protein>-<protein>cyclin B</protein>. However, phosphorylation of
      <protein>CDC25B</protein> does not stimulate its <protein>phosphatase</protein> activity, and mutation of serine
      146 had no effect on its catalytic activity. Serine 146 phosphorylation is
      proposed to be a key event in the regulation of the <protein>CDC25B</protein> function in the
      initiation of mammalian mitosis.
</DOC>
<DOC>
<DOC_ID>[208]</DOC_ID>
>208.NF00083111
PMID:11781319
TI  - The <protein>ankyrin-B</protein> C-terminal domain determines activity of <long_form><protein>ankyrin-B</protein>/G</long_form>
      chimeras in rescue of abnormal <long_form>inositol 1,4,5-trisphosphate and <protein>ryanodine
      receptor</protein></long_form> distribution in <protein>ankyrin-B</protein> (-/-) neonatal cardiomyocytes.
AB  - <protein>Ankyrins</protein> are a closely related family of membrane <protein>adaptor proteins</protein> that
      are believed to participate in targeting diverse <protein>membrane proteins</protein> to
      specialized domains in the plasma membrane and endoplasmic reticulum. This
      study addresses the question of how individual <protein>ankyrin isoforms</protein> achieve
      functional specificity when co-expressed in the same cell. Cardiomyocytes
      from <protein>ankyrin-B</protein> (-/-) mice display mis-localization of <protein>inositol
      1,4,5-trisphosphate receptors</protein> and <protein>ryanodine receptors</protein> along with reduced
      contraction rates that can be rescued by expression of green fluorescent
      protein (GFP)-<protein>ankyrin-B</protein> but not GFP-<protein>ankyrin-G</protein>. We developed chimeric GFP
      expression constructs containing all combinations of the three major
      domains of <protein>ankyrin-B</protein> and <protein>ankyrin-G</protein> to determine which domain(s) of
      <protein>ankyrin-B</protein> are required for <protein>ankyrin-B</protein>-specific functions. The
      death/C-terminal domain of <protein>ankyrin-B</protein> determined activity of <long_form><protein>ankyrin-B</protein>/G</long_form>
      chimeras in localization in a striated pattern in cardiomyocytes and in
      restoration of a normal striated distribution of both <long_form>ryanodine and
      <protein>inositol 1,4,5-trisphosphate receptors</protein></long_form> as well as normal beat frequency of
      contracting cardiomyocytes. Further deletions within the death/C-terminal
      domain demonstrated that the C-terminal domain determines <protein>ankyrin-B</protein>
      activity, whereas deletion of the death domain had no effect. C-terminal
      domains are the most divergent between <protein>ankyrin isoforms</protein> and are candidates
      to encode the signal(s) that enable <protein>ankyrins</protein> to selectively target
      proteins to diverse cellular sites.
</DOC>
<DOC>
<DOC_ID>[209]</DOC_ID>
>209.NF00074123
PMID:12154078
TI  - Regulation of the <protein>CDK-related protein kinase PCTAIRE-1</protein> and its possible
      role in neurite outgrowth in Neuro-2A cells.
AB  - <protein>PCTAIRE-1</protein> is a <protein>CDK-related protein kinase</protein> found in terminally
      differentiated cells in brain and testis, and in many immortalised and
      transformed cell lines. Bacterially expressed <protein>PCTAIRE</protein> is completely
      inactive as a <protein>protein kinase</protein>, but is a very good substrate for <protein>protein
      kinase A (PKA)</protein>, which phosphorylates a total of four sites in the
      N-terminus of <protein>PCTAIRE-1</protein>. Phosphorylation of one of these sites, Ser119,
      generates a 14-3-3 binding site, which is functional in vitro as well as
      in vivo. Mutation of another <protein>PKA</protein> site, Ser153, to an alanine residue
      generated an activated <protein>kinase</protein> in transfected mammalian cells. This
      activity was comparable to that of <protein>CDK5</protein> activated by a bacterially
      expressed, truncated version of <protein>p35</protein>(<protein>nck</protein>), <protein>p21</protein>. Gel filtration analysis of
      a brain extract suggested that <protein>monomeric PCTAIRE-1</protein> was the active species,
      implying that <protein>PCTAIRE-1</protein> may not be a true <protein>CDK</protein>, in that it does not require
      a partner (<protein>cyclin</protein>-like) subunit for <protein>kinase</protein> activity. Finally, we found
      that various <protein>forms of PCTAIRE-1</protein> transfected into neuroblastoma cell lines
      could either promote or inhibit neurite outgrowth, suggesting a potential
      role for the <protein>PCTAIRE-1</protein> gene product in the control of neurite outgrowth.
</DOC>
<DOC>
<DOC_ID>[210]</DOC_ID>
>210.NF00080523
PMID:11727264
TI  - Expression of <protein>multidrug resistance 1</protein> and <protein>glutathione-S-transferase</protein>-Pi
      protein in nasopharyngeal carcinoma.
AB  - Radiotherapy is the modality of choice for the treatment of nasopharyngeal
      carcinoma (NPC). However, systemic chemotherapy has recently been found to
      play an increasing role in the treatment of advanced or metastatic
      disease. The status of drug resistance gene expression that has crucial
      impact on chemotherapy has not been fully addressed for patients with <protein>NPC</protein>.
      In this study, we examined the expression of <protein>multidrug resistance 1
      (MDR-1)</protein> and <protein>glutathione-S-transferase-Pi (GST-Pi)</protein> in primary, recurrent,
      and metastatic NPC using results of immunohistochemical examinations. The
      results were correlated with the expression of <long_form>Epstein-Barr virus (EBV)
      <protein>latent protein</protein></long_form>, <protein>latent membrane protein 1 (LMP1)</protein>, and clinicopathologic
      features, including stage, histopathologic types, and survival rates.
      <protein>MDR-1 protein</protein> expression was detected in 18 (12.6%) of 143 patients with
      primary NPC, 14 (32.6%) of 43 with recurrent NPC, and O (0%) of 20 with
      metastatic NPC, whereas 83 (58%) of 143 patients with primary NPC, 30
      (69.8%) of 43 with recurrent NPC, and 13 (65%) of 20 with metastatic NPC
      expressed <protein>GST-Pi</protein>. <long_form>EBV-<protein>LMP1</protein></long_form> was expressed in 59 (41.3%) of 143 patients
      with primary NPC, 23 (53.5%) of 43 with recurrent NPC, and 9 (45%) of 20
      with metastatic NPC. Simultaneous expression of <protein>MDR1</protein> and <protein>GST-Pi</protein> was
      observed in 13 (72.2%) of 18 patients with primary NPC and 12 (85.7%) of
      14 with recurrent NPC. The expression of <protein>LMP1</protein> was detected in only 6 of
      the 13 patients with primary NPC and 6 of the 12 with recurrent NPC. We
      concluded that the expression of <protein>GST-Pi</protein> was more frequent in NPC tumor
      tissues than the expression of <protein>MDR-1</protein>. The expression of <protein>MDR-1</protein> correlated
      with clinicopathologic features of primary NPC, including the
      histopathologic types and survival rates, but not with disease stage. The
      expression of <protein>GST-Pi</protein> did not correlate with clinicopathologic features.
      The expression of <protein>MDR-1</protein> and <protein>GST-Pi</protein> did not correlate with expression of
      <long_form>EBV-<protein>LMP1</protein></long_form> for patients with NPC.
</DOC>
<DOC>
<DOC_ID>[211]</DOC_ID>
>211.NF00081416
PMID:12606287
TI  - Transcriptional activation of <protein>BMP-4</protein> and regulation of mammalian
      organogenesis by <long_form><protein>GATA-4</protein> and -6</long_form>.
AB  - <long_form><protein>Transcription factors GATA-4</protein>, -5, and -6</long_form> constitute an evolutionary
      conserved subfamily of vertebrate zinc finger regulators highly expressed
      in the developing heart and gut. Genetic evidence suggests that each
      protein is essential for embryonic development, but their exact functions
      are not fully elucidated. Moreover, because all three proteins share
      similar transcriptional properties in vitro, and because transcripts for
      two or more <protein>GATA</protein> genes are present in similar tissues, the molecular basis
      underlying in vivo specificity of <protein>GATA factors</protein> remains undefined.
      Knowledge of the exact cell types expressing each protein and
      identification of downstream targets would greatly help define their
      function. We have used high-resolution immunohistochemistry to precisely
      determine the cellular distribution of the <long_form><protein>GATA-4</protein>, -5, and -6 proteins</long_form> in
      murine embryogenesis. The results reveal novel sites of expression in
      mesodermal and ectodermal cells. In particular, <long_form><protein>GATA-4</protein> and -6</long_form> expression
      was closely associated with yolk sac vasculogenesis and early
      endoderm-mesoderm signaling. Additionally, <protein>GATA-6</protein> was strongly expressed
      in the embryonic ectoderm, neural tube, and neural crest-derived cells.
      This pattern of expression closely paralled that of <protein>BMP-4</protein>, and the <protein>BMP-4</protein>
      gene was identified as a direct downstream target for <long_form><protein>GATA-4</protein> and -6</long_form>. These
      findings offer new insight into the function of <long_form><protein>GATA-4</protein> and -6</long_form> during early
      stages of embryogenesis and reveal the existence of a positive
      cross-regulatory loop between <protein>BMP-4</protein> and <protein>GATA-4</protein>. They also raise the
      possibility that part of the early defects in <protein>GATA-4</protein> and/or <protein>GATA-6</protein> null
      embryos may be due to impaired <protein>BMP-4</protein> signaling.
</DOC>
<DOC>
<DOC_ID>[212]</DOC_ID>
>212.NF00124913
PMID:11756564
TI  - Isolation of the <long_form>human <protein>testatin</protein></long_form> gene and analysis in patients with
      abnormal gonadal development.
AB  - We have previously isolated the <protein>testatin</protein> gene using a modified mRNA
      differential display method on RNA from developing male and female mouse
      gonads. This gene is specifically expressed during early testis
      development, immediately after the onset of the testis-determining gene
      <protein>SRY</protein>: The protein encoded by <protein>testatin</protein> has features that are characteristic
      for <protein>type 2 cystatins</protein>, a family of <protein>small inhibitors of cystein proteases</protein>
      such as the <protein>cathepsins</protein>. We have now isolated the human orthologue of this
      gene. We describe here the sequence, genomic structure, chromosomal
      location, and expression pattern of the <long_form>human <protein>testatin</protein></long_form> gene. Like <long_form>mouse
      <protein>testatin</protein></long_form>, <long_form>human <protein>testatin</protein></long_form> is specifically expressed in the testis,
      suggesting that it has a function in reproduction. We have therefore also
      investigated whether the <long_form>human <protein>testatin</protein></long_form> gene plays a role in disorders of
      gonadal development, by sequencing the gene in patients with gonadal
      dysgenesis, with true hermaphroditism, and in children with less
      well-defined intersex conditions. We found no sequence aberrations in
      these patients apart from an H109P polymorphism which was also found in
      fertile controls. This is the first genetic analysis of <protein>testatin</protein> in
      humans.
</DOC>
<DOC>
<DOC_ID>[213]</DOC_ID>
>213.NF00081335
PMID:12064938
TI  - Cryo-electron microscopy of trichocyte (<protein>hard alpha-keratin</protein>) intermediate
      filaments reveals a low-density core.
AB  - Trichocyte intermediate filaments (IF) are the principal components of
      epidermal appendages such as hair and nail. Based on studies by a variety
      of techniques, it has been inferred that trichocyte IF are structurally
      similar to other kinds of IF. However, some basic structural attributes
      have yet to be established: in particular, it has remained unclear whether
      IF are hollow. We have examined trichocyte IF isolated from rat vibrissae
      and human hair follicles by electron microscopy. Scanning transmission
      electron microscopy of freeze-dried specimens yielded mass-per-unit-length
      values of approximately 32 kDa/nm, with the human preparations also
      containing filaments at half this density, corresponding to two rather
      than four protofibrils. Radial density profiles calculated from
      cryo-electron micrographs of vitrified specimens preserved in a
      near-native state revealed a low-density region of approximately 3 nm
      diameter around the filament axis. A minor species of filament with the
      same internal structure was surface-decorated with material arranged with
      a helical pitch length of 9.3 nm. These filaments appear to represent IF
      coated with associated proteins-perhaps, &quot;high-sulfur&quot; proteins-readied
      for incorporation into the filament-matrix biocomposite of the mature
      hair.
</DOC>
<DOC>
<DOC_ID>[214]</DOC_ID>
>214.NF00091136
PMID:12482935
TI  - The promoter of <protein>IL-18 binding protein</protein>: activation by an <protein>IFN-gamma</protein> -induced
      <long_form>complex of <protein>IFN regulatory factor 1</protein> and <protein>CCAAT/enhancer binding protein
      beta</protein></long_form>.
AB  - The <protein>IL-18 binding protein (IL-18BP)</protein> is a circulating <protein>inhibitor of the
      proinflammatory cytokine IL-18</protein>. It is constitutively expressed in
      mononuclear cells, and elevated expression is induced by <protein>IFN-gamma</protein>. In
      this study, we characterized the <protein>IL-18BP</protein> promoter. We first showed that
      induction is at the transcriptional level and requires de novo protein
      synthesis. The <protein>IL-18BP</protein> promoter resides within 1.6 kb DNA upstream of the
      first exon and includes at least six regulatory elements. We identified in
      the basal promoter a gamma-activated sequence (GAS) proximal to the
      transcription start site (base 1), followed by an <protein>IFN regulatory factor 1</protein>
      response element (IRF-E) and two <protein>CCAATenhancer binding protein beta
      (CEBPbeta)</protein> sites, all of which are essential for basal promoter activity.
      Furthermore, GAS and IRF-E were essential for <protein>IFN-gamma</protein>-induced
      transcription. Indeed, sera of <protein>IRF-1</protein>-deficient mice lacked basal and
      <protein>IFN-gamma-induced IL-18BP</protein>. We found that after induction of <protein>IRF-1</protein> by
      <protein>IFN-gamma</protein>, it formed a complex with <protein>CEBPbeta</protein>, which bound to the IRF-E and
      GAS-containing proximal DNA. In contrast, the <protein>IFN-gamma</protein>-induced <protein>signal
      transducer and activator of transcription 1 dimer</protein> did not associate with
      this GAS. In addition, we identified a silencer element and a distal
      enhancer at bases -1081 to -1272, which was also physically associated
      with <protein>IRF-1</protein>. The <long_form><protein>IRF-1</protein>-<protein>CEBPbeta</protein> complex</long_form> described here probably plays a
      fundamental role in regulating additional <protein>IFN-gamma</protein>-responsive genes.
</DOC>
<DOC>
<DOC_ID>[215]</DOC_ID>
>215.NF00117705
PMID:12608515
TI  - Autosomal dominant macular dystrophy in a large Canadian family.
AB  - BACKGROUND: We studied a large Canadian family (178 total family members)
      spanning seven generations with autosomal dominant macular dystrophy. We
      performed a study to identify the gene mutation responsible for the
      disease in the family. METHODS: Participating family members were
      evaluated clinically. Genetic linkage, genotyping, mutation screening and
      an extensive genealogic investigation were performed. RESULTS: The common
      clinical findings in affected family members included progressive early-
      to mid-onset visual loss and extensive areas of central chorioretinal
      atrophy. Two-point linkage analysis indicated linkage to chromosome 6p.
      Direct DNA sequencing showed a C/T transition in codon 172 of the <protein>retinal
      degeneration slow (RDS)</protein> gene creating an amino acid change to Arg172Trp.
      Haplotype analysis of affected family members using microsatellite markers
      distributed around the <protein>RDS</protein> gene locus revealed that the markers were not
      conserved when compared to members of British families with the Arg172Trp
      mutation. Genealogic studies indicated the family immigrated to Canada
      from Ireland in 1843. INTERPRETATION: A newly identified large family with
      autosomal dominant macular dystrophy is described. The phenotypic
      appearance of the fundus is similar to that of previously described
      patients with an Arg172Trp mutation in the <protein>RDS</protein> gene. Haplotype analysis of
      markers spanning the disease locus identified a new founder for this
      mutation. The identification of the disease-causing gene in this family
      allows for better genetic counselling for patients with this condition and
      provides a basis to distinguish clinically similar types of macular
      dystrophy based on the clinical phenotype.
</DOC>
<DOC>
<DOC_ID>[216]</DOC_ID>
>216.NF00075018
PMID:12213191
TI  - Intracellular signaling by <protein>growth hormone variant (GH-V)</protein>.
AB  - <protein>Placental growth hormone</protein>, or <protein>growth hormone variant (GH-V)</protein>, is a member of
      the <protein>growth hormone</protein> gene family. Its physiologic role during pregnancy
      remains undefined. Although extensive work has been done characterizing
      the signaling pathways activated by <protein>hGH</protein>, the signaling pathways which are
      activated by <protein>GH-V</protein> have not been characterized. We investigated cellular
      signaling by <protein>GH-V</protein> in model systems in which signaling by <protein>hGH</protein> has been well
      characterized. <protein>GH-V</protein> activates the <protein>STAT5b transcription factor</protein> in the IM-9
      human lymphocyte and 3T3-F442A preadipocyte cell lines, and in primary
      porcine smooth muscle cells, which all homologously express <protein>GH receptors</protein>.
      In contrast, <protein>hCS</protein> does not activate signaling in these <protein>GH
      receptor</protein>-expressing cells. Like <protein>hGH</protein>, signaling by <protein>GH-V</protein> is inhibited by the
      <protein>GH</protein> antagonist (G120K). These results provide preliminary evidence that
      <protein>GH-V</protein> plays a major role in affecting target cells expressing the <protein>GH
      receptor</protein>, thus potentially exerting significant <protein>GH</protein>-like effects on
      maternal physiology during pregnancy.
</DOC>
<DOC>
<DOC_ID>[217]</DOC_ID>
>217.NF00109445
PMID:11705854
TI  - <protein>Hypoxia-regulated carbonic anhydrase-9 (CA9)</protein> relates to poor
      vascularization and resistance of squamous cell head and neck cancer to
      chemoradiotherapy.
AB  - PURPOSE: <protein>Carbonic anhydrases</protein> are proteins involved in the catalytic
      hydration of carbon dioxide to carbonic acid. Recent studies show that
      <protein>carbonic anhydrase 9 (CA9)</protein> is up-regulated by hypoxia and that its
      immunohistochemical tissue distribution follows the distribution of the
      radiosensitizer pimonidazole (C. C. Wykoff et al., Cancer Res. 60:
      7075-7083, 2001). Therefore, <protein>CA9</protein> expression may show hypoxia levels of
      clinical importance. EXPERIMENTAL DESIGN: We assessed the expression of
      <protein>CA9</protein> and the microvessel density (MVD; CD31-positive) in 75 locally
      advanced squamous cell head and neck cancers treated with concurrent
      chemoradiotherapy with carboplatin. RESULTS: Strong membrane/cytoplasmic
      <protein>CA9</protein> expression, noted in 20/75 (26.6%) tumors, mainly occurred in tumors
      with very poor vascularization (expression in 63% versus 14%; P &lt; 0.0001),
      was located around areas of focal necrosis, and was related to poor
      complete response rate (40% versus 70%; P = 0.02). These observations
      suggested that <protein>CA9</protein> might be a marker of clinically important hypoxia.
      Combining the <protein>CA9</protein> staining and the tumor angiogenicity (MVD), we
      identified three groups of patients: (a) hypoxic tumors; (b) euoxic highly
      angiogenic tumors; and (c) euoxic non-highly angiogenic tumors. Groups (a)
      and (b) had a very poor local relapse-free survival (P &lt; 0.0001).
      CONCLUSIONS: Stratification of patients undergoing radical radiotherapy
      using the <protein>CA9</protein>/MVD model may be useful for the individualization of
      therapeutic strategies combining antiangiogenesis and hypoxia targeting
      with radiotherapy.
</DOC>
<DOC>
<DOC_ID>[218]</DOC_ID>
>218.NF00081257
PMID:12547389
TI  - Specific stimulation of <protein>human apurinic/apyrimidinic endonuclease</protein> by <protein>heat
      shock protein 70</protein>.
AB  - We previously demonstrated the stimulation of <protein>human apurinic/apyrimidinic
      <protein>endonuclease</protein> 1 (HAP1)</protein> by <protein>heat shock protein 70 (HSP70)</protein>. In this work, we
      further defined the functional interaction between these proteins.
      Digestion of <protein>HSP70</protein> by <protein>trypsin</protein> released 48 and 43 kDa amino terminal
      fragments that retained the ability to stimulate <protein>HAP1</protein>. In agreement with
      this result, an <protein>HSP70</protein> N-terminal deletion mutant protein containing amino
      acids 1-385 was comparable to the full-length protein in its ability to
      enhance <protein>HAP1</protein> activity. <protein>HSP70</protein> mutants containing carboxy terminal amino
      acids 386-640 stimulated <protein>HAP1</protein> only slightly, as did unrelated proteins.
      These results implicate the amino terminal portion of <protein>HSP70</protein> in stimulating
      the activity of <protein>HAP1</protein>.
</DOC>
<DOC>
<DOC_ID>[219]</DOC_ID>
>219.NF00124837
PMID:11809883
TI  - <protein>hMutSalpha</protein> forms an ATP-dependent complex with <protein>hMutLalpha</protein> and <protein>hMutLbeta</protein> on
      DNA.
AB  - The DNA binding properties of <protein>hMutSalpha</protein> and <protein>hMutLalpha</protein> and complex
      formation of <protein>hMutSalpha</protein> with <protein>hMutLalpha</protein> and <protein>hMutLbeta</protein> were investigated
      using binding experiments on magnetic bead-coupled DNA substrates with
      nuclear extracts as well as purified proteins. <protein>hMutSalpha</protein> binding to
      homoduplex DNA was disrupted by lower NaCl concentrations than <protein>hMutSalpha</protein>
      binding to a mismatch. ATP markedly reduced the salt resistance of
      <protein>hMutSalpha</protein> binding but <protein>hMutSalpha</protein> still retained affinity for
      heteroduplexes. <protein>hMutSalpha</protein> formed a complex with <protein>hMutLalpha</protein> and <protein>hMutLbeta</protein>
      on DNA in the presence of ATP. This complex only formed on 81mer and not
      32mer DNA substrates. Complex formation was enhanced by a mismatch in the
      DNA substrate, and <protein>hMutLalpha</protein> and <protein>hMutLbeta</protein> were shown to enter the
      complex at different ATP concentrations. Purified <protein>hMutLalpha</protein> showed an
      intrinsic affinity for DNA, with a preference for single-stranded over
      double-stranded DNA.
</DOC>
<DOC>
<DOC_ID>[220]</DOC_ID>
>220.NF00134639
PMID:12207887
TI  - <protein>VCY2 protein</protein> interacts with the HECT domain of <protein>ubiquitin-protein ligase
      E3A</protein>.
AB  - <protein>VCY2</protein> locates in the AZFc region on chromosome Yq and is frequently deleted
      in infertile men with severe oligozoospermia or azoospermia. <protein>VCY2</protein> is a
      <protein>testis-specific protein</protein> with unknown function. This study was to identify
      the protein that interacts with <protein>VCY2</protein>. We used the full-length <protein>VCY2</protein> as bait
      to screen the human testis cDNA library using yeast two-hybrid approach.
      We identified a number of positive-interacting clones that encode
      <protein>ubiquitin-protein ligase E3A (UBE3A)</protein>. <protein>UBE3A</protein> contains a HECT domain that
      binds <protein>VCY2</protein>. The specificity of the interaction was confirmed by
      co-immunoprecipitation and yeast mating. Northern blot analyses revealed
      two <protein>UBE3A</protein> transcripts 1.4 and 2kb that were abundantly expressed in human
      testis. We also showed that both <protein>VCY2</protein> and <protein>UBE3A</protein> mRNAs were expressed in
      ejaculated human spermatozoa, indicating that both genes localize in the
      germ cell compartment. These data suggest that <protein>UBE3A</protein> ubiquitination may be
      required for <protein>VCY2</protein> function.
</DOC>
<DOC>
<DOC_ID>[221]</DOC_ID>
>221.NF00932291
PMID:11727258
TI  - <protein>MUC4</protein> expression is increased in dysplastic cervical disorders.
AB  - The female uterine cervix has 2 characteristic populations of epithelial
      cells: the endocervix is composed by mucus-secreting cells that express
      several <protein>mucin</protein> genes, and the exocervix has a typical stratified squamous
      epithelium and does not express <protein>secreted mucins</protein>. Among <long_form>human <protein>mucin</protein></long_form> genes,
      the <protein>MUC4</protein> sequence has a transmembrane domain, and its molecular structure
      suggests that it has a protective role and also may be implicated in
      intracellular signalling. The aim of this study is to analyze whether
      changes in the expression of <protein>MUC4</protein> can be detected associated with the
      squamous dysplastic transformation of exocervical epithelium. <protein>MUC4</protein>
      expression has been analyzed by immunohistochemistry, Western blotting,
      and in situ hybridization. Using immunohistochemical techniques, <protein>MUC4</protein> is
      found in normal endocervix (n = 11) and is absent or only focally detected
      in the normal stratified cervical epithelium (n = 18). In samples from
      squamous metaplasia (n = 9), <protein>MUC4</protein> is variably expressed (10% to 50%
      positive cells), whereas <protein>MUC4</protein> is strongly detected in dysplastic cervical
      epithelia. The greatest number of positive cells is found in samples with
      moderate and severe dysplasia in which <protein>MUC4</protein> is detected in 100% of the
      analyzed samples (n = 16). These results have been confirmed by Western
      blotting and by detection of <protein>MUC4</protein> transcripts using in situ hybridization.
      The present data suggest that <protein>MUC4</protein> is activated during the process of
      squamous dysplastic transformation and may be used as a marker for this
      pathologic process.
</DOC>
<DOC>
<DOC_ID>[222]</DOC_ID>
>222.NF00088920
PMID:11836615
TI  - Expression of the genes of <protein>methyl-binding domain proteins</protein> in human
      gliomas.
AB  - DNA methylation is the most common epigenetic alteration in tumor genomes
      and might result in transcriptional repression of <protein>tumor suppressor</protein> genes.
      Moreover, recent results have demonstrated that both specific methylation
      patterns and functional <protein>components of the mismatch repair system</protein> are
      involved in the development of therapy resistance of tumor cells. Here we
      investigated the expression of the genes of <protein>methyl binding domain
      containing proteins (MBD)</protein> in human gliomas both in vivo and in vitro. We
      found expression of <protein>MBDs</protein> including <protein>MBD1</protein>, <protein>MBD2</protein>, <protein>MBD3</protein> and <protein>MBD4</protein>/<protein>MED1</protein> in all
      glioma cell lines and glioma biopsies. No differences existed in vitro
      with regard to individual <protein>MBDs</protein> and individual cell lines. In vivo, <protein>MBD1</protein>
      and <protein>MBD2</protein> were also expressed in all biopsies with only minor differences
      between individual tumors. <protein>MBD3</protein> and <protein>MBD4</protein>/<protein>MED1</protein>, however, showed a
      correlation of expression with the grade of malignancy. Astrocytomas and
      anaplastic astrocytomas showed a weak expression compared with a high
      expression in glioblastoma multiforme.
</DOC>
<DOC>
<DOC_ID>[223]</DOC_ID>
>223.NF00097597
PMID:11823470
TI  - <protein>Caspase-2</protein> can trigger <protein>cytochrome C</protein> release and apoptosis from the nucleus.
AB  - The <protein>cysteine proteases</protein> specific for aspartic residues, known as <protein>caspases</protein>,
      are localized in different subcellular compartments and play specific
      roles during the regulative and the executive phase of the cell death
      process. Here we investigated the subcellular localization of <protein>caspase-2</protein> in
      healthy cells and during the execution of the apoptotic program. We have
      found that <protein>caspase-2</protein> is a <protein>nuclear resident protein</protein> and that its import
      into the nucleus is regulated by two different nuclear localization
      signals. We have shown that in an early phase of apoptosis <protein>caspase-2</protein> can
      trigger mitochondrial dysfunction from the nucleus without relocalizing
      into the cytoplasm. Release of <protein>cytochrome c</protein> occurs in the absence of overt
      alteration of the nuclear pores and changes of the nuclear/cytoplasmic
      barrier. Addition of leptomycin B, an inhibitor of nuclear export, did not
      interfere with the ability of <protein>caspase-2</protein> to trigger <protein>cytochrome c</protein> release.
      Only during the late phase of the apoptotic process can <protein>caspase-2</protein>
      relocalize in the cytoplasm, as consequence of an increase in the
      diffusion limits of the nuclear pores. Taken together these data indicate
      the existence of a nuclear/mitochondrial apoptotic pathway elicited by
      <protein>caspase-2</protein>.
</DOC>
<DOC>
<DOC_ID>[224]</DOC_ID>
>224.NF00079777
PMID:11966773
TI  - Expression, modulation and signalling of <protein>IL-17 receptor</protein> in fibroblast-like
      synoviocytes of patients with rheumatoid arthritis.
AB  - <protein>Interleukin-17 (IL-17)</protein> has been characterized as a <protein>proinflammatory
      cytokine</protein> produced by <protein>CD4</protein>+ <protein>CD45RO</protein>+ memory T cells. Overproduction of <protein>IL-17</protein>
      was detected in the synovium of patients with rheumatoid arthritis (RA)
      compared to patients with osteoarthritis. In contrast to the restricted
      expression of <protein>IL-17</protein>, the <protein>IL-17 receptor</protein> (<protein>IL-17R</protein>/<protein>CDw217</protein>) is expressed
      ubiquitously. Using a real-time RT-PCR assay, we detected similar absolute
      levels of <protein>IL-17R</protein> mRNA expression in fibroblast-like synoviocytes (SFC)
      from patients with RA (mean 9 pg/microg total RNA; ranged from 0.1 pg to
      96 pg <protein>IL-17R</protein> mRNA/microg total RNA) compared to synoviocytes of non-RA
      patients. Analysis of the <protein>IL-17R</protein> surface expression confirmed the results
      obtained for <protein>IL-17R</protein> mRNA expression. Exposure of SFC to <protein>IL-17</protein> led to a
      mRNA induction of <protein>CXC chemokines IL-8</protein>, <protein>GRO-alpha</protein> and <protein>GRO-beta</protein>. An
      <protein>anti-IL-17 antibody</protein> blocked these effects of <protein>IL-17</protein>. The <protein>MAPK p38</protein> appears
      necessary for the regulation of <protein>IL-8</protein>, <protein>GRO-alpha</protein> and <protein>GRO-beta</protein> expression as
      shown by inhibition with SB203580. The inhibitors genistein (<protein>tyrosine
      kinase</protein> inhibitor) and calphostin C (inhibitor of <protein>protein kinase C</protein>) reduced
      significantly the <protein>IL-17</protein>-stimulated mRNA expression of <protein>IL-8</protein>, <protein>GRO-alpha</protein> and
      <protein>GRO-beta</protein> in SFC, whereas PD98059 (inhibitor of <long_form><protein>MEK-1</protein>/2</long_form>) was without
      effect. Pharmacological drugs used in therapy of RA, such as cyclosporin
      and methotrexate, induced a fourfold increase of <protein>IL-17R</protein> mRNA expression
      and augmented the <protein>IL-17</protein>-stimulated <protein>IL-8</protein> expression. Our results support
      the hypothesis that <protein>IL-17</protein>/<protein>IL-17R</protein> may play a significant role in the
      pathogenesis of RA contributing to an unbalanced production of <protein>cytokines</protein>
      as well as participating in connective tissue remodelling.
</DOC>
<DOC>
<DOC_ID>[225]</DOC_ID>
>225.NF00888526
PMID:12200131
TI  - Hypoxia activates <protein>beta(1)-integrin</protein> via <long_form><protein>ERK 1</protein>/2</long_form> and <protein>p38 MAP kinase</protein> in human
      vascular smooth muscle cells.
AB  - Hypoxia plays an important role in vascular remodeling and directly
      affects vascular smooth muscle cell (VSMC) functions. VSMC adhesion
      participates in changes of vascular structure; however, little is known
      about VSMC adhesion under hypoxic conditions. It was the aim of the
      present study to investigate the effects of hypoxia on adhesion mechanisms
      in human VSMCs. Compared to normoxic cells, hypoxia (1% O(2), 24h)
      significantly increased adhesion of VSMCs to <protein>collagen I</protein> by 30.2% and
      <protein>fibronectin</protein> by 58.0%. This effect was completely inhibited in the presence
      of the pharmacological <long_form><protein>ERK 1</protein>/2</long_form> <protein>mitogen-activated protein kinase (MAPK)</protein>
      pathway inhibitor PD98059 (30 microM) or the <protein>p38 MAPK</protein> inhibitor SB203580
      (1 microM). Basal adhesion of normoxic cells was not affected by
      pretreatment with PD98059 and SB203580. Hypoxia induced a time-dependent
      activation of <long_form><protein>ERK 1</protein>/2</long_form> and <protein>p38 MAPK</protein> activation in human VSMCs, which were
      completely abolished by PD98059 or SB203580, respectively. Since adhesion
      of VSMCs to <protein>fibronectin</protein> and <protein>collagen I</protein> involves <protein>beta(1)-integrin
      receptors</protein>, we used a blocking <protein>antibody against beta(1)-integrin</protein> (P5D2) to
      examine potential effects of hypoxia on <protein>beta(1)-integrins</protein>. P5D2
      significantly reduced VSMC adhesion to <protein>fibronectin</protein> and <protein>collagen I</protein> in
      normoxia and hypoxia in a comparable manner; however, <protein>beta(1)-integrin
      protein</protein> or mRNA levels were not affected by hypoxia. As evidenced by flow
      cytometry, hypoxia induced a activation of <protein>beta(1)-integrins</protein> by exposing
      an conformationally sensitive epitope on the beta(1)-subunit. These
      results demonstrate that hypoxia enhances adhesion of VSMC on
      <protein>extracellular matrix proteins</protein> by activating <protein>beta(1)-integrin</protein>.
</DOC>
<DOC>
<DOC_ID>[226]</DOC_ID>
>226.NF00111014
PMID:11988089
TI  - Crystal structure of <long_form>human <protein>dehydroepiandrosterone sulphotransferase</protein></long_form> in
      complex with substrate.
AB  - <protein>Dehydroepiandrosterone sulphotransferase (DHEA-ST)</protein> is an enzyme that
      converts dehydroepiandrosterone (DHEA), and some other steroids, into
      their sulphonated forms. The enzyme catalyses the sulphonation of DHEA on
      the 3alpha-oxygen, with 3'-phosphoadenosine-5'-phosphosulphate
      contributing the sulphate. The structure of <long_form>human <protein>DHEA-ST</protein></long_form> in complex with
      its preferred substrate DHEA has been solved here to 1.99 A using
      molecular replacement with <protein>oestradiol sulphotransferase</protein> (37% sequence
      identity) as a model. Two alternative substrate-binding orientations have
      been identified. The primary, catalytic, orientation has the DHEA
      3alpha-oxygen and the highly conserved catalytic histidine in nearly
      identical positions as are seen for the related <protein>oestradiol
      sulphotransferase</protein>. The substrate, however, shows rotations of up to 30
      degrees, and there is a corresponding rearrangement of the protein loops
      contributing to the active site. This may also reflect the low identity
      between the two enzymes. The second orientation penetrates further into
      the active site and can form a potential hydrogen bond with the
      desulphonated cofactor 3',5'-phosphoadenosine (PAP). This second site
      contains more van der Waal interactions with hydrophobic residues than the
      catalytic site and may also reflect the substrate-inhibition site. The PAP
      position was obtained from the previously solved structure of <protein>DHEA-ST</protein>
      co-crystallized with PAP. This latter structure, due to the arrangement of
      loops within the active site and monomer interactions, cannot bind
      substrate. The results presented here describe details of substrate
      binding to <protein>DHEA-ST</protein> and the potential relationship to substrate inhibition.
</DOC>
<DOC>
<DOC_ID>[227]</DOC_ID>
>227.NF00110043
PMID:12411321
TI  - <protein>Furin</protein> gene (<protein>fur</protein>) regulation in differentiating human megakaryoblastic Dami
      cells: involvement of the proximal <protein>GATA</protein> recognition motif in the P1
      promoter and impact on the maturation of <protein>furin substrates</protein>.
AB  - The <protein>convertase furin</protein> is involved in the maturation of key
      growth/aggregation mediators synthesized by the platelet producers,
      megakaryocytes, but the regulation of <protein>furin</protein> in these cells remains
      unknown. Computer-assisted search of the <protein>furin</protein> promoter sequence revealed
      multiple potential binding motifs for <protein>GATA-1</protein>, suggesting that <protein>furin</protein> is
      expressed and regulated in these cells. Using megakaryoblastic Dami cells,
      we observed that <protein>fur</protein> mRNA expression increased gradually on phorbol
      12-myristate 13-acetate-induced differentiation, reaching maximum levels
      (8.3-fold increase) at 10 days. Transient transfections with P1, P1A, or
      P1B <protein>fur</protein>-LUC-promoter constructs revealed that in Dami cells, the P1
      promoter is the strongest and the most sensitive to forced expression of
      <protein>GATA-1</protein>. Coexpression of <protein>GATA-1</protein> and its comodulator, <protein>Friend of GATA-1
      (FOG-1)</protein>, resulted in a cooperative increase in P1 activity. Deletion
      analysis indicated that important <protein>GATA-1</protein>-regulated sequences are located
      in the most proximal region of the P1 promoter. Further analysis revealed
      2 potential <protein>GATA</protein>-binding motifs at positions -66 and +62. Point mutation
      of each of the 2 motifs indicated that the intactness of the first <protein>GATA</protein>
      site is required for full basal and <protein>GATA-1</protein>-stimulated promoter activity.
      Finally, the inhibition of <protein>furin</protein> activity through gene transfer of the
      inhibitor alpha1-AT-PDX led to a block in maturation of the <protein>furin
      substrates</protein> <protein>transforming growth factor-beta1</protein> and <protein>platelet-derived growth
      factor</protein>. Taken together, these results indicate that the most proximal <protein>GATA</protein>
      element in the P1 promoter is needed for <protein>fur</protein> gene expression in
      megakaryoblastic cells. They also suggest that proper regulation of the
      <protein>fur</protein> gene in megakaryocytes has an impact on the activation of <protein>furin
      substrates</protein> involved in megakaryocyte maturation and platelet functions.
</DOC>
<DOC>
<DOC_ID>[228]</DOC_ID>
>228.NF00011064
PMID:12101100
TI  - Critical evaluation of the role of the <protein>Toll-like receptor 18-Wheeler</protein> in
      the host defense of Drosophila.
AB  - Essential aspects of innate immune responses to microbial infections
      appear to be conserved between insects and mammals. In particular, in both
      groups, <protein>transmembrane receptors</protein> of the <protein>Toll</protein> superfamily play a crucial
      role in activating immune defenses. The <long_form>Drosophila <protein>Toll</protein></long_form> family member
      <protein>18-Wheeler</protein> had been proposed to sense Gram-negative infection and direct
      selective expression of peptides active against Gram-negative bacteria.
      Here we re-examine the role of <protein>18-Wheeler</protein> and show that in adults it is
      dispensable for immune responses. In larvae, <protein>18wheeler</protein> is required for
      normal fat body development, and in mutant larvae induction of all
      <protein>antimicrobial peptide</protein> genes, and not only of those directed against
      Gram-negative bacteria, is compromised. <protein>18-Wheeler</protein> does not qualify as a
      <protein>pattern recognition receptor</protein> of Gram-negative bacteria.
</DOC>
<DOC>
<DOC_ID>[229]</DOC_ID>
>229.NF00100248
PMID:12138090
TI  - <protein>QM</protein>, a putative <protein>tumor suppressor</protein>, regulates proto-oncogene <protein>c-yes</protein>.
AB  - The <protein>QM</protein> gene encodes a <protein>24.5 kDa ribosomal protein L10</protein> known to be highly
      homologous to a <protein>Jun-binding protein (Jif-1)</protein>, which inhibits the formation
      of <long_form><protein>Jun</protein>-<protein>Jun</protein> dimers</long_form>. Here we have carried out screening with the <protein>c-Yes
      protein</protein> and found that a <protein>QM homologous protein</protein> showed interactions with
      <protein>c-Yes</protein> and other <protein>Src</protein> family members. We have found that two different
      regions of <protein>QM protein</protein> were associated with the SH3 domain of <protein>c-Yes</protein>. The <protein>QM
      protein</protein> does not contain canonical SH3 binding motifs or previously
      reported amino acid fragments showing interaction with SH3 domains.
      Several <protein>c-Yes kinase</protein> activity assays indicated that the <protein>QM protein</protein> reduced
      <protein>c-Yes kinase</protein> activity by 70% and that this suppression is related not only
      to the two SH3 binding regions but also to the C-terminal region of <protein>QM</protein>.
      Moreover, our autophosphorylation assays clarified that this regulation
      resulted from the inhibition of <protein>c-Yes</protein> autophosphorylation.
      Immunofluorescence studies showed that the <protein>QM proteins</protein> and <protein>c-Yes</protein> are able
      to interact in various tumor cell lines in vivo. The increases of the
      <protein>c-Yes protein</protein> and mRNA levels were detected when the <protein>QM</protein> was transfected.
      These results suggest that the <protein>QM protein</protein> might be a regulator for various
      signal transduction pathways involving <protein>SH3 domain-containing membrane
      proteins</protein>.
</DOC>
<DOC>
<DOC_ID>[230]</DOC_ID>
>230.NF00081421
PMID:11920156
TI  - Mutation screening and imprinting analysis of four candidate genes for
      autism in the 7q32 region.
AB  - Genetic studies indicate that chromosome 7q is likely to contain an autism
      susceptibility locus (<protein>AUTS1</protein>). We have followed a positional candidate gene
      approach to identify the relevant gene and report the analysis of four
      adjacent genes localised to a 800 kb region in 7q32 that contains an
      imprinted domain: <protein>PEG1/MEST</protein>, <protein>COPG2</protein>, <protein>CPA1</protein> and <protein>CPA5-a</protein> previously
      uncharacterised member of the <protein>carboxypeptidase</protein> gene family. Screening
      these genes for DNA changes and association analysis using intragenic
      single nucleotide polymorphisms (SNPs) provided no evidence for an
      etiological role in IMGSAC families. We also searched for imprinting
      mutations potentially implicated in autism: analysis of both DNA
      methylation and replication timing indicated a normal imprinting
      regulation of the <protein>PEG1</protein>/<protein>COPG2</protein> domain in blood lymphocytes of all patients
      tested. The analysis of these four genes strongly suggests that they do
      not play a major role in autism aetiology, and delineates our strategy to
      screen additional candidate genes in the <protein>AUTS1</protein> locus.
</DOC>
<DOC>
<DOC_ID>[231]</DOC_ID>
>231.NF00134722
PMID:11784720
TI  - <protein>Calpain</protein>-mediated cleavage of the <protein>cyclin-dependent kinase-5 activator p39</protein>
      to <protein>p29</protein>.
AB  - The activity of <protein>cyclin-dependent kinase-5 (Cdk5)</protein> is tightly regulated by
      binding of its <protein>neuronal activators p35</protein> and <protein>p39</protein>. Upon neurotoxic insults,
      <protein>p35</protein> is cleaved to <protein>p25</protein> by the <protein>Ca(2+)-dependent protease calpain</protein>. <protein>p25</protein> is
      accumulated in ischemic brains and in brains of patients with Alzheimer's
      disease. <protein>p25</protein> deregulates <protein>Cdk5</protein> activity by causing prolonged activation and
      mislocalization of <protein>Cdk5</protein>. It is unknown whether <protein>p39</protein>, which is expressed
      throughout the adult rat brain, is cleaved by <protein>calpain</protein>, and whether this
      contributes to deregulation of <protein>Cdk5</protein>. Here, we show that <protein>calpain</protein> cleaved
      <protein>p39</protein> in vitro, resulting in generation of a C-terminal <protein>p29</protein> fragment. In
      vivo, <protein>p29</protein> was generated in ischemic brain concomitant with increased
      <protein>calpain</protein> activity. In fresh brain lysates, generation of <protein>p29</protein> was
      Ca(2+)-dependent, and <protein>calpain</protein> inhibitors abolished <protein>p29</protein> production. The
      Ca(2+) ionophore ionomycin and the excitotoxin glutamate induced
      production of <protein>p29</protein> in cultures of cortical neurons in a <protein>calpain</protein>-dependent
      manner. Like <protein>p25</protein>, <protein>p29</protein> was more stable than <protein>p39</protein> and caused redistribution
      of <protein>Cdk5</protein> in cortical neurons. Our data suggest that neurotoxic insults lead
      to <protein>calpain</protein>-mediated conversion of <protein>p39</protein> to <protein>p29</protein>, which might contribute to
      deregulation of <protein>Cdk5</protein>.
</DOC>
<DOC>
<DOC_ID>[232]</DOC_ID>
>232.NF00106860
PMID:12016153
TI  - Polymorphism at <protein>GSTM1</protein>, <protein>GSTM3</protein> and <protein>GSTT1</protein> gene loci and susceptibility to
      oral cancer in an Indian population.
AB  - This study evaluates the influence of genetic polymorphism at <protein>GSTM1</protein>, <protein>GSTM3</protein>
      and <protein>GSTT1</protein> gene loci on oral cancer risk among Indians habituated to the
      use of, smokeless tobacco, bidi or cigarette. DNA extracted from white
      blood cells of 297 cancer patients and 450 healthy controls by the
      proteinase K phenol-chloroform extraction procedure were analyzed by the
      polymerase chain reaction (PCR) and PCR-restriction fragment length
      polymorphism (RFLP) analyses. Lifetime tobacco exposure was evaluated as a
      risk factor in relation to the polymorphism at the <protein>GST</protein> gene loci using
      logistic regression analysis. There was no significant difference in the
      distribution of the <protein>GSTM3</protein> and <protein>GSTT1</protein> genotypes between oral cancer patients
      and controls. In contrast, a significant 3-fold increase in risk was seen
      for patients with the <protein>GSTM1</protein> null genotype (age adjusted OR = 3.2, 95% CI
      2.4-4.3). The impact of the <protein>GSTM1</protein> null genotype on oral cancer risk was
      also analyzed in separate groups of individuals with different tobacco
      habits. The odds ratio associated with the <protein>GSTM1</protein> null genotype was 3.7
      (95% CI 2.0-7.1) in tobacco chewers, 3.7 (5% CI 1.3-7.9) in bidi smokers
      and 5.7 (95% CI 2.0-16.3) in cigarette smokers. Furthermore, increased
      lifetime exposure to chewing tobacco appeared to be associated with a
      2-fold increase in oral cancer risk in <protein>GSTM1</protein> null individuals. The results
      suggest that the <protein>GSTM1</protein> null genotype is a risk factor for development of
      oral cancer among Indian tobacco habitues.
</DOC>
<DOC>
<DOC_ID>[233]</DOC_ID>
>233.NF00125815
PMID:11960377
TI  - Overexpression of <protein>B-type cyclins</protein> alters chromosomal segregation.
AB  - To identify genes which overexpression results into chromosomal
      instability (CIN), we developed a biological approach based on a yeast
      indicator strain in which CIN can be detected by a sectoring phenotype.
      Screening in this strain of a yeast genomic library cloned into a high
      copy vector led us to identify, among the clones generating 100% of
      sectoring colonies, <protein>Clb5</protein>, one of the six <protein>B-type cyclins</protein> present in yeast.
      Overexpression of <protein>cyclin B2</protein> and <protein>cyclin B1</protein>, the two human homologs of <protein>Clb5</protein>,
      in the CIN indicator strain resulted also into a sectoring phenotype and
      induced, like overexpression of <protein>Clb5</protein>, an abnormal sensitivity to benomyl,
      indicating that overexpression of <protein>B-type cyclins</protein> alters the spindle
      checkpoint. In a series of 38 primary colorectal cancers, we detected in
      five tumors (13%) an accumulation of <protein>cyclin B1</protein>, which was neither related
      to mRNA overexpression nor to mutation within the coding region, and in
      five other tumors (13%) a 2-10-fold increase of <protein>cyclin B2</protein> mRNA which was
      not related to gene amplification. These results suggest that
      overexpression of <protein>cyclins B</protein>, resulting from different mechanisms, could
      contribute, through an alteration of the spindle checkpoint, to the
      chromosomal instability observed in cancer.
</DOC>
<DOC>
<DOC_ID>[234]</DOC_ID>
>234.NF00123871
PMID:11846980
TI  - Structure and function of <protein>IRF-7</protein>.
AB  - <protein>Interferon (IFN) regulatory factors (IRF)</protein> are a family of <protein>transcription
      factors</protein> with multiple functions. <protein>IRF-7</protein> was initially cloned within the
      biologic context of Epstein-Barr virus (EBV) latency and discovered to
      have an intimate relation with the EBV primary <protein>oncogenic protein</protein>, <protein>latent
      membrane protein-1 (LMP-1)</protein>. EBV regulates and uses <protein>IRF-7</protein> as a secondary
      mediator for several target genes involved in latency and immune
      regulation. Other than its functions in EBV latency, <protein>IRF-7</protein> has been
      identified as one of the major players in virally induced <protein>IFN</protein> production
      that is central to innate immunity. Thus, <protein>IRF-7</protein> plays important roles in a
      variety of biologic systems.
</DOC>
<DOC>
<DOC_ID>[235]</DOC_ID>
>235.NF00080537
PMID:12054577
TI  - Expression of the <protein>Musashi1</protein> gene encoding the <protein>RNA-binding protein</protein> in human
      hepatoma cell lines.
AB  - <protein>Musashi1</protein>, a <protein>neural RNA-binding protein</protein>, plays an important role in
      regulating cell differentiation in precursor cells. Recently, expression
      of <protein>Musashi1</protein> has been detected in human tumor tissues such as gliomas and
      melanomas, suggesting its involvement in oncogenic development. To
      determine any association between <protein>Musashi1</protein> and the development of liver
      cancer, we investigated its gene expression in seven human hepatoma cell
      lines: HuH6, HuH7, Hep3B, SK-Hep1, HepG2, HLE, and HLF. <protein>Musashi1</protein> mRNA
      expression was analyzed using the reverse-transcription polymerase chain
      reaction (PCR), and the PCR products were sequenced using a subcloning
      procedure. <protein>Musashi1 protein</protein> expression was analyzed in HuH7 and HepG2
      cells by Western blot and immunofluorescence staining. <protein>Musashi1</protein> mRNA was
      detected in the HuH6, HuH7, and Hep3B hepatoma cell lines, but not in the
      others. Sequencing of the PCR-amplified <protein>Musashi1</protein> cDNA in these three cell
      lines showed the expected sequence of the <long_form>human <protein>Musashi1</protein></long_form> gene. <protein>Musashi1
      protein</protein> expression was confirmed in HuH7 cells, which were positive for
      <protein>Musashi1</protein> mRNA expression, but not in HepG2 cells. These results suggest
      that <protein>Musashi1</protein> expression may be an important factor in the development of
      several types of carcinoma such as human hepatoma, and may be a useful
      molecular marker for tumor detection.
</DOC>
<DOC>
<DOC_ID>[236]</DOC_ID>
>236.NF00864016
PMID:12151362
TI  - Mutations in the <long_form>Drosophila <protein>glycoprotein hormone receptor</protein></long_form>, rickets,
      eliminate <protein>neuropeptide</protein>-induced tanning and selectively block a stereotyped
      behavioral program.
AB  - Adult insects achieve their final form shortly after adult eclosion by the
      combined effects of specialized behaviors that generate increased blood
      pressure, which causes cuticular expansion, and hormones, which plasticize
      and then tan the cuticle. We examined the molecular mechanisms
      contributing to these processes in Drosophila by analyzing mutants for the
      rickets gene. These flies fail to initiate the behavioral and tanning
      processes that normally follow ecdysis. Sequencing of rickets mutants and
      STS mapping of deficiencies confirmed that rickets encodes the
      <protein>glycoprotein hormone receptor DLGR2</protein>. Although rickets mutants produce and
      release the insect-tanning hormone bursicon, they do not melanize when
      injected with extracts containing bursicon. In contrast, mutants do
      melanize in response to injection of an analog of cyclic AMP, the second
      messenger for bursicon. Hence, rickets appears to encode a component of
      the bursicon response pathway, probably the <protein>bursicon receptor</protein> itself.
      Mutants also have a behavioral deficit in that they fail to initiate the
      behavioral program for wing expansion. A set of decapitation experiments
      utilizing rickets mutants and flies that lack cells containing the
      <protein>neuropeptide eclosion hormone</protein>, reveals a multicomponent control to the
      activation of this behavioral program.
</DOC>
<DOC>
<DOC_ID>[237]</DOC_ID>
>237.NF00125576
PMID:11836498
TI  - Hermansky-Pudlak syndrome is caused by mutations in <protein>HPS4</protein>, the human
      homolog of the mouse light-ear gene.
AB  - Hermansky-Pudlak syndrome (<protein>HPS</protein>) is a disorder of organelle biogenesis in
      which oculocutaneous albinism, bleeding and pulmonary fibrosis result from
      defects of melanosomes, platelet dense granules and lysosomes. <protein>HPS</protein> is
      common in Puerto Rico, where it is caused by mutations in the genes <protein>HPS1</protein>
      and, less often, <protein>HPS3</protein> (ref. 8). In contrast, only half of non-Puerto Rican
      individuals with <protein>HPS</protein> have mutations in <protein>HPS1</protein> (ref. 9), and very few in <protein>HPS3</protein>
      (ref. 10). In the mouse, more than 15 loci manifest mutant phenotypes
      similar to human <protein>HPS</protein>, including pale ear (<protein>ep</protein>), the mouse homolog of <protein>HPS1</protein>
      (refs 13,14). Mouse <protein>ep</protein> has a phenotype identical to another mutant, light
      ear (<protein>le</protein>), which suggests that the human homolog of <protein>le</protein> is a possible human
      <protein>HPS</protein> locus. We have identified and found mutations of the human <protein>le</protein> homolog,
      <protein>HPS4</protein>, in a number of non-Puerto Rican individuals with <protein>HPS</protein>, establishing
      <protein>HPS4</protein> as an important <protein>HPS</protein> locus in humans. In addition to their identical
      phenotypes, <protein>le</protein> and <protein>ep</protein> mutant mice have identical abnormalities of
      melanosomes, and in transfected melanoma cells the <protein>HPS4</protein> and <protein>HPS1 proteins</protein>
      partially co-localize in vesicles of the cell body. In addition, the <protein>HPS1
      protein</protein> is absent in tissues of <protein>le</protein> mutant mice. These results suggest that
      the <protein>HPS4</protein> and <protein>HPS1 proteins</protein> may function in the same pathway of organelle
      biogenesis.
</DOC>
<DOC>
<DOC_ID>[238]</DOC_ID>
>238.NF00025785
PMID:12208494
TI  - Towards a new <protein>T-fold protein</protein>?: the <protein>coproporphyrinogen III oxidase</protein> sequence
      matches many structural features from <protein>urate oxidase</protein>.
AB  - <protein>Urate oxidase (UOX)</protein> and <protein>coproporphyrinogen III oxidase (CPO)</protein> are two
      unusual <protein>oxidases</protein> as they accomplish their catalytic act with no co-factor
      nor metal ion. They both require molecular oxygen, and lead to hydrogen
      peroxide in addition to the product. <protein>UOX</protein> is composed of two contiguous
      Tunneling-fold domains and <protein>CPO</protein> appears to be also divided into two
      structurally equivalent domains. Moreover, each of these putative domains
      can be coherently aligned on <protein>UOX</protein> domains. Although their sequences are
      very distant, we therefore suggest that functional <protein>CPO dimer</protein> is built
      around a tunnel, with the substrate sitting above it, on the N- and
      C-terminal side. This overall model is supported by mutation data and is
      coherent with the chemical events expected for substrate processing by
      <protein>CPO</protein>.
</DOC>
<DOC>
<DOC_ID>[239]</DOC_ID>
>239.NF00828217
PMID:11928817
TI  - Distinct expression pattern of two related human proteins containing
      multiple types of <protein>protease</protein>-inhibitory modules.
AB  - We have recently identified a gene (the <protein>WFIKKN</protein> gene) on human chromosome
      16 (16p13.3) that encodes a <protein>secreted protein</protein> containing <long_form>WAP-type,
      Follistatin/ Kazal type, Kunitz-type and <protein>NTR-type protease</protein></long_form>-inhibitory
      modules and an <protein>Immunoglobulin</protein> domain [Trexler et al., Proc. Natl. Acad.
      Sci. USA 98 (2001), 3705 - 3709]. In the present work we show that a gene
      on chromosome 17 encodes a <protein>WFIKKN-related protein (WFIKKNRP)</protein> that has the
      same domain organization as the <protein>WFIKKN protein</protein>. The exon-intron structure
      of the two genes is also similar as both genes have a single phase 0
      intron that splits their <protein>WAP</protein> domains in equivalent positions. In view of
      the presence of several <protein>protease</protein> inhibitory modules in these proteins it
      seems likely that they serve to control the action of multiple types of
      <protein>proteases</protein>. The tissue expression pattern of the two proteins, however, is
      markedly different suggesting that they have distinct biological roles.
      Whereas the <protein>WFIKKN</protein> gene is expressed primarily in adult pancreas, liver
      and thymus but not in brain and ovary, significant expression of the
      <protein>WFIKKNRP</protein> gene is observed in ovary, testis and brain, but not in liver.
      Pronounced differences could also be seen in the case of fetal tissues:
      expression of the <protein>WFIKKN</protein> gene was highest in the lung, skeletal muscle and
      liver, whereas the <protein>WFIKKNRP</protein> gene was expressed primarily in brain,
      skeletal muscle, thymus and kidney.
</DOC>
<DOC>
<DOC_ID>[240]</DOC_ID>
>240.NF00141779
PMID:11972883
TI  - Identification of a novel <protein>HLA-DPB1</protein> allele, <protein>DPB1</protein>*02014, by sequence-based
      typing.
AB  - In this report we describe the identification of a novel <protein>DPB1</protein> allele,
      <protein>DPB1</protein>*02014, found in an Italian Caucasian individual.The new allele was
      detected during routine <protein>HLA</protein> sequence-based typing (SBT) for an individual
      undergoing bone marrow transplantation. <protein>DPB1</protein>*02014 was identical to
      <protein>DPB1</protein>*02012 except for a single nucleotide substitution in codon 72
      (GTG--&gt;GTT). This nucleotide change represents a synonimous mutation, as
      both triplets code for a valine.This new allele has been submitted to
      GenBank and assigned the accession number AF326565. The WHO Nomenclature
      Committee has officially assigned the name <protein>DPB1</protein>*02014.
</DOC>
<DOC>
<DOC_ID>[241]</DOC_ID>
>241.NF00132869
PMID:12421953
TI  - Characterization of the interaction between <protein>L-ficolin</protein>/<protein>p35</protein> and
      <long_form><protein>mannan-binding lectin-associated serine proteases-1</protein> and -2</long_form>.
AB  - <protein>Ficolins</protein> are <protein>oligomeric lectins</protein> comprising a <protein>collagen</protein>-like and a
      <protein>fibrinogen</protein>-like domain, with a binding specificity for
      N-acetylglucosamine. It has been reported recently that <protein>L-ficolin</protein>/<protein>P35</protein>
      associates with <protein>mannan-binding lectin (MBL)-associated serine proteases</protein>
      (<long_form><protein>MASP-1</protein> and -2</long_form>) and <protein>MBL-associated protein 19 (MAp19)</protein> in serum and forms
      complexes able to activate <protein>complement</protein>. Using surface plasmon resonance
      spectroscopy we have shown that recombinant <long_form><protein>MASP-1</protein> and -2</long_form>, their
      N-terminal CUB1 (module originally found in <protein>complement proteins C1r</protein>/<protein>C1s</protein>,
      <protein>Uegf</protein>, and <protein>bone morphogenetic protein-1</protein>)-<protein>epidermal growth factor (EGF)</protein>-CUB2
      and CUB1-<protein>EGF</protein> segments, and <protein>MAp19</protein> bind to immobilized L-<protein>ficolin</protein>/<protein>P35</protein> in the
      presence of Ca(2+) ions. Comparable K(d) values were obtained for the
      full-length <protein>proteases</protein> and their CUB1-<protein>EGF</protein>-CUB2 segments (9.2 and 10 nM for
      <protein>MASP-1</protein> and 4.6 and 5.4 nM for <protein>MASP-2</protein>, respectively), whereas higher values
      were obtained for the CUB1-<protein>EGF</protein> segments (26.7, 15.6, and 14.3 nM for
      <protein>MASP-1</protein>, <protein>MASP-2</protein>, and <protein>MAp19</protein>). These values are in the same range as those
      determined for the interaction of these proteins with <protein>MBL</protein>. Binding was
      Ca(2+) dependent and was only partly sensitive to EDTA for <protein>MASP-1</protein>, <protein>MASP-2</protein>,
      and <protein>MASP-2</protein> CUB1-<protein>EGF</protein>-CUB2. Half-maximal binding was obtained at comparable
      Ca(2+) concentrations for <protein>MASP-1</protein> and <protein>MASP-2</protein> (0.45 and 0.47 micro M,
      respectively), their CUB1-<protein>EGF</protein>-CUB2 segments (0.37 and 0.72 micro M), and
      their CUB1-<protein>EGF</protein> segments (0.31 and 0.79 micro M). These values are lower
      than those determined in the case of <protein>MBL</protein>, indicating a difference between
      <protein>MBL</protein> and <protein>L-ficolin</protein>/<protein>P35</protein> with respect to the Ca(2+) dependence of their
      interaction with the <protein>MASPs</protein>. Preincubation of the <protein>MASPs</protein> with soluble <protein>MBL</protein>
      inhibited subsequent binding to immobilized <protein>L-ficolin</protein>/<protein>P35</protein> and, conversely,
      suggesting that these <protein>lectins</protein> compete with each other for binding to the
      <protein>MASPs</protein> in vivo.
</DOC>
<DOC>
<DOC_ID>[242]</DOC_ID>
>242.NF00911891
PMID:12095414
TI  - Expression of the <protein>leucocyte common antigen-related (LAR) tyrosine
      phosphatase</protein> is regulated by cell density through functional <protein>E-cadherin
      complexes</protein>.
AB  - The <protein>leucocyte common antigen-related phosphatase (LAR)</protein> has been implicated
      in <protein>receptor tyrosine kinase</protein> signalling pathways while also displaying
      cell-density-dependency and localization to adherens junctions. Whereas
      physiological substrates for <protein>LAR</protein> have not been identified unequivocally,
      <protein>beta-catenin</protein> associates with <protein>LAR</protein> and is a substrate in vitro. With the
      implication that <protein>LAR</protein> may play a role in regulating <protein>E-cadherin</protein>-dependent
      cell-cell communication and contact inhibition, the relationship of <protein>LAR</protein>
      with <protein>E-cadherin</protein> was investigated. <protein>LAR</protein> expression increased with cell
      density in the human breast cancer cell line MCF-7 and in Ln 3 cells
      derived from the 13762NF rat mammary adenocarcinoma. <protein>LAR protein</protein> levels
      decreased rapidly when cells were replated at a low density after
      attaining high expression of <protein>LAR</protein> at high cell density. COS-7 cells
      displayed comparable density-dependent regulation of <protein>LAR</protein> expression when
      transiently expressing exogenous <protein>LAR</protein> under the control of a constitutively
      active promoter, indicating that the regulation of expression is not at
      the level of gene regulation. Disrupting homophilic <protein>E-cadherin complexes</protein>
      by chelating extracellular calcium caused a marked decrease in <protein>LAR protein</protein>
      levels. Similarly, blocking <protein>E-cadherin</protein> interactions with saturating
      amounts of <protein>E-cadherin antibody</protein> (HECD-1) also led to a rapid and pronounced
      loss of <protein>cellular LAR</protein>. In contrast, mimicking <protein>cell-surface E-cadherin</protein>
      engagement by plating cells at low density on to dishes coated with HECD-1
      resulted in a 2-fold increase in <protein>LAR</protein> expression compared with controls.
      These results suggest that density-dependent regulation of <protein>LAR</protein> expression
      is mediated by functional <protein>E-cadherin</protein> and may play a role in
      density-dependent contact inhibition by regulating tyrosine
      phosphorylation in <protein>E-cadherin complexes</protein>.
</DOC>
<DOC>
<DOC_ID>[243]</DOC_ID>
>243.NF00105899
PMID:11812157
TI  - Determining the differences in <protein>actin</protein> binding by <long_form>human <protein>ADF</protein></long_form> and <protein>cofilin</protein>.
AB  - The <protein>actin-depolymerizing factor (ADF)</protein>/<protein>cofilin</protein> family of proteins play an
      essential role in <protein>actin</protein> dynamics and cytoskeletal re-organization. Human
      tissues express two isoforms in the same cells, <protein>ADF</protein> and <protein>cofilin</protein>, and these
      two proteins are more than 70% identical in amino acid sequence. We show
      that <protein>ADF</protein> is a much more potent <protein>actin</protein>-depolymerizing agent than <protein>cofilin</protein>:
      the maximum level of depolymerization at pH 8 by <protein>ADF</protein> is about 20 microM
      compared to 5 microM for <protein>cofilin</protein>, but little depolymerization occurs at pH
      6.5 with either protein. However, we find little difference between the
      two proteins in their binding to filaments, their severing activities or
      their activation of <protein>subunit</protein> release from the pointed ends of filaments.
      Likewise, they show no significant differences in their affinities for
      <protein>monomeric actin</protein>: both bind 15-fold more tightly to <protein>actin</protein>.ADP than to
      <protein>actin</protein>.ATP. Complexes between <protein>actin</protein>.ADP and <protein>ADF</protein> or <protein>cofilin</protein> associate with
      both barbed and pointed ends of filaments at similar rates (close to those
      of <protein>actin</protein>.ATP and much higher than those of <protein>actin</protein>.ADP). This explains why
      high concentrations of both proteins reverse the activation of subunit
      release at pointed ends. The major difference between the two proteins is
      that the nucleating activity of <long_form><protein>cofilin</protein>-<protein>actin</protein>.ADP complexes</long_form> is twice that
      of <long_form><protein>ADF</protein>-<protein>actin</protein>.ADP complexes</long_form> and this, in turn, is twice that of <protein>actin</protein>.ATP
      alone. It is this weaker nucleating potential of <protein>ADF</protein>-<protein>actin</protein>.ADP that
      accounts for the much higher steady-state depolymerizing activity. The
      pH-sensitivity is due to the nucleating activity of complexes being
      greater at pH 6.5 than at pH 8. Sequence analysis of mammalian and avian
      isoforms shows a consistent pattern of charge differences in regions of
      the protein associated with <protein>F-actin</protein>-binding that may account for the
      differences in activity between <protein>ADF</protein> and <protein>cofilin</protein>.
</DOC>
<DOC>
<DOC_ID>[244]</DOC_ID>
>244.NF00097769
PMID:12393901
TI  - <protein>LIGHT</protein>, a member of the <protein>tumor necrosis factor ligand</protein> superfamily, prevents
      <protein>tumor necrosis factor-alpha</protein>-mediated human primary hepatocyte apoptosis,
      but not <protein>Fas</protein>-mediated apoptosis.
AB  - <protein>LIGHT</protein> is a member of <protein>tumor necrosis factor (TNF)</protein> superfamily, and its
      <protein>receptors</protein> have been identified as <protein>lymphotoxin-beta receptor (LTbetaR)</protein> and
      the <protein>herpesvirus entry mediator (HVEM)</protein>/<protein>ATAR</protein>/<protein>TR2</protein>, both of which lack the
      cytoplasmic sequence termed the &quot;death domain.&quot; The present study has
      demonstrated that <protein>LIGHT</protein> inhibits <protein>TNFalpha</protein>-mediated apoptosis of human
      primary hepatocytes sensitized by actinomycin D (ActD), but not <protein>Fas</protein>- or
      <protein>TRAIL</protein>-mediated apoptosis. Furthermore, <protein>LIGHT</protein> does not prevent some cell
      lines such as HepG2 or HeLa from undergoing ActD/<protein>TNFalpha</protein>-induced
      apoptosis. This protective effect requires <protein>LIGHT</protein> pretreatment at least 3 h
      prior to ActD sensitization. <protein>LIGHT</protein> stimulates <protein>nuclear factor-kappaB
      (NF-kappaB)</protein>-dependent transcriptional activity in human hepatocytes like
      <protein>TNFalpha</protein>. The time course of <protein>NF-kappaB</protein> activation after <protein>LIGHT</protein>
      administration is similar to that of the pretreatment required for the
      anti-apoptotic effect of <protein>LIGHT</protein>. <protein>LIGHT</protein> inhibits <protein>caspase-3</protein> processing on the
      <protein>apoptotic protease</protein> cascade in <protein>TNFalpha</protein>-mediated apoptosis but not
      <protein>Fas</protein>-mediated apoptosis. In addition, increased <protein>caspase-3</protein> and <protein>caspase-8</protein>
      activities in ActD/<protein>TNFalpha</protein>-treated cells are effectively blocked by <protein>LIGHT</protein>
      pretreatment. However, <protein>LIGHT</protein> does not change the expression of <protein>TNFRp55</protein>,
      <protein>TNFRp75</protein>, and <protein>Fas</protein>. These results indicate that <protein>LIGHT</protein> may act as an
      anti-apoptotic agent against <protein>TNFalpha</protein>-mediated liver injury by blocking
      the activation of both <protein>caspase-3</protein> and <protein>caspase-8</protein>.
</DOC>
<DOC>
<DOC_ID>[245]</DOC_ID>
>245.NF00100413
PMID:12096904
TI  - <protein>Nucleolin</protein> associates with a subset of the <long_form>human <protein>Ro ribonucleoprotein
      complexes</protein></long_form>.
AB  - <protein>Ro RNPs</protein> are evolutionarily conserved, <protein>small cytoplasmic RNA-protein
      complexes</protein> with an unknown function. In human cells, <protein>Ro RNPs</protein> consist of one
      of the four hY RNAs and two core proteins: <protein>Ro60</protein> and <protein>La</protein>. Recently, the
      association of <protein>hnRNP I</protein> and <protein>hnRNP K</protein> with particles containing hY1 and hY3
      RNAs has been described. The association of three other proteins, namely
      <protein>calreticulin</protein>, <protein>Ro52</protein> and <protein>RoBPI</protein>, with (subsets of) the <protein>Ro RNPs</protein> is still
      controversial. To gain more insight into the composition and function of
      the <protein>Ro RNPs</protein>, we have immunopurified these particles from HeLa cell
      extracts using monoclonal antibodies against <protein>Ro60</protein> and <protein>La</protein>. Using this
      approach, we have identified the <protein>RNA-binding protein nucleolin</protein> as a novel
      <protein>subunit of Ro RNP particles</protein> containing hY1 or hY3 RNA, but not hY4 and hY5
      RNA. Using an in vitro hY RNA-binding assay we established that the
      internal pyrimidine-rich loop of hY1 and hY3 RNA is essential for the
      association of <protein>nucleolin</protein>. The binding is critically dependent on the
      presence of all four <protein>RNP</protein> motifs of <protein>nucleolin</protein>, but not of the C-terminal
      RGG-box. Moreover, we demonstrate that, in contrast to <protein>nucleolin</protein> and <protein>hnRNP
      K</protein>, <protein>nucleolin</protein> and <protein>hnRNP I</protein> can bind simultaneously to the internal
      pyrimidine-rich loop of hY1 RNA. We postulate that <protein>nucleolin</protein> functions in
      the biogenesis and/or trafficking of <long_form>hY1 and <protein>hY3 RNPs</protein></long_form> through the
      nucleolus and subsequent transport to the cytoplasm.
</DOC>
<DOC>
<DOC_ID>[246]</DOC_ID>
>246.NF00082240
PMID:11896048
TI  - Characterization of a <protein>brain-enriched chaperone</protein>, <protein>MRJ</protein>, that inhibits
      Huntingtin aggregation and toxicity independently.
AB  - <protein>Molecular chaperones</protein> are involved in a wide range of cellular events, such
      as protein folding and oligomeric protein complex assembly. <long_form>DnaK- and
      <protein>DnaJ-like proteins</protein></long_form> are the two major classes of <protein>molecular chaperones</protein> in
      mammals. Recent studies have shown that <protein>DnaJ-like family proteins</protein> can
      inhibit polyglutamine aggregation, a hallmark of many neurodegenerative
      diseases, including Huntington's disease (HD). Although most <protein>DnaJ-like
      proteins</protein> studied are ubiquitously expressed, some have restricted
      expression, so it is possible that some specific <protein>chaperones</protein> may affect
      polyglutamine aggregation in specific neurons. In this report, we describe
      the isolation of a <protein>DnaJ-like protein MRJ</protein> and the characterization of its
      <protein>chaperone</protein> activity. Tissue distribution studies showed that <protein>MRJ</protein> is highly
      enriched in the central nervous system. In an in vitro cell model of HD,
      overexpressed <protein>MRJ</protein> effectively suppressed <protein>polyglutamine-dependent protein</protein>
      aggregation, <protein>caspase</protein> activity, and cellular toxicity. Collectively, these
      results suggest that <protein>MRJ</protein> has a relevant functional role in neurons.
</DOC>
<DOC>
<DOC_ID>[247]</DOC_ID>
>247.NF01034720
PMID:12110693
TI  - Identification, characterization, and functional study of the two novel
      human members of the <protein>semaphorin</protein> gene family.
AB  - We cloned two novel <long_form>human <protein>transmembrane semaphorins</protein></long_form>, (<protein>HSA</protein>)<protein>SEMA6C</protein> and
      (<protein>HSA</protein>)<protein>SEMA6D</protein>, that belong to the class VI subgroup of the <protein>semaphorin</protein>
      family. The genes for <protein>SEMA6C</protein> and <protein>SEMA6D</protein> are mapped on chromosome 1q12-21.1
      and 15q21.1, respectively. Among the adult tissues, <protein>SEMA6C</protein> is expressed
      only in skeletal muscle, whereas <protein>SEMA6D</protein> is expressed abundantly in kidney,
      brain, and placenta and moderately in the heart and skeletal muscles.
      During murine development, neither <protein>SEMA6C</protein> nor <protein>SEMA6D</protein> was expressed in
      embryonic day 10.5 (E10.5) embryos, but both were highly expressed in the
      areas of the lateral ventricle, the striatum, the wall of the midbrain,
      the pons/midbrain junction, and the choroid plexus of E13 embryos. Were
      neurons, neither axons nor astrocytes, highly expressed both <protein>semaphorins</protein>.
      Three <protein>isoforms of SEMA6C</protein> and five <protein>isoforms of SEMA6D</protein> derived from
      alternative splicing were identified, and their expression was regulated
      in a tissue- and development-dependent manner. Deletion analysis indicated
      that a sema domain and a PSI domain are integrally necessary for correct
      post-translation modification and subcellular localization. The
      extracellular domain of <protein>SEMA6C</protein> inhibited axonal extension of <protein>nerve growth
      factor</protein>-differentiated PC12 cells and induced the growth cone collapse of
      chicken dorsal root ganglion, rat hippocampal neurons, and rat cortical
      neurons in a dose-responsive manner. <protein>SEMA6D</protein> acted like <protein>SEMA6C</protein> except it
      had no significant effect on the growth cones of rat cortical neurons.
</DOC>
<DOC>
<DOC_ID>[248]</DOC_ID>
>248.NF00126711
PMID:12296995
TI  - <protein>TAK1</protein>-dependent activation of <protein>AP-1</protein> and <protein>c-Jun N-terminal kinase</protein> by <protein>receptor
      activator of NF-kappaB</protein>.
AB  - The <protein>receptor activator of nuclear factor kappa B (RANK)</protein> is a member of the
      <protein>tumor necrosis factor (TNF) receptor</protein> superfamily. It plays a critical role
      in osteoclast differentiation, lymph node organogenesis, and mammary gland
      development. The stimulation of <protein>RANK</protein> causes the activation of
      <protein>transcription factors NF-kappaB</protein> and <protein>activator protein 1 (AP1)</protein>, and the
      <protein>mitogen activated protein kinase (MAPK)</protein> <protein>c-Jun N-terminal kinase (JNK)</protein>. In
      the signal transduction of <protein>RANK</protein>, the recruitment of the adaptor molecules,
      <protein>TNF receptor-associated factors (TRAFs)</protein>, is an initial cytoplasmic event.
      Recently, the association of the <protein>MAPK kinase kinase</protein>, <protein>transforming growth
      factor-beta-activated kinase 1 (TAK1)</protein>, with <protein>TRAF6</protein> was shown to mediate the
      <protein>IL-1</protein> signaling to <protein>NF-kappaB</protein> and <protein>JNK</protein>. We investigated whether or not <protein>TAK1</protein>
      plays a role in <protein>RANK</protein> signaling. A dominant-negative form of <protein>TAK1</protein> was
      discovered to abolish the <protein>RANK</protein>-induced activation of <protein>AP1</protein> and <protein>JNK</protein>. The <protein>AP1</protein>
      activation by <protein>TRAF2</protein>, <protein>TRAF5</protein>, and <protein>TRAF6</protein> was also greatly suppressed by the
      dominant negative <protein>TAK1</protein>. The inhibitory effect of the <protein>TAK1</protein> mutant on <protein>RANK</protein>-
      and <protein>TRAF-induced NF-kappaB</protein> activation was also observed, but less
      efficiently. Our findings indicate that <protein>TAK1</protein> is involved in the <protein>MAPK</protein>
      cascade and <protein>NF-kappaB</protein> pathway that is activated by <protein>RANK</protein>.
</DOC>
<DOC>
<DOC_ID>[249]</DOC_ID>
>249.NF00118612
PMID:11891225
TI  - <long_form><protein>Laminin-10</protein>/11</long_form> and <protein>fibronectin</protein> differentially prevent apoptosis induced by
      serum removal via <protein>phosphatidylinositol 3-kinase</protein>/<protein>Akt</protein>- and
      <protein>MEK1</protein>/<protein>ERK</protein>-dependent pathways.
AB  - Cell adhesion to the extracellular matrix inhibits apoptosis, but the
      molecular mechanisms underlying the signals transduced by different matrix
      components are not well understood. Here, we examined <protein>integrin</protein>-mediated
      antiapoptotic signals from <long_form><protein>laminin-10</protein>/11</long_form> in comparison with those from
      <protein>fibronectin</protein>, the best characterized extracellular adhesive ligand. We
      found that the activation of <protein>protein kinase B</protein>/<protein>Akt</protein> in cells adhering to
      <long_form><protein>laminin-10</protein>/11</long_form> can rescue cell apoptosis induced by serum removal.
      Consistent with this, wortmannin, a specific inhibitor of
      <protein>phosphatidylinositol 3-kinase</protein>, or ectopic expression of a
      dominant-negative mutant of <protein>Akt</protein> selectively accelerated cell death upon
      serum removal. In contrast to <long_form><protein>laminin-10</protein>/11</long_form>, <protein>fibronectin</protein> rescued cells
      from serum depletion-induced apoptosis mainly through the <protein>extracellular
      signal-regulated kinase</protein> pathway. Cell survival on <protein>fibronectin</protein> but not
      <protein>laminin</protein> was significantly reduced by treatment with PD98059, a specific
      inhibitor of <long_form>mitogen- or <protein>extracellular signal-regulated kinase kinase-1
      (MEK1)</protein></long_form> and by expression of a dominant-negative mutant of <protein>MEK1</protein>.
      <long_form><protein>Laminin-10</protein>/11</long_form> was more potent than <protein>fibronectin</protein> in preventing apoptosis
      induced by serum depletion. These results, taken together, demonstrate
      <long_form><protein>laminin-10</protein>/11</long_form> potency as a survival factor and demonstrate that different
      extracellular matrix components can transduce distinct survival signals
      through preferential activation of subsets of multiple <protein>integrin</protein>-mediated
      signaling pathways.
</DOC>
<DOC>
<DOC_ID>[250]</DOC_ID>
>250.NF00521426
PMID:12167609
TI  - Generation and phenotypic analysis of <protein>CHIF</protein> knockout mice.
AB  - <protein>Corticosteroid hormone-induced factor (CHIF)</protein> is a short
      <protein>epithelial-specific protein</protein> that is independently induced by aldosterone
      and a high-K(+) diet. It is a member of the <protein>FXYD</protein> family of <protein>single-span
      transmembrane proteins</protein> that include <protein>phospholemman</protein>, <protein>Mat-8</protein>, and the
      <protein>gamma-subunit of Na(+)-K(+)-ATPase</protein>. A number of studies have suggested
      that these proteins are involved in the regulation of ion transport and,
      in particular, functionally interact with the <protein>Na(+)-K(+)-ATPase</protein>. The
      present study describes the characterization, targeted disruption, and
      phenotypic analysis of the <long_form>mouse <protein>CHIF</protein></long_form> gene. The <protein>CHIF</protein> knockout mice are
      viable and not distinguishable from wild-type littermates under normal
      conditions. Under K(+) loading, they have a twofold higher urine volume
      and an increased glomerular filtration rate. Similar but smaller effects
      are observed in mice fed a low-Na(+) diet. Treating K(+)-loaded mice for
      10 days with furosemide resulted in lethality in the knockout mice (17 of
      39) but not in the wild-type group (1 of 39). The data are consistent with
      an effect of <protein>CHIF</protein> on the <protein>Na(+)-K(+)-ATPase</protein> that is specific to the outer
      and inner medullary duct, its major expression site.
</DOC>
<DOC>
<DOC_ID>[251]</DOC_ID>
>251.NF00082407
PMID:12011083
TI  - Differences in the regulation of the classical and the alternative pathway
      for bile acid synthesis in human liver. No coordinate regulation of <protein>CYP7A1</protein>
      and <protein>CYP27A1</protein>.
AB  - It has been reported that there is a coordinate regulation of <protein>sterol
      27-hydroxylase (CYP27A1)</protein> and <protein>cholesterol 7alpha-hydroxylase (CYP7A1)</protein> in
      rats. Thus, the levels of the mRNA corresponding to these two enzymes were
      found to change in the same direction in rat liver and in isolated rat
      hepatocytes. In contrast, other groups have not seen such regulation of
      <protein>CYP27A1</protein> in rabbit liver or in rat liver when using an activity assay. In
      the present work, the effect of bile acid treatment on <long_form>human
      <protein>CYP27A1</protein></long_form>/luciferase reporter activity was studied in a transient
      transfection assay in human liver-derived HepG2 cells. Neither the
      endogenous <protein>27-hydroxylase</protein> activity nor the <protein>CYP27A1</protein>/luciferase reporter
      activity were down-regulated by treatment of HepG2 cells with
      chenodeoxycholic acid or taurochenodeoxycholic acid. We also measured
      <protein>CYP27A1</protein> mRNA and <protein>CYP7A1</protein> mRNA in liver of humans subjected to treatment
      with chenodeoxycholic acid, ursodeoxycholic acid, <protein>hydroxymethylglutaryl
      (HMG)-CoA reductase</protein> inhibitor and a combination of <protein>HMG-CoA reductase</protein>
      inhibitor and cholestyramine. There was a 60-fold variation in the levels
      of <protein>CYP7A1</protein> mRNA but only a 5-fold variation in the levels of <protein>CYP27A1</protein> mRNA.
      There was no correlation between the two mRNA species. It is concluded
      that, in humans, there is little or no coordinate regulation of <protein>CYP7A1</protein> and
      <protein>CYP27A1</protein> at the transcriptional level, and that <protein>CYP27A1</protein> is not subject to a
      negative feedback control by bile acids. The results underline that marked
      species differences may exist in mechanisms for control of synthesis of
      bile acids and cholesterol homeostasis.
</DOC>
<DOC>
<DOC_ID>[252]</DOC_ID>
>252.NF00083138
PMID:12135764
TI  - <protein>Memapsin 2</protein> (<protein>beta-secretase</protein>) cytosolic domain binds to the VHS domains of
      <protein>GGA1</protein> and <protein>GGA2</protein>: implications on the endocytosis mechanism of <protein>memapsin 2</protein>.
AB  - <protein>Memapsin 2</protein>, or <protein>beta-secretase</protein>, is a <protein>membrane-anchored aspartic protease</protein>
      that initiates the cleavage of <protein>beta-amyloid precursor protein (APP)</protein>
      leading to the production of <protein>beta-amyloid peptide</protein> in the brain and the
      onset of Alzheimer's disease. <protein>Memapsin 2</protein> and <protein>APP</protein> are both endocytosed into
      endosomes for cleavage. Here we show that the cytosolic domain of <protein>memapsin
      2</protein>, but not that of <protein>memapsin 1</protein>, binds the VHS domains of <protein>GGA1</protein> and <protein>GGA2</protein>.
      Gel-immobilized VHS domains of <protein>GGA1</protein> and <protein>GGA2</protein> also bound to full-length
      <protein>memapsin 2</protein> from cell mammalian lysates. Mutagenesis studies established
      that Asp(496), Leu(499) and Leu(500) were essential for the binding. The
      spacing of these three residues in <protein>memapsin 2</protein> is identical to those in the
      cytosolic domains of <protein>mannose-6-phosphate receptors</protein>, <protein>sortilin</protein> and <protein>low
      density lipoprotein receptor-related protein 3</protein>. These observations suggest
      that the endocytosis and intracellular transport of <protein>memapsin 2</protein>, mediated
      by its cytosolic domain, may involve the binding of <protein>GGA1</protein> and <protein>GGA2</protein>.
</DOC>
<DOC>
<DOC_ID>[253]</DOC_ID>
>253.NF00081197
PMID:12416719
TI  - The expression of <protein>alpha-dystrobrevin</protein> and <protein>dystrophin</protein> during skeletal muscle
      regeneration.
AB  - The expression of <protein>alpha-dystrobrevin</protein> and <protein>dystrophin</protein> in rat tibialis
      anterior muscles was chronologically evaluated during a cycle of
      regeneration after myonecrosis induced by the injection of <protein>cardiotoxin</protein>. In
      immunohistochemical studies, <protein>alpha-dystrobrevin</protein> and <protein>dystrophin</protein> were first
      stained weakly at the sarcolemma of some regenerating muscle fibers on day
      5. On day 7, <protein>alpha-dystrobrevin</protein> was still stained weakly, whereas
      <protein>dystrophin</protein> was stained conspicuously. After day 10, <protein>alpha-dystrobrevin</protein> and
      <protein>dystrophin</protein> were both stained conspicuously on almost all regenerating
      muscle fibers. In the Western blot analysis, <protein>alpha-dystrobrevin</protein> and
      <protein>dystrophin</protein> were first detected as visible bands on days 5 and 7,
      respectively. The bands of <protein>alpha-dystrobrevin</protein> and <protein>dystrophin</protein> both darkened
      sequentially up to day 10. The protein levels based on the densitometrical
      analysis of the bands on each day were converted to the percentage of the
      protein level on day 28, which was taken as 100%. The sequential line
      based on these data showed that <protein>alpha-dystrobrevin</protein> and <protein>dystrophin</protein> reached
      50% of the protein level on day 28 by 6.6 and 5.3 days, respectively.
      These data provide evidence that <protein>alpha-dystrobrevin</protein> regenerates more
      slowly than <protein>dystrophin</protein> in skeletal muscle.
</DOC>
<DOC>
<DOC_ID>[254]</DOC_ID>
>254.NF00137168
PMID:12084819
TI  - Live-cell imaging reveals divergent intracellular dynamics of
      <protein>polyglutamine disease proteins</protein> and supports a sequestration model of
      pathogenesis.
AB  - Protein misfolding and aggregation are central features of the
      polyglutamine neurodegenerative disorders, but the dynamic properties of
      expanded <protein>polyglutamine proteins</protein> are poorly understood. Here, we use
      fluorescence recovery after photobleaching (FRAP) and fluorescence loss in
      photobleaching (FLIP) with green fluorescent protein fusion proteins to
      study <protein>polyglutamine protein</protein> kinetics in living cells. Our results reveal
      markedly divergent mobility states for an expanded <protein>polyglutamine protein</protein>,
      <protein>ataxin-3</protein>, and establish that nuclear inclusions formed by this protein are
      aggregates. Additional studies of green fluorescent protein-tagged <protein>cAMP
      response element binding protein</protein> coexpressed with either of two mutant
      <protein>polyglutamine proteins</protein>, <protein>ataxin-3</protein> and <protein>huntingtin</protein>, support a model of
      disease in which coaggregation of transcriptional components contributes
      to pathogenesis. Finally, studies of a third <protein>polyglutamine disease
      protein</protein>, <protein>ataxin-1</protein>, reveal unexpected heterogeneity in the dynamics of
      inclusions formed by different disease proteins, a finding which may help
      explain disease-specific elements of pathogenesis in these
      neurodegenerative disorders.
</DOC>
<DOC>
<DOC_ID>[255]</DOC_ID>
>255.NF00135467
PMID:11948912
TI  - Cooperative E-box regulation of <long_form>human <protein>GLI1</protein></long_form> by <protein>TWIST</protein> and <protein>USF</protein>.
AB  - <protein>Sonic hedgehog</protein> signaling plays a critical role in vertebrate patterning,
      and signaling defects are associated with severe birth defects and cancer
      in man. <protein>GLI1</protein> encodes a critical <protein>transcription activator</protein> in this pathway.
      <protein>GLI1</protein> is expressed in human basal cell carcinomas and sarcomas. Despite the
      significance of the <protein>GLI1</protein> gene in human disease, few immediate upstream
      regulators of <protein>GLI1</protein> expression are known. We previously demonstrated that a
      5' region, including 5' flanking sequence, an untranslated exon, and 425
      bp of the first intron, regulates the <long_form>human <protein>GLI1</protein></long_form> gene. Here we show that
      inactivating mutations in E-box, GC box, <protein>AP-2</protein>, <protein>GATA</protein>, GSG, <protein>PuF</protein>, and <protein>Zeste</protein>
      sites identified three critical regulatory elements, including a GC box
      that binds <protein>Sp1</protein> and two intronic E-boxes that bind <protein>USF proteins</protein> or <protein>Twist</protein>.
      Expression of <protein>Twist</protein> but not a frame shift mutation of <protein>Twist</protein> activates the
      wild-type <long_form>human <protein>GLI1</protein></long_form> regulatory sequences but not with inactivating
      mutations of the E-boxes. <protein>Twist</protein> activates <protein>GLI1 reporter</protein> expression through
      E-box +482 but requires binding of <protein>USF proteins</protein> to E-box +157. <protein>Twist</protein>
      mutations cause human birth defects and <protein>Twist</protein> is overexpressed in many
      rhabdomyosarcomas, suggesting that one of <protein>Twist</protein>'s primary roles is the
      regulation of <protein>GLI1</protein>.
</DOC>
<DOC>
<DOC_ID>[256]</DOC_ID>
>256.NF00970219
PMID:12023963
TI  - Involvement of <protein>TRAF4</protein> in oxidative activation of <protein>c-Jun N-terminal kinase</protein>.
AB  - We previously found that the <protein>angiogenic factors TNFalpha</protein> and <protein>HIV-1 Tat</protein>
      activate an <protein>NAD(P)H oxidase</protein> in endothelial cells, which operates upstream
      of <protein>c-Jun N-terminal kinase (JNK)</protein>, a <protein>MAPK</protein> involved in the determination of
      cell fate. To further understand oxidant-related signaling pathways, we
      screened lung and endothelial cell libraries for interaction partners of
      <protein>p47</protein>(<protein>phox</protein>) and recovered the orphan adapter <protein>TNF receptor-associated factor
      4 (TRAF4)</protein>. Domain analysis suggested a tail-to-tail interaction between
      the C terminus of <protein>p47</protein>(<protein>phox</protein>) and the conserved <protein>TRAF</protein> domain of <protein>TRAF4</protein>. In
      addition, <protein>TRAF4</protein>, like <protein>p47</protein>(<protein>phox</protein>), was recovered largely in the
      cytoskeleton/membrane fraction. Coexpression of <protein>p47</protein>(<protein>phox</protein>) and <protein>TRAF4</protein>
      increased oxidant production and <protein>JNK</protein> activation, whereas each alone had
      minimal effect. In addition, a fusion between <protein>p47</protein>(<protein>phox</protein>) and the <protein>TRAF4</protein> C
      terminus constitutively activated <protein>JNK</protein>, and this activation was decreased
      by the antioxidant N-acetyl cysteine. In contrast, overexpression of the
      <protein>p47</protein>(<protein>phox</protein>) binding domain of <protein>TRAF4</protein> blocked endothelial cell <protein>JNK</protein> activation
      by <protein>TNFalpha</protein> and <protein>HIV-1 Tat</protein>, suggesting an uncoupling of <protein>p47</protein>(<protein>phox</protein>) from
      upstream signaling events. A secondary screen of endothelial cell proteins
      for <protein>TRAF4</protein>-interacting partners yielded a number of proteins known to
      control cell fate. We conclude that endothelial cell agonists such as
      <protein>TNFalpha</protein> and <protein>HIV-1 Tat</protein> initiate signals that enter basic signaling
      cassettes at the level of <protein>TRAF4</protein> and an <protein>NAD(P)H oxidase</protein>. We speculate that
      endothelial cells may target endogenous oxidant production to specific
      sites critical to <protein>cytokine</protein> signaling as a mechanism for increasing signal
      specificity and decreasing toxicity of these reactive species.
</DOC>
<DOC>
<DOC_ID>[257]</DOC_ID>
>257.NF00117649
PMID:11969340
TI  - The distribution of <protein>activin</protein> and <protein>activin receptors</protein> in gestational tissues
      across human pregnancy and during labour.
AB  - The aim of this study was to investigate localization and content of
      <protein>activin beta A-subunit</protein> and <protein>activin receptors</protein> in gestational tissues
      throughout pregnancy and in association with term labour. Placenta and
      fetal membranes were collected from women undergoing first and second
      trimester terminations and from women before and after term labour.
      <protein>Activin beta A-subunit</protein> and <long_form><protein>activin receptors IA</protein>, IB, IIA and IIB</long_form> were
      studied by immunohistochemistry. Term tissues were analysed for <protein>activin A</protein>
      and <protein>follistatin</protein> content by ELISA and the presence of <protein>receptor proteins</protein> was
      assessed by Western hybridization. <protein>Activin beta A-subunit</protein> was localized to
      the syncytiotrophoblast and cytotrophoblast in placentae from all
      gestational ages, and to the amniotic epithelial and chorionic trophoblast
      layer at term. In placentae of first and second trimester, <protein>receptor
      proteins</protein> were localized to the syncytium, whereas at term, the
      distribution was confined predominantly to vascular endothelial cells of
      villous blood vessels. <protein>Receptor proteins</protein> in amnion were localized to some
      epithelial cells, mesenchyme and chorionic trophoblast. These findings
      suggest that <protein>activin A</protein> is secreted by and targets the placental syncytium
      and amniotic epithelium in early pregnancy, but at term targets the
      vascular endothelium of placenta and the fetal membranes. There were no
      differences with labour onset.
</DOC>
<DOC>
<DOC_ID>[258]</DOC_ID>
>258.NF00089673
PMID:11883937
TI  - A novel negative regulatory element in the <long_form>human <protein>collagenase-3</protein></long_form> proximal
      promoter region.
AB  - We have identified in the <long_form>human <protein>collagenase-3</protein></long_form> promoter a novel negative
      regulatory element, GAAAAGAAAAAG, designated AGRE (AG-Rich Element). The
      AGRE site functionality was characterized in human osteoarthritic (OA)
      chondrocytes as well as four cell lines. The cells were transfected with a
      plasmid consisting of the first 133 bp of the <protein>collagenase-3</protein> promoter and
      its AGRE mutated or deleted derivatives. The absence of a functional AGRE
      site resulted in a statistically significant increase of the <protein>collagenase-3</protein>
      basal transcription that was not affected by the <protein>collagenase-3</protein> inducers
      <protein>IL-1beta</protein> and <protein>TGF-beta1</protein>. Two specific protein-AGRE binding complexes were
      detected by EMSA, and their presence depended on the physiological state
      of the cell. Indeed, normal chondrocytes and synovial fibroblasts and the
      four cell lines showed only a slower-migrating complex (complex 1). In OA
      chondrocytes, the type of complex discriminated two groups--the low-OA
      chondrocytes, showing low <protein>collagenase-3</protein> basal levels and high inducibility
      of <protein>IL-1beta</protein> stimulation (complex 1), and the high-OA chondrocytes with
      high <protein>collagenase-3</protein> basal levels and low <protein>IL-1beta</protein> inducibility (a
      faster-migrating complex, designated complex 2). UV cross-linking revealed
      the presence of <long_form>48 and <protein>97 kDa proteins</protein></long_form> in complex 1 and <long_form>27, 35, and <protein>73 kDa
      proteins</protein></long_form> in complex 2. These findings suggest that the AGRE site plays a
      rate-limiting role in <long_form>human <protein>collagenase-3</protein></long_form> production.
</DOC>
<DOC>
<DOC_ID>[259]</DOC_ID>
>259.NF01099179
PMID:12620808
TI  - The <protein>L1 major capsid protein</protein> of human papillomavirus type 11 interacts with
      <long_form>Kap beta2 and <protein>Kap beta3 nuclear import receptors</protein></long_form>.
AB  - We have previously shown that the <protein>L1 major capsid protein</protein> of low-risk
      HPV11 binds to the <protein>Kap alpha2 adapter</protein> and enters the nucleus via a <protein>Kap
      alpha2beta1</protein>-mediated pathway. In this study, we discovered that HPV11 L1
      capsomeres bind to <protein>Kap beta2 import receptor</protein>, known to mediate nuclear
      import of <protein>hnRNP A1</protein> via interaction with its nuclear localization signal
      termed M9. Significantly, binding of HPV11 L1 capsomeres to <protein>Kap beta2</protein>
      inhibited the nuclear import of <protein>Kap beta2</protein>, and its specific M9-containing
      cargo. Interestingly, HPV11 L1 capsomeres also interacted with <protein>Kap beta3
      import receptor</protein> and inhibited <protein>Kap beta3</protein> nuclear import. Moreover, the L1
      capsomeres of high-risk HPV-16 shared these activities. These data suggest
      that <long_form>HPV <protein>L1 major capsid proteins</protein></long_form> interact with <protein>Kap beta2</protein> and <protein>Kap beta3</protein>,
      and they may inhibit the <protein>Kap beta2</protein>- and <protein>Kap beta3</protein>-mediated nuclear import
      pathways during the productive phase of the viral life cycle when the
      virions are assembled and released.
</DOC>
<DOC>
<DOC_ID>[260]</DOC_ID>
>260.NF00089677
PMID:12049201
TI  - <protein>BAG-1</protein>, an anti-apoptotic tumour marker.
AB  - <protein>BAG-1</protein> is a multifunctional and anti-apoptotic or <protein>anti-cell death protein</protein>
      that interacts with a variety of <protein>cellular proteins</protein> and affects their
      functions. On the cell surface, it binds to the cytosolic domain of the
      <protein>growth factor receptors</protein> and enhances the protection from cell death
      triggered by <protein>growth factor receptors</protein>. In the cytosol, it binds to <protein>Bcl-2</protein>
      and <protein>heat shock protein</protein>, and modulates their functions. In the nucleus, it
      binds to a variety of <protein>nuclear hormone receptors</protein> and inhibits
      hormone-induced apoptosis. <protein>BAG-1</protein> is widely overexpressed in a variety of
      tumour cell lines and cancer tissues. In addition, differential expression
      of <protein>BAG-1 isoforms</protein> has been observed. Preclinical studies indicate that
      overexpression of <protein>BAG-1</protein>, especially its nuclear and cytoplasmic isoforms,
      may be useful as a prognostic and/or predictive biomarker. Pilot clinical
      studies have demonstrated that overexpression of <protein>nuclear BAG-1</protein> may be
      associated with a shorter survival in breast and laryngeal carcinomas.
      Conversely, overexpression of <protein>cytoplasmic BAG-1</protein> may be associated with a
      better clinical outcome in early stage breast cancer and in non-small cell
      lung cancer. Further large-scale clinical studies are warranted to
      establish the role of <protein>BAG-1</protein> as a novel prognostic and/or predictive
      biomarker in the clinical management of these common malignancies.
</DOC>
<DOC>
<DOC_ID>[261]</DOC_ID>
>261.NF00100423
PMID:11514614
TI  - <protein>Dynamin-related protein Drp1</protein> is required for mitochondrial division in
      mammalian cells